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Abstract
Clinicians constantly weigh the relative importance of multiple attributes when 
they make decisions about how to treat patients. The literature shows that 
this is generally done in a relatively informal manner using intuition rather than 
evidence-based medicine. Decision analysis methods and computer decision 
support systems (CDSS) have been developed to help implement evidence- 
based medicine and to aid clinicians in their decision making. Multi-criteria 
decision analysis (MCDA) is a methodology used to break complex problems 
into manageable pieces, allow data and judgement to bear on them and then 
reassemble them to present an overall picture of the problem. The aim of the 
study was to use MCDA to develop a model to aid practitioners to choose the 
most effective drug treatments for Parkinson’s disease (PD). A CDSS was 
developed from this model.
Two surveys were sent to 304 neurologists, 88 geriatricians as well as 
Parkinson’s disease nurse specialists across the UK to determine the criteria 
for the model. The seven steps of developing a MCDA model were earned 
out. A value tree was created from the criteria established from the surveys. 
The drugs were scored for their performance against the criteria using data 
from clinical trials and the weights were determined by the clinician for each 
individual patient. Software was developed using Excel and Visual Basic for 
Applications (VBA) to implement the functions of the model. A sensitivity 
analysis was carried out to determine whether the model was suitable for use 
with individual PD patients and whether the software was quick and easy to 
use.
A total of 68 criteria were generated from the surveys, which was reduced to 
11 .This showed that clinicians were perhaps using personal experience more 
than evidence-based medicine. Scoring the data on the drugs showed that 
some drugs performed either better or worse than expected. The weights 
were phrased so that users could use swing-weighting to weight the criteria 
for their importance to each patient. The combined scores and weights were 
calculated by Excel and the result returned on the screen to the user by VBA. 
An expert panel carried out the sensitivity analysis and showed that there 
were some issues with the scores developed, such as potential bias from the 
trials data and that not all the expected criteria were included in the model, for 
example bradykinesia and tremor were not included. However, the expert 
panel felt that the software was quick and easy to use and overall the principle 
of the model was approved, subject to some modifications.
Therefore, a model was successfully developed for Parkinson’s disease using 
MCDA and a CDSS developed to implement the model’s functions. The 
model needs further refinement but has the potential to be successfully used 
in a clinical setting. MCDA could additionally be used to develop models for 
other diseases.
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CHAPTER 1
General Introduction
“Decide promptly, but never give any reasons. Your decisions may be right, 
but your reasons are sure to be wrong.”
Lord Mansfield
BACKGROUND
The field of medical decision-making is a complex affair. The decisions 
clinicians make are an extremely important factor in the control of cost and 
quality in medical care. Medical decisions implement theory into practice and 
are part of the process that determines the promotion of particular prevention 
programmes, the diagnoses that are made and the treatments that are chosen 
(Eddy, 1986). Doctors need to meet the needs of patients by drawing on the 
5000 years’ worth of knowledge acquired by medicine (Smith, 1996).
Medical decisions, as with decisions in other fields, are often particularly 
complex. They may involve multiple factors, relationships and outcomes, with 
uncertainty involved in every aspect of the decision-making process (Eddy, 
1996). Physicians are trained to make endless decisions on a daily basis 
regarding patients’ diagnoses and treatments and have to consider huge 
quantities of often changing, incomplete and confusing information. They 
must do all this whilst under time pressure and having to consider what is 
often ambiguous information from the literature (Blumenthal, 2004).
There are many factors clinicians need to consider when choosing drug 
treatments for a patient. They need to consider all the outcomes that a patient 
may consider important for each possible treatment, to understand the value 
the patient places on each outcome and also to choose the treatment that is 
most appropriate for maximising the patient’s health. As well as all this, there 
may be uncertainty about the effects a treatment can have on outcomes, how 
the treatment may be affected by the patient’s individual characteristics and 
any interactions with other diseases the patient may have. Besides this, there 
used to be no formal languages that were available to clinicians for 
discovering or weighing patients’ preferences (Eddy, 1986). However, tools 
and scales have been developed for such a purpose, such as the Visual
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Analogue Scale, which measures how the patient ranks health outcomes 
according to their preferences (Torrance et al., 2001), the time-trade-off where 
the respondent gives their values of a lifetime in a perfectly healthy state 
compared to a period in a particular health state and the standard gamble 
where the patient chooses between the option of living all their life in a 
particular health condition against a gamble of either living in perfect health or 
facing certain death (Tijhuis et al., 2000).
Eddy (1986) suggests that medical practice would be virtually paralysed if 
physicians were to physically consider every possibility necessary when 
choosing a drug treatment for patients. For example, they would need to 
estimate the effect of the treatment on all the important clinical outcomes, to 
assess the patient’s preference for different outcomes and weight the patient’s 
preferences to choose the treatment with the most desirable effect. Instead of 
this, decisions are normally based on one or two of the most important 
outcomes. The decision problem then needs to optimise the outcomes 
selected, whilst trusting that any effects the procedure has on other outcomes 
is relatively unimportant. In dynamic work settings, it is often the decision­
maker’s aim to reach a satisfactory solution in order to gain control of a 
problem, rather than attempting to devise a perfect or optimal response. A 
continuous cycle of monitoring is involved in order to assess the situation, 
take appropriate actions and re-evaluate the results (Flin et al., 2007).
DIFFICULTIES IN MEDICAL DECISION-MAKING
Clinical decisions can be problematic for a number of reasons. Tavakoli et al. 
(2000) identified five main reasons why medical decisions are so problematic.
1. Complex information being integrated from a variety of sources
2. Information being imperfect or incomplete
3. The presence of uncertainty
4. The complex interaction between clinicians and patients
5. The imperative account for both costs and effectiveness of strategies.
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These will each now be detailed in turn.
Complex Information
Clinical decisions may mean choosing between broad approaches, such as 
surgical or pharmacological, or choosing the specific details of therapy, such 
as which drug, the dose or duration of treatment. The range of choices may 
be bewildering, with the clinicians having to make choices between alternative 
therapies and to revise and review treatment with regard to the patient’s 
status. The pathways between the actions and the outcomes may not be 
clear. Therefore, the problem may be unstructured but also the clinician may 
possess only an incomplete picture. Even if all the information is present, the 
clinician may lack the ability to integrate such complex information (Tavakoli et 
al., 2000).
Imperfect Or Incomplete Information
The rapid changes that take place in the knowledge base and the volume of 
information available often limit the individual’s capacity to maintain and 
develop their skills. Decisions may therefore often be made with incomplete 
or imperfect knowledge. Clinicians may be unsure of factors such as the full 
impact of interventions, the likelihood of specific outcomes or the value 
patients place on those outcomes. Perfect information is frequently 
unattainable and the evidence that is available may not be appropriate for the 
decision problem being considered. Randomised clinical trials, for example, 
are very specific and do not necessarily cover all potentialities (Tavakoli et al., 
2000).
Uncertainty
A good decision can often be affected by chance, turning it into a poor 
outcome. The clinician’s and patient’s attitudes to risk can also have a 
bearing on what constitutes a good decision (Tavakoli et al., 2000).
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Clinician I Patient Interaction
Patient involvement in decision-making has increased sharply in recent years. 
Patients are better informed and want more information on treatment options 
and the benefits and risks of treatments, which can place greater demands on 
clinicians when they are considering treatment options (Tavakoli et al., 2000). 
However, it can also help having the patient to be involved in the decision­
making process as they are able to inform the clinician of their values and 
preferences (Kaplan and Frosch, 2005).
Costs And Effectiveness Of Strategies
Despite the emphasis on effectiveness, the reality may be that decisions have 
to reflect a scarcity of resources. Therefore, decision-making has to consider 
both the costs of decisions and the values of the outcomes from those 
decisions (Tavakoli et al., 2000).
Decisions Under Uncertainty
Medical decision-making can be characterised by the need to make decisions 
despite having incomplete knowledge of the patient’s true condition or the 
therapeutic effect of a given management strategy (Kuipers et al., 1988). The 
critical decision a clinician must make between diagnostic and therapeutic 
alternatives is a paradigm example of decision-making under uncertainty 
(Hall, 2002). The spectrum of decision-making in medicine runs from simple 
to complex and relates to the level of uncertainty. A variety of tasks need to be 
carried out which have varying degrees of certainty (Croskerry, 2005). Rather 
than being certain most health outcomes from medical decisions are 
probabilistic (Lurie and Sox, 1999, Ratliff et al., 1999).
Many of the medical decisions made by clinicians can be classed as being 
made by intuition. This is a form of cognitive ‘short-circuiting’, where the 
decision may be made even though the reason for the decision cannot be fully 
described (Hall, 2002). Any decisions made are therefore made under 
uncertainty. Uncertainty may be classed as technical, personal or conceptual.
5
Technical uncertainty
Where there is insufficient information to predict prognosis or the effect of an 
intervention this could be classed as ‘technical’ uncertainty. There may not be 
adequate research on the best way to use new technologies. Uncertainty 
could also come from the rapid growth of medical knowledge, with the 
practitioner being unsure whether or not they are really up-to-date with all the 
current information (Hall, 2002).
Personal uncertainty
‘Personal’ uncertainty may arise from the doctor-patient relationship where the 
patient’s wishes may not be known and it may be difficult for the practitioner to 
establish what their wishes are. A practitioner may also be uncertain because 
of their own emotional attachment to a patient, leading to a fear that their 
decision-making may be impaired. Uncertainty may also arise from the 
practitioner’s lack of knowledge of their patients (Hall, 2002).
Conceptual uncertainty
Conceptual’ sources of uncertainty may stem from an inability to assess 
different patients’ needs competing for limited resources or the application of 
general criteria such as guidelines to individual patients. Another source may 
come from uncertainty about applying past experiences to current patients, as 
well as uncertainty about the future (Hall, 2002).
Decision-making Strategies
Decision-making in medicine can be broadly categorised into four groups of 
decision-making strategies. These are ‘intuitive’, ‘rule-based’, ‘option 
comparison’ and ‘creative’ decision-making.
Intuitive decision-making
‘Intuitive’ decision-making is where a problem can be recognised and a 
solution recalled from a rule that has been memorised or from a personal or 
observed technique that had been used before in a similar situation. The 
course of action chosen is likely to be an automatic process where little 
conscious deliberation has been involved (Flin et al., 2007). This strategy is
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most likely to be used by experienced practitioners as less experienced 
practitioners would by definition have less experience to draw on.
Rule-based decision-making
With this strategy procedures for a particular situation need to be looked up or 
remembered. This could mean referring to an evidence base or 
implementation of guidelines from a body such as the National Institute for 
Clinical Excellence (NICE). More mental effort is involved than intuition. This 
form of decision-making is often used by novice practitioners who learn 
particular procedures for certain situations. The process can become 
automatic with time and the rule retrieved from memory with little effort. It can 
however lead to skill decay if practitioners find themselves in an unfamiliar 
situation where no rule exists (Flin et al., 2007).
Option comparison decision-making
‘Option comparison’ is often referred to as ‘analytical’ or ‘rational choice’ 
decision-making. A number of possible courses of action are recalled and 
compared simultaneously to determine which is most fitting to a particular 
situation. A number of mathematical and statistical techniques can be used to 
help select the optimal choice. However considerable time and concentration 
is required to conduct a thorough analytical comparison (Flin et al., 2007).
Creative decision-making
This particular strategy is rarely used in high time pressure environments as a 
novel course of action must be devised for each new situation. However, it 
may be used in surgery, for example, for an intraoperative endoscopy to look 
for an occult bleeding source for a gastrointestinal bleed (Flin et al., 2007).
Bias In Decision-making
Heuristics are often used as part of intuitive decision-making. Heuristics are 
rules or guidelines that are used to make complex tasks simpler to streamline 
decision-making (Nierenberg et al., 2008, Hall, 2002). Heuristics are often 
regarded as being a source of error or bias (Hall, 2002). Individuals may be 
helped by heuristics in addressing complicated scenarios, but they can also
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lead them to make systematic errors in their interpretation of the probability of 
events. Personal events may help practitioners to formulate heuristics which 
can simplify and bias future decisions they make regarding complex case 
presentations. Personal clinical experience or the experience of other 
colleagues can unduly influence the prescribing choices they make by 
presenting them with easily recalled examples of events (Nierenberg et al., 
2008).
DECISION-MAKING MODELS
Several different models of medical decision-making exist: namely the 
‘paternalistic’, ‘informed’ and ‘shared’ models. These will each be outlined in 
turn.
Paternalistic Model
This is the model which was the dominant approach to decision-making in 
medicine for many decades (Charles et al., 1997, Charles et al., 1999a, 
Charles et al., 1999b). In this form of decision-making the patient adopts a 
passive role to the professional’s authority and agrees to their choice of 
treatment. There is an assumption that the doctor will make the best 
treatment decision and does not need to elicit personal information from, or 
involve the patient in, the decision-making process. The flow of information is 
one way from the physician to the patient (Charles et al., 1999a). The 
physician’s role in this model is as a guardian of the patient’s best interest 
(Charles et al., 1997). The physician weighs the benefits and risks of 
treatment options by himself or in conjunction with other physicians. In 
implementing a treatment choice the physician is the decision maker, although 
their decision is not totally autonomous as the patient’s consent must be 
obtained (Charles et al., 1999a). There is no sharing at any stage of the 
decision-making process though, so a doctor-patient partnership does not 
exist by definition (Charles et al., 1999b). It could be argued, states Charles 
et al. (1999b) that the doctor and patient enter a form of partnership based on 
agreement about how the process will be undertaken, but an explicit
discussion of alternative models of decision-making would be needed for this 
and the doctor may already have adopted a paternalistic approach from the 
outset of the process. In certain situations though, this may be the best 
approach for physicians to adopt, such as in emergency situations where no 
other model is feasible (Charles et al., 1997).
Informed Model
With the ‘informed’ model there is a partnership between the doctor and 
patient with a division of labour. The doctor communicates information to the 
patient on the relevant treatment options and their benefits and risks. This is 
the doctor’s main contribution to the decision-making process, with the patient 
deliberating the evidence and making the decision. The doctor has no 
involvement in these two phases or investment in the treatment decision the 
patient makes (Charles et al., 1999b, Gafni et al., 1998). The ‘informed’ 
decision-making model is based on the assumption that the patient is 
empowered by the information they receive to become a more autonomous 
decision maker (Charles et al., 1997).
Shared Model
The ‘shared’ model of decision-making is different, in that the doctor and 
patient share all stages of the decision-making process together (Frosch and 
Kaplan, 1999, Elwyn et al., 1999b, Charles et al., 1997, Charles et al., 1999a). 
There is therefore a two-way exchange of information, with both the doctor 
and the patient sharing their treatment preferences and both agreeing on the 
decision that will be implemented (Charles et al., 1999b). The patient must 
provide the physician with information about their values, preferences and 
beliefs, ensuring that both patient and doctor can evaluate the treatment 
options in light of the patient’s specific situation and needs (Charles et al., 
1999a, Kaplan and Frosch, 2005). Doctors may face a challenge with this 
approach in needing to create an environment in which patients feel 
comfortable about expressing their treatment preferences (Charles et al., 
1999b).
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Charles et al. (1997) identified several key characteristics of shared decision­
making. These they consider to be the minimum necessary criteria for 
classifying the physician-patient decision-making process as shared decision­
making.
• Two participants -  shared decision-making always involves two 
participants; the patient and the clinician. Very often more than two 
participants may be involved, particularly if the patient chooses a family 
member or carer to be present. There may also be more than one 
clinician involved in the process.
• Both parties participate in the process -  patient preferences for 
participation in decision-making may not match their actual participation 
however. Patients may express a preference for participation in 
decision-making but not actually translate this into actual information 
seeking behaviour. There may be a number of reasons why patients 
do not use the information they seek:
o Firstly, a patient’s preference not to participate may reflect 
personality characteristics; 
o Secondly, their preference not to participate may reflect a 
response specific to a certain situation; 
o Thirdly, patients may express a preference for a passive role in 
decision-making because previous experience has taught them 
that more active roles are not well received by clinicians; 
o Finally, taking a passive role may reflect a cohort effect, for 
example with elderly patients.
• Sharing information is a pre-requisite to shared decision-making -  the 
physician must as a minimum give patients treatment alternatives and 
their potential consequences so that the patient can obtain informed 
consent. Otherwise, it could be possible that the patient has nothing to 
evaluate. Both patients and clinicians bring information and values.
• Both parties agree on a decision -  shared decision-making can refer to 
an outcome as well as the type of decision-making process. If 
decision-making is shared clinician and patient may agree on one 
outcome or may make no decision or may disagree about the preferred
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treatment. If the decision is truly shared both parties should agree that 
a particular treatment should be implemented, regardless or whether 
they both think this is the best treatment for that patient. This 
distinguishes shared decision-making from other types of decision­
making processes.
Barriers to shared decision-making
Shared decision-making has been emphasised as the model of medical 
decision-making to be practised, yet despite this shared decision-making has 
not always been happening in practice, as was shown by one study of GPs in 
the UK (Stevenson et al., 2000) and their communication with patients 
showed that the first two of Charles et al.’s (1997) key characteristics of 
shared decision-making (patient participation and doctors sharing information) 
were not observed. Where information was shared patients’ beliefs were 
often not taken seriously, therefore there was little consensus about the 
preferred treatments. GPs in Stevenson et al.’s (2000) study cited lack of time 
and other organisational pressures as reasons for not engaging in shared 
decision-making, alongside a belief that patients may lack the will or ability to 
participate in decision-making. Further studies of GPs’ attitudes to shared 
decision-making (Weston, 2001, Elwyn et al., 2001b, Stevenson, 2003, Elwyn 
et al., 1999a, McKinstry, 2000) showed that doctors supported the idea of 
shared decision-making, although patients vary in the extent to which they 
wish to participate in shared decision-making and time constraints act as a 
barrier to shared decision-making being carried out. It has also been shown 
(Kaplan et al., 1995) that male patients were less likely to participate if they 
saw a male physician and that female patients participated more in shared 
decision-making regardless of the clinician’s gender. For shared decision­
making to be more widely accepted more time is needed for the consultation 
process and patients need to be more comfortable with the uncertainty and 
chance of less than perfect outcomes that medical decision-making offer 
(Holmes-Rovner et al., 2000).
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EVIDENCE-BASED MEDICINE
What Is Evidence-Based Medicine?
Evidence-based medicine (EBM) is an increasingly common approach to 
medical decision-making. It broadly encompasses a process of turning 
clinical problems into questions and locating, appraising and using research 
findings as the basis on which clinical decisions are made (Belsey and Snell, 
2001, Rosenberg and Donald, 1995). EBM, say Sackett et al. (1996) is the 
conscientious, explicit and judicious use of current best evidence to make 
decisions about individual patients’ care. EBM is important in helping to 
resolve some of the problems with uncertainty in medical decision-making 
(Kaplan and Frosch, 2005) and also attempts to eliminate bias as much as 
possible (Borry et al., 2006). Obtaining good quality evidence, such as from 
randomised trials, is essential in order to provide good quality healthcare 
(Barratt, 2008, Haynes, 2002). The randomised controlled trial generally 
provides the best means of determining the effect of therapy, therefore a 
randomised controlled trial or a meta-analysis of such trials should inform all 
medical decisions made (Devereaux and Yusuf, 2003). EBM integrates 
individual clinical expertise with the best external clinical evidence available 
from systematic research (Sackett et al., 1996), a necessary process when 
information on a specific field is lacking in the literature or is of poor quality 
(Lacaine, 2005). Clinicians also need to incorporate the opinions and values 
of the patients and their carers, as well as personal experience, judgement 
and skills (Akobeng, 2005).
EBM uses formal rules to allow clinicians to interpret and accept or refute 
results from clinical research (Lacaine, 2005, Kaplan and Frosch, 2005). 
Critical appraisal is used to determine the validity and applicability of the 
evidence found, which is then used to inform clinical decisions. Evidence- 
based medicine can be both taught to and practised by clinicians at all levels 
and can help to close the gulf between good clinical research and clinical 
practice. It can also help to promote self-directed learning and teamwork, 
producing faster and better doctors (Rosenberg and Donald, 1995). Good 
doctors tend to use both clinical expertise and the best available evidence,
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with neither proving to be enough on their own (Sackett et al., 1996). EBM 
emphasises that for clinical expertise to be used for optimal decision-making 
clinicians need to also understand rules of evidence to be able to interpret and 
apply literature on causation, prognosis, diagnostic tests and medical 
interventions (Chou, 2005). Reviewing the available evidence may help 
decision-making when there are several therapeutic options available, which 
allows clinical acumen and autonomy to still play a central role in the care of 
patients (Kruer and Steiner, 2008).
The basis of evidence-based medicine is not a new idea, as practitioners 
identify questions raised by caring for their patients and often consult the 
literature available. However, an explicit evidence-based framework provides 
two distinctions. Firstly, it makes consulting and evaluating the literature a 
routine and fairly simple procedure. Secondly, the process can be made 
workable for clinical teams as well as for individuals (Rosenberg and Donald, 
1995).
EBM is a term for five linked ideas (Sackett and Rosenberg, 1995a).
• Clinical and other healthcare decisions should be based on the best 
available patient and population-based evidence, not just 
laboratory-based evidence.
• The decision problem determines the nature and source of 
evidence that is searched for.
• In order to identify the best evidence epidemiological and 
biostatistical ways of thinking need to be integrated with those from 
pathophysiology and personal experience.
• The conclusions of the evidence search and critical appraisal of the 
evidence are only worthwhile if they are translated into actions 
which affect patients
• Clinicians’ performance should be continuously evaluated in the 
application of these ideas.
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The practice of EBM is therefore a process of life-long, self-directed learning.
The Process of Evidence-Based Medicine
There are four steps involved in the process of using evidence-based 
medicine (Rosenberg and Donald, 1995, Guyatt et al., 2000):
• Formulation of a clinical question from a patient’s problem
• Searching of the literature for relevant articles
• Critical appraisal of the evidence for its validity and usefulness
• Implementation of useful findings in clinical practice.
Setting the question
The question that is formed regarding a patient’s problem can be related to 
diagnosis, prognosis, treatment, iatrogenic harm, quality of care or health 
economics. The question should be as specific as possible and should 
include the type of patient, the clinical intervention and the relevant clinical 
outcome (Rosenberg and Donald, 1995).
Finding the evidence
Once the question has been set the best available evidence needs to be 
searched for next. Clinicians need to develop effective searching skills and 
have access to bibliographic databases, examples including the Cochrane 
Database of Systematic Reviews, the ACP Journal Club and search engines 
such as PubMed (Rosenberg and Donald, 1995).
Appraising the evidence
The evidence needs to be critically appraised for its validity and clinical 
usefulness. This step is crucial for the clinician to be able to decide whether 
an article can be relied on for its guidance. Clinicians need to be able to ask 
key questions about the validity of the evidence and its relevance to particular 
patients (Rosenberg and Donald, 1995). Good quality studies from higher 
levels of the evidence hierarchy should have more impact on clinical decisions 
than poorer quality or lower level evidence (Chou, 2005).
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Acting on the evidence
Once clinicians have identified valid and relevant evidence they can either 
implement it directly in patients’ care or develop team protocols or hospital 
guidelines. Evidence can also be used to change continuing medical 
education programmes or audit. According to Rosenberg and Donald (1995) 
implementation of evidence is best carried out through group discussions on 
ward rounds or other clinical team meetings.
Clear data presentation
Published evidence needs to be presented quickly and clearly. A one page 
user-friendly summary, similar to an abstract on a published paper can be 
used by clinicians to present evidence to their teams (Rosenberg and Donald, 
1995).
Advantages of Evidence-Based Medicine
Evidence-based medicine provides a number of advantages for clinicians. 
Firstly, it integrates medical education with clinical practice. Rosenberg and 
Donald (1995) state that doctors who begin learning evidence-based medicine 
become adept at generating their own questions and then following the 
questions through with literature searches. Evidence-based medicine can 
also be learnt by people from varied backgrounds and at any stage of their 
career. Additionally, evidence-based medicine has the potential for improving 
continuity and uniformity of care due to common approaches developed by its 
practitioners. It can provide a structure for effective team work and 
communication through team-generated guidelines. Evidence-based 
medicine can also help providers of healthcare make better use of limited 
resources by enabling them to evaluate the clinical effectiveness of various 
treatments and services.
A number of advantages also exist at individual and group level for 
practitioners and also for patients (Rosenberg and Donald, 1995):
Individuals:
• Clinicians can upgrade their knowledge base on a routine basis
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• Clinicians’ can improve their understanding of research methods and 
become more critical in their use of data
• Confidence is improved in management decisions
• Computer literacy and data searching techniques are improved
• Reading habits are improved 
Clinical teams:
• Gives a team a framework for group problem solving and teaching
• Junior staff can contribute usefully to teams 
Patients:
• Resources are used more effectively
• There is better communication with patients about the rationale behind
decisions.
Disadvantages of Evidence-Based Medicine
Despite the advantages of evidence-based medicine there are also a number 
of disadvantages. Firstly, the time it takes to both learn and practise it. For 
example, it takes time to set a proper research question, to find and appraise 
the evidence and act on the evidence. For teams to benefit from evidence- 
based medicine all members needs to be present when both the question is 
set and for the evidence to be acted on. There is also a cost involved in 
establishing an infrastructure for practising evidence-based medicine, such as 
purchasing the necessary hardware and software as well as subscriptions to 
databases. However, these costs may be small compared to the cost of many 
medial interventions and the costs may be recovered by reducing ineffective 
practice. Evidence-based medicine may also expose gaps in the evidence 
which can be frustrating for practitioners, particularly if they are not very 
experienced. The identification of such gaps can help to generate local and 
national research projects however (Rosenberg and Donald, 1995). Clinicians 
are assumed to be proficient in the methodology and statistics needed to 
validate the evidence, needing to be capable of analysing the methods used 
to achieve published results, something which Lacaine (2005) says many 
clinicians, particularly surgeons, are not ‘experts’ in. Many of the databases 
used for searching for literature, such as Medline, are not always terribly well
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indexed or comprehensive. Additionally, senior clinicians may see evidence- 
based medicine as a threat if a junior member of a team has as much 
authority on a subject as a senior member through literature searches and this 
can alter the team dynamic (Rosenberg and Donald, 1995). EBM however, 
can never replace clinical expertise and it is the clinician’s expertise which 
decides whether the evidence can be applied to an individual patient (Sackett 
et al., 1996). EBM provides clinicians with guides to help them decide how 
applicable evidence from randomised controlled trials is to individual patients 
and to quantify the risks and benefits for individual patients when treatment 
decisions are made (Bassler et al., 2008a). EBM can be considered to be 
patient-oriented and recognises individual patients’ needs (Bassler et al., 
2008b).
Barriers to Evidence-based Medicine
EBM constitutes a considerable challenge to clinicians, with many clinicians 
needing to develop skills that they would not have acquired during medical 
school. This could lead some clinicians to reject EBM due to their lack of the 
specific skills needed, leading them to consider it as impractical or 
inappropriate (Ghali et al., 1999, Guyatt et al., 2000). Clinicians may also feel 
that they are too busy to have time to search for and critically appraise the 
relevant published evidence (Guyatt et al., 2000, Ghali et al., 1999). 
Clinicians often find when they are searching for information that the existing 
knowledge is not accessible to them in real time and may not even map to the 
issue they are concerned with (Clancy and Cronin, 2005). A study of 
clinicians’ attitudes towards EBM found that clinicians’ lack of knowledge and 
familiarity with the skills needed was the main barrier against them using 
EBM, although they were not necessarily sceptical about the concept 
(McAlister et al., 1999). There still remains, however, a huge problem with 
implementing EBM and its implementation is therefore only achieved in a fairly 
patchy manner in practice (Barratt, 2008).
Three strategies have been suggested for removing barriers to EBM (Sackett 
and Rosenberg, 1995b, Sackett and Rosenberg, 1995a). The first of these is 
learning evidence-based medicine so that clinicians become life-long, self­
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directed learners of EBM. Secondly, clinicians need to seek and apply 
evidence-based medical summaries created by other clinicians. Lastly, 
clinicians must accept the evidence-based practice protocols that have been 
developed by their colleagues. Sackett and Rosenberg (1995a and 1995b) 
consider that these three strategies would be effective in helping overcome 
some of the barriers imposed on clinicians by lack of information and the 
context within which medicine is practiced. In order to improve uptake of 
evidence into practice those working in evidence translation need to be more 
acquainted with clinician behaviour and the clinician’s view of compelling 
evidence. Being more aware of clinicians behaviour could lead to a clearer 
map of the barriers to, and incentives for, evidence uptake (Scott, 2007).
Teaching Evidence-based Medicine
A commentary (Dobbie et al., 2000) suggested that there was little good 
evidence that teaching programs of EBM changed learners’ practice 
behaviour or improved patient treatments and outcomes. However, other 
studies (Ghali et al., 2000, Schilling et al., 2006, Dorsch et al., 2004) have 
shown that introducing EBM into medical students’ teaching programs 
improved students’ literature searching and critical appraisal skills and their 
knowledge and awareness of EBM. Ghali et al (2000) state that educational 
interventions targeting each of the skills necessary to use EBM must be 
taught to undergraduate medical students if they are to become effective 
evidence-based practitioners. Dorsch et al.’s (2004) study showed that 
introducing EBM to third year medical students gave them an opportunity to 
practice the skills and reinforced that current best evidence should be used to 
make decisions about individual patient care, even if they did not have all the 
necessary skills to do so at that stage. Schilling et al. (2006) used e-learning 
technologies to teach EBM to undergraduate medical students and found that 
it increased the likelihood of them identifying the best available evidence for 
patient management. They further found that students who had completed 
their on-line curriculum showed superior performance over control students in 
areas such as literature searching. Contrary to these studies, an evaluation of 
EBM teaching to undergraduates in Thailand (Wanvarie et al., 2006) showed 
that students were able to complete the EBM steps, but the results for their
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final multiple choice question examination were less satisfactory than was 
hoped. Handheld computers (PDAs) have also been developed to help 
students use EBM (Lam et al., 2004, Johnston et al., 2004). One was 
developed for medical students to use to facilitate the adoption of EBM at the 
point of care (Johnston et al., 2004) which the students found useful, although 
its utilisation was low overall. Lam et al. (2004) found that there were barriers 
to implementing the learning of EBM in an undergraduate setting though, such 
as a limit to its usefulness because students felt that their use of the PDA 
would be criticised by their teachers and the PDAs were therefore considered 
to not be as useful as they could have been.
Reviews and appraisals of teaching of EBM skills (Taylor et al., 2000, Parkes 
et al., 2001, Coomarasamy and Khan, 2004, Straus et al., 2005, Yew and 
Reid, 2008, Smith et al., 2000, Dinkevich et al., 2006, Moharari et al., 2008, 
Norman and Shannon, 1998, Shuval et al., 2007a) showed mixed results. 
Both Taylor et al.’s (2000) review and Straus et al.’s (2005) study showed an 
improvement in clinicians’ EBM skills, Taylor et al. (2000) showing that an 
improvement in assessed outcomes of 68% was demonstrated after critical 
appraisal skills training, although they state the results should be viewed with 
caution due to the poor quality of the studies reviewed. Straus et al. (2005) 
showed that a multifaceted EBM intervention improved evidence-based 
practice patterns among clinicians and residents in a district general hospital. 
However, Shuval et al.’s (2007a) study showed no statistically significant 
impact on doctors’ performance in test ordering or on their patients’ use of 
drug treatments after an EBM educational intervention. Three studies of 
teaching EBM skills to residents (Smith et al., 2000, Dinkevich et al., 2006, 
Moharari et al., 2008) showed improvements in EBM skills, although contrary 
to this other studies (Norman and Shannon, 1998, Yew and Reid, 2008) 
showed either only small changes in knowledge of critical appraisal after 
changes in EBM education or that residents did not practise the EBM skills 
they had learnt. An interactive, longitudinal EBM course was shown to 
improve the main skills needed for practising EBM; literature retrieval and 
critical appraisal skills (Nicholson et al., 2007). A two week EBM rotation for 
residents was shown to increase their skills and confidence, with residents
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and faculty staff feeling that the teaching improved the quality of patient care 
(Thom et al., 2004). Parkes et al.’s (2001) review showed there are large 
gaps in the evidence as to whether the teaching of critical appraisal could 
have a positive impact on decision-making or patient outcomes. One study 
showed the need to enhance physicians’ skills and perceptions of EBM and to 
also improve the ease with which evidence-based resources can be used at 
the point of care (Shuval et al., 2007b). Evidence-based information retrieval 
could be simplified by tailoring the system to the clinic, such as through 
integration with a CDSS (Shuval et al., 2007b). Coomarasamy and Khan 
(2004) suggest that the teaching of EBM should be moved from the classroom 
to clinical practice in order to achieve improvements in patient outcomes.
Application of Evidence-based Medicine
Various studies (McAlister et al., 1999, Fairhurst and Huby, 1998, Douketis 
and Lloyd, 2008, Forbes et al., 2008, Rigg et al., 1999, Lockwood et al., 2004) 
have looked at the impact of EBM on clinicians’ practice. Fairhurst and Huby 
(1998) looked at GPs’ use of EBM for prescription of statin drugs and found 
that GPs were aware of evidence for statins in secondary prevention of 
coronary heart disease but not so clear about the evidence for primary 
prevention, but they lacked technical skills for appraising the evidence from 
clinical trials. A study in Canada developed new practice algorithms based on 
EBM to prevent surgical site infections (Forbes et al., 2008) and found that 
evidence-based care pathways could be feasibly implemented in their day to 
day patient care, although they suggest a larger, multi-centre study would 
need to be carried out in the future. Also in the field of surgery, a programme 
of ‘fast-track’ surgery (Kehlet and Wilmore, 2008), that is accelerated recovery 
and decreased convalescence, has been shown to enhance postoperative 
recovery. This ‘fast-track’ surgery is based on evidence-based care and both 
enhanced postoperative recovery and reduced morbidity. Lockwood et al. 
(2004) assessed the impact of routine EBM meetings on routine clinical 
practice over a period of seven years and found that treatment guidelines 
became more closely based on published evidence and led to improvements 
in patient care.
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DECISION ANALYSIS
Decision analysis is a process which is undertaken prior to the decision being 
made, using the available evidence to create a model. The subsequent 
decision is informed by the model, although not necessarily predicted from it 
(Waller and Evans, 2003). Decision analysis techniques formalise the 
question of whether an intervention should be adopted or rejected. It 
identifies the set of consequences of concern for the decision maker that 
could result from each of the available options and determines the associated 
probabilities. An expected net impact can be obtained for each option from 
the aggregation of the probability-weighted consequences (Claxton et al.,
2005). Decision analysis can help overcome decision-making complexity by 
structuring the problem clearly and providing a formal analysis of the 
implications of different treatment outcomes (Tavakoli et al., 2000).
One of the strengths of decision analysis is that it offers an explicit and 
systematic approach to decision-making based on rationality, rather than 
intuition (Elwyn et al., 2001a). Many factors can be presented and 
incorporated in decision analysis, with the decision being based on a fuller 
range of information than it would be in an unstructured approach. Another 
strength is that it is not just based on probabilities, but also on the value 
placed on various outcomes. Thus, it represents a method for synthesising 
both facts and human values, which, put together, determine the best course 
of action (Lilford et al., 1998).
Healthcare is a clear example of an area where human ability to integrate the 
range of relevant variables is outstripped. With clinical decision analysis, 
choices and potential outcomes need to be defined and ideally contextualised 
for individual patients. This may make the decision-making process more 
rigorous and tailored to the individual (Elwyn et al., 2001a). Decisions made 
by healthcare professionals based on intuition do not lessen the problem that 
the basis for the decisions cannot be made with certainty. Clinicians need to 
be able to relate the results of a trial to particular patients. Although this is 
usually done intuitively, formal decision analysis provides a framework for
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developing decision-making algorithms. Making complex decisions intuitively 
can result in oversimplification of the problem as it is difficult to consider 
several components of the decision simultaneously. However, using decision 
analysis provides transparency through the decision-making process as well 
as providing an audit trail, both of which lead to an improvement in the quality 
of decision-making.
Decision analysis can help clinicians choose between different treatment 
options in the following ways. Firstly, a decision tree is used to present the 
options graphically, with all the possible outcomes being displayed for all the 
treatments and ‘nodes’ signifying which paths can be influenced by decisions 
and which cannot (Yentis, 2006, Tavakoli et al., 2000). The aim of the 
decision analysis is to reduce the decision process into the relevant individual 
decision points (Lilford et al., 1998). The clinician then assists the patient in 
assigning a ‘utility’ to each outcome, this is often a figure between zero (the 
worst possible outcome) and one (the best possible outcome) these then 
allow meaningful comparison to be made between the alternative outcomes 
(Yentis, 2006, Lilford et al., 1998).The utilities are then multiplied by the 
probability of each outcome, with the sum of the values indicating which 
treatment is the best option for that particular patient (Yentis, 2006). 
Sensitivity analysis is used to determine how robust the choices that have 
been made by the decision analysis are. The utilities can be varied to see 
how a decision might change, determining the sensitivity of the analysis 
(Lilford et al., 1998).
Decision analyses can be carried out for groups of patients with similar clinical 
features and personal utilities. Decision analysis can therefore provide a 
means for clinicians to move from finding evidence to implementing it (Lilford 
et al., 1998). Decision analysis can help the ethical principle of veracity be 
achieved as the analysis is explicit about the uncertainties in clinical practice 
and also uncovers the complexity of decision-making (Elwyn et al., 2001a). 
The robustness of a decision analysis model can be tested by carrying out the 
sensitivity analyses which will show the model and its decisions are credible if 
the decisions suggested by the model are stable when underlying
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assumptions are varied. Stakeholders can openly interrogate or challenge the 
problem definition and identify parts of the model or assumptions which they 
may disagree with. These can then be tested with further sensitivity analysis. 
Such a process leads to clearer conceptualisations, better models and better 
decision-making (Tavakoli et al., 2000).
The problems of using probabilities and values, which cannot be measured 
with any certainty, are not lessened if clinicians approach decisions intuitively. 
Decision analysis is needed to make uncertainties explicit. Complex 
decisions cannot be made intuitively because it is not possible to incorporate 
and consider the various components of the decision simultaneously and 
clinicians need help in thinking about such complex situations (Lilford et al., 
1998, Elstein, 2004). Decision analysis is an aid to solving complex problems 
in a systematic way within a background of imperfect information and 
uncertainty. It is not, however, designed to replace the judgement of the 
decision maker (Tavakoli et al., 2000).
Decision Aids
Both evidence-based medicine and decision analysis are involved with 
improving the quality of medical decisions and both emphasise a quantitative 
approach to providing guidance to clinical decision makers (Elstein, 2004). 
Decision aids have been developed as a way of creating a mechanism for 
empowering patients and applying research evidence to clinical practice. 
Decision aids can therefore help to align medical practice with the best 
available evidence (Holmes-Rovner et al., 2007). They can also assist in 
improving the amount of informing and decision sharing with patients. Many 
clinicians believe they practice EBM, although the rules of evidence have 
rarely been formally applied (Kaplan and Frosch, 2005). Practitioners may 
therefore be exercising their own opinions of what treatments do or do not 
work (Davidson et al., 2003). Decision aids may be used to help patient 
involvement in decision-making in order to facilitate shared decision-making 
(Kaplan and Frosch, 2005) as well as incorporating evidence-based medicine. 
Decision aids are not designed to replace the consultation between physician
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and patient but to provide information about clinical options and their likely 
outcomes (Barry, 2002, O'Connor et al., 1999).
A decision aid was developed for vascular surgeons (Timmermans et al., 
2001), which showed that surgeons agreed with the model’s choices in 81% 
of cases. Timmermans et al. (2001) suggest that the model can be used by 
inexperienced surgeons to improve their decision-making and that an 
evidence-based decision analytical tool can increase the quality of clinical 
decisions. They further suggest that any discrepancies between the decisions 
clinicians make and the recommendations the decision aid makes can be 
used to teach clinicians to make better decisions. A decision analysis based 
support tool was developed for use of warfarin for patients in AF (Thomson et 
al., 2002). This was developed with the aim of supporting better shared 
decisions in an area which they say has suffered from lack of implementation 
of the evidence base. Thomson et al. (2002) state that use of such a tool can 
help incorporating the patient in decision-making under uncertainty, whilst also 
bringing the evidence base to the consultation.
Patient decision aids
Patient decision aids are designed to improve sharing of information and 
decision-making between clinician and patient, an area which has been 
shown to be suboptimal (Holmes-Rovner et al., 2007). Patient decision aids 
can help reduce decisional conflict so that patients are more comfortable with 
their choices and decisions match more closely with their personal values 
(Barnato et al., 2007). Decision aids help to provide a structure for making a 
choice and present patients with information on the available options and the 
risks and benefits those options bring with them. Evidence-based decision 
aids provide a synthesis of up to date evidence on the risks and benefits of 
each available option (Graham et al., 2003). Some have raised concerns 
though about the quality of patient decision aids, especially with regard to 
them being updated with new information about treatment options, benefits 
and risks (Deyo, 2001). This, state Barnato et al. (2007), is particularly 
important in an area like cancer screening and treatment, where new 
technologies are constantly emerging. Patient decision aids had tended to be
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focused on single-event decision-making, such as choice of surgery, although 
more recently more decision aids have been produced for chronic care 
(Holmes-Rovner et al., 2007).
It has been suggested that the usefulness of patient decision aids remains to 
be tested (O’Connor et al., 2004). Incorporating patient decision aids into 
medical care could require much reengineering of the processes of care 
through the health system (Blumenthal, 2004). In order to support patient 
welfare by using good quality decision aids such decision aids must be 
disseminated and research carried out on the best ways to develop cost- 
effective and feasible mechanisms for disseminating the aids into daily clinical 
practice (Barnato et al., 2007). However, a symposium held by the 
International Patient Decision Aid Standards in 2006 failed to determined 
whether or not patient decision aids are the best way to improve clinical 
decisions or whether they might become the best way (Holmes-Rovner et al.,
2007).
A review of patient decision aids (O'Connor et al., 1999) showed that decision 
aids improved the patients’ average knowledge score of options and 
outcomes by 13 to 25 points, whilst patient decision aids have been shown to 
have a positive impact on decisional conflict in many studies (Murray et al., 
2001b, O'Connor et al., 1999, Molenaar et al., 2000, Barry, 2002, Murray et 
al., 2001a). O’Connor et al. (1999) also assessed the impact of the decision 
aids on patients’ decisions about major surgery, showing that the decision 
aids reduced patients’ preference for more intensive surgery by 21-42%. 
They also discovered that three of the decision aids increased the proportion 
of participants taking a more active part in the decision-making, a finding 
echoed in two trials of interactive multimedia decision aids (Murray et al., 
2001a, Murray et al., 2001b). O’Connor et al.’s (1999) review showed that 
patient decision aids were better than usual care for improving patients’ 
knowledge about options and reducing decisional conflict, as well as 
encouraging patients to play a more active role in decision-making. Molenaar 
et al.’s (2000) review described a need for more and better controlled studies 
of the effectiveness of decision aids. The studies of interactive multimedia
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decision aids also showed that using web-based technology would reduce the 
cost of intervention and could be delivered cheaply over the internet (Murray 
et al., 2001a, Murray et al., 2001b).
Graham et al. (2003) assessed physicians’ attitude towards decision aids to 
gauge their acceptability and the factors that influence their interest in using 
them with patients. They assessed three decision aids with 141 clinicians and 
identified factors such as the content and format of the decision aid, their 
patients’ abilities to use the decision aid and the extent to which the aid might 
facilitate or impact on their work as factors which would influence their 
decision to use the aid with patients. A study carried out with patients 
assessing the usefulness of a decision aid for hypertension (Thomson et al.,
2006) showed that patients found the decision aid useful for providing 
individualised information, taking account of their own values and preferences 
for different treatment options. Some patients felt this approach was not 
particularly helpful and patients varied in the amount of information which they 
wanted and the extent to which they wanted to be involved in the decision­
making process. It has been shown that some patient groups, such as the 
elderly, may not always want to be involved in shared decision-making 
(McKinstry, 2000). Thomson et al. (2006) however, found that the decision 
aid could be a useful way to provide patients with individualised information in 
order to promote shared decision-making.
COMPUTER DECISION SUPPORT SYSTEMS (CDSS)
Evidence shows that CDSSs are a valuable tool for fostering the process of 
dissemination and uptake of clinical guidelines, which can improve medical 
decision-making and clinical outcomes (Coiera, 2003, Kotze and Brdaroska, 
2004). Use of CDSS has increased as they are able to provide clinicians with 
patient-specific recommendations which can aid with clinical decision-making 
(Kawamoto et al., 2005, Sucher et al., 2008). CDSS have been considered to 
increase healthcare quality (Sim et al., 2001).
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Use of CDSS can mean better access to and improved use of clinical 
evidence, as well as more appropriate clinical decision-making and an 
improvement in the quality of care, and also improving clinical performance 
and very often patient outcomes (Galanter et al., 2008, Sintchenko et al.,
2007). CDSS offer a method of implementing a broad range of evidence 
based guidelines so that patients receive the best care available (Sucher et 
al., 2008). One study showed that a CDSS could successfully be used to 
adapt national clinical guidelines to local needs in an outpatient setting (Steele 
et al., 2005). However, to develop more effective CDSSs there is a need to 
develop more high quality useful clinical research evidence that is easily 
accessible and machine interpretable (Sim et al., 2001). Evidence at the point 
of care can lead to positive outcomes in the use of evidence and for teaching 
and learning (Christakis et al., 2001, Ghali et al., 2000, Sackett and Straus, 
1998).
Evidence-based medicine has been promoted as a means of improving 
clinical outcomes. As CDSS have been recognised for their potential to 
reduce medical errors and improve healthcare quality and efficiency, using 
CDSS to facilitate evidence-based medicine could substantially improve 
healthcare quality (Sim et al, 2001). CDSS provide a powerful method of 
implementing a broad range of evidence-based guidelines (Sucher et al.,
2008). A study carried out in Hong Kong (Leung et al., 2003) showed that 
medical students given a CDSS improved their education experience of EBM. 
One review of CDSS found that they improved clinician performance in 40% 
of diagnostic systems, 76% of reminder systems, 62% of disease 
management systems and 66% of prescribing systems, although the 
improvement in patient outcomes was less than anticipated, particularly for 
chronic diseases (Garg et al., 2005).
One review looked at the use of CDSS in prescribing for older adults 
(Yourman et al., 2008) and found that CDSS generally had a positive effect, 
such as by lowering rates of prescribing inappropriate drugs and greater 
adherence to better drug choices or dosages, although the effect on patient 
outcomes was less clear. At the other end of the age spectrum, a review of
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CDSS for neo-natal care (Tan et al., 2005) found that there was only limited 
data from randomised clinical trials of CDSS on which to assess their effect in 
neo-natal care.
CDSS incorporated into computerised physician order entry systems have 
been shown to reduce medication errors and improve the quality and 
efficiency of medication use (Bates et al., 2001). They have also been shown 
to reduce the use of antimicrobials and improve prescribing of antimicrobials 
(Sintchenko et al., 2008, Samore et al., 2005, McGregor et al., 2006, 
Sintchenko et al., 2005, Thursky et al., 2006) demonstrating that CDSS can 
be a useful tool for the optimisation of antibiotic use and the improvement of 
patient care (Shebl et al., 2007, Sintchenko et al., 2008).
CDSS are also considered to be potentially useful for the Medicare program in 
the United States as a means of minimising inappropriate use and overuse of 
drugs, particularly for newly approved drugs (Clancy and Cronin, 2005).
An early review of CDSS showed that whilst some CDSSs had a positive 
effect on patient outcomes others had a lack of effect on patient outcomes 
(Johnston et al., 1994). However, the review authors state that this lack of 
effect could be because of inappropriate study design or failure to measure 
outcomes that would be responsive to the use of CDSSs. Another review 
(Kaplan, 2001) suggested that there was a lack of useful information for 
understanding why CDSSs were or were not effective and whether they 
affected patient outcomes. Kaplan’s (2001) review also suggested that many 
systems are often not used that much despite their benefits. A further review 
(Kawamoto et al., 2005) found four features of CDSSs that were associated 
with improved clinical practice: automatic provision of decision support as part 
of clinicians’ workflow; provision of a CDSS at the time and place of the 
decision-making; provision of a recommendation rather than an assessment; 
and the decision support system being computer based. The authors suggest 
that the common theme of these four features is that they make a CDSS 
easier for clinicians to use and that for a CDSS to be effective the effort
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required by a clinician to receive and act on the system’s recommendations 
should be minimal.
An article looking at CDSSs in electronic prescribing (Teich et al., 2005) 
identified four barriers to the adoption and effectiveness of CDSSs. These 
were limited functionality or usability problems; lack of data integration; 
uneven availability, standards and management of best-practice knowledge 
and costs of implementation and ongoing use. A survey of factors examining 
clinicians’ acceptance of CDSSs (Sittig et al., 2006) identified that patient 
characteristics were often associated with a decision to either accept or ignore 
CDSS features. For instance, clinicians were more likely to use CDSS 
support if the patient was elderly, had multiple medications or a chronic 
condition, but less likely to use it for acute patients. Clinicians were also less 
likely to accept alerts from a CDSS if they were behind schedule, although 
those who were behind schedule were also more likely to have less access to 
computers in their examining rooms. Another three barriers which were 
identified in the use of a CDSS as a computer-based prescription reminder 
(Agostini et al., 2008) were demands of reading the reminder, in the time it 
took to read it and having to view an additional screen whilst prescribing; the 
role of clinical experience, in that the CDSS was seen as possibly intrusive 
and eroding clinicians’ autonomy; and the information content of the CDSS, 
where some clinicians disagreed with the content of the CDSS. The literature 
shows, therefore, that different barriers have been identified to the 
implementation and adoption of CDSSs in clinical practice. Although 
Kawamoto’s (2005) review identified features associated with improvements 
in clinical practice through the use of CDSS, subsequent literature shows 
these may not be being put into practice or that there may be further factors 
involved that limit the uptake of CDSSs.
A pyramid of the ‘5S’ levels of organisation of evidence from healthcare 
research, puts ‘systems’, such as computer decision support systems, at the 
top of the pyramid as the most compiled source of evidence available to 
clinicians (Haynes, 2006). This, suggests Haynes (2006), means that 
clinicians searching for evidence to guide their clinical decisions can use
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CDSS as a system integrated with electronic medical records which links the 
patient’s characteristics with evidence-based guidelines, meaning that they 
need look no further for the best evidence than using the CDSS. CDSSs that 
give patient-specific recommendations in such a way that clinicians save time 
have been shown to be effective and sustainable tools for changing clinicians’ 
behaviour (Payne, 2000). If CCDSs are designed to implement and refine 
evidence-based protocols they can provide standardized decision-making that 
will decrease variability, test interventions and validate whether quality of care 
has been improved (Sucher et al., 2008). It has also been suggested 
(Chaudhry, 2008) that a greater understanding is needed of the complex 
dynamics underlying system adoption and that future research should focus 
on the effectiveness of adopted systems.
CONCLUDING REMARKS
This critical review of the literature has shown that traditionally in medicine 
decision-making was intuitive and based on the paternalistic model where the 
clinician made the decision and the patient was told what treatment they 
would receive. Intuitive decision-making has been shown to often be lacking 
in evidence, incorporating too much uncertainty and with too much potential 
for bias, particularly from the use of heuristics.
Evidence-based medicine has been in common use since it was popularised 
around 1992. However, it has not always been as widely used as it could be, 
due to various barriers to implementation, either real or perceived. This is 
despite the fact that it provides a sounder method for making medical 
decisions than intuition or pure personal experience.
Decision analysis has been shown to be a way of implementing evidence- 
based medicine, which, as an approach based on rationality, excludes 
intuitive decision-making and the bias that goes with it, but which also 
incorporates human values and provides a means of implementing evidence 
into everyday clinical practice. The use of decision aids has also been shown
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to be an effective method of incorporating shared decision-making, particularly 
as many decision aids are developed solely for patients’ use.
In recent years CDSSs have become more widely available and more widely 
used in medicine and have shown themselves to be useful tools for 
implementing evidence-based medicine and incorporating an element of 
shared decision-making, whilst also reducing the amount of time practitioners 
need to spend on searching for and evaluating evidence.
This review has shown that evidence-based medicine and decision analysis 
are the way forward for medical decision-making and that CDSSs are a useful 
means of implementing the two together. There is a need for more CDSSs to 
be developed using decision analysis in order for a broader range of areas 
within medicine to have such useful tools. New CDSSs will need to be quick 
to use, provide comprehensive functionality and implementation of evidence- 
based medicine. Therefore, the subject of this thesis will incorporate the 
development of a new CDSS using decision analysis.
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STUDY AIMS AND OBJECTIVES
The overall aim of this research was to develop a model and electronic 
decision aid (CDSS) to help practitioners choose the most effective drug 
treatments for a particular medical condition.
Objectives:
• To develop a model using a form of decision analysis called ‘Multi­
criteria decision analysis’ to be applied to Parkinson’s disease
• To develop a computer system to implement the model’s functions
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CHAPTER 2
Study Rationale and Methodological Framework
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“Make decisions from the heart and use your head to make it work out.”
Sir Girad
STUDY RATIONALE
Decision making, states (Coiera, 2003), is rarely a clear cut affair. Decisions 
do not just concern evidence, logic and probability, but also the goals, values 
and available resources of the people making them. Decisions are nearly 
always compromised by uncertainty and by people’s in-built cognitive biases. 
Yet medical practitioners are expected to make complex and often difficult 
decisions on patients’ treatment options with the aim of maximising the benefit 
to the patient whilst minimising the risks. In times of financial restraints and 
the constraint of guidelines and policies at both local and national levels, 
choosing the most effective treatment for a patient is not always a 
straightforward affair. Practitioners face an overwhelming volume of 
information from clinical trials and new research articles. As the review in 
chapter one showed, medical decision making has moved from its traditional 
position of using intuition and personal experience to the use of evidence- 
based medicine. Decision aids, and in more recent years CDSSs, have been 
shown to help incorporate evidence-based medicine into daily clinical practice.
METHODOLOGICAL FRAMEWORK
The Need For Decision Analysis
Coiera (2003) describes the process of decision making as firstly, identifying 
the problem, defining it, determining whether it needs to be solved and its 
relevant importance, as this process determines what the next steps are. 
Secondly, the alternative solutions need to be considered, by creating a list of 
alternatives to be selected from. The final step is to actually make the 
decision. The list of competing solutions is examined, supported by their 
evidence, and the most appropriate one is chosen.
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Scientific evidence on clinical practice and cost-effectiveness is increasingly 
being used by health care purchasers as the criteria by which resources are 
allocated, with NHS trusts and GP practices being encouraged to adopt more 
cost-effective and clinically effective practices. Physicians, however, are 
constantly faced with complex, involved decision-making on patients’ 
treatment. They are currently encouraged to make their decisions on the 
basis of evidence-based medicine, yet with the volume of information that 
must be assimilated and processed, making such decisions is not easy and 
there is little available to aid practitioners in their decision-making. Cost- 
effectiveness issues are also becoming of paramount importance in health 
care today, with NHS Trusts and GP practices having to justify their use of 
drug treatments. Alongside this, involvement of the patients themselves, and 
the patient’s subjective interpretation of their condition, for example through 
health-related quality of life (HRQoL) assessment, in the decision-making 
process is ever more a consideration for practitioners. Using decision 
analysis to aid decision-makers with their clinical treatments means that the 
complexity and volume of information are removed, leaving the practitioner 
with clearer guidance on the suitability and relevance of individual treatments 
and more time for the patient.
Decision Analysis Models
A model is created as part of decision analysis to define the predicted health 
outcomes that are associated with each option being considered. This means 
that modelling allows issues to be fully explored rather than automated 
decisions being made (Waller et al, 2003). The process of developing a 
model begins with the creation or design of the model followed by the 
construction or instantiation of the model, where the model is used as a 
template to build an artefact that is an instance of the model in the physical 
world. Before a model can be used it is necessary to be clear about what has 
been modelled, as the circumstances at the time the model is developed can 
influence the final value of the model. The model needs to be designed with 
the environment in which it will be used in mind (Coiera, 2003).
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The advantages of modelling include increased transparency, explicit 
reasoning, limitations on evidence and uncertainty clearly identified, 
assessment of the impact of all assumptions and better justified decisions. 
The disadvantages include the time taken for the modelling, additional 
resources and expertise and the possibility of the model itself becoming the 
focus of debate (Waller et al, 2003).
Among the types of model one may use for decision analysis are Markov 
models, decision trees, Bayesian networks, Artificial Neural Networks and 
Multi-Criteria Decision Analysis (MCDA). Each of these will be looked at in 
turn and a more detailed analysis will be given of MCDA.
Markov models
A Markov model consists of a finite number of health states which are defined 
by the disease severity. The progression of the disease is represented by 
patients progressing from one health state to another. The time horizon of the 
model is divided into Markov cycles, which are equal increments of time. The 
length of each cycle is a time interval that is clinically meaningful for the 
disease and represents the time that a patient spends in one health state 
before progressing to the next (Kamal et al., 2006). In each cycle it is 
assumed that a patient transfers from one health state to another and the net 
probability of making a transition is called the transition probability. The model 
can be evaluated by using a first-order Monte Carlo simulation or by using a 
cohort design. Markov models can be used to model stochastic processes 
which evolve over time and can therefore be useful for modelling chronic 
diseases.
Decision trees
A decision tree is a simple structure used to represent possible treatment and 
progression pathways. It starts with a treatment decision then branches out to 
look at all the potential health outcomes and costs that can arise from a 
decision between two alternative treatments. The pathways can be modelled 
using probabilities of events and relevant outcomes measures such as costs 
and effectiveness measures. The advantage of using decision trees is that
36
missing or incomplete data can be easily identified and can be replaced by 
expert opinion or assumptions. The effect of this data can then be tested 
using sensitivity analysis (Kamal et al., 2006).
Bayesian networks
A Bayesian network, a type of expert system, is a probabilistic model that 
consists of a dependency structure and local probability models. The 
dependency structure specifies how the variables relate to each other, with 
each variable depending on a possibly empty set of other variables called the 
parents (Gevaert et al., 2006). The variables are visualised in a graph, with 
each attribute being visualised by a node and a direct dependency by an arc. 
The local probability model specifies how the variables depend on their 
parents.
Artificial neural networks (ANN)
Artificial neural networks, another expert system, are an interconnected group 
of artificial neurons inspired by the way biological nervous systems process 
information(www.doc.ic.ac.uk/~nd/surprise_96/journal/vol14/cs11/report.html). 
ANNs are able to adapt their structure based on internal or external 
information flowing through the network and thus learn a new process by 
example. They can model complex relationships between inputs and outputs 
and learn to find patterns in data and model these. A trained neural network 
is considered to be an ‘expert’ in the category of information it is analysing. It 
can therefore provide projections for new situations or answer ‘what if 
questions.
Other advantages of an ANN are that it can learn how to do tasks based on 
training or experience, can create its own organisation or representation of 
information and it can carry out parallel computations.
As neural networks cannot be programmed to perform a task a disadvantage 
can be that unless examples are carefully selected for them to learn from 
useful time may be wasted or the network might not function correctly. ANNs 
can be unpredictable as they work out how to solve a problem themselves.
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Multi-criteria decision analysis (MCDA)
MCDA is a way of breaking complex problems into manageable pieces, 
allowing data and judgement to bear on them, then reassembling them to 
present an overall picture of the problem. It can be used either retrospectively 
to evaluate things which have already had resources allocated to them, or 
prospectively to evaluate things which are proposed. The main role of such a 
technique is to enable decision-makers to be able to handle large volumes of 
complex information in a consistent way (Department of Transport, 2000).
Development of the model involves seven stages:
1. The context needs to be established; the aims of the MCDA, the decision 
makers and other key players are established.
2. The options are next identified.
3. The objectives and criteria then need to be established and the objectives 
organised as a value tree by clustering them under higher-level and lower- 
level objectives.
4. The options are each scored from 0 to 100. Each option’s performance 
against the criteria is assessed as well as the value associated with the 
consequences of the option for each criterion (Department of Transport, 
2000). The consequences of the options are described and the options then 
scored.
5. Weights are then assigned to the criteria as a reflection of their importance 
to the decision problem.
6. The weight and score of each option is then derived as an overall value; the 
weighted scores are calculated at each level of the hierarchy and the overall 
weighted scores then calculated.
7. The final step is to carry out a sensitivity analysis, by considering whether 
other preferences or weights affect the ordering of the options, looking at the 
advantages and disadvantages of selected options and comparing pairs of 
options and creating possible new options that could be better than the 
original. These three steps are repeated until a ‘requisite’ model has been 
obtained.
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There are many different procedures in MCDA which will each be examined 
here in turn.
Analytical Hierarchy Process (AHP)
The AHP is a linear additive model which uses a procedure to make pair-wise 
comparisons between criteria and options in order to derive weights and 
scores. The decision-maker makes a pair-wise comparison by assessing how 
important one criterion is against another, which is generally a straightforward 
and convenient process. Some doubts have been raised about the theoretical 
basis of AHP (Department of Transport, 2000).
Outranking
Outranking may be used as a methodology to eliminate ‘dominated’ 
alternatives. Weights are used to give more influence to some criteria than 
others. One option outperforms another if it outranks it on enough important 
criteria and is not outperformed by the other option. The options are then 
assessed on how they outrank all of the options being considered, by 
measuring them against a pair of threshold parameters. Two options can be 
considered either incomparable or difficult to compare. This methodology has 
shown some cause for concern in respect of its dependence on arbitrary 
definitions of what constitutes outranking and how the threshold parameters 
are set and manipulated by the decision-maker. However, it can be effective 
in exploring how preferences between options are formed (Department of 
Transport, 2000).
Multi attribute utility theory (MAUT)
This is the methodology which is considered to have the widest acceptance 
and was developed by Keeney and Raiffa in 1976. There are three building 
blocks to this methodology; the performance matrix, the procedures that 
determine whether criteria are independent of each other or not and the ways 
that estimate parameters in a mathematical formulation to allow a single 
number index to be estimated to represent the decision-maker’s valuation of 
an option by the value of its performance on each criterion (Department of 
Transport, 2000). This is a relatively complex procedure which takes
39
uncertainty formally into account and builds it into decision support models, 
allowing attributes to interact with each other. It does not assume, however, 
mutual independence of preferences.
Fuzzy sets
Fuzzy sets were developed from the idea that language used in discussing 
issues is imprecise, such as ‘rather attractive’ or ‘fairly expensive’. Fuzzy 
arithmetic captures these elements using membership function, so that an 
option would belong to a set of say ‘attractive’ options with a degree of 
membership between 0 and 1. Fuzzy models then use weights, often 
represented as fuzzy quantities, to aggregate fuzzy performance levels. Such 
a method can be difficult to understand, has no clear theoretical foundation for 
modelling decision-maker’s preferences and no clear advantages over other 
models that have been established (Department of Transport, 2000).
Linear Additive Models
This particular type of model is applicable where it has been established that 
criteria are preferentially independent of each other and uncertainty is not built 
into the model. The values of an option on the criteria can be combined into 
one value. The score on the value of each of the criteria are then multiplied 
by a criterion’s weight and the weighted scores are added together. This 
methodology has a well-established record for providing robust and effective 
support for decision-makers (Department of Transport, 2000).
Key features of MCDA
• It establishes preferences between the options by referring to an 
identified set of objectives and establishes measurable criteria to 
assess the extent to which the objectives have been achieved;
• It enables the data on individual criteria to be aggregated to provide an 
indicator of the overall performance of options;
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• It emphasises the judgement of the decision-making team to establish 
objectives and criteria, estimate the weights and judge the contribution 
of each option,
• It brings a degree of structure, analysis and openness to classes of 
decision (Belton and Stewart, 2002).
Advantages of MCDA
• It is open and explicit;
• The objectives and criteria are open to analysis and will be changed if 
they are considered inappropriate;
• The scores and weights are explicit, if they are used and developed 
according to established techniques, and they can be cross-referenced 
and amended if necessary;
• Performance management can be sub-contracted, if required, so it 
does not have to be left to the decision making body;
• It can provide a means of communication within the decision-making 
body itself and also between the decision-making body and the wider 
community;
• It provides an audit trail (Belton and Stewart, 2002),
• Criteria can be both financial and non-financial; therefore drug costings 
can be taken into account, as well as issues such as HRQoL.
Use of MCDA in practice
MCDA is well established and frequently used as a modelling technique in 
various fields, particularly in areas such as environmental management and 
operational research. For example, MCDA was used to support decisions on 
land use around chemical sites (Papazoglou et al., 2000), where the decision 
is complex due to the range of criteria that need to be considered such as 
economics, public health, environment etc. Similarly, MCDA was used to 
create a tool for people to assess the many available technologies for spent 
oil regeneration and select their preferred option (Khelifi et al., 2006).
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In the last few years, MCDA has also started to be used as a modelling 
technique in medicine in a small number of cases. For example, MCDA was 
used to create a decision analysis tool to choose the most effective triptan in 
the treatment of migraine (Ferrari et al., 2005); an algorithm was developed 
for the optimal management of pharyngitis using MCDA (Singh et al., 2006) 
and MCDA was also used to evaluate the importance of treatment 
characteristics and the performance of different treatment approaches for 
people with tetraplegia (Hummel et al., 2005).
Application Of The Model
The model will need to be applied to a disease or condition and it was decided 
that it would be applied to Parkinson’s disease (PD). The characteristics of 
the disease will be briefly discussed and the justification for applying the 
model to this disease elaborated on here.
Parkinson’s disease
Parkinson’s disease is a chronic, progressive neurodegenerative disease 
characterised by bradykinesia, tremor and rigidity (Saami et al., 2004). Other 
motor and non-motor symptoms may also be present. Currently, symptomatic 
treatments of the disease are the only effective treatments offered. These 
include pharmacotherapy, such as the gold-standard levodopa, or dopamine 
agonists such as ropinirole, as well as surgical treatments such as deep-brain 
stimulation (Thobois et al., 2005).
Advanced stage PD patients tend to present with complications of the disease 
which are generally classified as motor abnormalities and behavioural 
disorders. Chronic levodopa therapy can lead to motor response 
complications, with motor fluctuations appearing in relation to the timing of 
levodopa dosage, known as wearing-off phenomenon. Responses to 
levodopa can also manifest as the “on-off’ phenomenon, shifting between an 
under-treated state to an over-treated state (Waters, 2002). Advanced PD 
patients may also suffer from symptoms not present in the early stages of the 
disease such as freezing spells, falls and neuro-psychiatric problems, with 
advanced-stage treatment problems advancing as the disease progresses.
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The complications of PD mean that treating the disease effectively is a 
constant challenge for practitioners, from the decisions in the early stages of 
the disease of which drug to use and when, to the problems in the later stages 
of the disease of managing the complications resulting from long-term drug 
therapy (Stocchi, 2003).
The difficulties of treating PD mean that a decision analysis tool could aid 
practitioners in their decision making. A decision tool does not make the 
decision for the practitioner, but aids them in their decision-making. By 
implementing guidelines, such as the NICE guidelines and research evidence 
from trials into the model it will be possible to incorporate evidence-based 
medicine in the tool, enabling practitioners to apply the theory. Use of a 
model such as this would also ensure that current NHS policies and 
guidelines, such as the National Service Framework (NSF) for Older People, 
the NSF for long-term conditions and the NICE guidelines would be adhered 
to, as would be applicable for a disease such as PD. This could be 
particularly useful for practitioners with little or no experience of treating such 
a complicated condition as PD.
Computer Decision Support Systems
Having a model to aid in decision-making is not enough on its own however. 
By implementing a model in a computer decision support system (CDSS) 
practitioners will be able to apply the model quickly and effectively in clinical 
practice. CDSS have been defined as knowledge systems using two or more 
items of patient data to generate case-specific advice. The key components 
of CDSS are medical knowledge, patient data and specific design (Kotze and 
Brdaroska, 2004).
Electronic access to the model means it could be applied through a web 
connected desktop PC, a laptop or a hand-held computer such as a personal 
digital assistant (PDA) for example. A decision support system being 
computer-based is considered to be one of the main features of a system’s 
ability to improve clinical practice (Kawamoto, 2005).
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Development of CDSS
CDSSs began to be developed from the 1950s, although it was not until the 
1970s that research in this area began to really take form, along with the 
implementation of medical diagnostic systems (Kotze and Brdaroska, 2004). 
CDSSs were developed to improve healthcare quality by providing accurate 
and timely diagnostic information to clinicians. Systems can be programmed 
to provide a range of patient-centred actions such as management plans, 
reminders, prompts and record-keeping (Kotze and Brdaroska, 2004).
Advantages of CDSS
They have been shown to be very helpful to medical practitioners (Achour et 
al., 2001). Coiera (2003) suggests the benefits fall into three broad 
categories. Firstly, that they improve patient safety, by reducing medication 
errors and adverse events and also improve medication and test ordering. 
Secondly, they improve the quality of care, by increasing clinicians’ time for 
patient care, increasing the application of clinical guidelines and pathways, 
facilitate the use of up-to-date clinical evidence and improve clinical 
documentation and patient satisfaction. Lastly, they improve the efficiency of 
health care delivery, by reducing costs through faster order processing, 
reduce test duplication, decrease adverse events and change patterns of drug 
prescribing by favouring cheaper generic brands.
OUTLINE OF THE CHAPTERS
Chapter three will look at establishing the decision context for the decision 
problem, establishing the options available and developing the criteria. In 
order to establish what criteria practitioners use to decide on treatments a 
survey will be developed and sent to practitioners in the field of PD. These 
will include geriatricians, neurologists and Parkinson’s disease nurse 
specialists. The results of the practitioner survey will be entered into the 
spreadsheet package Excel and the statistical package SPSS for frequency 
analysis. From the survey responses that are received a list of all criteria 
mentioned by practitioners will be compiled and this will be sent as a second 
survey to the same practitioners to elicit which of the listed criteria are used.
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The data from this survey will again be entered into Excel and to SPSS for 
frequency analysis. A list of eight considerations will then be applied to all the 
criteria from the second survey in order to establish which of the criteria are 
feasible to be used in the model. Finally, the remaining list of criteria will be 
divided into ‘risk’ and ‘benefit’ criteria and a decision tree developed.
Once the criteria have been established, the model will then be developed. 
This will be discussed in chapter four where the options will need to be scored 
and weights developed for the criteria. Data will be collected on all the 
available options using Phase III clinical trial data and measurement scales 
will be developed for the scoring on each of the options, with ‘least’ and ‘most’ 
preferred scales developed for each of the criteria scores. The options will be 
scored on a scale from 0 to 100 against the criteria, with each option being 
allocated a number to produce a preference order on the alternatives. 
Weights will be calculated on the criteria. Importance weights will be assigned 
to the criteria, and the weights combined with the scores to find the overall 
value for each option.
Once developed, the model will then need to be implemented by developing a 
software system, in order to develop the model into a computer decision 
support system; this process will be described in chapter five. Chapter six will 
then describe the process of testing that the user’s data is in the correct 
format by incorporating data validation methods. The software will then need 
to be thoroughly tested to ensure that it performs the way that it is expected 
to, this too will be described in chapter six.
Chapter seven will look at validating the model and CDSS as a whole. This 
will involve an expert panel using the model and comparing the results it 
produces for certain patient scenarios against the choices they would have 
made themselves for the patients. They will also assess the CDSS for its 
ease and practicality of use. The final chapter will discuss the project as a 
whole and discuss future work.
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DATA PROCESSING AND ANALYSIS
Data processing will be exploratory, by means of a written survey to establish 
any protocol practitioners use, the criteria they use to decide on treatment and 
their views on whether they think an electronic decision aid would be useful. 
Data from the survey will be entered into SPSS and simple descriptive 
analysis will be carried out. A further survey will be sent to the same 
practitioner with a list of criteria from the first survey, asking them to select all 
the criteria from the list that they use. A survey will also be given to 
practitioners involved in the validation exercise of the model and CDSS to 
assess their views of both aspects of the project.
POTENTIAL BENEFITS OF THE STUDY
The intention of this study is to produce an aid for practitioners in the field of 
PD which helps them to choose the most effective drug treatment for 
Parkinson’s disease and encourages the use of evidence-based medicine. 
Producing such a decision aid could ensure equity of access to the most 
effective PD medications for all patients, where the decision aid is used in 
clinical practice.
It would make decisions simpler, rationalised and explicit, bringing particular 
benefits for new or less experienced practitioners, and those such as GPs 
who may not come into contact with many PD patients. This would also be 
beneficial for Parkinson’s disease nurse specialists who are new to 
prescribing Parkinson’s medications. It could also be used as a teaching aid 
in medical schools for newly qualified doctors or medical students.
Developing a CDSS would mean that the model could be used anywhere by 
anyone with access to a computer where the software had been installed. 
Such an electronic decision aid would be unique for the field of PD, where 
only paper-based algorithms have been developed so far. To date, none of 
the models which has been developed using MCDA has been incorporated 
into a CDSS. Therefore, this would also be a unique development with MCDA 
in the field of medicine by incorporating the model into a CDSS.
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SUMMARY
• This chapter has explored the rationale and methodology for the 
project.
• Decision analysis and the benefits of using it have been discussed.
• The basis of what a model is and the advantages of using them have 
been discussed and the different types of models have been 
discussed, with Multi-criteria decision analysis being discussed in more 
depth and detail. The different types of MCDA have also been 
discussed.
• The key features of MCDA and the benefits of using it have been 
discussed, as well as some applications of MCDA in medicine.
• An outline was given of Parkinson’s disease and the rationale for using 
this form of decision analysis with Parkinson’s disease was discussed.
• The background of CDSSs has been discussed, as well as the 
rationale for using them in clinical practice.
• An outline has been given of the chapters for the rest of this thesis and 
the potential benefits of the study discussed.
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CHAPTER 3
Development of the Decision Context and Criteria for 
a Prescribing Support System In Parkinson’s Disease
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INTRODUCTION
The process of developing a MCDA model consists of seven stages. The first 
of these is to establish the decision context. Once this is established one 
must then identify the options to be appraised. The third, and perhaps most 
important stage, is to establish the criteria. The options then need to be 
scored for their performance against the criteria and the criteria themselves 
weighted for their importance to the decision problem. The scores and 
weights are then combined as an overall value. The final stage is to carry out 
a sensitivity analysis of the model. Stages one to three will be discussed in 
this chapter, with the remaining stages covered in the following chapter.
DECISION CONTEXT
For this project the decision context quite simply was to select the most 
effective treatment for a patient with Parkinson’s disease.
THE OPTIONS
In terms of the options to be appraised, for Parkinson’s disease this consisted 
of six groups of drug treatments comprising a total of 19 different drugs. The 
drug groups consist of levodopa, dopamine agonists, catechol-o-methyl 
transferase (COMT) inhibitors, glutamate antagonists, monoamine oxidase 
type B (MAOB) inhibitors and anticholinergics (Table 3.1).
Levodopa is an amino-acid precursor of dopamine which replenishes depleted 
striatal dopamine. It is administered alongside a dopa-decarboxylase inhibitor 
(benserazide hydrochloride in co-beneldopa and carbidopa in co-careldopa) 
which reduces the peripheral conversion of levodopa to dopamine and limits 
levodopa side-effects. Effective brain-dopamine concentrations can then be 
achieved with lower doses of levodopa (www.bnf.org/bnf/bnf/54/129828.htm, 
www.thebnf.org).
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Dopamine agonists act directly on dopamine receptors and can be used alone 
or alongside levodopa (www.bnf.org/bnf/bnf/54/129827.htm). Apomorphine is 
administered by subcutaneous injection or continuous subcutaneous infusion, 
whilst rotigotine
Table 3.1 Parkinson’s disease medications
Drug group Drug name Brand name
Levodopa Co-Beneldopa Madopar
Co-Careldopa Sinemet
Levodopa/Carbidopa/
Entacapone
Stale vo
Duodopa Duodopa
Dopamine Agonists Apomorphine Apo-go
Bromocriptine Parlodel
Cabergoline Cabaser
Pergolide Celance
Pramipexole Mirapexin
Ropinirole Requip
Rotigotine Neupro
COMT Inhibitor Entacapone Comtess
Tolcapone Tasmar
Glutamate Antagonist Amantadine Symmetrel
MAOB Inhibitor Selegiline Eldepryl
Rasagiline Azilect
Anticholinergics Trihexyphenidyl Broflex
Orphenadrine Biorphen
Orphenadrine
Hydrochloride
Disipal
is administered as a 24 hour self-adhesive patch. All other dopamine agonists 
are administered orally.
COMT inhibitors prevent the peripheral breakdown of levodopa which allows 
more levodopa to reach the brain. They are used as an adjunct to co- 
beneldopa or co-careldopa (www.bnf.org/bnf/bnf/54/129830.htm).
The Glutamate antagonist amantadine is believed to enhance the release of 
dopamine and to delay its reuptake into synaptic vesicles. It may also exert 
anticholinergic activity. It can be administered alone or as combination 
therapy (www.alliancepharma.co.uk).
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MAOB breaks down dopamine in the brain, therefore the MAOB inhibitor 
selegiline works by blocking the MAOB. Selegiline is administered as an 
adjunct to levodopa. Rasagiline can be administered alone or in combination 
with other therapy and works by slowing the breakdown of dopamine in the 
brain (www.parkinsons.org.uk).
The anticholinergic drugs, or antimuscarinic drugs, work by reducing the 
effects of the central cholinergic excess which occurs because of a deficiency 
in dopamine
(www.bnf.org/bnf/bnf/56/2057.htm?q=%22anticholinergics%22#hit). These 
drugs are used for broader forms of parkinsonism, but are not now generally 
recommended for idiopathic Parkinson’s disease and were therefore excluded 
from this model.
THE CRITERIA
For the third stage of the process one needs to establish the criteria. This is 
the basis from which the rest of the model will be developed. In order to 
establish the criteria for the model, two surveys were sent to PD practitioners. 
The process for surveying the practitioners will now be discussed in detail.
Methods 
First survey
The first survey was sent to over 300 clinical practitioners working with PD 
patients in the UK. These included neurologists, geriatricians and Parkinson’s 
disease nurse specialists (PDNSs). Details of neurologists were obtained 
from the British Association of Neurologists website (www.theabn.org). 
Details of geriatricians could not be obtained directly, as no list of UK 
geriatricians was publicly available, so a geriatrician in Cardiff contacted all 
geriatricians across Wales through his own personal list of contacts. 
Unfortunately, details of geriatricians across other parts of the UK could not be 
obtained. Neurologists were contacted by means of a confidential postal 
survey and geriatricians by email. It was not possible to obtain a list of
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PDNSs to contact directly, so they were contacted by means of a short article 
published in their association newsletter with the survey attached. The nurses 
were then able to reply anonymously. Details of the types of practitioners the 
survey was sent to and their locations are outlined in Table 3.2.
Table 3.2 Type and location of practitioner the survey was sent to
Practitioner Number sent Location
Neurologists 304 Across the UK
Geriatricians 88 Wales
PDNSs Unknown Across the UK
The survey comprised of three questions (Figure 3.1). Practitioners were 
firstly asked whether they used a recognised algorithm, such as Olanow’s, 
any algorithm or treatment protocol of their own to decide on treatments, or 
whether their decisions were based on personal experience. The second 
question asked them to list the criteria they use to decide on treatments for 
PD patients. The final question asked whether they would consider using an 
electronic decision aid for their treatment decisions if one were developed. 
Two subsequent follow-ups were sent to elicit further responses. The PDNSs 
were not able to be sent a follow-up as they could not be contacted directly.
The responses were entered into an Excel spreadsheet, where the criteria 
were extracted and listed individually in a separate worksheet. From this 
worksheet it was possible to compile a complete list of all the criteria. The 
data were subsequently entered into SPSS and frequency analyses carried 
out.
Second survey
A second survey was sent to the same practitioners as previously, excluding 
those who were known to be retired or who had moved workplace and for 
whom there was no change of address. This consisted of the compiled list of 
criteria from the previous responses (Figure 3.2). Respondents were asked to 
tick the criteria which they would use in their treatment decision making and 
add any further criteria not listed. The results were again entered in an Excel 
spreadsheet as they were received and then entered into SPSS for analysis.
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Figure 3.1 First practitioner survey
DEVELOPMENT OF AN ELECTRONIC DECISION SUPPORT 
SYSTEM FOR PARKINSON’S DISEASE
1. Do you routinely use a protocol or algorithm for making decisions on 
drug treatment for PD, such as Olanow’s algorithm? If so, what sort of 
protocol / algorithm do you use? Please send a copy or reference.
2. Have you seen any PD patients in the last month? If so, did you use 
any of the following to decide which treatment to use:
Olanow’s algorithm:
Other algorithm -  please specify:
Personal experience:
Any other criteria -  please specify:
3. Whether or not you have seen any PD patients, what criteria would you 
consider appropriate for use in treatment decision making?
4. If an electronic treatment decision aid were to be developed, do you 
think you would use it?
Thank you for your time and help.
53
Figure 3.2 Second practitioner survey
Please tick all the criteria which you use when choosing a treatment for 
a patient with Parkinson’s disease. Please add any additional criteria.
Drug response
Drug interactions
Patient’s other current medication
Drug side effects
Adverse Drug Reactions
Drug contraindications
Is the medication of benefit?
Evidence of treatment efficacy
Cost-effectiveness of treatment
Literature and systematic reviews
Data from clinical trials
How the patient feels
The patient's choice
The nature of their deficits
Clinical guidelines
Hospital guidelines
NICE guidelines
Clinical appraisal / clinical state
PDMED/randomisation into trials
Functional assessment
Clinical assessment
Age
Life expectancy
Co-morbidities
ADLs
Severity of symptoms
Severity of disability
Stage of disease/H&Y score
American Association of Neurologists’ guidelines
Risks/benefits
Keep medication low
Patient’s occupation
Duration of disease
Predominant symptom
Type of symptom
Support/carer
Patient’s understanding of condition
Patient’s capacity to deal with simple/complex regimes
Neuro-psychiatric problems
Cognitive impairment
Mental state
Confusion
Hallucinations
MMSE score
Depression
Perceived disability
Motor fluctuations
Non-motor complications
Olanow's algorithm
HRQoL
Evidence
Nature of patient’s symptoms 
Underlying pathology 
Postural hypotension
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General recommendations - initially levodopa, stepwise introduction of other drugs
Dyskinesias
End of dose symptoms
Mobility
General health
Progression of symptoms
Avoid treatment until loss of function/patient request
Use dopamine agonists for as long as possible
Use amantadine / rasagiline in young patients
Age at onset
Functional impairment
Parkinson's Plus syndrome
Is the patient a wage earner?
Psychological response to diagnosis 
Social circumstances
Criteria considerations
In order to establish a set of criteria which are fully relevant to the decision 
problem, one needs to incorporate the following eight considerations (Belton 
and Stewart, 2002).
1. Value relevance. The decision maker needs to be clear that the concept 
links to their goals, so that the specified preferences relate directly to the 
concept. This ensures that the criteria relate to their values. For example, if 
size is a criterion for a decision problem of choosing a new car, how does one 
define the importance of size? It could mean that the car should be small or 
should be big, or that it is the size of the boot that is important. Thus, the 
decision maker needs to be clear how the value is relevant to their goal 
(Belton and Stewart, 2002).
2. Understandability. The decision makers should have a shared 
understanding of the concepts being used in the analysis, to provide 
constructive discussion and mutual learning, rather than confusion and conflict 
(Belton and Stewart, 2002). There should be no ambiguity and no loss of 
information when decision makers interpret the criteria (Keeney, 1992). For 
example, similarly to the previous example, one decision maker may 
understand size to mean the people carrying capacity of the car, whereas 
another may understand it to relate to the status of the car.
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3. Measurability. The performance of the alternatives against the criteria 
needs to be measured, and this must be done in a consistent way (Belton and 
Stewart, 2002). For example, it may be difficult to have a consistent and 
explicit measure of something such as a patient’s life expectancy.
4. Non-redundancy. A factor should not be measured by more than one 
criterion. A concept may have been considered under different headings 
during the initial development, but if both are included in the analysis it may 
lead to a concept being attributed greater importance than it warrants. 
Generally, similar criteria should be incorporated into one concept. On 
occasion there may be a need to have similar factors considered separately if 
those factors reflect different values in different contexts (Belton and Stewart, 
2002).
5. Judgemental independence. Criteria are considered to be judgementally 
independent if a criterion is not dependent on the level of another criterion. 
Judgemental dependence can be overcome by redefining criteria.
6. Balancing completeness and conciseness. A value tree should be 
complete, in that all the important aspects of the problem are captured, and 
also concise, in that the level of detail should be kept to a minimum (Keeney 
and Raiffa, 1976).
7. Operationality. Along with considering completeness and conciseness, one 
needs to ensure that the model is usable and that it does not place excessive 
demands on the decision makers. Thus, one needs to consider the context in 
which the model is being used in order to judge the usability (Belton and 
Stewart, 2002).
8. Simplicity versus complexity. Although the value tree is itself a simple 
representation of the essence of the problem, some representations will be 
simpler than others as a consequence of the amount of detail incorporated. 
The modeller should strive for the simplest value tree which captures the 
decision maker’s problem. However, sometimes in practice the initial
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representation may be more complex or detailed than is operationally 
desirable. It is through practical application of the model that this may become 
apparent, which should then lead to further refinement (Belton and Stewart, 
2002).
These eight considerations were applied to all the criteria from the second 
survey in order to establish whether the criteria were suitable for inclusion in 
the model.
RESULTS 
First Survey
A total of 153 practitioners responded to the first survey, including from the 
two follow-ups, giving a response rate of 43.9%. The results of the first survey 
showed that a staggering 93.5% of respondents used personal experience as 
the basis of their decision-making on choice of Parkinson’s treatments. Of the 
criteria listed, age (32.1%) was the most common, with other common criteria 
including co-morbidities, patient’s choice and neuro-psychiatric features. A 
total of 69 different criteria were established from the survey responses.
Second Survey
The second survey had a slightly lower response rate, with 135 (37.8%) 
responders, including the two follow-ups. This survey produced some 
interesting results. Respondents selected between 10 and 68 of the 69 
criteria, giving a wide-ranging variation in responses, although there was little 
difference between groups of respondents. The mean number selected was 
45 (range 10-68) overall, with the mean for the neurologists being 44 (range 
10-68) and 47 (range 26-65) for the geriatricians. Only one response was 
received from a PDNS. Twenty-two (31.8%) criteria were selected by over 
80% of respondents and eight (11.6%) by over 90%. The most selected 
criteria were ‘motor fluctuations’ (93.3%), ‘drug side-effects’ (93.3%) and 
‘cognitive impairment’ (92.6%). The least selected criteria were ‘health- 
related quality of life’ (7.4%), ‘American Association of Neurologists’
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guidelines’ (5.2%) and ‘Olanow’s algorithm’ (3.7%). All of the criteria were 
selected at least once.
Development Of The Criteria
Once the results of the survey were established, it was then necessary to 
apply the considerations mentioned before: value relevance; measurability; 
usability; operationality; redundancy; completeness and conciseness, 
simplicity versus complexity and judgemental independence. Table 3.3 shows 
the results from these considerations being applied to the criteria. The 
application of the considerations meant that the number of criteria that could 
be included in the model had been considerably reduced, from 69 to 17.
Risks And Benefits
After these considerations had been applied the remaining criteria were then 
divided into two categories: ‘benefit’ and ‘risk’. A criterion would fall into the 
‘risk’ category if it could be shown to either cause or worsen a symptom. For 
example, ‘motor fluctuations’ could be considered a ‘risk’ because a drug 
might either cause the symptom of ‘motor fluctuations’ or worsen the symptom 
if the patient was already suffering from it. Conversely, with ‘benefits’ a 
criterion may be considered a ‘benefit’ if a drug were to improve the symptom, 
for example a drug might improve the patient’s mobility, therefore ‘mobility’ 
would be considered a ‘benefit’. Of these 17, only 14 could clearly be divided 
and these are listed below:
Risks:
• Motor fluctuations
• Cognitive impairment
• Confusion
• Hallucinations
• Dyskinesias
• Postural hypotension
• Depression
• Drug contraindications
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• Drug interactions
• Adverse drug reactions
Benefits:
• Mobility
• Activities of daily living
• Cost-effectiveness
• Stage of disease (Hoehn &Yahr)
The criteria that fell under the ‘risk’ category were all considered to be 
potentially caused or worsened by PD treatments, with all the ‘benefit’ criteria 
being improved, with the exception of ‘cost-effectiveness’ which would equate 
to being a benefit if the drug were shown to be cost-effective.
The benefit and risk criteria can be organised into a value tree, so that the 
criteria are clustered in a hierarchical format, and the decision problem thus 
being represented clearly and simply. This was created with ‘benefit’ and 
‘risk’ being established as the first level criteria, with the five ‘benefit’ and ten 
‘risk’ criteria forming a second level of criteria clustered underneath their 
respective first level criteria. This is shown in Figure 3.3.
The remaining criteria were difficult to fit into either category, as they were 
considered to prompt questions to be asked of the clinician about their patient. 
These criteria are shown in Table 3.4 below with their respective questions.
It was decided then that the remaining criteria should form the basis of 
information gathering about the patient, with this information being used to 
inform the model in the way that the options would be included or excluded, or 
in the case of the criteria amended or excluded. For example, it would be 
necessary to know if the patient had previously had a poor response to a 
particular PD medication so that this could be excluded from the list of 
options. Likewise, it would be necessary to know the patient’s co-morbidities 
in order to identify whether any of the options would be contraindicated.
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Table 3.3 Considerations applied to criteria
Criterion Problem Consideration Reason
Motor fluctuations None
Drug side effects Same as 'Adverse drug reactions’ Redundancy Another criterion already measures this factor
Cognitive impairment None
Drug response (Information needed about individual 
patient)
Severity of symptoms Can be measured by UPDRS score Operationality If clinicians don’t regularly record UPDRS 
score could mean extra time needed to do so 
to be able to input data for this criterion
Confusion None
Drug contraindications None
Hallucinations None
Neuro-psychiatric problems General, covers hallucinations, 
confusion etc
Judgemental independence, 
redundancy
A general term that covers a number of 
individual criteria
Severity of disability Similar/same as H&Y Redundancy Another criterion already measures this factor
Dyskinesias None
Evidence of treatment efficacy Same as data from clinical trials Redundancy Another criterion already measures this factor
Age (Information needed about individual 
patient)
Is medication of benefit How measured? Measurability How can this criterion be measured? Needs to 
be measured the same way by all clinicians 
using model to ensure consistency
Postural Hypotension None
End of dose symptoms Incorporated under 'motor 
fluctuations’
Redundancy Another criterion already measures this factor
Clinical assessment General -  meaningless Understandability Need to ensure all users of model have same 
understanding of what this entails
Patient’s choice Difficult to incorporate Measurability
Co-morbidities (Information needed about individual 
patient)
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Table 3.3 Considerations applied to criteria (continued)
Criterion Problem Consideration Reason
Mental state Meaningless -  not defined Understandability, measurability Do all model users have the same 
understanding of what this means? Are all 
model users measuring this in the same way?
Data from clinical trials Forms part of evidence for scoring Redundancy Same as evidence that will be used to 
measure drugs against criteria
Predominant symptom How can define how they affect 
treatment?
Measurability Cannot be measured
Drug interactions None
Nature of deficits What does this mean? Understandability Do model users have the same understanding 
of what this means?
Patients’ other medication Same as drug contraindications Redundancy Another criterion already measures this factor
Risks/benefits General overview of s/e, 
contraindications, drug response etc
Redundancy Another criterion already measures this factor
Mobility None
Non-motor complications Sum of other criteria- neuro­
psychiatric etc
Redundancy Another criterion already measures this factor
How patient feels Same as patient’s choice Redundancy Another criterion already measures this factor
Adverse drug reactions None
Literature/systematic reviews Same as evidence/clinical trials Redundancy Another criterion already measures this factor
Patient’s capacity to deal with 
simple/complex regimes
How measured? Connected with 
cognitive impairment?
Measurability Do all model users measure this in the same 
way? How is it defined?
Functional impairment Generalised -  what does it mean 
specifically?
Measurability/Understandability How would this be measured? Do all model 
users have the same understanding of what 
this means?
Parkinson’s plus syndrome Type of parkinsonism, not idiopathic 
PD
Redundancy
Type of symptoms How can define how they affect 
treatment?
Measurability Cannot be measured
Depression None
Nature of patient’s symptoms Generalised -  meaning? Understandability Do all model users have the same 
understanding of what this means?
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Table 3.3 Considerations applied to criteria (continued)
Criterion Problem Consideration Reason
Age at onset Might not be known, different to age? Redundancy, judgemental 
independence to age, 
measurability
Could be considered redundant if same as 
patient’s age. Is it judgementally independent 
of ‘age’ if it is the same as their age? Can this 
be measured, as their age at onset may not 
be known?
Progression of symptoms How measured? Eg if H&Y score got 
worse, but is there evidence on how 
this is affected by drugs?
Measurability Difficult to measure precisely. Could use H&Y 
score, but if this not recorded at previous 
stage would not know difference at current 
stage. Is there enough evidence on how 
progression affected by drugs?
General health How defined? Understandability/measurability Do all model users have same definition of 
what this is? How is it measured?
Life expectancy How measured? Evidence that this 
impacts on anything?
Measurability How is this measured? Is there evidence it 
should affect their treatment?
Clinical appraisal Meaning? Definition? Generalised Understandability/redundancy Do all model users have the same 
understanding of what this entails? 
Redundant because covers several individual 
criteria
Functional assessment Similar to above, generalised Understandability, redundancy Do all model users have the same 
understanding of what this entails? 
Redundant because covers several individual 
criteria
Keep medication low Irrelevant to model Redundancy
Patient’s occupation Difficult to define effect for purposes 
of model?
Measurability How can the effect of this be measured?
Avoid treatment until loss of function Irrelevant to model Redundancy
Activities of Daily Living None
Use dopamine agonists as long as 
possible
Cannot be defined Measurability How do you define as long as possible?
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Table 3.3 Considerations applied to criteria (continued)
Criterion Problem Consideration Reason
Clinical guidelines Depend on individual 
trusts/hospitals/Drs? Whose 
guidelines?
Value
relevance/understandability
Measurability
Do users have same goal if depends who sets 
clinical guidelines? Do all users understand 
the same thing from guidelines? Can the 
guidelines be measured?
Perceived disability Meaning? How defined? Measurability, understandability How can this be measured? Do all users have 
same interpretation of what it means?
Cost-effectiveness of treatment None
Stage disease/H&Y None
Underlying pathology Relevance/meaning? Understandability Do all users have same understanding of how 
it affects model/patient?
Duration of disease Doesn’t tell us about individual 
patients -  one patient could be much 
more advanced after 5 years than 
another
Measurability Can’t tell how patient affected by this
Evidence Will already be incorporated into 
model
Redundancy Another criterion already measures this factor
NICE guidelines Incorporated into evidence? Redundancy Becomes redundant because already part of 
evidence
MMSE score Definition of whether cognitive 
impairment or not
Redundancy Another criterion already measures this factor
Social circumstances Same/similar to "support/carer” Redundancy Another criterion already measures this factor
Support/carer Cannot tell how this affects treatment Measurability Difficult to measure this
Patient’s understanding of condition How measured? Measurability Difficult to measure this
Psychological response to diagnosis How measured? Measurability Difficult to measure this
Is patient wage earner? Cannot tell how this affects treatment Measurability Difficult to measure this
General recommendations What does this mean? Who from? Understandability, measurability
Hospital guidelines Cannot be incorporated into model 
because would have individual model 
for each hospital
Measurability/ Value relevance
PDMED/trials Would /could the model be used for 
these patients? Just used to choose 
a drug within a group?
Redundancy
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Table 3.3 Considerations applied to criteria (continued)
Criterion Problem Consideration Reason
Use amantadine/rasagiline in young 
patients
Can this be included? How would it 
be defined?
Measurability/understandability
HRQoL How measure? Which scale? Time Measurability
AAN guidelines Wouldn’t be applicable to 
geriatricians
Value relevance
Olanow’s algorithm Could not be incorporated into model Redundancy
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Figure 3.3 ‘Benefit’ / ‘Risk’ value tree
Cost-effectiveness
Improves mobility
Improves ADL
Stage of disease / Hoehn 
&  Yahr
Depression 
Confusion 
Dyskinesias 
Hallucinations 
Cognitive impairment 
Postural hypotension 
Motor fluctuations 
Drug contraindications 
Drug interactions 
Adverse drug reactions
Table 3.4 Criteria with questions
Criterion Question
Age How old is the patient?
Previous drug response What PD medications has the patient had 
previous poor response to?
Co-morbidities What co-morbidities does the patient have?
Finally, it would also be necessary to establish what non-PD medication the 
patient was currently taking, in order to know any interactions that might occur 
with whichever PD medication was to be prescribed. Although this was not 
one of the criteria mentioned in the survey, it would be necessary information 
to be obtained.
Overall
Benefits
Risks
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DISCUSSION
In this chapter the first three stages of developing the model with MCDA were 
completed. The decision context was simple and straightforward to establish. 
The options were also straightforward to establish, as the available drug 
treatments for Parkinson’s disease were already well known and the three 
anticholinergic were straight away excluded from the model, as per current 
recommendations for treatment of PD.
Establishing the criteria was a lengthier and more complex process in terms of 
the detail involved. For the first practitioner survey that was carried out it was 
difficult to obtain details of many of the practitioners, which meant that it was 
not possible to contact people across the UK for all the practitioner groups. It 
was difficult to be sure how many PDNSs were contacted and what 
geographical areas they responded from. Also, the fact that only geriatricians 
in Wales were contacted meant that the survey results obtained may not have 
been representative of geriatricians across the UK. The results showed that a 
wide number of different criteria were being considered by practitioners, 
meaning that a huge volume of information must be considered and 
remembered in each consultation.
The conclusion we can draw from the results of the two surveys together is 
that there is no clear treatment protocol for Parkinson’s disease in the UK. In 
fact, treatment can vary not only from hospital to hospital, but from consultant 
to consultant within a hospital. We would therefore have to question whether 
practitioners are using evidence-based medicine in their clinical practice. The 
human short-term memory is considered to be capable of remembering seven 
plus or minus two items, but some of the consultants we surveyed were 
considering up to 68 criteria for their treatment decisions. This is an incredible 
volume of information to be considered, and one would have to question 
whether anyone is capable of considering so much information in medical 
decision making and whether in fact they are able to make the best decisions 
from such information. A clinical decision support system could therefore be 
a valuable tool for helping clinicians to consider large volumes of information
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and could improve the decisions that are made. A decision aid would also 
help to ensure that evidence-based medicine was being incorporated into 
decision making.
Applying the considerations to the original list of criteria meant that criteria 
which were redundant or meaningless and so forth were able to be eliminated, 
so that a rationalised list of criteria which were meaningful and coherent was 
established. However, it also means that the criteria which are included in the 
model can be clearly established as being pertinent and relevant for the 
model.
Dividing the criteria in to ‘risk’ and ‘benefit’ categories meant that the criteria 
could be clearly divided. Using a value tree also meant that the decision 
problem was presented more clearly. This process showed a few of the 
criteria (age, previous drug response and co-morbidities) did not fit clearly into 
the ‘risk’/’benefit’ division and needed to be dealt with in a different way. 
Formulating them as information gathering questions rather than standard 
criteria meant that the information about the patient could still be included 
providing additional information to inform the model. This extra information 
could also mean that the model would incorporate more individualised 
information about each patient, helping to provide a model that would be 
suitable for each unique patient. Ultimately, a finished list of 14 criteria was 
developed, with the three additional criteria being transformed into questions 
for data to be elicited about the patient. These criteria were then able to 
provide the basis for developing the rest of the model. This will be discussed 
in chapter four.
SUMMARY
In this chapter the first three of seven stages for developing the model were 
covered.
• The decision context was established.
• The options to be appraised were established.
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• The criteria were developed firstly by sending two surveys to 
practitioners, the first of which asked for all the criteria practitioners use 
to choose drug treatments for PD. The second of these used a 
compiled list of all criteria from the first survey to ascertain which 
criteria were used in practice.
• The results from the second survey were whittled down by applying the 
considerations value relevance; understandability; measurability; non­
redundancy; judgemental independence; completeness and 
conciseness; operationality, and simplicity versus complexity, to rule 
out unnecessary or impractical criteria.
• A list of 14 suitable criteria was established.
• Three remaining criteria were transformed into questions to be asked of 
patients to establish individual data.
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CHAPTER 4
Development of the Model using the Multi-Criteria 
Decision Analysis Technique
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INTRODUCTION
In the previous chapter the methodology for the development of the model 
using MCDA was outlined, the decision context defined, the options identified 
and the criteria were developed. In this chapter the process for the 
development of the rest of the model will be discussed. This involves four 
steps: scoring the options against the criteria; developing weights for the 
criteria in respect of their importance to the decision problem and combining 
the scores and weights as an overall value. The final stage in the 
development of a model is to carry out a sensitivity analysis. That stage will 
be discussed in chapter seven. The aim of this chapter, therefore, is to 
develop a model to choose the most effective drug treatment for PD based on 
the criteria previously devetoped.
METHODS
Developing The Scores
Once the criteria have been established the next stage in the development of 
a model using MCDA is to establish the scores for the options.
Scoring is carried out by deriving a value for each option on how it performs 
against the criteria. When criteria are structured as a value tree the 
alternatives are scored against the bottom-level criteria of the tree. The 
values are assessed on an interval scale where the importance of the score is 
based on the difference between points. Two reference points are defined 
and numerical values assigned to each. These are generally taken as the top 
and bottom of the scale, with scores of 100 and 0 being assigned respectively 
(Belton and Stewart, 2002).
Scales can be either ‘local’ or ‘global’. A ‘local’ scale refers to the set of 
options under consideration. The option which performs best on a given 
criterion is assigned a score of 100, and that which does least well is allocated 
a score of 0. The remaining options receive scores in between the two 
figures, reflecting their performance relative to each end of the scale. A ‘local’
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scale allows for a fairly speedy assessment of values and can be used for 
‘roughing out’ a problem, or where time constraints are tight (Belton and 
Stewart, 2002).
A ‘global’ scale, on the other hand, refers to a wider set of possibilities. The 
two extremes of the scale can be defined by the ideal and worst conceivable 
performance on a given criterion, or by the best and worst performance that 
could occur. A ‘global’ scale has the advantage over a ‘local’ scale of being 
more general and can be defined before the options have been considered 
(Belton and Stewart, 2002).
Collecting the data
The list of drug treatment options available for PD was outlined in chapter 
three. Data from Phase III pivotal trials was collected for all the drugs. 
Where the pivotal trial data could not be collected, for example with older 
drugs such as Madopar, literature searches were carried out using databases 
such as PubMed to find trials which contained the data that would provide 
information for all the criteria. The data was then examined for information 
relevant to the model criteria. For each drug a table was constructed listing all 
of the model criteria in one column and the variables that were used to 
establish the relevant information on each drug in the other columns 
(Appendix I). These consisted of the following:
• Comparator
• Stage of disease
• Primary/Secondary outcome measures
• Significance level
• How the drug performed.
Different approaches were used to calculate the scores for different criteria. 
For example, the majority of the criteria, such as ‘hallucinations’ and 
‘dyskinesia’ were relatively straightforward to score, based on the data that 
was obtained from trials and other publications. However, two criteria were an 
exception to this and proved to be more complex and needed a more detailed
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scoring methodology. These two were: adverse drug reactions and drug 
interactions. The methodologies for all the criteria will now be described in 
detail.
Defining the measurements
Firstly, a set of measurements for each of the criteria was defined. A global 
scoring scale was used, meaning that individual end points were defined on a 
basis of the best and worst possible cases. These were allocated scores of 
100 and 0, respectively. Each of the criteria needed to be examined 
individually and a point defined that best described the least and most 
preferred scores.
‘Risk’ criteria
Motor fluctuations
For ‘motor fluctuations’ it was known that many drugs caused or worsened 
motor fluctuations for Parkinson’s patients, so the best possible case that 
could be expected for a drug would be to improve the level of motor 
fluctuations. On the other hand, the worst case would be that a drug caused a 
high degree of worsening of motor fluctuations. The least and most preferred 
points for ‘motor fluctuations’ were therefore set as ‘high level of worsening of 
motor fluctuations’ and ‘improved level of motor fluctuations’ respectively. 
Most of the other ‘risk’ criteria followed in the same vein.
'Benefit' criteria
The ‘benefit’ criteria had to be treated slightly differently, however. For 
example, ‘stage of disease’ was likely to be demonstrated in the trials as 
either an improvement or no improvement, therefore, the scales were set as 
‘no improvement in stage of disease’ for the least preferred end and ‘improved 
stage of disease’ for the most preferred end.
Adverse drug reactions
Defining a scale of preference for ‘adverse drug reactions’ proved to be more 
complicated. There are several aspects to consider when looking at the 
occurrence of adverse drug reactions, namely the frequency of occurrence, 
the severity of the ADRs and the number of patients who withdrew from a trial
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because of ADRs directly related to the study drug. Therefore, it was decided 
that each of these points would need to be assessed, resulting in the least 
preferred end of the scale being defined as ‘high level of serious ADRs, high 
number of frequencies of ADRs and high number of withdrawals due to 
ADRs’. The most preferred point was defined as ‘incidence of adverse events 
is similar to placebo’. A full list of the least and most preferred definitions is 
shown in Table 4.1.
Developing the scoring scales
Once the measurements were established, the actual scoring scale was 
developed. This meant a scale from 0 to 100 was broken down into tenths 
and a definition allocated to each tenth. The majority of the criteria were 
scored from the same scale, as shown in Table 4.2, where 0 equated to the 
worst possible score and 100 to the best possible score. The midpoint was 
given a score of 50 which equated to a drug having no effect on the criterion, 
neither improving the condition, nor worsening it. Where there was no data 
for a particular drug on any criterion a score of 50 was also allocated, as it 
could not be known whether the drug would have a positive or negative effect. 
For the scores 10 to 40, which were deemed to have a negative effect, each 
tenth equated to a frequency of occurrence as an ADR, for example a 
common ADR scored 10. On the other hand, the scores 60 to 90, which were 
deemed to have a positive effect, were assessed by the degree to which they 
improved the condition, for example a small improvement equated to a score 
of 60, whereas a large improvement equated to a score of 80. The score 
definitions are shown in Table 4.3.
Motor fluctuations
One exception to the scoring scales discussed above was the criterion ‘motor 
fluctuations’. The results of analysing the data on ‘motor fluctuations’ showed 
that there were three main outcomes that were used consistently through the
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Table 4.1 Least and most preferred definitions for criteria scores
Criterion Least preferred Most preferred
Motor fluctuations High level o f worsening of 
motor fluctuations
Improves levels of motor 
fluctuations
Cognitive
impairment
High incidence of cognitive 
impairment as ADR
No incidence of cognitive 
impairment as ADR or 
effect similar to placebo
Confusion High incidence of confusion as 
ADR
No incidence of confusion 
as ADR or effect similar to 
placebo
Hallucinations High incidence of hallucinations 
or caused as ADR
No incidence of 
hallucinations as ADR or 
effect similar to placebo
Dyskinesias High incidence of dyskinesias or 
caused as ADR
No incidence o f dyskinesias 
as ADR or effect similar to 
placebo
Depression High incidence of depression or 
caused as ADR
No incidence o f depression 
as ADR or effect similar to 
placebo
Postural
Hypotension
High incidence of postural 
hypotension or caused as ADR
No incidence of postural 
hypotension or effect 
similar to placebo
Stage of disease No improvement in stage of 
disease
Improves stage o f disease
ADL No improvement in ADL Improves ADL
Adverse drug 
reactions
High level of serious adverse 
events, high number of 
frequencies, high number of 
withdrawals due to ADR
Incidence of adverse effects 
is similar to placebo
Drug interactions Unmanageable interactions with 
other drugs
No clinically significant 
interactions with other 
drugs
Contraindications High level o f serious 
contraindications
Incidence of
contraindications similar to 
placebo
trials, namely: the Unified Parkinson’s Disease Rating Scale (UPDRS) part III; 
the amount of time ‘on’ and the amount of time ‘off’. The UPDRS (Fahn et 
al., 1987) is a multi-dimensional assessment tool used to measure severity of 
disease, with part three measuring motor examination. Time ‘on’ describes 
the periods when the patient is receiving benefit from the anti-PD medication 
and time ‘off the converse. These three assessments (UPDRS III, time ‘on’ 
and time ‘off’) were therefore scored separately, following the methods 
discussed above, and a mean obtained from the three results which became
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Table 4.2 Definitions of scores scale
0 10 20 30 40 50 60 70 80 90 100
Worst
possible
score
Common 
A D R /  
very large 
worsening
Less
common
A D R /
large
worsening
Rare ADR  
/ medium 
worsening
Very rare 
A D R /  
small 
worsening
Lack of
effect/
no
change
Small
improvement
Medium
improvement
Large
improvement
Very large 
improvement
Best
possible
score
Table 4.3 Definition of scores
0 10 20 30 40 50 60 70 80 90 100
High
incidence
Common
ADR
Less
Common
ADR
Rare
ADR
Very
rare
ADR
‘No data
therefore
neither
improves
nor
worsens’ / 
‘no effect’
Small
improvement
Medium
improvement
Large
improvement
Very large 
improvement
No
incidence 
or effect 
similar to 
placebo
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the overall score. The definitions are shown in Table 4.4.
Adverse drug reactions
Further exceptions were the criteria ‘adverse drug reactions’ and ‘drug 
interactions’. ‘Adverse drug reactions’, similarly to ‘motor fluctuations’ was 
broken down into three categories and each category scored before the mean 
of the three was calculated. These categories were the frequency of 
occurrence of the ADR, the severity of the ADR and the number of patients 
withdrawn from a trial because of the ADR.
Frequency of occurrence
The frequency of occurrence of the ADR was broken down into a further five 
categories, determining whether the occurrence was ‘common’, ‘less 
common’, ‘rare’, ‘very rare’ or ‘also reported’ (Table 4.5). These data were 
taken from the British National Formulary (www.bnf.org, 2008). The drugs 
were scored on the basis of the number of ADRs they had in each category. 
Each grade of occurrence was scored on a different scale. It was decided 
that a form of weighting needed to be allocated to the grades to distinguish 
the importance of, for example, common against rare occurrences. Therefore, 
for common occurrences the worst score, i.e. a score of 0, was allocated to an 
occurrence of >30 different ADRs for any drug. A score of 100 was obtained if 
there were no occurrences of ADRs for a particular drug. The highest number 
of occurrences for less common frequencies was set at 40 for a score of 0, 
with the score increasing as the occurrences decreased. The categories ‘very 
rare’ and ‘also reported’ were allocated the same scores, both having the 
highest number of occurrences for the lowest score, with an occurrence of 60 
equalling a score of 0. Again, the mean was calculated from the five 
categories.
Severity of ADRs
To calculate the severity of the ADRs the trial data was examined for the 
number of serious ADRs that were reported. Many of the trials only reported 
that the ‘majority’ of the ADRs were mild or moderate or used terms such as 
‘overall’ or ‘mainly’. It was therefore decided to class all these general terms
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Table 4.4 Motor fluctuations score definitions
UPDRS
scores
0 10 20 30 40 50 60 70 80 90 100
>0 < -2 -5 -8 -10 -12 -14 -17 -20 -23 -25
Time ‘on’ 
scores
0 10 20 30 40 50 60 70 80 90 100
0 hours 2 hours 5 hours 8 hours 10 hours 12 hours 15 hours 17 hours 19 hours 22 hours 24 hours
Time ‘o ff  
scores
0 10 20 30 40 50 60 70 80 90 100
0 hours 2 hours 5 hours 8 hours 10 hours 12 hours 15 hours 17 hours 19 hours 22 hours 24 hours
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Table 4.5 ADR frequency score definitions
Common
0 10 20 30 40 50 60 70 80 90 100
>30 27 24 21 18 15 12 9 6 3 0
Less Common
0 10 20 30 40 50 60 70 80 90 100
>40 36 32 28 24 20 16 12 8 4 0
Rare
0 10 20 30 40 50 60 70 80 90 100
>50 45 40 35 30 25 20 15 10 5 0
Very rare
0 10 20 30 40 50 60 70 80 90 100
>60 54 48 42 36 30 24 18 12 6 0
Also reported
0 10 20 30 40 50 60 70 80 90 100
>60 54 48 42 36 30 24 18 12 6 0
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together and allocate the same score to them, rather than try to distinguish, 
perhaps pedantically, any differentiation between them. They were allocated 
a score of 75, as this was judged to be roughly between a midpoint of no 
effect and the highest possible score. The worst possible score was deemed 
to be 50% of all ADRs being serious, and the scores between 10 and 40 were 
divided into tenths between 40% and 10%. The ADR severity score 
definitions are shown in Table 4.6.
Withdrawals from trial
The withdrawals from trial were calculated with 0 relating to 0% withdrawals 
and 100 relating to 40% withdrawals, which was deemed to be a high figure. 
The midpoint of 50 related to 20%, with the points 10 to 40 and 60 to 90 filling 
in the percentages in between (Table 4.7).
Drug interactions
To determine the scores for the criterion ‘drug interactions’ a panel of experts 
was consulted. This panel consisted of ten doctors, neurologists, geriatricians 
and academics, who were all experienced practitioners with PD patients. A 
table was compiled (Table 4.8) listing all the interactions for each of the drugs. 
For each drug the interactions were grouped together according to their effect, 
for example a number of drugs all caused a hypotensive effect if taken with 
co-beneldopa, so these were listed together as one interaction. The expert 
panel were then asked to complete a column headed ‘Seriousness’, giving 
their opinion on whether the interactions were ‘most serious’ (MS), ‘very 
serious’ (VS), ‘fairly serious’ (FS) or ‘not serious’ (NS). When the responses 
were received a score was allocated to each category, with the least preferred 
category ‘most serious’ having a score of 0 and the most preferred category 
‘not serious’ having a score of 100. ‘Very serious’ and ‘fairly serious’ were 
given scores of 30 and 65 respectively as two roughly mid-points between 0 
and 100. The responses from the panel were totalled up as means for each 
category and the overall mean score calculated for each drug.
79
Table 4.6 ADR severity score definitions
0 10 20 30 40 50 60 70 75 80 90 100
Highest 
level of 
occurrence 
/ Highest 
number of 
patients 
=50% 
patients
40%
occurrence
30%
occurrence
20%
occurrence
10%
occurrence
No data
therefore
neither
improves
nor
worsens
‘overall’
‘ low
intensity’
‘generally’
‘mainly’
‘most’
No pts 
affected/ no 
occurrences
Table 4.7 ADR withdrawal score definitions
0 10 20 30 40 50 60 70 80 90 100
40% 
patients 
withdrawn 
from trial
36% 32% 28% 24% 20% / No 
data
available
16% 12% 8% 4% 0% / same 
as placebo
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Table 4.8 Interactions of all the PD drugs
Drug Interaction Seriousness:
Most serious 
(MS)/very serious 
(VS)/fairly serious 
(FS)/not serious 
(NS)
Co-beneldopa Enhanced hypotensive effect with ACE inhibitors, 
adrenergic neurone blockers, alpha-blockers, 
antiotensin-ll receptor antagonists, beta-blockers, 
calcium-channel blockers, clonidine, diazoxide, 
diuretics, hydralazine, methyldopa, minoxidil, 
nitrates, sodium nitroprusside
Amisulpiride
Absorption of levodopa possibly reduced by: 
antimuscarinics, oral iron, phenytoin;
Effects of levodopa antagonised by: antipsychotics, 
possibly benzodiazepines;
Agitation, confusion & hallucinations with baclofen
Increased risk side effects with buproprion, 
moclobemide
Risk hypertensive crisis with MAOIs
Enhanced effect and increased toxicity with 
selegiline (reduce dose levodopa)
Co-careldopa Enhanced hypotensive effect with ACE inhibitors, 
adrenergic neurone blockers, alpha-blockers, 
antiotensin-ll receptor antagonists, beta-blockers, 
calcium-channel blockers, clonidine, diazoxide, 
diuretics, hydralazine, methyldopa, minoxidil, 
nitrates, sodium nitroprusside
Amisulpiride
Absorption of levodopa possibly reduced by: 
antimuscarinics, oral iron, phenytoin;
Effects of levodopa antagonised by: antipsychotics, 
possibly benzodiazepines;
Agitation, confusion & hallucinations with baclofen
Increased risk side effects with buproprion, 
moclobemide
Risk hypertensive crisis with MAOIs
Enhanced effect and increased toxicity with 
selegiline (reduce dose levodopa)
Stalevo Enhanced hypotensive effect with ACE inhibitors, 
adrenergic neurone blockers, alpha-blockers, 
antiotensin-ll receptor antagonists, beta-blockers, 
calcium-channel blockers, clonidine, diazoxide, 
diuretics, hydralazine, methyldopa, minoxidil, 
nitrates, sodium nitroprusside
Amisulpiride
Absorption of levodopa possibly reduced by: 
antimuscarinics, oral iron, phenytoin;
Effects of levodopa antagonised by: antipsychotics, 
possibly benzodiazepines;
Agitation, confusion & hallucinations with baclofen
Increased risk side effects with buproprion, 
moclobemide
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Risk hypertensive crisis with MAOIs
Enhanced effect and increased toxicity with 
selegiline (reduce dose levodopa)
Duodopa Enhanced hypotensive effect with ACE inhibitors, 
adrenergic neurone blockers, alpha-blockers, 
antiotensin-ll receptor antagonists, beta-blockers, 
calcium-channel blockers, clonidine, diazoxide, 
diuretics, hydralazine, methyldopa, minoxidil, 
nitrates, sodium nitroprusside
Amisulpiride
Absorption of levodopa possibly reduced by: 
antimuscarinics, oral iron, phenytoin;
Effects of levodopa antagonised by: antipsychotics, 
possibly benzodiazepines;
Agitation, confusion & hallucinations with baclofen
Increased risk side effects with buproprion, 
moclobemide
Risk hypertensive crisis with MAOIs
Enhanced effect and increased toxicity with 
selegiline (reduce dose levodopa)
Ropinirole Avoid antipsychotics, metoclopramide
Metabolism inhibited by ciprofloxacin
Plasma concentration increased by oestrogens
Pramipexole Amantadine -  may slightly decrease the oral 
clearance of pramipexole
Cimetidine -  caused a 50% increase in pramipexole 
AUC and 40% increase in half-life
Drugs secreted by cationic transport system 
(cimetidine, ranitidine, diltiazem, triamterene, 
verapamil, quinidine & quinine)
Rotigotine Manufacturer of rotigotine advises avoid 
concomitant use of antipsychotics (antagonism of 
effect)
manufacturer of rotigotine advises avoid 
concomitant use of metoclopramide (antagonism of 
effect)
Pergolide effects of pergolide antagonised by anti-psychotics
Anti-parkinsonian effect of pergolide antagonised by 
metoclopramide
Bromocriptine Hypoprolactinaemic and antiparkinsonian effects of 
bromocriptine antagonised by antipsychotics
Hypoprolactinaemic effect of bromocriptine possibly 
antagonised by domperidone and metoclopramide
Plasma concentration of bromocriptine increased by 
erythromycin (increased risk of toxicity) and 
octreotide and possibly increased by macrolides 
(increased risk of toxicity),
Risk of toxicity when bromocriptine given with 
isometheptene and phenylpropanolamine
Cabergoline Hypoprolactinaemic and antiparkinsonian effects 
antagonised by antipsychotics
Hypoprolactinaemic effect of cabergoline 
antagonised by metoclopramide and possibly 
domperidone,
Plasma concentration of cabergoline increased by 
erythromycin (increased risk of toxicity) and possibly 
macrolides
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Apomorphine Effects of apomorphine antagonised by 
antipsychotics
Effects of apomorphine possibly enhanced by 
entacapone
Selegiline CNS toxicity: tricyclics
Risk serotonin syndrome: citalopram
Risk hypertensive crisis: dopamine
Increased risk hypertension and CNS excitation: 
fluoxetine, fluvoxamine, paroxetine, sertraline, 
venlafaxine
Enhanced effect and increased toxicity: levodopa
Enhanced hypotensive effect: MAOIs
Effects selegiline enhanced: Memantine
Avoid use: moclobemide
Plasma concentration increased: oestrogens, 
progesterone
Hyperpyrexia and CNS toxicity (avoid use): 
pethidine
Manufacturer advises caution: tramadol
Rasagiline Avoid dextromethorphan and sympathomimetics
Increased risk of CNS toxicity with antidepressants 
(SSRIs & Tricyclics)
Wait 2 weeks before using: fluoxetine, fluvoxamine, 
MAOIs, pethidine
Plasma concentration of rasagiline reduced by 
entacapone
Amantadine Increased risk of antimuscarinic side-effects when 
given with antimuscarinics
Increased risk of side-effects when given with 
bupropion
Increased risk of CNS toxicity when given with 
memantine (manufacturer of memantine advises 
avoid concomitant use)
Increased risk of extrapyramidal side-effects when 
given with methyldopa, metoclopramide, 
tetrabenazine, antipsychotics, domperidone
Entacapone Possibly enhances effects of: adrenaline, 
apomorphine, dobutamine, dopamine, methyldopa, 
noradrenaline
Manufacturer advises caution with: tricyclics, 
moclobemide, paroxetine, venlafaxine
Absorption of entacapone reduced by oral iron
Avoid use with non-selective MAOIs
Possibly reduces plasma concentration of rasagiline
Enhances anticoagulant effect of warfarin
Tol capone Avoid MAOIs
Contraindications
‘Contraindications’ proved to be a difficult criterion to try to score. Whilst 
definitions such as frequency or severity could be used to determine the 
scores, it was felt that neither of these definitions would be applicable. For
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example, although frequency of occurrence of a contraindication would give 
some idea of the effect this particular criterion would have on the PD drugs, 
this alone would not give a true picture of the impact. For instance, a higher 
number of minor contraindications should not necessarily receive a worse 
score than a low number of serious contraindications. However, if one took 
severity into account as well as frequency this would not give a true reflection 
of the impact of the drug either. For example, many of the drugs are 
contraindicated for pregnancy, which, whilst a serious contraindication is only 
relevant to the female half of the population, but also only a small proportion 
of female PD patients, as the age of PD patients is on average well above the 
age range for conception. Therefore, it was decided not to score 
‘contraindications’ as a criterion, but to show a list of all contraindications for 
the recommended drugs which the model chose.
Total scores
The mean score for each drug was calculated and the overall mean of all the 
drugs calculated to give an idea how each drug had performed before the 
weights were calculated.
Developing The Weights
In evaluating a decision problem it is generally clear that not all criteria will 
carry the same weighting, or importance, therefore the relative importance of 
each of the criteria should be assessed. Decision makers are able to respond 
to a question such as: ‘What is more important to you when buying a car: 
safety or comfort?’. They are also able to respond to questions that ask them 
to rate the relative importance of the criteria ‘safety’ and ‘comfort’ against a 
numerical or verbal scale. However, it has been argued that responses to 
questions such as these are essentially meaningless. The questions can be 
interpreted in many different ways, people’s responses may not be consistent 
and their responses may not relate to the way in which weights are used to 
synthesise information (Belton and Stewart, 2002).
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Swing weighting
However, weights used in a multi-criteria decision model are well defined. 
Weights are essentially scaling factors that relate scores on one criterion to 
scores on all the other criteria. This means that if criterion one has a weight 
that is twice that of criterion two this signifies that the decision maker values 
ten value points on criterion one the same as 20 value points on criterion two 
and would be willing to trade one for the other. This form of weighting is 
referred to as ‘swing weighting’, which is distinct from the less well defined 
concept ‘importance weighting’. ‘Swing weighting’ is considered to capture 
both the psychological concept of ‘importance’ as well as the extent to which 
the measurement scale used discriminates between the alternatives. The 
weights and the measurement scale used are intimately connected (Belton 
and Stewart, 2002).
The swing is from the worst value to the best value on each criterion. If the 
value tree is small the decision maker may consider all bottom-level criteria 
simultaneously and assess the swing which gives the greatest increase in 
overall value; this criterion will then be given the highest weight. The process 
is then repeated on the remaining set of criteria, until a swing from worst to 
best has been determined on each criterion, defining a ranking of the criteria 
weights. In order to assign values to the weights the decision maker has to 
assess the relative value of the swings. For example, a swing from worst to 
best on the highest weighted criterion is assigned a value of 100; the decision 
maker must then decide what the relative value of a swing from worst to best 
on the second ranked criterion is. The decision maker must remember that 
the weights are dependent on the scales used for scoring as well as the 
importance of the criteria. This means that swing weights cannot be assigned 
until the scales for each criterion are defined. If a criterion that is considered 
intrinsically important does not differentiate much between the options, that is 
to say, if the difference between the minimum and maximum points is only 
small, then that criterion may be given quite a low weight (Belton and Stewart, 
2002).
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Once the rank order for the weights has been established, values can be 
assigned to them. For each criterion the decision maker assesses the 
increase in overall value which results from an increase from 0 to 100 on that 
criterion as a percentage of the increase in overall value resulting from an 
increase from 0 to 100 on the most highly ranked criterion (Belton and 
Stewart, 2002).
Weights within value trees
If the decision problem is structured as a multi-level value tree, weights should 
be considered at different levels of the tree. Relative and cumulative weights 
should be defined. Relative weights are assessed within criteria sharing the 
same parent and the weights in each family are normalised to sum to 1 (or 
100). The cumulative weight of a criterion is the product of its relative weight 
compared to the siblings and the relative weights of the parent, parent’s 
parent and so on, up to the top of the tree. The cumulative weights of all 
bottom-level criteria must sum to 1 (or 100). The cumulative weight of a 
parent criterion is the sum of the cumulative weights of its children.
On the other hand, if there are not too many leaves in the value tree the 
weights can be assessed by directly comparing all the bottom-level criteria to 
calculate the cumulative weights. The higher level weights are then calculated 
by adding the cumulative weights of all members of the family to determine 
the cumulative weight of the parent. The cumulative weights of family 
members are normalised to sum to one in order to determine the relative 
weights (Belton and Stewart, 2002).
The bottom-up approach assesses relative weights within families which only 
contain bottom-level criteria. Cross family comparisons are carried out using 
one criterion from each family and comparisons with any unitary bottom-level 
criteria. This process gives the cumulative weights of bottom-level criteria 
which can then be aggregated to higher levels of the value tree (Belton and 
Stewart, 2002).
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Phrasing the weightings
To develop the weights using swing-weighting a series of phrases were 
developed based on the results from the criteria scores. These were 
developed for the user to be able to choose their own weighting relevant to 
the patient’s particular condition, based on whether, for example, 
‘hallucinations’ was a relevant criterion for that particular patient or not. This 
would mean that the weights would change with each new user of the model. 
Although the phrasing would be the same for each user, as they were based 
on the highest and lowest score ranges, the figures allocated for the weights 
would vary from user to user, thus producing in effect a new model with each 
use. Evidence-based medicine encourages physicians to involve patients in 
the decision making process as shared decision making ensures the patient’s 
voice is heard when choices are made (Whitney, 2003). Thus, the physician 
and patient choosing the weights together would ensure the patient was 
involved in the decision-making as the model is effectively reproduced anew 
with each use.
To choose the wording for the weights for each of the criteria the lowest and 
highest scores were taken, representing either end of the scale for that 
criterion’s scores. For example, for ‘motor fluctuations’ the lowest score was 
represented by ‘no improvement in motor fluctuations’ and the highest score 
by ‘a big improvement in motor fluctuations’. The weighting for ‘motor 
fluctuations’ therefore read as The drugs cause from ‘no improvement in 
motor fluctuations’ to ‘a big improvement in motor fluctuations’. This was 
considered to represent the full range of effects that the PD drugs caused for 
that criterion. As there was not a large number of criteria they were all taken 
as the same level in the value tree and weighted all together.
Normalisation
Weights are usually normalised to sum to 1 or 100. Normalisation allows 
decision makers to interpret the original weight of say 0.6 to be normalised to 
19% of the total importance weight, giving a useful interpretation. In some 
cases decision makers may find it more intuitive to specify a reference 
criterion which is weighted at one and which all the other criteria are
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compared against (Belton and Stewart, 2002). The weights for this model 
were not normalised as the user would be choosing one criterion as the 
reference criterion and comparing all the other criteria against it.
Consistency checks
In order to specify the set of criteria weights it is considered good practice to 
carry out more than the minimum number of comparisons necessary. This 
builds in a check on how consistent the decision makers’ judgements are. 
The assessment of weights is implicitly a process of pair-wise comparison. 
This may be carried out by specifying a reference criterion against which all 
other criteria are compared, which requires the minimal number of 
comparisons, or each criterion can be compared with all the others, giving a 
full specification which would require m{m -  1)/2 comparisons (Belton and 
Stewart, 2002). This would mean if there were for example ten criteria the 
number of comparisons needed would be 10(10-1 )/2. This would equal 10 
(9)/2, or 90 divided by 2, which equals 45. Thus the total number of 
comparisons needed for 10 criteria would be 45.
For this model, carrying out consistency checks in this fashion would not have 
been possible, as the user would define the weights themselves. Therefore, 
only the user would be able to determine how many comparisons were made 
between criteria at the point of use. However, a help facility was installed in 
the application designed to run the model, which is discussed in chapter five. 
This explained the process for carrying out swing weighting to ensure that the 
user used the correct methodology for choosing the weights. This provided 
an alternative safeguard to ensure consistency in the choice of weights.
Combining The Scores And Weights
In order to combine the scores and weights the score for each option on each 
criterion is first multiplied by the weight for the criterion. For instance, if co- 
beneldopa scored 50 for ‘dyskinesia’ which was given a weight of seven the 
combined result would be 350. The scores and weights of the rest of the 
criteria are each multiplied and the results for each of the options then 
summed.
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This is represented by the following algorithm, where ‘S’ represents the score 
for each option, ‘Sjj’ represents the score for option ‘i’ on criterion ‘j ’ and the 
weight by ‘Wj’, so for ‘n’ criteria the overall score for each option ‘s{ is shown 
underneath (DTLR, 2000):
n
Si =  W t Si! +  W2Si2 + ......... +  W nSin =  I  WjSjj
j=1
This would mean that, for example, if there were ten criteria the weight of 
criteria one and score of option one would be multiplied together; these would 
be added to the multiplication of the weight of criteria two and score of option 
two and so on until the multiplication of all ten criteria weights and option 
scores were added together.
RESULTS
Calculating The Scores 
Motor fluctuations
As mentioned in the methods sections of this chapter, ‘motor fluctuations’ was 
scored on three different aspects: the change in UPDRS score; time spent 
‘on’ and time spent ‘off. The results of each of these will now be described in 
turn.
The UPDRS scores were assessed on whether the drug caused an 
improvement or worsening in score, with a reduction of the score by 25 points 
taken as the best possible scenario. All the drugs bar three (Duodopa, 
pramipexole and amantadine) had data from the trials on their UPDRS 
scores. Two drugs scored 90 or higher, namely pergolide and apomorphine. 
One drug, entacapone, scored 0. The other drugs all scored between ten and 
30.
Fewer trials recorded time ‘on’ and ‘off. Only six trials recorded time ‘on’, with 
a mean score of 26 (range 0 to 100). Duodopa was the only drug to score 
100, whilst both co-careldopa and amantadine scored 0. The remaining drugs
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scored between five and 40. There was slightly more data for time ‘off, with 
seven trials recording data with a range of scores between 10 and 55. The 
mean was 20.
The total score for each drug was calculated by taking the mean of the scores 
available for the three categories (Table 4.9). If data was only available for 
one or two categories then the mean was calculated accordingly, eg for co- 
careldopa there was a score for two categories (UPDRS score and time ‘on’) 
so the mean was calculated for the two categories and the third category 
(time ‘off) was ignored as there was no data. The overall scores for the drugs 
for ‘motor fluctuations’ ranged between five and 100, with the mean score 
being 28. Amantadine scored the lowest (5), whilst Duodopa scored the 
highest with the top score of 100. Five drugs had a low score of 10 and three 
other drugs scored less than 20.
Cognitive impairment
The scores for ‘cognitive impairment’ (Table 4.10) were much more even, as 
there was little data about this criterion in the trials. All but three of the drugs 
were therefore allocated a score of 50, although cabergoline was also 
allocated 50 as it was reported in the trials as having no change over time. 
Both co-beneldopa and duodopa were given a score of 10, as ‘cognitive 
impairment’ was a common ADR for both drugs.
Confusion
Both co-careldopa and rotigotine scored 50 as trials claimed no effect for 
either of them. Ropinirole had one trial reporting ‘confusion’ as a serious ADR 
and the BNF reporting it is as common, which gave it scores of 5 and 10, the 
mean of which was rounded down to seven. Bromocriptine had one trial 
reporting a serious ADR and another an ADR at high doses only, leading to 
scores of five and 15, the mean of which being ten. Nine drugs had confusion 
as a common ADR, either from trial data or the BNF, which merited them a 
score of ten (Table 4.11).
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Table 4.9 ‘Motor fluctuations’ scores
Drug UPDRS
score
Time
‘on’
score
Time ‘ofF 
score
Total
Score
Overall 
benefit 
or risk
Co-beneldopa 10 No data No data 10 Risk
Co-careldopa 20 0 No data 10 Risk
Stalevo 15 No data No data 15 Risk
Duodopa No data 100 No data 100 Benefit
Ropinirole 10 No data No data 10 Risk
Pramipexole No data No data 10 10 Risk
Rotigotine 25 5 10 13 Risk
Pergolide 95 No data 20 57 Benefit
Bromocriptine 25 No data No data 25 Risk
Cabergoline 30 No data 55 42 Risk
Apomorphine 90 No data No data 90 Benefit
Selegiline 17 No data No data 17 Risk
Rasagiline 10 No data No data 10 Risk
Amantadine No data 0 10 5 Risk
Entacapone 0 10 10 7 Risk
Tolcapone 12 40 28 27 Risk
Hallucinations
A total of nine drugs listed ‘hallucinations’ as a common ADR (Table 4.12), 
either from BNF or trial data, and were therefore allocated a score of ten. All 
the drugs scored poorly, with bromocriptine scoring the highest with a total of 
15, as it was only listed as causing hallucinations as an ADR at high doses. 
Cabergoline scored a mean of 12, from a score of 10 for causing a common 
ADR and 15 for ADR at high doses. One drug, entacapone, scored nine, five 
trials and the BNF reporting it as a common ADR and one trial reporting a 
higher percentage of occurrences meriting a score of five. The remaining four 
drugs (ropinirole, pramipexole, amantadine and tolcapone) all scored seven 
from having a mean calculated from mainly higher scores as well as being a 
common ADR.
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Table 4.10 ‘Cognitive impairment’ scores
Drug Benefit/risk/neutral Scores Total
(mean)
Score
Overall 
benefit or 
risk
Co-beneldopa Risk -  common 
ADR
10 10 Risk
Co-careldopa Neutral - no data 50 50 Neutral
Stalevo Neutral - no data 50 50 Neutral
Duodopa Risk -  common 
ADR
10 10 Risk
Ropinirole Neutral - no data 50 50 Neutral
Pramipexole Neutral - no data 50 50 Neutral
Rotigotine Neutral - no data 50 50 Neutral
Pergolide Neutral - no data 50 50 Neutral
Bromocriptine Neutral - no data 50 50 Neutral
Cabergoline Neutral -  no change 
over time (non­
significant)
50 50 Neutral
Apomorphine Neutral - no data 50 50 Neutral
Selegiline Neutral -  MMSE 
score worsened but 
non-significant
50 50 Neutral
Rasagiline Neutral -  MMSE 
score improved but 
on-significant
50 50 Neutral
Amantadine Neutral -  no data 50 50 Neutral
Entacapone Neutral - no data 50 50 Neutral
Tolcapone Neutral - no data 50 50 Neutral
Dyskinesia
‘Dyskinesia’ produced more varied results, ranging from means of three to 
75,with a mean total score of 22. Two drugs produced a low mean score of
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Table 4.11 ‘Confusion’ scores
Drug Benefit/risk/neutral Scores Total
(mean)
Score
Overall 
benefit 
or risk
Co-beneldopa Risk -  common ADR 10 10 Risk
Co-careldopa Neutral -  no data 50 50 Neutral
Stalevo Risk -  common ADR 10 10 Risk
Duodopa Risk -  common ADR 10 10 Risk
Ropinirole Risk -  relatively high 
incidence, common 
ADR
5, 10 7 Risk
Pramipexole Risk -  common ADR 10 10 Risk
Rotigotine Neutral -  no data 50 50 Neutral
Pergolide Risk -  common ADR 10 10 Risk
Bromocriptine Risk -  relatively high 
incidence, between 
common and less 
common ADR
5, 15 10 Risk
Cabergoline Risk -  between 
common and less 
common ADR
15 15 Risk
Apomorphine Risk -  common ADR 10 10 Risk
Selegiline Risk -  common ADR 10 10 Risk
Rasagiline Neutral -  no effect 50 50 Neutral
Amantadine Neutral -  no data 50 50 Neutral
Entacapone Risk -  common ADR 10 10 Risk
Tolcapone Risk -  common ADR 10 10 Risk
three, co-beneldopa and tolcapone, due to a high percentage of patients 
occurrences during the trial. Pergolide scored the highest, due to a reduction 
in UPDRS IV score and a reduction in hours per day producing dyskinesias. 
Amantadine also scored well, with a total mean of 65, produced from a 
reduction in dyskinesia score and small improvements in duration and
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disability and UPDRS scores. Similarly, rasagiline scored 60 from a small 
reduction in UPDRS IV score, as shown in Table 4.13.
Depression
The results for ‘depression’ were fairly evenly split between those scoring 
around the middle mark, to those with fairly low scores. The mean total score 
was 27 (range 5 to 65). Pramipexole scored highest, with a medium 
improvement and a small improvement in depression combining to form a 
mean of 65. Pergolide also had a positive result, with two small 
improvements resulting in a score of 60. There was no data for rotigotine, and 
both apomorphine and selegiline showed non-statistically significant results, 
giving all three drugs a score of 50. Ropinirole showed the poorest result, 
with two trials showing depression as a more serious ADR, meriting a mean 
score of five. Four drugs scored ten from having depression as a common 
ADR (Table 4.14).
Postural hypotension
‘Postural hypotension’ scored poorly for all the drugs. The lowest score was 
nine and the highest only a rather poor 20. Six drugs scored a mean of ten, 
mainly from having ‘postural hypotension’ as a common ADR, with three 
drugs having a slightly lower mean score of nine because of slightly higher 
occurrences of the condition as an ADR. Apomorphine had the top score of 
20, with both a trial and the BNF reporting ‘postural hypotension’ as a less 
common ADR.
Activities of daily living
Most of the drugs scored better on ADL, with a mean total score of 58 (range 
50 to 80). A few of the drugs (four) did not have ADL reported on in their 
trials, or had non-significant results and therefore scored 50. The majority of 
the drugs that showed some improvement had only a small improvement and 
therefore scored between 52 and 60. The exceptions to this were Duodopa 
and cabergoline, which both showed a large improvement.
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Table 4.12 ‘Hallucinations’ scores
Drug Benefit/risk/neutral Scores Total
(mean)
Score
Overall 
benefit or 
risk
Co-beneldopa Risk -common ADR 10 10 Risk
Co-careldopa Risk -  common ADR 10 10 Risk
Stalevo Risk -  common ADR 10 10 Risk
Duodopa Risk -  common ADR 10 10 Risk
Ropinirole Risk -  common ADR, 
relatively high occurrence
10, 5 7 Risk
Pramipexole Risk -  common ADR, 
relatively high occurrence
10, 5 7 Risk
Rotigotine Risk -  common ADR 10 10 Risk
Pergolide Risk -  common ADR 10 10 Risk
Bromocriptine Risk -  ADR -  high doses 
only
15 15 Risk
Cabergoline Risk -  common ADR, ADR 
at high doses
10, 15 12 Risk
Apomorphine Risk -  common ADR 10 10 Risk
Selegiline Risk -  common ADR 10 10 Risk
Rasagiline Risk -  common ADR 10 10 Risk
Amantadine Risk -  common ADR, 
relatively high occurrence
10,5 7 Risk
Entacapone Risk -  common ADR, 
common ADR, common 
ADR, common ADR, 
common ADR, common 
ADR, relatively high 
occurrence
10, 10, 
10, 10, 
10, 10, 5
9 Risk
Tolcapone Risk -  common ADR, 
relatively high occurrence
10, 5 7 Risk
Table 4.13 Scores for ‘dyskinesias’
Drug Benefit/risk/neutral -  
trial results
Scores Total
(mean)
Score
Overall 
benefit 
or risk
Co-beneldopa Risk -  relatively high 
occurrence as ADR, 
relatively high occurrence 
as ADR
3,4 3 Risk
Co-careldopa Risk -  common ADR, 
relatively high occurrence 
as ADR
10, 5 7 Risk
Stalevo Risk -  less common ADR, 
relatively high incidence, 
common ADR
20, 3, 10 16 Risk
Duodopa Neutral - no change, Risk- 
common ADR, common 
ADR
50, 10, 
10
35 Risk
Ropinirole Risk -  less common ADR, 
common ADR, relatively 
high incidence, less 
common ADR
20, 10, 4, 
20
13 Risk
Pramipexole Risk -  common ADR 10 10 Risk
Rotigotine Risk -  common ADR, 
relatively high incidence
10, 5 7 Risk
Pergolide Benefit -  reduction 
UPDRS IV score, 
reduction hours per day 
producing dyskinesia
80, 70 75 Benefit
Bromocriptine Risk -  less common ADR, 
common ADR
20, 10 15 Risk
Cabergoline Benefit -  medium 
improvement, Risk -  
common ADR, less
70, 10, 
20, 10
27 Risk
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common ADR, common 
ADR
Apomorphine Risk -  less common ADR, 
not suitable for severe 
dyskinesia, common ADR
20, 5, 10 11 Risk
Selegiline Risk -  relatively high 
incidence occurrence, 
common ADR
5, 10 7 Risk
Rasagiline Benefit -  reduction 
UPDRS IV score
60 60 Benefit
Amantadine Benefit -  reduction 
dyskinesia score, 
improvement duration, 
improvement disability, 
improvement UPDRS IV 
score,
80, 60, 
60, 60
65 Benefit
Entacapone Risk -  relatively high 
occurrence, common 
ADR, relatively high 
occurrence, relatively high 
occurrence, relatively high 
occurrence, relatively high 
occurrence, common ADR
5, 10, 3, 
4, 4, 5, 
10
6 Risk
Tolcapone Risk -  relatively high 
occurrence as ADR, 
relatively high occurrence 
as ADR, relatively high 
occurrence as ADR
2, 3,3 3 Risk
Stage of disease
The criterion ‘stage of disease’ was the only one on which all the drugs bar 
one scored the same. The one exception was rasagiline, which showed a tiny 
improvement and therefore merited a score of 52. Of the drugs scoring 50,
97
Table 4.14 ‘Depression’ scores
Drug Benefit/risk/neutral -  
from trial data
Scores Total
(mean)
Score
Overall 
benefit 
or risk
Co-beneldopa Risk -  relatively high 
incidence ADR, common 
ADR
5, 10 7 Risk
Co-careldopa Risk -  common ADR, 
relatively high incidence 
ADR, relatively high 
incidence ADR
10, 5, 5 7 Risk
Stalevo Risk -  common ADR 10 10 Risk
Duodopa Risk -  common ADR, 
common ADR
10, 10 10 Risk
Ropinirole Risk -  relatively high 
incidence as ADR, 
relatively high incidence as 
ADR
5, 5 5 Risk
Pramipexole Benefit -  medium 
improvement, small 
improvement
70, 60 65 Benefit
Rotigotine Neutral -  no data 50 50 Neutral
Pergolide Benefit -  small 
improvement, small 
improvement
60, 60 60 Benefit
Bromocriptine Risk -  common ADR 10 10 Risk
Cabergoline Risk -  common ADR 10 10 Risk
Apomorphine Neutral -  no change, 
(result non-significant)
50 50 Neutral
Selegiline Neutral -  hardly any 
change (non-significant)
50 50 Neutral
Rasagiline Benefit -  small 
improvement, Risk -
55, 10 32 Risk
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common ADR
Amantadine Risk -  relatively high 
incidence, common ADR
5, 10 7 Risk
Entacapone Risk -  common ADR, 
relatively high incidence as 
ADR, common ADR
10, 5, 10 8 Risk
Tolcapone Neutral -  no data 50 50 Neutral
there was no data for 11 of them, with the remaining four (pergolide, 
bromocriptine, selegiline and entacapone) being either unchanged 
(entacapone), having non-significant results (selegiline) or having a positive 
result counterbalanced by a negative result (pergolide). The result for 
bromocriptine gave no detail of the amount the stage of disease was improved 
by, stating only that the score was lower than for the comparator; therefore 
this was given a neutral score of 50.
Adverse drug reactions
To calculate the frequency of occurrence of ADRs for each drug, the 
occurrences were divided into five categories, namely: ‘common’; ‘less 
common’; ‘rare’; ‘very rare’ and ‘also reported’. When the scores for the 
number of occurrences in each group was totalled up it was shown that the 
mean score was 46 (range 0 to 83) for ‘common’, with stalevo scoring 0 and 
two drugs, bromocriptine and cabergoline, both scoring 83. No drug scored 
100. The mean was 82 for ‘less common’ (range 40 to 100), with six drugs 
(pramipexole, pergolide, selegiline, amantadine, entacapone and tolcapone) 
scoring 100. 72 (range 20 to 100) was the mean for ‘rare’, all the levodopa 
drugs scoring in the 20s, and six drugs (ropinirole, pramipexole, pergolide, 
rasagiline, amantadine and tolcapone) having the top score of 100. The 
mean was 97 for ‘very rare’ (range 89 to 100), only two drugs, bromocriptine 
and cabergoline, scoring less than 90. The mean for ‘also reported’ was 93 
(range 60 to 100), with again six drugs (rotigotine, bromocriptine, 
apomorphine, rasagiline, amantadine and tolcapone) scoring 100 and seven 
drugs (co-beneldopa, co-careldopa, Duodopa, ropinirole, pramipexole,
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Table 4.15 ‘Postural hypotension’ scores
Drug Benefit/risk/neutral -  
results from trial data
Scores Total
(mean)
Score
Overall 
benefit or 
risk
Co-beneldopa Risk -  common ADR, 
common ADR
10, 10 10 Risk
Co-careldopa Risk -  common ADR, 
common ADR, 
common ADR
10, 10, 10 10 Risk
Stalevo Risk -  common ADR 10 10 Risk
Duodopa Risk -  common ADR, 
common ADR
10, 10 10 Risk
Ropinirole Risk -  common ADR, 
common ADR, 
relatively high 
incidence as ADR
10, 10,8 9 Risk
Pramipexole Risk -  common ADR, 
common ADR, 
relatively high 
incidence as ADR
10, 10,8 9 Risk
Rotigotine Risk -  common ADR 10 10 Risk
Pergolide Risk -  common ADR, 
common ADR
10, 10 10 Risk
Bromocriptine Risk -  relatively high 
incidence, less 
common ADR
8,20 14 Risk
Cabergoline Risk -  less common 
ADR, relatively high 
incidence
20, 5 12 Risk
Apomorphine Risk -  less common 
ADR, less common 
ADR
20, 20 20 Risk
Selegiline Risk -  common ADR, 10, 20 15 Risk
100
less common ADR
Rasagiline Risk -  common ADR 10 10 Risk
Amantadine Risk -  between 
common and less 
common
15 15 Risk
Entacapone Risk -  common ADR, 
common ADR, 
relatively high 
incidence as ADR
10, 10, 8 9 Risk
Tolcapone Risk -  between 
common and less 
common
15 15 Risk
selegiline and entacapone) scoring in the 90s. The scores for each drug were 
then totalled for each category and the mean calculated for each drug. The 
range for the totals was 52 to 92, with the mean 77. Apomorphine had the top 
score, with amantadine a close second on 90 and stalevo the lowest on 52.
Severity
The mean score for ‘severity’ was 53 (range 32 to 83). Co-careldopa scored 
the lowest and stalevo the highest. Duodopa was the only other drug to score 
more than 70, with a score of 73. Co-beneldopa, bromocriptine and 
amantadine all scored 50 as there was no data on any of them for severity.
Withdrawal
The scores for ‘withdrawal’ ranged from 18 to 91, with a mean of 66. Co- 
beneldopa scored the lowest and rasagiline the highest. Co-beneldopa had 
a score considerably lower than the second lowest, ropinirole, on 48, scoring 
only 18. The other scores were more evenly spaced. Two drugs (amantadine 
and tolcapone) scored in the 50s, four drugs (bromocriptine, cabergoline, 
selegiline and entacapone) in the 60s, five (duodopa, pramipexole, pergolide, 
rotigotine and rasagiline) in the 70s and three (co-careldopa, stalevo and 
apomorphine) in the 80s.
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Table 4.16 ‘Activities of daily living’ scores
Drug Benefit/risk/neutral -  
results from trial data
Scores Total
(mean)
Score
Overall 
benefit 
or risk
Co-beneldopa Neutral -  improvement 
but non-significant
50 50 Neutral
Co-careldopa Benefit -  small 
improvement, small 
improvement, Risk -  
small worsening
60, 55, 
40
52 Benefit
Stalevo Benefit -  small 
improvement
60 60 Benefit
Duodopa Benefit -  large 
improvement
80 80 Benefit
Ropinirole Risk -  small worsening, 
Benefit -  small to medium 
improvement
40, 65 52 Benefit
Pramipexole Benefit -  small 
improvement
60 60 Benefit
Rotigotine Benefit -  small to medium 
improvement, medium 
improvement, very small 
improvement
65, 70, 
55
63 Benefit
Pergolide Benefit -  large 
improvement, Risk -  
medium worsening
90, 30 60 Benefit
Bromocriptine Benefit -  small 
improvement
60 60 Benefit
Cabergoline Benefit -  medium 
improvement, very large 
improvement
70,90 80 Benefit
Apomorphine Neutral -  no data 50 50 Neutral
Selegiline Neutral -  small change 50 50 Neutral
102
but non-significant
Rasagiline Benefit -  very small 
improvement, very small 
improvement, very small 
improvement, Risk -  very 
small worsening
55, 55, 
55, 45
52 Benefit
Amantadine Benefit -  small 
improvement
60 60 Benefit
Entacapone Benefit -  very small 
improvement, small 
improvement, very small 
improvement, very small 
improvement, Neutral -  
no change non­
significant, slight 
improvement non­
significant, improvement 
non-significant
55, 60, 
55, 55, 
50, 50, 
50
53 Benefit
Tolcapone Benefit -  very small 
improvement, Risk -  very 
small worsening
55, 45 50 Neutral
Total scores for ADRs
For the total score for ADRs, the mean for ‘frequency’ and the scores for 
‘severity’ and ‘withdrawal’ were totalled and the overall mean calculated, 
yielding a mean of 65 (range 43 to 76). However, the ergot dopamine 
agonists pergolide, bromocriptine and cabergoline are only recommended by 
National Institute for Clinical Excellence (NICE, 2006) as second choice drugs 
to the non-ergot dopamine agonists because of their serious potential 
cardiovascular side-effects. It was therefore felt that this should be 
acknowledged in some way in the scoring, as the criteria scores thus far had 
not been able to take account of this aspect. The overall scores for the non­
ergot dopamine agonists were therefore reduced to ten, which would reflect
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Table 4.17 ‘Stage of disease’ scores
Drug Benefit/risk/neutral -  
results from trial 
data
Scores Total
(mean)
Score
Overall 
benefit or 
risk
Co-beneldopa Neutral -  no data 50 50 Neutral
Co-careldopa Neutral -  no data 50 50 Neutral
Stalevo Neutral -  no data 50 50 Neutral
Duodopa Neutral -  no data 50 50 Neutral
Ropinirole Neutral -  no data 50 50 Neutral
Pramipexole Neutral -  no data 50 50 Neutral
Rotigotine Neutral -  no data 50 50 Neutral
Pergolide Benefit -  small 
improvement, Risk -
55, 45 50 Neutral
Bromocriptine Neutral -  result better 
for comparator but 
amount not stated 
therefore judged as 
neutral
50 50 Neutral
Cabergoline Neutral -  no data 50 50 Neutral
Apomorphine Neutral -  no data 50 50 Neutral
Selegiline Neutral -  non­
significant result
50, 50 50 Neutral
Rasagiline Neutral -  no change, 
small improvement
50, 54 52 Benefit
Amantadine Neutral -  no data 50 50 Neutral
Entacapone Neutral -  no change 50 50 Neutral
Tolcapone Neutral -  no data 50 50 Neutral
what was effectively a ‘penalty’ against them. The mean score overall 
therefore became 54 (range 10 to 76). All the results for ADRs are shown in 
Table 4.18.
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Table 4.18 Scores for ‘ADRs’
Drug Frequency Frequency
Total
Severity Withdrawal Total 
(penalty 
score in 
brackets)
Common Less
common
Rare Very rare Also
reported
Co-beneldopa 23 62 24 99 93 60 50 18 43
Co-careldopa 23 62 24 99 93 60 32 84 59
Stalevo 0 62 20 91 87 52 83 85 73
Duodopa 23 62 24 99 93 60 73 70 68
Ropinirole 54 90 100 99 99 54 35 48 46
Pramipexole 44 100 100 100 93 88 62 70 73
Rotigotine 33 40 96 100 100 74 46 70 63
Pergolide 67 100 100 100 60 85 75 60 73(10)
Bromocriptine 83 78 88 89 100 88 50 66 68(10)
Cabergoline 83 78 88 89 75 83 47 72 67(10)
Apomorphine 80 90 92 100 100 92 48 88 76
Selegiline 57 100 90 100 99 89 49 66 68
Rasagiline 44 90 100 100 100 87 43 91 74
Amantadine 50 100 100 100 100 90 50 50 63
Entacapone 47 100 96 93 93 86 46 67 66
Tolcapone 20 100 100 100 100 84 57 52 64
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Drug interactions
Six out of the ten experts consulted responded to the short questionnaire sent 
out. The mean score overall was 71 (range 59 to 82). Pramipexole scored 
the highest with 82, whilst pergolide and rotigotine both scored the lowest on 
59. The scores for the vast majority of the drugs fell in the 60s and 70s, 
suggesting that the average severity was ‘fairly serious’ for most of the 
interactions. The responses of the expert panel were fairly varied, with all the 
experts only agreeing on their response for a small number of interactions. 
For several interactions the responses encompassed ‘not serious’ to ‘very 
serious’, covering all the grades of severity per interaction. The results for all 
the interactions are shown in Table 4.19.
Contraindications
There were no results for ‘contraindications’ as this was not being used as a 
criterion anymore, as mentioned in the methodology section. However, both 
the contraindications and cautions for all the drugs were taken from the BNF 
to be displayed to the user alongside the recommended treatments by the 
computer decision support system which is discussed in chapter five. Tables 
4.20 and 4.21 show the contraindications and the cautions respectively.
Total scores
The mean scores for all the drugs ranged between 28 and 48, with co- 
beneldopa scoring the lowest and apomorphine the highest. The overall 
mean was 39. Although co-beneldopa had a low score the scores for the 
other levodopa based drugs were fairly similar, ranging between 37 and 44. 
Besides co-beneldopa all the other drugs scored in the 30s and 40s. The 
mean score for all the dopamine agonists was 40 (range 32 to 48). The total 
scores and means are shown in Table 4.22.
Working out the weights
‘Adverse drug reactions’ and ‘drug interactions’ were the only criteria to be 
pre-weighted, as it was assumed that both were essential criteria to consider 
for all patients. They were both given a weight of 10, this being the highest
106
Table 4.19 Scores for ‘Interactions’
Drug Interaction
Seriousness:
Most serious (MS)/very 
serious (VS)/fairly 
serious (FS)/not serious 
(NS)
Respondent
1
Respondent
2
Respondent
3
Respondent
4
Respondent
5
Respondent
6
Mean Overall
mean
Co-beneldopa Enhanced hypotensive 
effect with ACE inhibitors, 
adrenergic neurone 
blockers, alpha-blockers, 
antiotensin-ll receptor 
antagonists, beta-blockers, 
calcium-channel blockers, 
clonidine, diazoxide, 
diuretics, hydralazine, 
methyldopa, minoxidil, 
nitrates, sodium 
nitroprusside
65 65 65 65 65 65 65 67
Amisulpiride 65 100 30 65 Not
completed
65 65
Absorption of levodopa 
possibly reduced by: 
antimuscarinics, oral iron, 
phenytoin;
100 100 100 100 65 100 94
Effects of levodopa 
antagonised by: 
antipsychotics, possibly 
benzodiazepines;
100 65 30 65 30 65 59
Agitation, confusion & 
hallucinations with 
baclofen
65 65 30 65 30 65 53
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Table 4.19 Scores for ‘Interactions’ (continued)
Drug Interaction seriousness: 
MS/VS/FS/NS
Respondent
1
Respondent
2
Respondent
3
Respondent
4
Respondent
5
Respondent
6
Mean Overall
mean
Increased risk side effects 
with buproprion, 
moclobemide
65 100 65 65 65 100 77
Risk hypertensive crisis 
with MAOIs
65 100 30 30 30 30 47
Enhanced effect and 
increased toxicity with 
selegiline (reduce dose 
levodopa)
100 100 65 65 65 100 82
Co-careldopa Enhanced hypotensive 
effect with ACE inhibitors, 
adrenergic neurone 
blockers, alpha-blockers, 
antiotensin-ll receptor 
antagonists, beta-blockers, 
calcium-channel blockers, 
clonidine, diazoxide, 
diuretics, hydralazine, 
methyldopa, minoxidil, 
nitrates, sodium 
nitroprusside
65 65 65 65 65 65 65 70
Amisulpiride 65 100 30 65 Not
completed
65 65
Absorption of levodopa 
possibly reduced by: 
antimuscarinics, oral iron, 
phenytoin;
100 100 100 100 65 100 94
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Table 4. 9 Scores for ‘Interactions’ (continued)
Drug Interaction seriousness: 
MS/VS/FS/NS
Respondent
1
Respondent
2
Respondent
3
Respondent
4
Respondent
5
Respondent
6
Mean Overall
mean
Effects of levodopa 
antagonised by: 
antipsychotics, possibly 
benzodiazepines;
100 65 30 65 30 65 59
Agitation, confusion & 
hallucinations with 
baclofen
100 65 30 65 30 65 59
Increased risk side effects 
with buproprion, 
moclobemide
100 100 65 65 65 100 82
Risk hypertensive crisis 
with MAOIs
100 100 30 30 30 30 53
Enhanced effect and 
increased toxicity with 
selegiline (reduce dose 
levodopa)
100 100 65 Not
comleted
65 100 86
Stalevo Enhanced hypotensive 
effect with ACE inhibitors, 
adrenergic neurone 
blockers, alpha-blockers, 
antiotensin-ll receptor 
antagonists, beta-blockers, 
calcium-channel blockers, 
clonidine, diazoxide, 
diuretics, hydralazine, 
methyldopa, minoxidil, 
nitrates, sodium 
nitroprusside
65 65 65 65 65 65 65 73
Amisulpiride 100 100 30 65 Not
completed
65 72
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Table 4.19 Scores for ‘Interactions’ (continued)
Drug Interaction seriousness: 
MS/VS/FS/NS
Respondent
1
Respondent
2
Respondent
3
Respondent
4
Respondent
5
Respondent
6
Mean Overall
mean
Absorption of levodopa 
possibly reduced by: 
antimuscarinics, oral iron, 
phenytoin;
100 65 100 100 65 100 88
Effects of levodopa 
antagonised by: 
antipsychotics, possibly 
benzodiazepines;
100 65 30 65 30 65 59
Agitation, confusion & 
hallucinations with 
baclofen
100 65 30 65 30 65 59
Increased risk side effects 
with buproprion, 
moclobemide
100 100 65 65 65 100 82
Risk hypertensive crisis 
with MAOIs
100 100 30 30 30 30 53
Enhanced effect and 
increased toxicity with 
selegiline (reduce dose 
levodopa)
100 100 65 65 65 100 82
Possibly enhances effects 
of: adrenaline, 
apomorphine, dobutamine, 
dopamine, methyldopa, 
noradrenaline
100 100 65 65 65 65 77
Manufacturer advises 
caution with: tricyclics, 
moclobemide, paroxetine, 
venlafaxine
100 65 65 65 100 100 82
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Table 4.19 Scores for ‘Interactions’ (continued)
Drug Interaction seriousness: 
MS/VS/FS/NS
Respondent
1
Respondent
2
Respondent
3
Respondent
4
Respondent
5
Respondent
6
Mean Overall
mean
Absorption of entacapone 
reduced by oral iron
100 65 100 100 100 100 94
Avoid use with non- 
selective MAOIs
100 65 65 65 65 65 71
Possibly reduces plasma 
concentration of rasagiline
100 100 100 100 100 100 100
Enhances anticoagulant 
effect of warfarin
65 65 30 30 30 65 47
Duodopa Enhanced hypotensive 
effect with ACE inhibitors, 
adrenergic neurone 
blockers, alpha-blockers, 
antiotensin-ll receptor 
antagonists, beta-blockers, 
calcium-channel blockers, 
clonidine, diazoxide, 
diuretics, hydralazine, 
methyldopa, minoxidil, 
nitrates, sodium 
nitroprusside
65 65 65 65 65 65 65 64
Amisulpiride 100 100 30 65 N ot
completed
65 60
Absorption of levodopa 
possibly reduced by: 
antimuscarinics, oral iron, 
phenytoin;
100 65 30 30 65 100 65
Effects of levodopa 
antagonised by: 
antipsychotics, possibly 
benzodiazepines;
100 100 30 65 30 65 65
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Table 4.19 Scores for ‘Interactions’ (continued)
Drug Interaction seriousness: 
MS/VS/FS/NS
Respondent
1
Respondent
2
Respondent
3
Respondent
4
Respondent
5
Respondent
6
Mean Overall
mean
Agitation, confusion & 
hallucinations with 
baclofen
65 65 30 65 30 65 53
Increased risk side effects 
with buproprion, 
moclobemide
100 65 65 65 65 100 77
Risk hypertensive crisis 
with MAOIs
100 100 30 30 30 30 53
Enhanced effect and 
increased toxicity with 
selegiline (reduce dose 
levodopa)
100 100 65 65 65 100 82
Ropinirole Avoid antipsychotics, 
metoclopramide
100 65 30 65 30 65 59 80
Metabolism inhibited by 
ciprofloxacin
100 100 100 65 65 100 88
Plasma concentration 
increased by oestrogens
100 100 100 65 100 100 94
Pramipexole Amantadine -  may slightly 
decrease the oral 
clearance of pramipexole
65 100 100 100 100 100 94 82
Cimetidine -  caused a 
50% increase in 
pramipexole AUC and 
40% increase in half-life
100 100 65 65 47 65 74
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Table 4.19 Scores for ‘Interactions’ (continued)
Drug Interaction seriousness: 
MS/VS/FS/NS
Respondent
1
Respondent
2
Respondent
3
Respondent
4
Respondent
5
Respondent
6
Mean Overall
mean
Drugs secreted by cationic 
transport system 
(cimetidine, ranitidine, 
diltiazem, triamterene, 
verapamil, quinidine & 
quinine)
100 100 65 65 47 100 79
Rotigotine Manufacturer of rotigotine 
advises avoid concomitant 
use of antipsychotics 
(antagonism of effect)
100 65 30 65 30 65 59 59
manufacturer of rotigotine 
advises avoid concomitant 
use of metoclopramide 
(antagonism of effect)
100 65 30 65 30 65 59
Pergolide effects of pergolide 
antagonised by anti­
psychotics
100 65 30 65 30 65 59 59
Anti-parkinsonian effect of 
pergolide antagonised by 
metoclopramide
100 65 30 65 30 65 59
Bromocriptine Hypoprolactinaemic and 
antiparkinsonian effects of 
bromocriptine antagonised 
by antipsychotics
65 65 30 65 30 65 53 65
Hypoprolactinaemic effect 
of bromocriptine possibly 
antagonised by 
domperidone and 
metoclopramide
100 65 30 100 30 65 65
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Table 4.19 Scores for ‘Interactions’ (continued)
Drug Interaction seriousness: 
MS/VS/FS/NS
Respondent
1
Respondent
2
Respondent
3
Respondent
4
Respondent
5
Respondent
6
Mean Overall
mean
Plasma concentration of 
bromocriptine increased by 
erythromycin (increased 
risk of toxicity) and 
octreotide and possibly 
increased by macrolides 
(increased risk of toxicity),
100 65 65 65 65 100 77
Risk of toxicity when 
bromocriptine given with 
isometheptene and 
phenylpropanolamine
65 65 65 65 30 100 65
Cabergoline Hypoprolactinaemic and 
antiparkinsonian effects 
antagonised by 
antipsychotics
100 65 30 65 65 65 65 75
Hypoprolactinaemic effect 
of cabergoline antagonised 
by metoclopramide and 
possibly domperidone,
100 65 30 100 65 100 77
Plasma concentration of 
cabergoline increased by 
erythromycin (increased 
risk of toxicity) and 
possibly macrolides
100 65 65 100 65 100 82
Apomorphine Effects of apomorphine 
antagonised by 
antipsychotics
100 30 30 65 65 65 59 70
Effects of apomorphine 
possibly enhanced by 
entacapone
100 65 65 100 100 65 82
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Table 4.19 Scores for ‘Interactions’ (continued)
Drug Interaction seriousness: 
MS/VS/FS/NS
Respondent
1
Respondent
2
Respondent
3
Respondent
4
Respondent
5
Respondent
6
Mean Overall
mean
Selegiline CNS toxicity: tricyclics 65 65 65 65 65 65 65 69
Risk serotonin syndrome: 
citalopram
65 30 65 65 30 65 53
Risk hypertensive crisis: 
dopamine
100 65 30 30 65 65 59
Increased risk 
hypertension and CNS 
excitation: fluoxetine, 
fluvoxamine, paroxetine, 
sertraline, venlafaxine
65 65 65 65 30 65 59
Enhanced effect and 
increased toxicity: 
levodopa
100 100 100 65 100 100 94
Enhanced hypotensive 
effect: MAO Is
100 65 65 65 65 100 77
Effects selegiline 
enhanced: Memantine
100 65 65 65 65 100 77
Avoid use: moclobemide 100 100 30 65 30 65 65
Plasma concentration 
increased: oestrogens, 
progesterone
100 100 100 65 100 100 94
Hyperpyrexia and CNS 
toxicity (avoid use): 
pethidine
100 65 30 65 0 65 54
Manufacturer advises 
caution: tramadol
100 65 30 100 30 65 65
Rasagiline Avoid dextromethorphan 
and sympathomimetics
100 65 30 65 30 65 59 73
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Table 4.19 Scores for ‘Interactions’ (continued)
Drug Interaction seriousness: 
MS/VS/FS/NS
Respondent
1
Respondent
2
Respondent
3
Respondent
4
Respondent
5
Respondent
6
Mean Overall
mean
Increased risk of CNS 
toxicity with
antidepressants (SSRIs & 
Tricyclics)
65 65 65 65 82 65 68
Wait 2 weeks before using: 
fluoxetine, fluvoxamine, 
MAOIs, pethidine
65 100 65 65 65 65 71
Plasma concentration of 
rasagiline reduced by 
entacapone
100 65 100 100 100 100 94
Amantadine Increased risk of 
antimuscarinic side-effects 
when given with 
antimuscarinics
100 100 65 65 30 65 71 69
Increased risk of side- 
effects when given with 
bupropion
100 100 65 65 65 100 82
Increased risk of CNS 
toxicity when given with 
memantine (manufacturer 
of memantine advises 
avoid concomitant use)
100 65 65 65 30 65 65
Increased risk of 
extrapyramidal side-effects 
when given with 
methyldopa, 
metoclopramide, 
tetrabenazine, 
antipsychotics, 
domperidone
100 65 30 65 30 65 59
116
Table 4.19 Scores for ‘Interactions’ (continued)
Drug Interaction seriousness: 
MS/VS/FS/NS
Respondent
1
Respondent
2
Respondent
3
Respondent
4
Respondent
5
Respondent
6
Mean Overall
mean
Entacapone Possibly enhances effects 
of: adrenaline, 
apomorphine, dobutamine, 
dopamine, methyldopa, 
noradrenaline
100 100 65 65 65 65 77 78
Manufacturer advises 
caution with: tricyclics, 
moclobemide, paroxetine, 
venlafaxine
100 65 65 65 100 100 82
Absorption of entacapone 
reduced by oral iron
100 65 100 100 100 100 94
Avoid use with non- 
selective MAOIs
100 65 65 65 65 65 71
Possibly reduces plasma 
concentration of rasagiline
100 100 100 100 100 100 100
Enhances anticoagulant 
effect of warfarin
65 65 30 30 30 65 47
Tolcapone Avoid MAOIs 100 100 30 65 100 Not
completed
79 79
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Table 4.20 Contraindications for all the drugs
Drug Contraindications
Co-beneldopa Breast-feeding
Co-careldopa Breast-feeding
Stalevo Breast-feeding; pregnancy; hepatic impairment; 
phaeochromocytoma; history o f neuroleptic malignant syndrome 
or non-traumatic rhabdomyolysis
Duodopa Breast-feeding,
Ropinirole Breast-feeding; pregnancy
Pramipexole Breast-feeding
Rotigotine Breast-feeding; pregnancy; remove patch before M R I or 
cardioversion
Pergolide History of fibrotic disorders; cardiac valve disease
Bromocriptine Shouldn’t be used in patients with a hypersensitivity to ergot 
alkaloids; avoid in pre-eclampsia
Cabergoline Shouldn’t be used in patients with a hypersensitivity to ergot 
alkaloids; avoid in pre-eclampsia; history of pulmonary, 
pericardial or retroperitoneal fibrotic disorders; cardiac 
valvulopathy
Apomorphine Respiratory depression; hypersensitivity to opiods; not suitable i f  
‘on’ response to levodopa marred by severe dyskinesia, hypotonia 
or psychiatric effects; hepatic impairment; breast-feeding; not for 
IV  administration
Selegiline Pregnancy; breast-feeding
Rasagiline None
Amantadine Epilepsy; history of gastric ulceration; pregnancy; breast-feeding
Entacapone Pregnancy; breast-feeding; hepatic impairment; 
phaeochromocytoma; history of neuroleptic malignant syndrome 
or non-traumatic rhabdomyolysis
Tol capone Hepatic impairment or raised liver enzymes; severe dyskinesia; 
phaeochromocytoma; previous history of neuroleptic malignant 
syndrome, rhabdomyolysis or hyperthermia; breast-feeding
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Table 4.21 Cautions for all the drugs
Drug Caution
Co-beneldopa Severe cardiovascular or pulmonary disease, psychiatric illness 
(avoid i f  severe), endocrine disorders (including hyperthyroidism, 
Cushing’s syndrome, diabetes mellitus, osteomalacia, and 
phaeochromocytoma), history of convulsions, malignant 
melanoma, or peptic ulcer. Use with caution in open-angle 
glaucoma and patients susceptible to angle-closure glaucoma, and 
in hepatic or renal impairment. Avoid abrupt withdrawal (risk of 
neuroleptic malignant syndrome and rhabdomyolysis), be aware of 
the potential for excessive drowsiness and sudden onset o f sleep. 
Use with caution in pregnancy
Co-careldopa Severe cardiovascular or pulmonary disease, psychiatric illness 
(avoid i f  severe), endocrine disorders (including hyperthyroidism, 
Cushing’s syndrome, diabetes mellitus, osteomalacia, and 
phaeochromocytoma), history of convulsions, malignant 
melanoma, or peptic ulcer. Use with caution in open-angle 
glaucoma and patients susceptible to angle-closure glaucoma, and 
in hepatic or renal impairment. Avoid abrupt withdrawal (risk of 
neuroleptic malignant syndrome and rhabdomyolysis), be aware of 
the potential for excessive drowsiness and sudden onset o f sleep. 
Use with caution in pregnancy
Stalevo Severe cardiovascular or pulmonary disease, psychiatric illness 
(avoid i f  severe), endocrine disorders (including hyperthyroidism, 
Cushing’s syndrome, diabetes mellitus, osteomalacia, and 
phaeochromocytoma), history o f convulsions, malignant 
melanoma, or peptic ulcer. Use with caution in open-angle 
glaucoma and patients susceptible to angle-closure glaucoma, and 
in hepatic or renal impairment. Avoid abrupt withdrawal (risk of 
neuroleptic malignant syndrome and rhabdomyolysis), be aware of 
the potential for excessive drowsiness and sudden onset o f sleep. 
Use with caution in pregnancy
Duodopa Severe cardiovascular or pulmonary disease, psychiatric illness 
(avoid i f  severe), endocrine disorders (including hyperthyroidism, 
Cushing’s syndrome, diabetes mellitus, osteomalacia, and 
phaeochromocytoma), history of convulsions, malignant 
melanoma, or peptic ulcer. Use with caution in open-angle 
glaucoma and patients susceptible to angle-closure glaucoma, and 
in hepatic or renal impairment. Avoid abrupt withdrawal (risk of 
neuroleptic malignant syndrome and rhabdomyolysis), be aware of 
the potential for excessive drowsiness and sudden onset of sleep. 
Use with caution in pregnancy
Ropinirole Severe cardiovascular disease, major psychotic disorders; hepatic 
impairment; renal impairment. Associated with more 
neuropsychiatric side-effects than levodopa. Dopamine receptor 
agonists can cause excessive daytime sleepiness and sudden onset 
of sleep. Hypotensive reactions can occur in some patients taking
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dopamine agonists; these can be particularly problematic during 
the first few days of treatment and care should be exercised when 
driving or operating machinery. Doses o f dopamine receptor 
agonists should be increased slowly according to response and 
tolerability. Treatment with dopamine receptor agonists should not 
be withdrawn abruptly.
Pramipexole Psychotic disorders; ophthalmological testing recommended (risk 
of visual disorders); severe cardiovascular disease; renal 
impairment, pregnancy. Associated with more neuropsychiatric 
side-effects than levodopa. Dopamine receptor agonists can cause 
excessive daytime sleepiness and sudden onset of sleep. 
Hypotensive reactions can occur in some patients taking dopamine 
agonists; these can be particularly problematic during the first few 
days of treatment and care should be exercised when driving or 
operating machinery. Doses of dopamine receptor agonists should 
be increased slowly according to response and tolerability. 
Treatment with dopamine receptor agonists should not be 
withdrawn abruptly.
Rotigotine Ophthalmic testing recommended; avoid exposure of patch to 
heat; hepatic impairment. Associated with more neuropsychiatric 
side-effects than levodopa. Dopamine receptor agonists can cause 
excessive daytime sleepiness and sudden onset o f sleep. 
Hypotensive reactions can occur in some patients taking dopamine 
agonists; these can be particularly problematic during the first few 
days of treatment and care should be exercised when driving or 
operating machinery. Doses of dopamine receptor agonists should 
be increased slowly according to response and tolerability. 
Treatment with dopamine receptor agonists should not be 
withdrawn abruptly.
Pergolide Associated with more neuropsychiatric side-effects than levodopa. 
Dopamine receptor agonists can cause excessive daytime 
sleepiness and sudden onset of sleep. Hypotensive reactions can 
occur in some patients taking dopamine agonists; these can be 
particularly problematic during the first few days o f treatment and 
care should be exercised when driving or operating machinery. 
Doses of dopamine receptor agonists should be increased slowly 
according to response and tolerability. Treatment with dopamine 
receptor agonists should not be withdrawn abruptly. Ergot-derived 
dopamine receptor agonists have been associated with pulmonary, 
retroperitoneal, and pericardial fibrotic reactions. Before starting 
treatment with these ergot derivatives it may be appropriate to 
measure the erythrocyte sedimentation rate and serum creatinine 
and to obtain a chest X-ray. Patients should be monitored for 
dyspnoea, persistent cough, chest pain, cardiac failure, and 
abdominal pain or tenderness. I f  long-term treatment is expected, 
then lung-function tests may also be helpful. Arrhythmias or 
underlying cardiac disease; history of confusion, psychosis, or 
hallucinations, dyskinesia (may exacerbate); porphyria; 
pregnancy; breast-feeding
Bromocriptine Associated with more neuropsychiatric side-effects than levodopa.
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Dopamine receptor agonists can cause excessive daytime 
sleepiness and sudden onset o f sleep. Hypotensive reactions can 
occur in some patients taking dopamine agonists; these can be 
particularly problematic during the first few days of treatment and 
care should be exercised when driving or operating machinery. 
Doses of dopamine receptor agonists should be increased slowly 
according to response and tolerability. Treatment with dopamine 
receptor agonists should not be withdrawn abruptly. Ergot-derived 
dopamine receptor agonists have been associated with pulmonary, 
retroperitoneal, and pericardial fibrotic reactions. Before starting 
treatment with ergot derivatives it may be appropriate to measure 
the erythrocyte sedimentation rate and serum creatinine and to 
obtain a chest X-ray. Patients should be monitored for dyspnoea, 
persistent cough, chest pain, cardiac failure, and abdominal pain or 
tenderness. I f  long-term treatment is expected, then lung-function 
tests may also be helpful, specialist evaluation— monitor for 
pituitary enlargement, particularly during pregnancy; monitor 
visual field to detect secondary field loss in macroprolactinoma; 
contraceptive advice i f  appropriate (oral contraceptives may 
increase prolactin concentration); avoid breast-feeding for about 5 
days i f  lactation prevention fails; hepatic impairment
Cabergoline Ergot-derived dopamine receptor agonists have been associated 
with pulmonary, retroperitoneal, and pericardial fibrotic reactions. 
Before starting treatment with these ergot derivatives it may be 
appropriate to measure the erythrocyte sedimentation rate and 
serum creatinine and to obtain a chest X-ray. Patients should be 
monitored for dyspnoea, persistent cough, chest pain, cardiac 
failure, and abdominal pain or tenderness. I f  long-term treatment 
is expected, then lung-function tests may also be helpful. 
Associated with more neuro-psychiatric side-effects than 
levodopa. Dopamine receptor agonists can cause excessive 
daytime sleepiness and sudden onset of sleep. Hypotensive 
reactions can occur in some patients taking dopamine agonists; 
these can be particularly problematic during the first few days of 
treatment and care should be exercised when driving or operating 
machinery. Doses of dopamine receptor agonists should be 
increased slowly according to response and tolerability. Treatment 
with dopamine receptor agonists should not be withdrawn 
abruptly. Severe hepatic impairment; monthly pregnancy tests 
during the amenorrhoeic period; advise non-hormonal 
contraception i f  pregnancy not desired
Apomorphine Associated with more neuropsychiatric side-effects than levodopa. 
Dopamine receptor agonists can cause excessive daytime 
sleepiness and sudden onset of sleep. Hypotensive reactions can 
occur in some patients taking dopamine agonists; these can be 
particularly problematic during the first few days of treatment and 
care should be exercised when driving or operating machinery. 
Doses of dopamine receptor agonists should be increased slowly 
according to response and tolerability. Treatment with dopamine 
receptor agonists should not be withdrawn abruptly. Pulmonary or
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cardiovascular disease, history o f postural hypotension (special 
care on initiation); neuropsychiatric problems or dementia; 
hepatic, haemopoietic, renal, and cardiovascular monitoring; on 
administration with levodopa test initially and every 6 months for 
haemolytic anaemia (development calls for specialist 
haematological care with dose reduction and possible 
discontinuation); renal impairment; pregnancy
Selegiline avoid abrupt withdrawal; gastric and duodenal ulceration (avoid in 
active ulceration), uncontrolled hypertension, arrhythmias, angina, 
psychosis, side-effects of levodopa may be increased, concurrent 
levodopa dosage can be reduced by 10-20%
Rasagiline avoid abrupt withdrawal; hepatic impairment; pregnancy, breast­
feeding
Amantadine hepatic impairment; renal impairment (avoid i f  creatinine 
clearance less than 15mL/minute); congestive heart disease (may 
exacerbate oedema), confused or hallucinatory states, elderly; 
avoid abrupt withdrawal in Parkinson's disease
Entacapone avoid abrupt withdrawal; concurrent levodopa dose may need to 
be reduced by about 10-30%
Tol capone Avoid abrupt withdrawal; most patients receiving more than 
600mg levodopa daily require reduction of levodopa dose by 
about 30%; renal impairment; pregnancy. Potentially life- 
threatening hepatotoxicity including fulminant hepatitis reported 
rarely, usually in females and during the first 6 months, but late- 
onset liver injury has also been reported; test liver function before 
treatment, and monitor every 2 weeks for first year, every 4 weeks 
for next 6 months and every 8 weeks thereafter (restart monitoring 
schedule i f  dose increased); discontinue i f  abnormal liver function 
tests or symptoms of liver disorder (counselling, see below); do 
not re-introduce tol capone once discontinued.
Counselling: Patients should be told how to recognise signs of liver 
disorder and advised to seek immediate medical attention i f  
symptoms such as anorexia, nausea, vomiting, fatigue, abdominal 
pain, dark urine, or pruritus develop
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Table 4.22 Total scores for all the criteria
Drug name Motor
flues
Cog
impair
Confusion Hallucns Dyskinesia Depression Post
Hypot
ADL Stage
disease
ADR Interact Total Mean
Co-beneldopa 10 10 10 10 3 7 45 50 50 43 67 238 28
Co-careldopa 10 50 50 10 7 7 50 52 50 59 67 345 37
Stalevo 15 50 10 10 16 10 50 60 50 73 72 344 38
Duodopa 100 10 10 10 35 10 50 80 50 68 67 423 44
Ropinirole 10 50 7 7 13 5 47 52 50 46 79 287 33
Pramipexole 10 50 10 7 10 65 50 60 50 73 81 385 42
Rotigotine 13 50 50 10 7 50 50 63 50 63 58 406 42
Pergolide 57 50 10 10 75 60 47 60 50 10 58 429 44
Bromocriptine 25 50 10 15 15 10 50 60 50 10 61 295 32
Cabergoline 42 50 15 12 27 10 45 80 50 10 72 341 37
Apomorphine 90 50 10 10 11 50 60 50 50 76 72 457 48
Selegiline 17 50 10 10 7 50 55 50 50 68 68 367 39
Rasagiline 10 50 50 10 60 32 50 52 52 74 69 440 46
Amantadine 5 50 50 7 65 7 45 60 50 63 68 402 43
Entacapone 7 50 10 9 6 8 47 53 50 66 78 306 35
Tolcapone 27 50 10 7 3 50 50 50 50 64 79 361 40
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possible weighting. As mentioned in the methodology, the model was 
designed for the users to be able to choose the weights themselves between 
0 and 10, so only the phrasing of the weights was developed here. An 
example of the phrasing of the weights is shown for ‘motor fluctuations’ below:
The drugs cause from ‘no improvement in motor fluctuations’ to ‘a big 
improvement in motor fluctuations’.’
This was calculated from the lowest score for ‘motor fluctuations’ for all the 
drugs being five (i.e. virtually zero improvement) to the highest score obtained 
being 100 (i.e. the highest improvement). Table 4.23 shows the weight 
definitions.
Combining the scores and weights
It was not possible to combine the scores and weights at this stage to 
calculate overall values as the model was designed for the users to choose 
the weights themselves, as mentioned above. The advantage of the user 
choosing the weights though is that the patient can be fully involved in the 
decision-making process. The practitioner and patient choosing the weights 
together means that they would be involved in shared decision-making. This 
is one way of ensuring that the patient’s voice is heard when the relevant 
choices are made (Whitney, 2003).
DISCUSSION
The aim of this chapter was to develop a model to choose the most effective 
drug treatment for Parkinson’s disease, based on criteria developed in the 
previous chapter. This was achieved through the process of MCDA, by 
scoring the options and developing a system to enable the user to weight the 
criteria so that the scores and weights can then be combined to establish the 
overall values. A model for drug treatment choice has thus been developed 
for Parkinson’s disease for the first time. It is also the first time that MCDA 
has been used for such a complicated disorder in medicine.
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Table 4.23 Weight definitions
Criterion Lowest
score
Highest
score
Weight
Motor fluctuations 5 100 From ‘no improvement in motor 
fluctuations’ to ‘a big improvement 
in motor fluctuations’
Cognitive
impairment
10 50 From ‘cognitive impairment being a 
common occurrence’ to ‘no 
incidence of cognitive impairment’
Confusion 7 50 From ‘a high incidence of 
confusion’ to ‘neither improving 
nor worsening confusion’
Hallucinations 7 15 From ‘a high incidence of 
hallucinations’ to ‘a fairly common 
occurrence of hallucinations’
Dyskinesia 3 75 From ‘a high incidence of 
dyskinesia’ to ‘a medium 
improvement o f dyskinesia’
Depression 5 65 From ‘a high incidence o f 
depression’ to ‘a small 
improvement on depression’
Postural
hypotension
9 20 From ‘a common occurrence of 
postural hypotension’ to ‘a less 
common occurrence o f postural 
hypotension’
Activities of daily 
living
50 80 ‘Neither improve nor worsen the 
stage of disease’
Stage of disease 50 50 From ‘ neither worsening nor 
improving ability to carry out A D L ’ 
to ‘a large improvement in ability to 
carry out A D L ’
A number of problems were encountered in scoring the options. Firstly, in 
obtaining data to establish the scores. Some drugs, such as Madopar and 
Sinemet, were very difficult to obtain any data on at all, mainly due to the age 
of them as they had been developed perhaps 30 or 40 years ago and 
therefore the original trial data was not easily obtainable any more. For the 
most recent drugs, such as duodopa, trial data was readily available and 
easily obtained. This, however, meant that there was a lack of consistency in 
the data obtained on the drugs. For the older drugs and also some other 
drugs, where there was a lack of data in the trials pertinent to the criteria 
required, it was necessary to obtain data by searching for relevant literature. 
Another problem with the trial data was the lack of uniformity in the data. For
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example, in assessing the data on the criterion ‘activities of daily living’ it 
became clear that different trials used different assessment scales, typically 
either the UPDRS II or the Schwab and England scale. Although both these 
scales assess the same thing, that is the extent to which the patient’s 
activities of living are affected by the disease, it is not possible to directly 
compare the results because the scales produce different results. Therefore, 
the solution had to be to solely use one scale, which in this case was the 
UPDRS as it was the most commonly used. This though meant that data was 
excluded and therefore the picture obtained of the drugs’ performance was 
not as complete as it could have been.
This suggests that if clinical trial data is to be meaningfully compared it would 
be useful if drug companies had an established protocol for uniformity in all 
their trials. Although at the time older trials were carried out many of the 
assessment tools commonly used in current trials were not available, for more 
recent trials there are still discrepancies in the assessments used, despite all 
the tools being widely available. In recent trials, for example, it was 
interesting to note that the same assessment scales were not necessarily 
used nor indeed even that the same criteria were assessed. It would be 
interesting to ascertain why, for example, some trials did not assess cognitive 
impairment when there is a readily available tool, the MMSE, available for 
such a purpose. This is particularly pertinent in the case of anti-parkinsonian 
drugs as not only is cognitive impairment a problem for the main age group of 
Parkinson’s patients, i.e. the over 65s, but also that the condition can be both 
brought on and aggravated by Parkinson’s disease. Therefore, one would 
have to question why drug companies had not assessed such an important 
condition in their trials.
There were varying results from the scores of the individual criteria. ‘Motor 
fluctuations’ showed a wide variation in scores, with the mean being quite low. 
With only three drugs being shown to benefit the user for ‘motor fluctuations’ 
one can see a lack of choice available for prescribers for patients with this 
often debilitating symptom. One of these drugs, Duodopa, is particularly
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expensive to prescribe, and another, pergolide, has some serious side-effects, 
meaning that options could be even more limited for prescribers.
The main conclusion one can draw about ‘cognitive impairment’ is that a lack 
of trial data gives no answers for prescribers. Two drugs were shown to have 
a negative effect, but prescribers would have no information to go on when 
making an informed choice for the other drugs.
A lack of data was also a problem for ‘confusion’, with several drugs having no 
data available. The majority of the drugs were shown to cause confusion, but 
as there was no data on the other drugs, prescribers would only have a choice 
of prescribing a drug that was known to cause confusion or one for which the 
effect was not known. Again, this shows an area that more researchers need 
to look at in clinical trials.
‘Hallucinations’ proved to be a problem for all the drugs, being a side-effect of 
all of them. This could perhaps be an area that needs looking at for future 
drug development, as an obvious niche exists for a drug that does not cause 
this side-effect.
There was a wide variation in the scores for ‘dyskinesias’, ranging almost from 
one end of the scale to the other. Only three drugs were shown to improve 
this symptom, and two of those only showed a small improvement.
‘Depression’ was another criterion that the drugs seemed to show little benefit 
for, with only two drugs exhibiting any improvement. Depression has been 
shown to be a major problem among Parkinson’s patients and these results 
show there are little alternatives available for practitioners wishing to reduce 
the condition among their patients.
‘Postural hypotension’ was also a poorly scoring criterion, with all the drugs 
causing the condition as a side-effect, although this may be considered a less 
serious condition than some of the other criteria.
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‘Activities of daily living’ on the other hand was the highest scoring criterion, 
with drugs at worst having a neutral effect, but many of the drugs showing a 
benefit for patients. This showed an encouraging aspect of the drug 
treatments.
There was a real lack of data for ‘stage of disease’, similarly to ‘cognitive 
impairment’. Although this might be considered by the people running the 
trials to not be a particularly important aspect of the effects of the drug 
treatments in PD, it could be useful data if it were assessed more often. It 
would give a picture of the effect the drugs have on the patient’s condition 
overall, with a clear comparison to be made if the patients have either reduced 
a stage or increased a stage by the end of their treatment period for example. 
The difficulty in scoring the ADRs was shown by the problems with the ergot 
dopamine agonists. It is unclear whether the seriousness of their potential 
cardiovascular side-effects is truly reflected in the ‘penalty’ score they were 
awarded for this criterion. They would otherwise have scored better than one 
might have imagined. Perhaps also surprising was the difference in the 
scores for the four levodopa drugs, which one might expect to score within a 
fairly close range.
The overall results from the scores showed some perhaps surprising results. 
Although one would perhaps expect drugs such as apomorphine and 
rasagiline to score well, one would not have expected the same for pergolide. 
This particular non-ergot dopamine agonist has generally been prescribed 
less in recent years due to the seriousness of the cardiovascular side-effects it 
can cause. The other non-ergot dopamine agonists bromocriptine and 
cabergoline did not fare quite so well with their scores, but still scored more 
highly than co-beneldopa, despite the fact that levodopa is still considered the 
‘gold standard’ among anti-parkinsonian medications. It was also surprising 
that co-beneldopa scored so poorly, having the lowest overall score of all the 
drugs. As mentioned before, levodopa is the current ‘gold standard’, therefore 
one would expect all the levodopa drugs to score well.
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Devising a means for the weights to be calculated was initially quite a 
difficulty. However, the resulting method of allowing the user to choose their 
own weights enabled a unique model to be developed for each user. The 
development of a generic ‘one size fits all’ model, with the weights pre­
defined, would mean the model was not necessarily applicable to each 
individual patient. Developing the weights this way meant that the user, and 
by implication the patient, would be fully involved in the process and a unique 
model developed for each individual patient. Although the scores and weights 
could not be combined to form an overall result within the process of 
developing the model, the advantage of developing the weights in this way 
has meant that shared decision-making has become an integral part of the 
model. The aim of this is to give patients enough information about the 
treatments and their effects that they are able to make an informed 
choice(Schneider et al, 2008). This is particularly important for chronic long­
term conditions such as Parkinson’s disease where practitioners need to work 
closely with patients to choose the optimum pharmacological solution, which 
may take time, continuous monitoring and adjustment of medication type and 
level. The process works best where both practitioners and patients are 
involved in the management of medication regimens (Charles et al., 1997).
It should therefore be recognised that a model has been successfully 
developed for Parkinson’s disease. This model must be considered as a 
prototype and as a proof of concept. Importantly, the model would aid 
clinicians to make drug treatment decisions using evidence-based medicine 
and could be particularly useful for inexperienced doctors and nurses with little 
experience of prescribing. It also incorporates shared decision-making and 
therefore includes what have been considered by some to be two of the most 
important aspects of medicine in recent years. The model will need to be 
validated by an expert panel and this will be examined in chapter seven. The 
model will also be implemented within a computerised decision support 
system in order for it to become an electronic decision aid and this will be 
discussed in the next chapter.
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SUMMARY
In summary, in this chapter a model to choose the most effective drug 
treatment for Parkinson’s disease was developed using the methodology of 
MCDA. The development of the model involved the following steps:
• Pivotal trials and other trial articles were examined to obtain data to 
score the options
• Scales were developed to define the least and most preferred points for 
each of the criteria, as well as the intermediary points
• The trial data was analysed to determine the scores for each drug
• Scores were developed for each of the drugs on each of the criteria
• The phrasing of the weights was developed
• The scores and weights could not be combined to form overall values 
as the users would be choosing the weights themselves
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CHAPTER 5
Development of the Computer Decision Support
System
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INTRODUCTION
In chapter four the model was developed for Parkinson’s disease using 
MCDA. In order to operationalise the model and carry out the mathematic 
calculations within the model it was deemed necessary to develop a software 
system. It was hoped that this system would enable the model to become an 
electronic prescribing decision aid.
The use of proprietary software developed for MCDA models was considered 
initially, but was considered to be unsuitable for the model developed here. 
Software was needed that would allow the user to enter information about the 
patient other than the criteria or weights, such as the patient’s medication. 
Proprietary software, such as Hiview, would not provide this feature. 
Therefore, it was decided that it would be necessary to develop a bespoke 
piece of software to operationalise all the functions needed within the model. 
Deciding on all the issues involved with developing a new piece of software, 
such as choosing a suitable programming language can often be a difficult 
process. However, a methodology exists which gives a process to follow to 
ensure user requirements are established and met and that the software 
performs all the functions it is intended to. This process and the software 
developed will therefore be discussed in this chapter.
SOFTWARE DEVELOPMENT METHODS
A number of stages are involved in developing a new piece of software. 
Firstly, one chooses a software development model. The next stage is the 
specification and design, where Unified Modelling Language is used to model 
the requirements. The system requirements are also developed in this stage. 
The software or programming language is next chosen and the interface then 
designed. The final stage is the implementation of the software. These 
stages are represented diagrammatically in Figure 5.1. Each stage will now 
be described in detail.
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Figure 5.1 Software development methods
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Types of Software Development Models
The first stage when designing a new piece of software is to choose a 
development model. Several different kinds of development models exist and 
it is important to choose the right kind of model depending on the type of 
software that is being developed and the way that it will be used. The types of 
software development models consist of the four models listed below:
• Waterfall
• Incremental
• Spiral
• Prototyping
Waterfall model
This technique requires completion of one phase of the software development 
process before proceeding onto the next phase. The process of these phases 
is demonstrated graphically to resemble the downward flow of a waterfall 
(Sommerville, 2001), as shown in Figure 5.2. The model consists of five 
stages:
1. Requirements analysis and definition -  the system’s services, 
constraints and goals are established through consulting with the 
system’s users. They are defined in detail and become the system 
specification.
2. System and software design -  systems design separates the 
requirements for hardware and software systems. The overall system 
architecture is established. The software design process incorporates 
identification and description of the fundamental software system 
abstractions and their relationships.
3. Implementation and unit testing -  the software design is realised as a 
set of program unit and each unit is tested to ensure it meets its 
specification.
4. Integration and system testing -  the program units are integrated and 
tested together as a whole to ensure that the software requirements
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have been met. The software system is then delivered to the 
customer.
5. Operation and maintenance -  this is usually the longest life-cycle 
phase. The system is installed and put into operation. The 
maintenance phase includes correcting errors not previously 
discovered, improving the implementation of system units and 
enhancing the system as new requirements are uncovered.
Incremental model
The incremental model was developed as a means of reducing rework during 
the development process and also to give customers opportunities to delay 
decisions on their requirements until they had experience of using the system 
(Sommerville, 2001). It consists of three main stages:
1. Customers identify the services they want the system to provide. 
Several increments are defined, which each provide a subset of the 
system functionality. The highest priority services are the first to be 
delivered to customers.
2. The requirements for the first increment are next defined in detail and 
developed.
3. When each increment is completed and delivered the customers are 
able to put it straight into service. They can experiment with the 
system, allowing them to clarify requirements for later increments. Each 
new increment that is completed is integrated with existing increments 
(Sommerville, 2001). The graphic representation of an incremental 
model is shown in Figure 5.3.
Spiral model
For this model, as the name suggests, the software development process is 
represented as a spiral, with each loop in the spiral representing a phase of 
the process (Sommerville, 2001). There are four sections in each loop of the 
spiral:
1. Objective setting -  objectives for each phase of the project are defined, 
constraints identified and a management plan drawn up.
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Figure 5.2 Waterfall model (Sommerville, 2001)
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Figure 5.3 Incremental model (Sommerville, 2001)
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3. Risk assessment and reduction -  a detailed analysis is carried out for 
each risk identified in the project.
4. Development and validation -  a development model for the system is 
chosen after the risks are evaluated. For example, if user interface 
risks are identified as the dominant ones an evolutionary prototyping 
model may be the most appropriate model.
5. Planning -  the project is reviewed and decisions made whether to 
continue with another loop of the spiral.
The spiral model is the only one to explicitly consider risks. The spiral model 
is demonstrated graphically in Figure 5.4.
Prototype model
Prototyping gives the client a working version of a system early on in the 
development lifecycle and the prototype is then amended until the client’s 
requirements are fully met (Bell, 2000). Two types of prototyping exist; 
evolutionary and throwaway. Evolutionary prototyping involves the prototype 
becoming the final version after it has been transformed with new facilities or 
features added, according to the user’s requirements. Throwaway 
prototyping, on the other hand, involves the system being implemented in a 
way which is distinct from the original version. A prototype model is 
demonstrated in Figure 5.5.
A prototype model was chosen for this particular software development, as it 
meant a system could be developed and refined according to what the user 
would be expecting to do with it. It would not be possible to consult with any 
users as to their requirements, but the software would be developed based on 
what the users’ requirements were assumed to be. Using an evolutionary 
prototyping model would mean that the software could be continuously 
redeveloped until user requirements were completely met. This would allow 
for refinement and further development, but would also allow for a more or 
less finished product to be presented to users. The users would then be able
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Figure 5.4 Spiral model (Sommerville, 2001)
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to see what the software was able to do and assess whether it suited their 
requirements.
SPECIFICATION AND DESIGN
Unified Modelling Language
The second stage in the software development process involves developing 
the requirements specification and system requirements. Unified Modelling 
System (UML) diagrams are used to illustrate the specification and design of 
the system. UML is not a way of designing a system, but of modelling a
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Figure 5.5 Prototype model (Bell, 2000) 
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system. It can be broken down into two main aspects; structural diagrams 
and behavioural diagrams.
Structural diagrams
Structural diagrams include two types of diagram; class and implementation 
diagrams.
Class diagrams
This is used to represent the underlying pieces, or classes, of a system, their 
relationship to each other and which subsystem they belong to. They include
140
attributes and operations, as well as roles and associations. Object diagrams 
are similar except that they show objects that are instances of classes. 
Objects deal with individual unique things, whilst classes are more generic 
(Roff, 2003).
Implementation diagrams: component and deployment
Component diagrams illustrate how a system’s components interact with each 
other and show the dependencies between source files and classes, along 
with the components they belong to. A deployment diagram models where 
the components will end up after they are installed on a system and how the 
systems interact.
Behavioural diagrams
These are used to show how a process flows between components, classes, 
users and the system. There are five different types, as detailed below.
Use Case diagrams
These contain use cases and actors and illustrate the relationship between 
the two sets. The use cases are joined by associations and linked to the 
actors to project the overall structure and availability in a system.
Activity diagrams
These are used to analyse the behaviour within more complex use cases and 
show their interaction. They can model business workflows during the design 
of use cases. They are usually used to represent more complicated business 
activities.
Sequence diagrams
These show the interaction between actors and objects and other objects. 
Messages are sent from actors to objects, between objects and from objects 
to actors to show how the flow of control progresses through the system. 
Sequence diagrams document how a use case is solved with the current 
system design. They can show every possible path through an interaction or 
show a single path through an interaction (Roff, 2003).
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Collaboration diagrams
These help class diagrams progress to the next stage. They represent the 
interaction and relationship between objects created in earlier stages of the 
domain modelling process. Collaboration diagrams can also model messages 
between different objects.
Statechart diagrams
These diagrams model the behaviour of subsystems, the interaction with 
classes and the system interface and also realise use cases. They can help to 
visualise the flow of an application.
The functional requirements for the system will be illustrated by a Use Case 
Diagram. The system requirements will also be discussed and illustrated by 
an Activity Diagram to explain how the system functions.
Requirements Specification
The requirements of a system are the properties that the system should 
exhibit to meet particular needs. Requirements specification focuses on what 
is needed, rather than how it will be achieved. Requirements can be split into 
two distinct types: functional and non-functional. Functional requirements 
describe the system’s services or functions, that is to say, what the system 
should do. Non-functional requirements, on the other hand, are the qualities 
of the system. These may relate to system properties such as reliability, 
response time and store occupancy. Failure to meet a non-functional 
requirement can make the whole system unusable. Therefore, they are often 
more critical than individual functional requirements (Sommerville, 2001).
Functional requirements
The functional requirements for this system are that it allows the user to do 
the following:
• User enters data about the patient
• User rates importance of criteria to doctor/patient
• User receives the recommended treatment
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• User receives list of all the treatments with their overall result
Use Case diagrams
A Use Case Diagram shows how the system is intended to behave from the 
user’s point of view and can be used in elicitation of the user’s requirements. 
It is the highest form of details about a system and describes what the system 
does for the user, but not how it is done. The top level use case represents 
functionalities that the system provides for the user. This can then be further 
expanded into a lower level giving extra detail by means of the relationships 
‘includes’, ‘extends’ and ‘generalisation’. However, for this system a top level 
use case was considered sufficient to represent the functionalities of the 
system.
Use Case diagrams consist of four parts: the system, actors, use cases and 
relationships. A system is something that performs a function, eg a piece or 
multiple pieces of software. The system is generally not identified in a Use 
Case diagram and in this case there is only one overall system represented. 
The actors represent something or someone that uses the system, that is, 
either a person or another system. This is depicted by a stick figure with the 
user’s name underneath. A use case is the action that a user makes by using 
the system. For example, a developer ‘creates software’. This is represented 
by text in an oval for each use case and all the use cases displayed in a text 
box. Finally, the relationships are represented by a line connecting the actors 
to the use cases. This shows which actors relate to which use cases and vice 
versa. Actors can relate to multiple use cases and use cases to multiple 
actors (Roff, 2003). Figure 5.6 represents the Use Case diagram for the 
system.
System requirements
The system requirements demonstrate how the system will carry out the 
functional requirements that have been established.
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Figure 5.6 Use Case Diagram
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Activity diagrams
The behaviour of the system is demonstrated by use of an UML Activity 
Diagram. This type of UML diagram shows the procedural flow of control 
through the system as well as the dependencies between the activities. 
Activity diagrams allow the reader to see how the system executes and how it 
changes direction according to different conditions and stimuli. They also give 
an obvious start and end state (Roff, 2003).
Activity diagrams are represented by activities, states and transitions. 
Activities are actions that the system will carry out. These are depicted by 
rectangles with rounded corners. States, represented by rectangles with less
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rounded corners than activities, use a word or phrase to indicate the current 
being of a system, such as ‘stop’. There are two special states, ‘start’ and 
‘end’. The ‘start’ state is represented by a solid black circle and the ‘end’ state 
by a solid black circle with a white circle around it. Transitions show the 
control flow from one state to another and can show flow from a state to an 
activity, between activities and between states. They are depicted by an open 
arrow which points in the direction of the control flow. Figure 5.7 shows the 
Activity diagram for the CDSS.
Non-functional requirements
There were no non-functional requirements for this software development, as 
no specific users had been defined at this stage. Therefore, it was not 
possible to consider issues such as budget constraints, organisation policies 
or interoperability with other software systems and so on as none of these 
issues was applicable.
CHOICE OF SOFTWARE
Excel
In order to develop the software for the decision support system, an Excel 
spreadsheet with Visual Basic for Applications (VBA) was chosen. Excel is an 
electronic spreadsheet program used for storing, organising or manipulating 
data (www.spreadsheets.about.com, 2008). The spreadsheet would provide 
the calculations and maths side of the Computer Decision Support System, 
whilst VBA would provide the user interface and data input side of the 
application. Excel is a widely available piece of software, which meant 
access would be easy for all users.
Visual Basic for Applications (VBA)
VBA is an embeddable programming environment which enables developers 
to build custom solutions (Microsoft, 2008). It allows the user to manipulate 
data in spreadsheets, whilst providing the user with a ‘user-friendly’ interface 
that avoids them seeing the calculations and manipulations being carried out 
by the spreadsheet. The coding for the software is detailed in Appendix II.
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Figure 5.7 Activity diagram
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INTERFACE DESIGN
Schneiderman’s Golden Rules
A well designed interface is an important part of improving the usability of an 
application. Schneiderman's ‘Eight Golden Rules of Interface Design’ 
(http://faculty.washington.edu/jtenenbg/courses/360/f04/sessions/schneiderm 
anGoldenRules.html, 2008) are a guide to good interface design. 
Schneiderman’s collection of principles is derived heuristically from 
experience and is applicable in most interactive systems once it has been 
properly refined, extended, and interpreted. They consist of the following:
1. Strive for consistency -  actions that are consistent in nature should be 
used in similar situations; with identical terminology used in prompts, 
menus and help screens and consistent commands used throughout.
2. Enable frequent users to use shortcuts -  with increased frequency of 
use comes a user’s desire to reduce the number of interactions and 
increase the pace of interaction. Functions such as abbreviations and 
command keys can be useful for an experienced user.
3. Offer informative feedback -  there should be system feedback for 
every operator action. This could be a modest response for frequent or 
minor actions but a more substantial response for infrequent or major 
actions.
4. Design dialogue to yield closure -  sequential actions should be 
designed in groups with a beginning, middle and end. Feedback at the 
completion of a group of actions gives the user the satisfaction of 
accomplishment and an indication that they are ready to prepare for 
the next group of actions.
5. Offer simple error handling -  the system should be designed as much 
as possible so that the user cannot make a serious error. The system 
should detect any errors made and offer a mechanism for handling the 
error.
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6. Permit easy reversal of actions -  this enables users to know that errors 
can be undone and encourages them to explore unfamiliar options.
7. Support internal locus of control -  experienced users need to know that 
they are in charge of the system and the system will respond to their 
actions. The system should be designed so that users are the initiators 
of actions not responders.
8. Reduce short-term memory load -  displays should be kept simple, 
multiple pages consolidated, and window-motion frequency reduced 
due to the limitations of human information processing in short-term 
memory.
Application of the rules 
Strive for consistency
A series of command buttons were used for the controls, and these were 
mainly added together at the bottom of the page. Only a small number of 
actions are needed from the user and these are consistent as far as they can 
be, as the user is either clicking a radio button, selecting from a list or entering 
a figure and clicking a ‘submit’ button where appropriate.
Enable frequent users to use shortcuts
The form is designed to be quick in use, so this is not really relevant for this 
application. A more lengthy and time-consuming application would 
necessitate shortcuts.
Offer informative feedback
Feedback is given to the user where necessary, for example a form displaying 
the results when they click ‘calculate answer’. However, further feedback was 
not deemed appropriate as the user actions are so few and the form is so 
quick to use. Feedback for user errors, providing error message boxes where 
the incorrect type of data has been entered for example, will be looked at in 
chapter six where data validation is discussed.
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Design diaiogue to yield closure
The form was designed as a series of sequential actions, so the user is 
quickly through each stage and receiving the requested result.
Offer simple error handling
The system was designed to have little data input from the user so serious 
user errors would be extremely unlikely. However, as mentioned previously 
simple error handling, e.g. use of message boxes to give feedback to users, is 
discussed in chapter six under data validation.
Permit easy reversal o f actions
A ‘clear’ button was added to the form so that users could clear all the data 
they had added if they had made a mistake.
Support internal locus o f control
As this was a relatively small application this item was perhaps not so relevant 
for this development. The system did however allow users to proceed 
through the form on their own, only prompting where errors occur.
Reduce short-term memory load
The interface for the CDSS was designed to be simple and easy to use. 
Everything was put on one page so that the user did not have to move from 
page to page or to remember what was on one page when they were on 
another.
IMPLEMENTATION
A user form was developed for the user to enter data about the patient and 
select the weights. The data would then be submitted to Excel, where the 
calculations would be carried out and the results returned to the user.
Setting Up The Form
The form was to be divided into different sections for the user to complete. A 
label was therefore first of all added to the top of the form giving the user the
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overall instruction for completing the form. Another label was then added 
underneath the first with the first question for the user asking them to answer 
the questions about the patient. A list box was next added to the form. The 
list box, which was named ‘ListBoxPoorResp’, was for users to select any 
Parkinson’s disease drugs the patient had previously had a poor response to. 
A label alongside the text box displayed the statement ‘Select any PD drugs 
the patient has previously had a poor response to’. This was set to null on 
initialisation of the form so that none of the options would be pre-selected. 
This was shown through the following code:
TxtName. Value = “ ”.
Data was added to the list box by means of the following code, which shows 
the example for the item ‘not applicable’:
.Addltem “Not applicable”.
In section two of the form a label was added giving the instructions for 
completing the first section on the weightings. A frame was then added 
underneath with a series of nine option buttons. These provided a radio 
button for the user to tick by clicking on their mouse, where they chose the 
applicable criterion they wanted to give the highest weighting to. A frame was 
used here, because it contained all the options in one section and meant the 
user would only be able to select one option. If a frame had not been used, 
the user would have been able to have selected multiple options, rather than 
just the one that was required. Underneath this frame a label with the number 
‘3’ was added alongside a command button with the caption ‘Submit section 
2 ’ .
Another label was added for section four, asking the user to complete the 
second section on the weightings. A second label was added underneath this 
one, giving an explanation of how to complete section four. Another frame 
was then added with the weighting labels alongside text boxes for the user to 
enter their figures for the weights. A frame was not necessary here to prevent
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the user selecting more than one option, as in fact the user was required to 
complete all the boxes, but for design consistency with the weights section 
above it. As text boxes were added rather than option boxes the user was 
automatically able to add data into more than one box.
Command buttons were added for sections five ‘Submit responses’ and six 
‘Calculate answer’ in the bottom left-hand corner of the form. A further two 
command buttons were added for ‘List all responses’ and ‘Reset’ next to 
these, whilst smaller command buttons were added in the bottom right-hand 
corner of the form for the commands ‘Clear’ and ‘Close’. Finally, a command 
button titled ‘Help’ was added in the top right-hand corner of the form to 
provide a help facility for the user. The screenshot in figure 5.8 shows the full 
user form.
Submitting The Data 
Submit section two’
Once the user has clicked the command button ‘Submit section 2’, the 
criterion which has been chosen for a weight of 100 is entered into the 
relevant text box in section four. This was done by using the ‘If Then Else’ 
syntax and offsetting the selected value into the relevant text box, as the 
following code demonstrates for the options ‘motor fluctuations’ and ‘cognitive 
impairment’:
I f  OptMotorFlucs.Value = True Then 
Acti veCell. Value = 10 
TextBoxMotorFlucs. Value = 10
Else I f  OptCoglmpair.Value = True Then 
ActiveCell.Offset( 1,0). Value = 10 
TextBoxCoglmpair. Value = 10
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Figure 5.8 Screenshot of the user form
Please fill in the following form, proceeding through steps 1 to 6 sequentially
1. Please answei the following question about youi patient:
Help
Select any PD drugs the patient has 
previously had a poor response to:
Not Applicable -  j 
Co-benektopa 
Co-car ekiopa
2. If ail the following criteria start with a scoie of 0, which would you and your patient choose to give a score of 10? |10 being the highest 
possible scoref Each criterion statement explains the range of effects that the PD diugs can have on that criterion (re. the worst case to 
best case scenario).
The drugs cause from 'no improvement m mot or 
fluctuations’to ’8 big improvement in motor fluctuations'
The drugs cause from loognfte impairment bemg a ' frwTl *  ^  of
f  common occurrence to Y * incidence of cognitive * ........... . . . -
impairment' to 'neither improving nor worsening contusion1
^  The cfrugs cause lr om 'a Ingh incidence of hallucinations' to ^  The drugs cause from 'a trgti ncidence ot dysldnesia' ^  The drugs cause from 'a high incidence of
‘a tarty corrmon occurrence of haSucirarfions' to 'a medsum improvement of dyskinesia’ depression' to 'a smal improvemert on depression'
^  The drugs cause from 'a corrmon occurrence of postural ^  The drugs 'nether improve nor worsen the stage of The drugs cause from 'nether worsening nor improving 
; r  hypotension’ to 'a less common occurrence of postural disease' T  to carry out ADL'to‘a terge improvement in abity
hypotension’ to carry out ADL'
3, Submit section 2
4. H the  highest value criterion has a scoie of 10. how impoitant are your and your patient’s othet choices in relation to the first choice? 
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5- Submit responses 6- Calculate answer List all results Reset Clear so een dose
Once section four is completed, when the user has selected the figures they 
want for the rest of the weights, the command button ‘Submit responses’ is 
clicked and the weights are submitted to an Excel spreadsheet. Initially, the 
cell ‘A1’ is selected as the active cell with the code:
Range(“A l”). Select
and the active cell offset by one row and one column to the cell ‘B2’, the cell 
for the weight of ‘motor fluctuations’:
ActiveCell.Offset(l, l).Select.
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The values for the rest of the weights were inserted below, offsetting the 
active cell by one row and zero columns each time, as demonstrated in the 
code below for the criterion weight ‘cognitive impairment’ in cell ‘B3’:
ActiveCell.Offset(l, 0).Value = TextBoxCoglmpair.Value.
‘Submit responses’
When the user clicks on the command button ‘Submit responses’ the figures 
for the weights in section four are entered into the Excel spreadsheet in 
column B, rows two to ten. This is done using the following code, which 
shows the examples for ‘motor fluctuations’, ‘cognitive impairment’ and 
‘confusion’:
ActiveCell.Offset (0, 0).value = TextBoxMotorFlucs.value 
ActiveCell.Offset (1, 0).value = TextBoxCoglmpair.value 
ActiveCell.Offset (2, 0).value = TextBoxConfusion.value.
The value that the user inputs in each text box is taken and copied into the 
relevant cell in the spreadsheet. For example, the ‘motor fluctuations’ value is 
placed in the first cell, B2, and the ‘cognitive impairment’ value in the cell one 
row underneath, C2.
Calculate answer’
Once the weights have been placed in the spreadsheet, the calculations can 
be performed when the user clicks ‘Calculate answer’. As discussed in 
chapter four, the scores and weights must be multiplied together and the 
results summed to find an overall value. These calculations are carried out by 
Excel according to the coding in VBA. This is carried out using nested loops. 
This involves one loop being implemented within another loop. For example, 
the outside loop starts from column C (column number three) and proceeds 
through to column R (column number 18). The loop stops when it gets to the 
column after the last one required:
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Figure 5.9 Screenshot showing the weights added to column B, rows 2 to 10
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2 motor fluctuations 10 10 10 15 100 10 10 13 57 25 42 90 17 10i 5
3 cognitive impairment 9 10 50 50 10 50 50 50 50 50 50 50 50 50 50
4 confusion 8 10 50 10 10 7 10 50 10 10 15 10 10 50 50
5 hallucinations 7 10 10 10 10 7 7 10 10 15 12 10 10 10 7
6 dyskinesias 8 3 7 16 35 13 10 7 75 15 27' 11 7 60 65
7 depression 7 7 7 10 10 5 65 50 60 10 10 50 50 32 7
8 postural hypotension 6 45 50 50 50 47 50 50 47 50 45 60 55 50 45
9 stage of disease 5 50 52 50 50 50 50 50 60 60 80 50 50 52 50
10_ADL 4 50 50 60 80 52 60 63 50 50 50 50 50 52 60
11 adverse drug reactions 10 43 59 73 68 46 73 63 10 10 10 76 68 74 63
12 drug interactions 10 5 5 5 5 5 5 5 5 5 5 5 5 5 5
13
14
15
16
17
18
19
20
21
r v
DrugCol = 3
Do Until DrugCol = 19
Loop.
The internal loop starts from row two of the weights column and loops down to 
row 12, again the loop stops at the row after the last required one:
WeightRow = 2
Do Until WeightRow = 13
Loop.
The scores and weights are then multiplied together, starting at column C, 
working down all the rows in that column then proceeding to each subsequent 
column until column R. The results for each column are posted two rows 
underneath the respective scores columns. The whole nested loop with 
calculations is represented in the following code, with comments explaining 
the code represented by sentences beginning with an apostrophe:
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'start from column C and loop through to column R 
DrugCol 3 
Do U ntil DrugCol 19
’start from row 2 and loop through to row 12 
W eightRow 2 
Do Until W eightRow 13
’m ultip ly score by weight, loop down rows and across columns, 
position results underneath each column 
Cells(W eightRow  ♦ 13, DrugCol).-value Cells(W eightRow ,
2 ).value * C ells(W eightR ow , D rugCol).value  
W eightRow W eightR ow  f 1
Loop
DrugCol DrugCol + 1
I .oop
Figure 5.10 shows a screenshot of the results of the multiplication inserted 
underneath the scores columns.
The next step is for the multiplication results to be summed and the result 
entered three rows underneath the multiplication values. This is again carried 
out with a loop, working from column three onwards as shown by the code 
below:
’sum m ultiplication values - (no sum function)
'start from column C, loop through to column R 
M ultiC ol 3 
Do Until M u ltiC o l 19
’put result o f  addition 2 rows below scores 
Cclls(2X. M u ltiC o l).va lue  (C ells(15, M u ltiC o l).va lu e  ♦ Cells(16, M ultiC ol).va lue + 
Cells( 17, M u ltiC o l).va lue  ♦ Cells( 18, M u ltiC o l).va lu e  ♦ Cells(19, M ultiC ol).va lue + 
Cclls(2(), M u ltiC o l).va lue  + Cclls(21,
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Figure 5.10 Screenshot showing the results of the multiplication
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MultiCol).value +  Cells(22, MultiCol).value + Cells(23, MultiCol).value + 
Cells(24. MultiCol).value + Cells(25. MultiCol).value) \ 100
MultiCol = MultiCol + 1 
Loop
The drug names are already listed in a row below the multiplication results 
and the result of the sum are inserted in the row below this, as shown by the 
screenshot in Figure 5.11.
The final stage for Calculate answer’ is to sort the results in ascending order 
so that the top three treatments can be returned to the user. First of all, the 
drug names, results and each drug s cautions and co-morbidities (which area 
already listed in the spreadsheet) are copied and pasted a few rows below:
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Figure 5.11 Screenshot showing the results of the sum in row 28
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'copy rows with names o f drugs and results o f multiplication and cautions and co- 
morbidities
Rangc("C27:R30”).Select
Selection.Copy
'paste drug names into row 33. results to row 34, cautions to row 35 and co­
morbidities to row 36 
R ange( ”C3 3: R 3 6”) .Select
Selection.PastcSpecial Paste: xIPasteValues, Operation:—xlNonc, SkipBlanks 
:=False, T ransposes False
The results are then sorted in ascending order, along with the drug name, 
cautions and co-morbidities using the Excel sort’:
'select drug names, results, cautions and co-morbidities and sort in ascending order
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Range( ”('3 3 : R 36"). Select
Selection.Sort K e y l: Range("C34"), Order 1: xlAseending, Header:^xlNo,
( )rdert'ustom : 1. MatehC’ase: False. Orientation:^ xlLeftToRight,
D a ta O p tio n l: xlSortN om ial
Finally, the results are returned to the user in a pop-up user form on screen, 
showing the top three recommended treatments and their respective cautions 
and co-morbidities:
'take top 3 results in columns R, Q  and P and return their names in a message box 
w ith their cautions and co-morbidities
'results 1. 2 and 3 return results for top drug w ith cautions and co-morbidities 
SortResultl C’ells(33. IX).value  
SortResult2 C‘ells(35, IX).value  
SortResult3 Cells(36. IX).value
'results 4. 5 and 6 return results for 2nd drug w ith cautions and co- morbidities 
SortResult4 C ells(33. 17).value 
SortResult5 C'ells(35. 17).value 
SortResultb C clls(36. 17).value
'results 7. X and 9 return results for 3rd drug w ith cautions and co-morbidities 
SortResult7 C clls(33. 16).value 
SortResultX Cells(35. 16).value 
SortRcsult9 C clls(36. 16).value
'show results oI sort in ResultsForm - top 3 recommended treatments 
ResultsFonn lex tB ox  1 SortResultl &  v b C rL f&  v b C rL f&  SortResult2 &  
v b O L f  &  vbC r l.l &  SortResult3
ResultsFonn. I extl^ox2 SortResult4 &  v b C rL f &  vbC'rLf &  SortResultS &
v b C rL f &  v b C rL f &  SortResult6
ResultsFonn. I extBox3 SortRcsult7 &  v b O L f  &  vbC’rL f  &  SortResultX &  
vbC’r l.f &  vbC'rl.l &  SortResult9 
ResultsFonn.Show
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The Excel results are demonstrated in Figure 5.12 and the user form results 
which the user sees in figure 5.13.
'List all results’
As well as viewing the top three results the user can see all the results by 
clicking the command button List all results’. This is coded in a similar way to 
Calculate answer’. The value of the drug name in row 33 is taken along with 
the value of the drug result in row 34 and these are displayed alongside each 
other in a message box. The message box lists all the drugs with their 
respective results in descending order. The code for the top scoring drug is 
shown below:
Sort Result I C ells(33, 18).value 
SortResultl Fig (*ells(34, 18).value
where SortResultl’ is the name of the drug, and ‘SortResultl Fig’ is the 
associated result.
The code for the message box to display the results is as follows, which just 
shows the code for results one and two:
M sgBox "The results for all the drugs are as follow s:” &  vb C rL f &  "1. " &  
SortResultl &  " ” &  SortResultl Fig &  v b C rL f &  ”2. " &  SortResult4 &  " ” &  
SortResult4Fig ’*
Figure 5.14 shows the message box displayed on the user form.
‘Reset’ original values
Once the results have been displayed the original values of any drugs that 
were set to ‘0’ for poor response need to have their original values reset. A 
list of all the drugs’ values is stored at the bottom of the spreadsheet, in rows 
41 to 51, and this was set to be copied and pasted back over the values in 
rows two to 12. This is shown in the following code:
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Figure 5.12 Screenshot showing results sorted in ascending order, rows 33 to
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'Copy original scores from cells C41 to R51 
Range ("C41 :R51").Select 
Selection.Copy
Taste scores hack into cells C2 to R 12 after poor responses have been selected 
Range ( ”C2:R12").Select 
Selection.PasteSpccial Paste: xIPasteValues, Operation:=xlNone, 
SkipBlanks:=False, Transpose: False
Help’ facility
A basic help facility was added to explain to the user how to use the form and 
the order in which the sections should be completed. This was developed 
using a simple message box that is displayed when the user clicks on the 
Help button. Figure 5 .15  shows the screenshot.
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Figure 5.13 Screenshot showing the top three results returned to the user in a
user form
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‘Clear screen’ button
A clear’ button was added to the user form to enable the user to clear 
previous data entered if a mistake had been made or when the model was 
being run for a subsequent patient. This worked by setting the value of each 
option box and text box to null’. The values for each of the list box items 
were set to false’. This is illustrated in the following code for the ‘motor 
fluctuations’ option box and text box respectively and the first item in the list of 
drugs the patient has had a poor response to:
Opt MotorFlucs, value = Null 
TextBoxMotorFlucs.valuc Null 
List Box PoorResp.Sclccted(O) F alse
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Figure 5.14 Screenshot showing message box with all the results
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‘Close’ button
The final button was the close’ button which enables the user to close the 
application. This was very simply coded with the following syntax:
Unload Me
DISCUSSION
In conclusion, a computerised prescribing decision support system was 
successfully developed using Excel and Visual Basic for Applications. The 
functional requirements, which were: the user being able to enter data, rate
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Figure 5.15 Screenshot of the help facility
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the criteria; receive the top results and receive a list of all the treatments with 
their results, were all met.
The CDSS was a relatively small application to develop. It was also relatively 
easy to fulfil the requirements of making the application quick and easy to use 
as it was possible to put all the data input requirements on a one page form. 
The amount of data required from the user was also quite small which helped 
to keep the application smaller.
VBA as a programming language is quite simple to use. The coding was 
successfully developed with no previous experience of this programming 
language. There are many books published on VBA and also many websites 
with tips, suggestions, coding ideas and user forums. One of these in 
particular, (www.ozgrid.com, 2008) proved to be very useful for tips and ideas.
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In all. VBA performed the functions required of it, enabling a user interface to 
be developed, sub-routines to be developed to submit the data to the 
spreadsheet, the calculations to be performed in Excel and the results 
returned to the user. It proved to be a sufficient programming language for 
the type of application required. There were no particular problems 
encountered in developing the application.
The user interface designed appeared to meet the requirements set out in this 
chapter. The interface is simple and easy to use, with each step proceeding 
sequentially from the previous one and the results displayed clearly on the 
user form. The help facility also provides details of the steps to be carried out 
by the user in case they are not clear how to use the form. The help facility is 
fairly basic, but this is all that was deemed necessary for this application as it 
is simple and straightforward to use. The only part of the form that could be 
considered time-consuming to use is section four, where the user chooses the 
weights. This could lengthen the time needed to complete the form as it is 
quite a complicated process for the user and could take quite some time to
i
think about before selecting the appropriate weights. However, if this is to be 
considered a limitation then it is more a limitation of the modelling 
methodology than of the CDSS. There is no way to make the user form 
quicker to complete without changing the methodology used for the weights 
section. This would of course mean the methodology was not being 
adequately or properly applied and this is therefore impractical. If the user is 
able to decide on the weights fairly quickly then the user form is still quick to 
use, but it is not the form or CDSS itself which makes it slower to use.
This stage of development of the CDSS did not include any validation of the 
data the user inputs, error handling or testing of the CDSS. These will all be 
discussed in chapter six. The CDSS should also be evaluated by external 
users, such as an expert panel, and this will be discussed in chapter seven 
when the model is validated.
Although the CDSS is adequate for the model developed, if the model were to 
be developed further a more sophisticated application would need to be
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developed. There may be limitations to the functionality that VBA could 
incorporate. Both Excel and, therefore, VBA are widely available and most 
users would already have Excel installed on their machine as part of the 
Windows operating system. However, for the CDSS to be used in a live clinic 
situation it would mean having to send the application to each user 
individually. There could also potentially be problems for the user if they are 
using a different Windows operating system. The CDSS was developed using 
Excel 2003 as part of the Microsoft Office package. If a user had Excel 2007 
installed on their machine or an older version of Windows the CDSS may not 
install or run correctly.
Another important facet of the CDSS which has not been able to be 
developed is explaining the result to the user. Therefore, the user has no way 
of knowing why particular drugs have been chosen for their patient. To 
incorporate this sort of facility in the CDSS would mean developing a far more 
sophisticated system, which was beyond the scope of this PhD. An expert 
system would be able to explain the reasoning behind the decision made to
«
the user. Expert systems, an application of artificial intelligence, consist of a 
database, knowledge base and a rule interpreter. The knowledge base holds 
the rules of inference that are used for reasoning, with such systems typically 
containing hundreds or thousands of rules. The database contains the rules 
about the problem and the rule interpreter makes the inferences. This type of 
system would be able to deal with the complexity of the algorithm that would 
be necessary to make the decision on the best treatment for a particular 
patient and explain why that decision had been made. Therefore, for the 
CDSS to be used in clinical practice it would be necessary to develop an 
expert system.
SUMMARY
• Software development methods were explained and the prototyping 
method used discussed
• Unified modelling language was explained and the different kinds of 
UML diagrams explained
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• The functional requirements of the system were elaborated and 
demonstrated diagrammatically by use of a Use Case Diagram
• The system requirements were elaborated and demonstrated in 
diagram form by means of an Activity Diagram
• The choice of software was explained
• The interface design was explained
• The implementation of how the form was set up was shown and 
demonstrated with sections of the coding used
• The process for the coding and submission of the user’s data was 
elaborated on, including how the data was submitted, how the results 
were calculated and how the results were returned to the user
• The development of the help facility along with the clear’ and close’ 
buttons were examined.
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CHAPTER 6
Validation of Data Entry and Testing of the Computer
Decision Support System
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INTRODUCTION
Once a software application has been developed it is necessary to fully test 
the application to ensure it meets its requirements and that everything 
functions the way that it is expected to. In the context of the software 
developed for the electronic prescribing support system described in chapter 
five, it was necessary to incorporate validation of the data that could be 
entered by the user and to test the prescribing support system overall. 
Therefore, the application developed in chapter five underwent a thorough 
testing process, which will be described in detail in this chapter.
METHODS
Software testing involves executing an implementation of the software and 
examining the outputs and its operational behaviour to check whether it 
performs as required. Testing is a dynamic technique, which works with an 
executable representation of the system. It can only be used when a 
prototype or an executable program has been developed (Sommerville,, 
2001).
Verification And Validation
Verification and validation (V&V) is the checking and analysis process which 
ensures that software conforms to its specification and meets the needs of the 
end users. It is a whole life-cycle process. It starts with requirements 
reviews, continues through design reviews and code inspections and finishes 
with testing of the product. V&V activities should be incorporated at each 
stage of the software process. These activities check whether the results of 
process activities are the same as were specified in the requirements 
(Sommerville, 2001).
Verification and validation do not specify the same thing. Validation can be 
summarised as are we building the right product?’ and verification as are we 
building the product right?’ Verification checks whether the software meets 
both its functional and non-functional specification. Validation, on the other 
hand, is a more generalised process which demonstrates that the software
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fulfils the end user’s expectations. This may be distinct from what has been 
specified, in that the end product may not match the user’s original 
specifications even if it meets their specification at the end of the process.
Program testing is still the predominant verification and validation technique 
used. The existence of program defects or inadequacies is detected by 
examining the program s outputs and looking for anomalies. Testing may be 
carried out during the implementation phase, which verifies that the software 
behaves as its designer intended, and also after the implementation is 
complete (Sommerville, 2001).
The ultimate goal of verification and validation is to establish confidence that 
the software system is fit for purpose’. This does not mean that the program 
is completely free of defects, but that the system is good enough for its 
intended use. The level that is considered adequate depends on the system’s 
purpose and the expectations of the users (Sommerville, 2001). Therefore, a 
series of tests were carried out to ensure the software system functioned the
t
way it was intended to.
Testing Methods Used 
Validating the user’s data entry
Before any testing could be carried out a series of data validation techniques 
were incorporated into the coding to check the data that the user entered. 
These were added to ensure that the user only entered the correct form of 
data, such as figures not letters, for each section and also that each section 
had been completed so that the application would work as intended. These 
will now be outlined in turn.
Selecting a weight: section 2
The first stage of the validation was section two, where the user had to 
allocate the top weight to their criterion of choice. This was to check that a 
criterion had been selected when the Submit section 2’ button was clicked.
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Choosing a ll the weights: section 4
The next stage was to check that all the weights in section four had been filled 
in by the user once they clicked on Submit responses’. This would ensure 
none of the criteria weights had been inadvertently omitted.
Completing the weights w ith figures on ly
This stage was to check that the weights had been completed with figures and 
not with letters or other non-numeric characters.
Com pleting the weights with numbers between 0 and 10
A check was added here to ensure that the user had only used figures 
between 0 and 10, as requested, to complete the weights and had not entered 
a negative number or a figure over 10.
Completing each section before c lick ing  ‘Calculate answers’
This stage checked that the user had entered data for sections two and four 
and clicked both the Submit section 2’ and Submit responses’ buttons in 
order for the result to be returned to them.
Completing each section before c lick ing  'L is t a ll resu lts ’
Another check was added to ensure that the user had completed all the 
sections and clicked both the submit buttons before they tried to view the 
results.
Resetting scores before c losing the application
This ensured that the user had clicked the ‘Reset’ button before they closed 
the application so that any drug scores that had been set to 0 when the drug 
was selected for poor response would be reset to their original values so that 
the model could be run again.
Closing the application
The final check was to ensure that the user closed the application by clicking 
on the Close’ button, rather than using the automatically generated ‘X’ on the
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top right-hand comer of the form. This thus ensured also that the scores 
would be reset, as in the check above.
Testing the application sections
Once all the data validation had been added it was necessary to test the 
whole application to ensure that the validation checks all worked as they were 
supposed to and that the application worked as expected overall. The first 
step in the process of testing the application was to develop the methodology 
to be carried out. The functionality of the application was broken down into a 
series of sections or steps that the user would have to work through when 
using the software. The options available to the user for each section were 
then outlined. Each section included options that the user was not supposed 
to use, such as inputting the wrong type of data for example, as well as the 
option that was expected of the user. The next step was to then run the 
application performing all the different options the user might carry out to see 
how the application would respond and to establish whether the data 
validation techniques detailed above performed as expected. The sections
«
and available options are shown in the flowchart in Figure 6.1. A table was 
constructed (Table 6.1) with a list of possible inputs for each section and the 
result that would be expected from each input. Two further columns showed 
the actual result of each test and comments about the result.
RESULTS
Data Validation
Selecting a weight: section 2
To validate that a weight had been selected in section two when the ‘Submit 
section 2’ button was clicked an error message was included in the section of 
code that submitted the value 10’ into the chosen weight in section four. The 
validation formed part of the If...Then... Else’ structure submitting the value 
‘10’ to section four. This is demonstrated in the code below:
I f  OptMotorFlucs. Value True Then 
AetiveCell.Value l()
TextBoxMotorFlucs. Value 10
171
Figure 6.1 Flowchart to show testing procedure
Choose more than 1 weight
I ill in all the figures
Put non-numeric characters
Click ‘submit responses’
Don't choose a weight
Don't click submit'
Don't click ‘calculate answer'
Click ‘calculate answer'
Don't click reset'
Click submit'
Select one
Choose a weight
Don’t select anv
Select more than 1
Don't click submit responses'
Click ‘reset'
Close application
1 ill in none of the figures
Submit section 2
Choose other weights
Calculate answer
Submit section 4
Reset
Close
Choose weight for top criterion
Don't close application
Select poor response drugs
1 ill in some o f the figures but not 
all o f them
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Table 6.1 Testing process documentation
Section Input to be entered Expected result Actual Result Comments
Select poor 
response select
One drug No weights Should be prompted by error message 
for weight when click ‘submit section 2’
top weight No drugs One weight Should submit data to spreadsheet
One drug One weight Should submit data to spreadsheet
Two drugs One weight Should submit data to spreadsheet
* ----f  1 1
Two drugs No weights Should be prompted by error message 
for weight when click ‘submit section 2'
T
i
1
1
Three drugs One weight Should submit data to spreadsheet i j '
Four drugs One weight Should submit data to spreadsheet
Five drugs One weight Should submit data to spreadsheet
Choose other 
weights
No weights Should get error message ‘you must 
complete a value fo r ... * for each 
criterion in turn when click ‘submit 
responses*
i
One weight Should get error messages as above for 
all the other criteria f
Two weights Should get error messages as above for 
all the other criteria j
Three weights Should get error messages as above for 
all the other criteria
Four weights Should get error messages as above for 
all the other criteria
All the weights Should submit all the weights into j 
spreadsheet when click ‘submit j 
responses*
|
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Table 6.1 Testing process documentation (continued)
Section Input to be entered Expected result Actual Result Comments
Letters not numbers for one weight Should get error message for that 
criterion ‘enter numerals and not any 
other characters for (criterion name)'
Letters not numbers for two weights Should get error message for each 
criterion ‘enter numerals and not any 
other characters for (criterion name)'
i
Number above 10 for one weight Should get error message ‘You must 
choose a number between 0 and 10 for 
(criterion name)' for that criterion
Number above 10 for two weights Should get error message ‘You must 
choose a number between 0 and 10 for 
(criterion name)' for each criterion
Number below 0 for one weight Should get error message ‘Number must 
be 0 or more for (criterion name)' for 
that criterion
Number below 0 for three weights Should get error message ‘Number must 
be 0 or more for (criterion name)' for 
each criterion
Calculate answer Click calculate answer Should return user form with top 3 
results displayed along with cautions 
and contraindications for each drug
Don't click calculate answer Should receive no results -  nothing will 
appear to have happened to user
List all results All results are listed Should receive list o f all results in order 
of overall score with their total score i f  j 
all sections have been completed and 
submitted
i
i
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Table 6.1 Testing process documentation (continued)
I Section________  Input to be entered_____________Expected result____________   Actual Result Comments
No results are listed Should receive error message “You must
enter data for all the sections, click 
! ‘submit section 2* and ‘submit
! responses' before you can view the 
; results" if  have not entered and
submitted data
Reset Click ‘reset’ : Should copy and paste original values of 
scores o f all drugs into relevant cells
j
Don't click ‘reset' j Should get error message ‘You must 
| click ‘reset* before you can close the ; 
• form' when click ‘close' i
Close application Click ‘close* j Application should close |
Click cross on top right o f form 
; instead o f ‘close* button
I Should get error message ‘You must use 
i the ‘Close' button to close the form’
f
j
i
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F.lself O ptADL.Value True Then 
ActivcCcll. Value 10
TextB oxA D LV alue - 10
Else
MsgBox “You must select an option for section 2 before you click 
submit section 2*
Therefore, any time the user clicked Submit section 2’ without having 
selected a weight in section two they would receive the above error message.
Choosing all the weights: section 4
For each of the criteria in section four a validation technique was added, so 
that the user was prompted with an error message if any of the criteria were 
omitted. This is demonstrated with the code below for the criterion ‘motor 
fluctuations’:
I f  IsNull(TextBoxMotorFlucs) Or Me.TextBoxMotorFlucs = “" Then
MsgBox "You must complete a value for motor fluctuations" ,
The user would receive the error message for that criterion and if any other 
criteria text boxes were also empty once they had clicked Ok’ on the first error 
message box they would receive the error message for all the subsequent 
missing criteria.
Completing the weights with figures only
To check that the user only entered figures and not letters or any other non­
numeric characters, another error message was added to prompt them if they 
had entered incorrect data. This was also coded as an ‘If..Then..Else’ 
statement, as the code below demonstrates:
Elself Not IsNumeric(TcxtBoxMotorFlucs.Value) Then
MsgBox “Enter numerals and not any other characters for motor 
fluctuations".
Completing the weights with numbers between 0 and 10
Two If . . . Then. . . Else’ statements were used to ensure that the user had
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submitted a number that was between 0 and 10. The first statement checked 
that the number was not negative and the second that the number was not 
greater than ten. These two statements are shown in the following code:
FIself IsNumeric(TextBoxMotorFlucs.Value)And  
ValfTcxtBoxMotorFlucs.Value)  ^ 0 Then 
MsgBox ‘Number must be 0 or more for motor fluctuations*'
F.lsell Val(TcxtBoxMotorFlucs.Value) .> 10 Then
MsgBox “You must choose a number between 0 and l() for motor 
fluctuations".
Completing each section before clicking ‘Calculate answer’
In order to check that the user had completed each of the sections when they 
clicked Calculate answer’ a flag was set in the spreadsheet in cell A56 which 
was set to False’ in section two. This was done with the following code:
Rangc(“A 56").Value = “ FALSE" «
This flag was then to be set to T rue’, once section four had been completed, 
under the following section.
Private Sub cmdSubmitWeights C'lick()
using the following code.
Range("A56"). Value “True” .
When the user clicked on Calculate answer’ the code would first check that 
the flag had been set to T rue ’ in the SubmitWeights’ section, implying that 
each section had been completed, and the calculations would be carried out 
and the results returned to the user. If the previous sections had not been 
completed an error message would be returned to the user telling them to 
complete the previous sections first. This is demonstrated by the following 
code:
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I f  R ange("A 56").V a lue  -  “True”
.. perform calculations and return results__
Hlse
M sgBox “You must select figures for section 4 and click ‘submit 
responses* before you can receive the recommended treatments".
Completing each section before clicking ‘List all results’
Similarly to the validation check for Calculate answers’, a flag was created in 
the spreadsheet in cell A60. This flag was set to False’ in section two and 
then set to True’ once the user had completed all the sections and clicked 
Submit responses’. A check was then made under the section
Private Sub OmdListResult 01ick()
to see if the flag had been set to T rue ’. If it had the list of results was 
returned to the user, otherwise they received an error message telling them to , 
complete all the sections, as demonstrated by the following code:
I f  Rangc(“A 6 0 ").V a lu e  ~ True Then  
. . . re turn  list o f  results to user...
Else
M sgBox “You must enter data for all the sections, click ‘submit section2* 
and ‘submit responses' before you can view  the results".
Resetting scores before closing the application
Another flag was used to check that the user had clicked the ‘Reset’ button 
before they closed the application. This was set to ‘False’ in section two and 
set to T rue ’ in the section
Public Sub CmdReset_Click().
This demonstrated that the user had clicked Reset’ if the flag had been 
changed to ‘True’. An ‘If...Then...Else’ statement was again used in the close
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application section, giving the user an error message telling them to click 
Reset if they had not already done so. This is shown in the following code:
I f  Range(“A54” ).Value “True” Then 
Unload M e  
I: I sc
MsgBox “You must click reset* before you can close the form”
Closing the application
To ensure the user only closed the application by means of the Close’ button 
an error message was added if they tried to use the cross in the top right-hand 
comer of the form to close the application. This used an If...Then’ statement 
which prevented them from closing the application with the cross, as 
demonstrated below:
I f  CloscModc -  vbFormControlMenu Then 
C ancel = True
MsgBox “You must use the close* button to close the form”.
Testing Process
The tests described in the methods section of this chapter are demonstrated n 
Table 6.2 with the actual result and comments about each test. The test 
results are then described individually in more detail.
Poor response / selection of weight 
One drug, no weight
The first test examined what happened if an option was selected for the ‘poor 
response’ drugs but no option was selected in section two for the weights. An 
error message had been expected if no weight was selected telling the user 
they must select an option and this was what was returned (Figure 6.2).
No drugs, one weight
The second test examined what happened when no option was selected for 
the poor response drugs but a weight was selected in section two. The
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Table 6.2 Testing process documentation completed
Section Input to be entered Expected result Actual Result Comments
Select poor One drug No weights Should he prompted by Received error message Result as expected
response select 
top weight
error message for weight 
when click ‘submit section 
2’
saying ‘You must select an 
option from section 2 
before you click ‘submit 
section 2"
No drugs One weight Should submit data to 
spreadsheet
Submitted data to 
spreadsheet
Result as expected
One drug One weight Should submit data to 
spreadsheet
Set poor response drug 
scores to 0 in spreadsheet 
and submitted weight into 
section 4 and spreadsheet
Result as expected
Two drugs One weight Should submit data to 
spreadsheet
Set two poor response 
drugs’ scores to 0 in 
spreadsheet and submitted 
weight into section and 
spreadsheet
Result as expected
Two drugs No weights Should be prompted by 
error message for weight 
when click ‘submit section 
2*
Set two poor response 
drugs’ scores to 0 in 
spreadsheet and got error 
message ‘you must submit 
a value in section 2 ’
Result as expected
1
|
j
i.........1
Three drugs / One weight Should submit data to 
spreadsheet
Set three poor response 
drugs' scores to 0 in 
spreadsheet and submitted 
weight into section and 
spreadsheet
Result as expected 1[
j
I
i
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Table 6 .2  Testing process documentation completed (continued) 
Section ' " ~Input to be entered
Four drugs One weight
Expected result____
Should submit data to 
spreadsheet
Actual Result
Five drugs One weight
Set four poor response 
drugs* seores to 0 in 
spreadsheet and submitted 
weight into section and 
spreadsheet ___
Should submit data to 
spreadsheet
Set five poor response 
drugs’ seores to 0 in 
spreadsheet and submitted 
weight into section and 
spreadsheet__________
Choose other No weights 
weights
Should get error message 
‘you must complete a 
value for ...* for each 
criterion in turn when click 
‘submit responses'
Got error message ‘You 
must complete a value for 
motor fluctuations', 
clicked ok, got error 
message for ‘cognitive 
impairment', clicked ok. 
got error message for 
‘confusion' and so on 
through all the criteria 
except the one submitted 
in section 2
 ^Comments
Result as expected
Results as expected
Results as expected
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Table 6.2 Testing process documentation completed (continued) _____________ __________ __________ ______ ___________________
| Section \ Input to be entered ; Expected result ^Actual Result_________  Comments______
One weight Should get error messages Got error message‘You Result as expected
as above for all the other must submit a value for
criteria cognitive impairment'.
clicked ok then got error 
messages for all 
subsequent criteria except
| the one entered and the
one submitted from
__________________________________      __ section 2   .....   ^ _______
Two weights Should get error messages Got error message ‘You Results as expected
as above for all the other must submit a value for 
i criteria confusion', clicked ok then
got error messages for all 
subsequent criteria except 
the ones entered and the 
I i one submitted from
! section 2
Three weights Should get error messages 
as above for all the other 
criteria
Got error message * You 
must submit a value for 
dyskinesia', clicked ok 
then got error messages for 
all subsequent criteria 
except the ones entered 
and the one submitted 
from section 2
Result as expected
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Table 6.2  Testing process documentation completed (continued)
: Section Input to be entered Expected result Actual Result Comments
Four weights Should get error messages 
as above for all the other 
criteria
Got error message ‘You 
must submit a value for 
depression', clicked ok 
then got error messages for 
all subsequent criteria 
except the ones entered 
and the one submitted 
from section 2
Result as expected
All the weights Should submit all the 
weights into spreadsheet 
when click ‘submit 
responses*
All the weights submitted 
into the spreadsheet
Result as expected
Letters not numbers for one weight Should get error message 
for that criterion ‘enter 
numerals and not any other 
characters for (criterion 
name)*
All the weights were 
submitted into the 
spreadsheet including the 
letter, got error message 
‘ Enter numerals and not 
any other characters for 
motor fluctuations', once 
the letter was changed to a 
number the letter was 
over-written with the 
number in the spreadsheet
Result as expected
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Table 6.2  Testlncj process documentation completed (continued) 
Section Input to be entered Expected result Actual Result Comments
Letters not numbers for two weights Should get error message 
for each criterion ‘enter 
numerals and not any other 
characters for (criterion 
name)’
All the weights were 
submitted into the 
spreadsheet including the 
letters, got error message 
‘ Enter numerals and not 
any other characters for 
confusion' and the same 
for ‘hallucinations', once 
the letters were changed to 
numbers the letters were 
over-written with the 
numbers in the spreadsheet
Result as expected
Number above 10 for one weight Should get error message 
‘You must choose a 
number between 0 and 10 
for (criterion name)* for 
that criterion
Got error message * you 
must choose a number 
between 0 and 10 for 
‘depression'
Result as expected
Number above 10 for two weights Should get error message 
‘You must choose a 
number between 0 and 10 
for (criterion name)' for 
each criterion
Got error message ‘you 
must choose a number 
between 0 and 10 for 
confusion* and same 
message for ‘depression’
Result as expected
Number below 0 for one weight Should get error message 
‘Number must be 0 or 
more for (criterion name)' 
for that criterion
Got error message 
‘Number must be 0 or 
more for dyskinesias'
Result as expected
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Table 6.2 Testing process documentation completed (continued)
Section Input to be entered Expected result Actual Result Comments
Number below 0 for three weights Should get error message 
‘Number must be 0 or 
more for (criterion name)' 
for each criterion
Got error message 
‘Number must be 0 or 
more for motor 
fluctuations', click ok and
Result as expected
get same message tor 
‘cognitive impairment', 
click ok and get same 
message for ‘stage of 
disease'
Calculate answer Click calculate answer Should return user form 
with top 3 results 
displayed along with 
cautions and
contraindications for each 
drug
Got unexpected error 
message “You must select 
figures for section 4 and 
click ‘submit responses' 
before you can receive the 
recommended treatments", 
even though all sections 
had been completed and 
submitted
Re-checked code, 
discovered inconsistency 
in way true flag was 
recorded in code, 
sometimes written as 
“TRUE" and sometimes as 
“True", therefore VBA  
wasn't recognising that 
sections had been 
completed. All flags were 
written as “True" and the 
test re-run with the results 
then being as expected
Don't click calculate answer Should receive no results -  
nothing will appear to 
have happened to user
Received no results, 
nothing happens that user 
can see
As expected
i
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Table 6.2  Testing process documentation completed (continued)
Section Input to be entered Expected result Actual Result
T....  ...... . ................. ...................
Comments
List all results All results are listed Should receive list o f all 
results in order o f overall 
score with their total score 
i f  all sections have been 
completed and submitted
Got error message ‘‘You 
must enter data for all the 
sections, click ‘submit 
section2' and ‘submit 
responses’ before you can 
view the results", even 
though all sections had 
been completed and 
submitted
Re-checked code, 
discovered inconsistency 
in way true 11 ag was 
recorded in code, 
sometimes written as 
‘‘TRUE" and sometimes as 
“True", therefore VBA  
wasn't recognising that 
sections had been 
completed. All flags were 
written as ‘‘True" and the 
test re-run with the results 
then being as expected
No results are listed Should receive error 
message "You must enter 
data for all the sections, 
click ‘submit section 2' 
and ‘submit responses' 
before you can view the 
results" if  have not entered 
and submitted data
Got error message "You 
must enter data for all the 
sections, click ‘submit 
section 2' and ‘submit 
responses' before you can 
view the results"
Result as expected
Reset Click 'reset' Should copy and paste 
original values o f scores of 
all drugs into relevant cells
Copied and pasted original 
values of scores o f all 
drugs into relevant cells
Result as expected
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Table 6.2  Testing process documentation completed (continued)
Section Input to be entered Expected result Actual Result Comments
Don't click ‘ reset' Should get error message 
‘You must click ‘reset' 
before you can close the 
form* when click ‘close*
Got error message ‘‘You 
must click reset' before 
you can close the 
application"
Result as expected
; Close application [_Click ‘close' Application should close Application closed Result as expected
I ;
Click cross on top right o f form 
instead o f ‘close* button !
Should get error message 
‘You must use the ‘Close' 
button to close the form’
Got error message ‘You 
must use the ‘Close* 
button to close the form’
Result as expected
Figure 6.2 Test to see if user can submit one drug but no weight
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expected result was that the figure ‘10’ would be inserted in the relevant 
criterion text box in section four for the chosen w eight and that there would be 
no error m essage as the user had done what w as required o f them. An error 
message was not expected for the lack of se lection of poor response drugs, 
as it did not m atter if the user did not select any o f the options. An option Not 
applicable’ had been included if the patient had not had a poor response to 
any of the drugs, but it was decided that it did not matter if this was not 
selected. The results received were the sam e as the expected result, as 
shown in Figure 6.3.
One drug, one weight
A test was next run to see the result if one drug was selected for the poor 
response drugs and one weight for the w e igh ts in section two. It was expected 
that no error message would be produced as the user was doing what was 
required of them  and that the figure 10’ for the selected weight would be
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Figure 6.3 Test to see if user can subm it no drugs but one weight
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selected. The results received were the sam e as the expected result, as 
shown in Figure 6.4.
Two drugs, one weight
Having tested the selection of one drug for the poor response’ options the 
next step was to test what happened if m ore than one drug was selected. 
Two drugs were therefore selected, along w ith a weight in section two, with 
the result being expected that there would be no error messages and the 
relevant weight in section four would receive the figure 10’. The result was 
indeed as expected (Figure 6.5).
Two drugs, no weight
After testing the selection of two drugs w ith one weight the next stage was to 
test two drugs with no weight in section two, to see if the result would be the 
same as for selecting one drug with no weight. That is to say, there would be
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Figure 6.4 Test to see if user can input one drug and one weight
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Figure 6.5 Test to see if user can input two drugs and one weight
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an error m essage telling the user they needed to select a weight in section 
two Once the test was run the error m essage was received (Figure 6.6).
Three drugs, one weight
Another test was carried out with m ultip le  drugs selected for poor re spon se , 
totalling three drugs, along w ith one w eight in section two. It was expected 
that there would be no problem  in se lecting three drugs at a time and that
Figure 6.6 Test to see if user can input two drugs but no weight
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there would be no error m essage as a w e igh t had been selected in section 
two. The result was indeed as expected, as the screenshot in Figure 6.7 
shows.
Four drugs, one weight
The penultim ate test with the num ber o f drugs selected in the poor response 
category tested what happened w hen four drugs were selected and one 
weight was selected in section two. The expected result was that there would 
be no problem selecting four drugs and that there would be no error message
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Figure 6.7 Test to see if user can input 3 drugs with one weight
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for the user as they had done what they w ere  expected to in selecting their 
choice of weight in section two. The actual result showed that the selection of 
four drugs did not cause any problem s and there was no error message to the 
user (Figure 6.8).
Five drugs, one weight
The final test with the num ber o f drugs selected fo r ‘poor response’ whilst 
selecting one weight in section two w as expected to cause no problems in the 
number of drugs selected (five) and to insert the figure ‘10 in the relevant 
weight text box in section four. The result w as as expected (Figure 6.9).
Choosing other weights 
No weights
A test was carried out to see w hat w ould happen if none of the weight text 
boxes was com pleted in section four, o the r than the one that had already 
been inserted from section two. It w as expected that when submit responses
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Figure 6.8 Test to see if user can input four drugs and one weight
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Figure 6 . 9  Test to see if user can input five drugs and one weight
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was clicked an error message would be shown telling the user to complete a 
value for motor fluctuations’. Once they had clicked ‘ok’ on this error 
message another error message would appear telling them to complete a 
value for cognitive impairment’ and so on through each of the criteria until 
they were all completed. When the test was run ‘cognitive impairment’ was 
the criterion that had been selected from section two and so the first error 
message appeared for the criterion ‘motor fluctuations’, ok’ was clicked and 
then the next error message appeared for confusion , hallucinations’ and so 
on through all the other criteria. This was therefore the result that was 
expected and showed that the data validation worked effectively. The error 
message for motor fluctuations' is shown in Figure 6.10.
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One weight completed
Next, a test was run with the figure ‘10’ inserted from section two for 
dyskinesia’ and just one other weight completed for motor fluctuations. 
Similarly to the previous test it was expected that an error message would
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appear for cognitive im pairm ent as it had not been com pleted and then once 
ok was clicked for that m essage a m essage w ould appear for ‘ha llucinations’ 
and so on through all the criteria which had not had a weight inserted. The 
actual results of the test showed that an e rro r m essage appeared for each 
missing criterion weight, as expected. Th is  is dem onstrated w ith the error 
message for one of the criteria in F igure 6.11.
Figure 6.11 Test to see what happens if user on ly  inputs 1 extra weight for 
section 4 and clicks Subm it responses ’
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Two weights completed
Another s im ilar test was run with just two o f the w eigh ts com pleted, aside from  
the one inserted from section two, w ith the expected result being that an error 
message would appear for each of the crite rion  w eights not com pleted. Th is 
was in fact what happened, show ing the actua l result was the sam e as the 
expected result (F igure 6.12).
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Figure 6.12 Test to see what happens if user only inputs two weights for
section 4 then clicks ‘Submit responses’
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Three and four weights completed
Further s im ilar tests were run w ith th ree  and then fou r weights being entered 
along with the weight inserted from  section two. Each time the expected 
result was fo r the error m essage to appea r fo r each criterion weight that was 
missing and this was the result that w as received fo r each of the two tests. 
The results for three weights and fou r w e igh ts  are shown in Figures 6.13 and 
6.14 respectively.
All weights completed
In the next test all the weights w ere en te red  fo r the criteria in section four and 
the ‘submit responses’ button c licked . Th is tim e it was expected that there 
would be no error message, as eve ry th ing  had been com pleted as it should 
be, and that the figures for all the w e igh ts  w ould be inserted into column B in 
the spreadsheet. The results w ere as expected  and the weights were inserted 
into column B. The screenshot in F igure  6.15 shows part of the spreadsheet
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Figure 6.13 Test to see what happens if user only inputs weights for 3 criteria 
then clicks Submit responses'
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Figure 6.14 Test to see what happens if user only inputs 4 weights in section 
4 then clicks ‘Submit responses’
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Figure 6.15 Test to see what happens when user inputs values for all the 
weights in section 4 and clicks Subm it responses’
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showing colum n B as well as a partial shot o f the user form with the weights 
completed.
Non-numeric characters
Tests were also carried out to see what would happen if something other than 
a numeric character were entered for the w eights in section four. In Figure 
6.16 the result is shown of a test to see w hat would happen if a letter were 
inserted instead of a numeral. The expected result was that an error message 
would appear telling the user to insert num bers only for that criterion. This 
was the result that was received.
Non-numeric characters two weights
A similar test was carried out inserting a letter for two of the criterion weights 
instead of numbers, with the expected result being the same as for the 
previous test that there would be an error m essage for each of the criteria with 
letters. This was the actual result, show ing that the validation worked for both
!9cS
criteria. The result for the second criterion w ith a letter (‘hallucinations’) is 
shown in the screenshot in F igure 6.17.
Figure 6.16 Test to see what happens if user inputs a letter instead of a 
number for a criterion in section 4 then clicks ‘subm it responses’
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Number greater than 10: one weight
A test was next run to see what would happen if a number greater than ten 
was inserted for one weight. The expected result was that there would be an 
error m essage telling the user to choose a num ber between 0 and ten for that 
criterion. W hen the test was run the expected error message was received 
(Figure 6.18).
Number greater than 10: two weights
Another sim ilar test was run inputting two weights with values greater than 
ten. The expected result here was that there would be an error message for 
the first criterion and once ok w as clicked there would be a sim ilar error 
message for the second criterion. Th is w as the result that occurred, with both 
error m essages shown as expected. The result of the second criterion 
( depression ) is shown in Figure 6.19.
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Figure 6.17 Test to see what happens when user enters letters for two criteria
in section 4 then clicks submit responses’
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Figure 6.18 Test to see if user can input one number >10 for weight
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Figure 6.19 Test to see what happens if user enters number >10 for two 
weights
its-------------------------------------------------- ---------------------------
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Number below 0: one weight
The penultim ate test for this section was run to test what would happen if a 
number below 0 (i.e. a negative num ber) w as entered for one of the weights 
instead of a number between 0 and ten. It was expected that the user would 
receive an error message telling them to se lect a num ber of 0 or more for that 
criterion. W hen the test was run that was the error message that was 
received, showing that the test worked as expected (Figure 6.20).
Number below 0: three weights
The last test for this section was sim ilar to the penultim ate one, testing what 
would happen if a negative number was inserted for three of the weights. The 
expected result was that the user would receive an error message for the first 
criterion with a negative number; once they had clicked ‘ok they would 
receive the message for the second criterion and then the same for the third
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Figure 6.20 Test to see if user can input a negative number for weights in
section 4
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criterion. This was the actual result, show ing that the test worked for all three 
criteria (F igure 6.21).
Calculate answer 
Click ‘Calculate answer’
The first test in this section looked at w hat should happen if the user clicked 
the ‘Calculate answ er’ button. The expected result was for a user form to be 
returned to the user with the top three results displayed along with their 
respective cautions and contra indications. Unexpectedly, an error message 
was returned to the user telling them  to com plete all the sections before 
clicking calcu late answ er’, even though they had already done so. It was 
discovered that there was an inconsistency in the code with the T ru e ’ flag, as 
it was written as ‘T rue ’ in one place, but as T R U E ’ in another. This was not 
expected to cause any problem s w ith the execution of the code, but the test 
showed that it was in fact a problem. The word was changed to read T ru e ’ in 
both places for consistency and the test w as run again. The second run of the
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Figure 6.21 Test to see if user can input three negative numbers for weights in
section 4
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test showed better results, returning the user form  to the user as had been 
originally expected. The unexpected error m essage is shown in Figure 6.22 
and the actual result of the second run of the test in Figure 6.23.
Don’t click ‘Calculate answer’
The other test in this section exam ined what would happen if the user did not 
click ‘Calculate answ er. It was expected that there would be no results 
returned to the user and this was what happened when the test was run 
(Figure 6.24).
List all results 
Click ‘List all results’
When the button ‘List all results ’ was clicked it was expected that a message 
box would be returned to the user w ith a list of all the drugs returned in the
Figure 6.22 Test to see what happens when user clicks ‘Calculate answer’ —
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Figure 6.23 Corrected error from 6.22 w ith test re-run and correct results 
given
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Figure 6.24 Test to show result o f user not c lick ing ‘Calculate answer’
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order of highest to lowest scoring, a longside the ir actual result. The result of 
this test was another unexpected one, as the user received an error message 
telling them  to com plete all the sections and click ‘subm it responses’. It was 
discovered that a flag was written as T ru e ’ in one place and T R U E ’ in 
another in the code, sim ilarly to the prob lem  encountered with ‘Calculate 
answer’. The code was corrected so tha t both flags were written as ‘True’ and 
the test re-run. The result was then as orig ina lly  expected with the message 
box of results returned to the user. The e rro r m essage is shown in Figure 
6.25. Figure 6.26 shows the corrected results.
Click ‘List all results’: no data entry
The final test in this section looked at w hat would happen if the user clicked 
List all resu lts ’ w ithout having entered any data in sections two and four and 
without clicking the two ‘subm it buttons. It was expected that they should 
receive an error m essage telling them  to com ple te  all the sections and click
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Figure 6.25 Test to show what happens when user clicks ‘List all results’
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Figure 6.26 Test to show List all results’ works ok once bug had been 
corrected 
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submit section 2 and subm it responses ’. Th is was the result that was 
received and the screenshot in F igure 6.27 shows the result.
Reset
Click ‘Reset' button
A test was run to see what would happen w hen the user clicked the R eset’ 
button. It was expected that the orig inal score values fo r all the drugs would 
be copied and pasted over the scores at the top o f the spreadsheet as som e 
may have been set to 0 when the user selected any ‘poor response’ drugs. 
The result was as expected and is shown in F igure 6.28, with the copied 
scores shown in the blue cells.
Click ‘Reset' without ‘Close'
A test was next run w ithout clicking ‘R ese t’ but click ing the ‘c lose ’ button to 
close the application. The expected result w as fo r the user to receive an error 
message telling them to click R eset’ before closing the  application. This was 
the result that was received (F igure 6.29).
Figure 6.27 Test to see what happens when user c licks ‘List all results ’ when 
haven't entered or submitted any data
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Figure 6.28 Test to see what happens when user clicks Reset’
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Figure 6.29 Test to show what happens when user clicks ‘C lose’ without 
having clicked Reset'
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Close application 
Click ‘Close’ button
A test was carried out to see the result if the user clicked the C lose’ button to 
close the application. The expected result was that the application would 
close and this was what happened. There is no screenshot to show this as 
the application was of course closed.
Close without ‘close’ button
A final test was carried out using the cross in the top right-hand corner of the 
user form  to close the application, instead of the ‘C lose’ button. It was 
expected that the user would receive an error m essage telling them to close 
the application with the ‘c lose’ button and this was what happened (Figure
6.30).
Figure 6.30 Test to see what happens if user tries to use cross on top right of 
form to close form instead of C lose’ button
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DISCUSSION
In conclusion, a series of data validation techniques was added to the 
application and a number of tests carried out to validate how well the software 
performed. The tests on the whole proved successful and showed that all 
aspects of checking the user had inputted the correct types of data were 
covered and that the software performed as it should.
Incorporating methods of checking the user’s data input proved that the data 
validation included was pertinent and comprehensive. Many types of data 
validation were included and were designed to be as thorough as possible so 
that the user would not be able to intentionally or unintentionally input the 
wrong data. Accounting for every possible step a user may take can be a 
difficult process, but as this application was fairly straightforward the user only 
had a small number of possible options available and it was therefore easier 
to anticipate what data they may input. It was important to include this step in 
the testing process to ensure that the program was not affected by the user’s 
incorrect data input or that the user did not become stuck because they had 
missed a step in the software’s sequence or inadvertently entered incorrect 
data. Additionally, it ensured that the user’s intentional or unintentional 
incorrect data did not mean that they received incorrect results because they 
entered incorrect data. It was important to ensure that the result the user 
received was the correct one relevant to the data they had input. An incorrect 
result occurring because of a mistake in data entry by the user or because an 
instruction had not been read properly, for instance, would reduce the model’s 
validity as a decision aid. Therefore, the data validation incorporated played 
an important role in ensuring the model performed as expected.
The testing process itself proved its own importance and validity by producing 
two unexpected errors. Careful development of the software and the addition 
of data validation meant the processes incorporated were expected to work 
exactly as intended. However, the testing showed that this was not the case. 
Importantly, it was two major parts of the application which did not function as 
expected and meant the user would not be able to view the results. Detecting
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errors such as these was fundamental to ensuring that the model was not 
effectively made redundant by simple coding errors. The surprising factor was 
the type of error detected, as in both cases it was simply a problem with a mix 
of lower and upper case lettering. It had not been expected that this would 
cause problems with code syntax and in fact both functions had worked 
adequately during development. However, it was fortunately a simple error to 
correct and retesting showed that the correction meant the software then 
worked as expected. This showed that overall testing was a valuable and 
essential process. Detecting errors showed the necessity of the testing 
process and that value was gained from carrying out thorough and 
comprehensive testing. After the testing process the software could then be 
considered as being fit for purpose’.
The application having been thoroughly tested the next stage was to test the 
application with other users and for them to validate the ease and practicality 
of use of the whole application. This will be discussed in chapter seven.
SUMMARY
The software developed in chapter five was thoroughly tested to ensure the 
application worked as was intended.
• Functions were incorporated in the software to ensure the user could 
only input relevant data types
• Tests were carried out on all aspects of the application to ensure every 
section worked as was intended
• Two tests showed errors in coding which were easily corrected
• All other tests showed everything worked as expected
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CHAPTER 7
Validation of the Model and Computer Decision
Support System
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INTRODUCTION
In chapter four the model for Parkinson’s disease using MCDA was 
developed, in chapter five the software was developed and in chapter six the 
software was tested. These two products needed to both be validated. The 
process of validation shows whether something has met its requirements and 
is fit for purpose. Therefore, the purpose of the validation carried out in this 
chapter was to show whether the model and software had met their objectives 
and whether the model in particular would produce results that would make it 
suitable for use with Parkinson’s patients.
A panel of experts in the field of Parkinson’s disease would therefore need to 
be invited to take part in a validation exercise to test the model and associated 
software. These experts would need to be practitioners who were regularly in 
contact with Parkinson’s disease patients and had substantial years of 
experience of treating this group of patients. This would give the panel the 
expertise to be able to assess a number of factors that would determine the 
suitability and usefulness of the model and software. For example, whether 
the model included all the necessary aspects and if the weighting 
methodology was apt.
This chapter will therefore report on the validation process that was carried 
out.
METHODS
Sensitivity Analysis Perspectives
Sensitivity analysis is carried out to investigate whether preliminary 
conclusions are robust or if they are sensitive to changes in certain aspects of 
the model. Changes can be made to investigate the significance of any 
information that may be missing, to explore any effect a decision maker’s 
uncertainty about their values and priorities may have or to give a different 
perspective on the problem. Alternatively, there may be no practical or 
psychological motivation for changing values; the analysis may be led by a
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wish to test the robustness of the results (Belton and Stewart, 2001). There 
are three different perspectives on sensitivity analysis:
Technical perspective:
From a technical perspective sensitivity analysis is the objective examination 
of the effect of changes in input parameters on the output of a model. The 
input parameters are the value functions, scores and weights that have been 
determined by the decision makers. The output is the synthesis of this 
information -  the overall evaluation of alternatives, for example. The technical 
sensitivity analysis determines which, if any, of the input parameters have a 
critical influence on the evaluation overall. For example, a small change in a 
criterion weight or an alternative’s score may affect the overall preference 
order (Belton and Stewart, 2001).
Individual perspective:
The function of a sensitivity analysis from an individual’s perspective is to 
allow them to test their intuition and understanding of the problem. For 
example, whether they feel comfortable with the results of the model and if 
not, why not? They can also use the analysis to look at whether important 
criteria have been overlooked (Belton and Stewart, 2001).
Group perspective.
The function of a sensitivity analysis in a group context is to allow the 
exploration of alternative perspectives on the problem, which are often 
captured by using different sets of criteria weights (Belton and Stewart, 2001).
Sensitivity Analysis Perspectives Used
Both the individual perspective and the group perspective were used for this 
validation. The individual to give panellists a chance to express their own 
views and opinions on the model and its results, and the group perspective to 
try the use of different weights to see how this affected the results the model 
produced, for example if panellists received different recommendations from 
having entered different weights to each other.
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The Expert Panel
A group of expert practitioners in the field of Parkinson’s disease was selected 
from the Cardiff and Vale, Bridgend, Swansea, Newport and Powys areas to 
take part in the validation exercise. A preliminary panel of practitioners was 
invited to the initial validation: two consultant geriatricians and one 
Parkinson’s disease nurse specialist, all from the Cardiff and Vale area. Two 
subsequent validation exercises were planned to take place at later dates, 
each with a further panel of three practitioners selected from consultant 
geriatricians, consultant neurologists and Parkinson’s disease nurse 
specialists from the other areas of south and mid-Wales mentioned above. 
The second panel would comprise a geriatrician and PD nurse specialist from 
Bridgend and a neurologist from Swansea and the third panel two 
neurologists from Newport and a geriatrician from Powys.
Date And Location
The preliminary validation was held on Monday 29 September 2008 at Cardiff 
University, and took place over an afternoon. The validation exercise was 
held in a specialist training room, which was part of the Information Services 
department of Cardiff University, and which was chosen for its provision of IT 
facilities and layout. The panel members were seated next to one another 
near the front of the room, each in front of their own desktop PC. The panel 
members all faced the leader of the validation session. A projector screen at 
the front of the room showed the details of the validation leader’s screen. 
Also present were Professor Sam Salek of the Welsh School of Pharmacy, 
who followed the details of the session and Dr Andy Skyrme of the Information 
Services Department, who provided IT support.
Points Covered By The Expert Panel
• whether or not the model included all the aspects, i.e. criteria, they 
would need to consider in treating a PD patient
• if the scoring effectively reflected the way they considered each drug 
would perform against the given criteria
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• if the weighting involved, i.e. swing weighting, was a practical 
methodology to be used for choosing drug treatments for Parkinson’s 
patients
• if the results produced reflected their own choice of treatments for each 
patient
• their thoughts and opinions on why different results were produced by 
the model to those they had chosen, if that was the case
• whether the software was quick and easy to use
Validation Procedure 
Aims and objectives of work
The aim and objectives of the PhD as a whole were outlined to the panel.
Aim:
• To develop an electronic decision aid to help practitioners choose the 
most effective drug treatments for Parkinson’s disease
Objectives:
• To develop a model using multi-criteria decision analysis for 
Parkinson’s disease
• To develop a computer system to implement the model’s functions
Methodology used
An explanation of the methodology used, i.e. MCDA, was given to the panel, 
detailing each stage of the work that had been carried out. This was delivered 
through a PowerPoint presentation.
Patient scenarios
The panel were given details of three different patient scenarios. These were 
taken from the Welsh Movement Disorder eNetwork, a database of movement 
disorder patients in South Wales, using details of three patients on the 
database. All data presented to the panel were completely anonymised.
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Patient Scenario 1:
Patient 1 Symptoms:
• Slight dizziness: BP 142/91 sitting, 158/82 standing
• Occasional hallucinations
• Minimal PD symptoms -  rigidity, bradykinesia
• Quite active -  rides a bike
• Constipation and dreams since on pramipexole
Current medication:
• Madopar 125mg 1x QDS
• Madopar CR 125 1x nocte
• Pramipexole 1 mg 1 x TDS
• Voltarol 50mg 1 x PRN
Previous medication not tolerated:
• Stalevo -  bloated, loose stools, wind, nauseous
• Cabergoline -  dizziness, SOB
Patient Scenario 2:
Patient 2 Symptoms:
• Slow in mornings and freezes
• Oro-facial dyskinesias. Sinemet 110 reduced by one tablet to improve 
dyskinesias but mobility deteriorated
• Voice softer and quieter, unable to hold long conversations
• Drags left leg
Current medication:
• Co-careldopa 125mg x1 nocte
• Co-careldopa 110mg x2 TDS
• Pergolide 1mg x1 TDS
• Domperidone 10mg x1 TDS
• Oxybutynin 5mg x1 OD
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Previous medication not tolerated: 
• None
Patient Scenario 3:
Patient 3 Symptoms:
• Increasing “offs”, 4 bad days per week
• Huge loss of energy
• Sleep is variable: no dreams or nightmares but occasional transient 
hallucinations
• Mood is ok
• Increased sweating during “offs”
Current medication:
• Madopar 62.5mg dispersible x1 PRN
• Stalevo 150mg 1x6 times per day
• Pramipexole 0.7mg 1x5 times per day
• Rasagiline 1mg 1x OD
Previous medication not tolerated:
• Sinemet 110 -  motor control worse
• Zelapar 1.25mg -  lack of effect
• Selegiline 1.25mg -  dyskinesia
• Ropinirole 2mg TDS -  nausea and vomiting
• Entacapone 200mg -  nightmares/sleep disturbance
Panel’s choice of treatments
The panel were given the three scenarios in turn and asked to make their 
choice of treatment(s) for each scenario. Each panellist made their own 
recommendation initially, which was handed to the facilitator and the results 
read out anonymously. The panel then had to try to reach a consensus on the 
treatment(s) they would recommend. If a consensus could not be reached the
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panel’s individual choices were recorded. All the recommendations were 
recorded on a white board in the room for each patient scenario.
Model’s recommended treatments
Having chosen their own treatments, the panel were then taken through the 
user form designed in VBA, referred to in the validation exercise as an 
‘electronic prescribing support system (EPSS)’. Each section of the form was 
explained to them. They completed the first section of the form individually for 
patient scenario one, selecting any drugs the patient had had a poor response 
to. The methodology for choosing the weights, swing weighting, was then 
explained to them and the panel each selected their own weights for patient 
one. They then submitted their responses by clicking on the ‘Submit section 
2’ button and the ‘Submit responses’ button and clicked ‘Calculate answer’ to 
receive their three recommended treatments. The results each panellist had 
received were entered on the white board and discussed. The procedure was 
then repeated for the subsequent two patient scenarios.
Comparison of results
The results from the panellists’ choices and the results the model had 
recommended were compared and discussed for each patient scenario. The 
panel members were asked to comment on whether they thought the results 
the model had produced were unexpected, and if so why they thought the 
model may have produced such results. They were also asked to discuss any 
changes or improvements they thought could be made to the model to 
produce different results, if this was deemed necessary.
Evaluation questionnaire
As a final part of the validation exercise the panel members were given a 
short questionnaire to complete eliciting their views on both the model and 
EPSS. The first section of the questionnaire, section A, evaluated their 
opinions on the criteria and scores used in the model, the ease of the 
methodology used to ascertain the weights and their opinions of the model 
overall. Section B questioned them on their opinions of the EPSS, as to how 
easy and practical they found it to use and whether its speed of use was
219
acceptable. They were also asked whether they would recommend it to 
colleagues or use it themselves in a clinic situation. Panellists were given 
space in appropriate questions to add their own comments. The 
questionnaire is shown in Figure 7.1.
RESULTS
The results of the validation exercise will be presented in three different parts. 
Part one will address the validity of the model and EPSS, part two the panel’s 
general comments and suggestions and part three the applicability and 
practicality of the model and EPSS.
Part I -  Validity Of The Model And EPSS 
Panel's choice of treatments 
Patient scenario one
The recommendations the panellists made individually for patient one followed 
two options: to make no drug changes or to discontinue the pramipexole. On 
discussion the group agreed as a consensus that both these options should 
be considered.
Patient scenario two
The panellists were in agreement on only one aspect of treatment for the 
second patient, which was to discontinue pergolide. No consensus could be 
reached on any other options for this patient, so all the possible options were 
considered. These included adding a non-ergot dopamine agonist, adding 
Stalevo, increasing the co-careldopa and to consider adding amantadine.
Patient scenario three
The panellists all thought that patient three was the most complicated 
scenario of the three. Each panellist described different options for treatment. 
These were: defer to other PD experts, consider increasing pramipexole if the 
patient was depressed; increase stalevo and consider an apomorphine trial; 
increase the dose of dispersible Madopar in the early part of the day, consider
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Figure 7.1 Questionnaire used to measure applicability and practicability of 
the model and EPSS
Evaluation of Parkinson’s disease model and Electronic 
Prescribing Support System (EPSS)
Please complete both sections of the questionnaire selecting the 
response which you feel is most appropriate for each question:
A. Parkinson’s disease Model
1. Mow do you rate the criteria chosen? Please choose one option
Very  good Good Pair Poor Very poor
J  J  J  J  □
2. Do you think any important criteria have been missed out?
Yes No Not sure
J  □  □
2. Mow do you rate the way the drugs have been scored against the criteria?
Very good Good Fair Poor Very poor
J  □  □  □  □
4. Mow do you rate the ease or d ifficu lty  o f  weighting the criteria?
Very easy Easy Fair D ifficu lt Very difficult□ □ □ □ □
5. Do the weights need rewording to improve their clarity?
Yes No Not sure□ □ □
I f  yes. please give any suggestions here:
6. W hat is your opinion o f  the model overall?
V ery  good Good Fair Poor Very poor□ □ □ □ □
7. Are there any amendments you think could be made to improve the model?
Yes No Not sure□ □ □
8. Do you think this is a suitable methodology for use in PD?
Yes No Not sure□ □ □
Please give details:__________________________________________________
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9. W ould you use this model in clinic yourself or recommend it to colleagues to use? 
Yes No Not sure
J  J  □
Please give details, for example, would you use it yourself for difficult cases only, 
w ould you recommend it for colleagues:___________________________________________
B. Software (EPSS)
10. How easy did you find the EPSS to use? Please tick one option
Verveasy Easy fa ir  D ifficult Very difficult
J  J  □  □  □
11. Are there any amendments you think could be made to the EPSS to make it easier 
to use?
Yes No Not sure□ □ □
Please give any suggestions here:
12. How  well do you think the questions are explained on the EPSS?
Very well W ell Fair Poorly Very poorly
□ □  □ □ □
13. How quick w as the EPSS to use?
Verv quick Quick Fair Slow' Very slow
□ □  □ □ □
14. How w ould you rate your own knowledge and experience o f  computers?
V ery good Good Fair Poor Very poor
□ □  □ □ □
15. W ould you be happy to use the EPSS in your clinic or to recommend it to 
colleagues to use?
Yes No Not sure□ □ □
Please give any details:
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the timing of tablets and take them before rather than after meals. Much 
discussion of these options ensued, with consensus being difficult to reach. 
Eventually the panellists agreed to increase the levodopa, in whatever format, 
and to consider a trial of apomorphine.
The panel’s overall decisions for the three patient scenarios were:
• Patient 1: discontinue pramipexole, no change of treatment
• Patient 2: discontinue pergolide, add a non-ergot dopamine agonist, 
add stalevo, increase co-careldopa, consider adding amantadine
• Patient 3: increase the levodopa, consider a trial of apomorphine
Model’s recommendations 
Patient scenario one
All the panellists opted to give the highest weight of ten to the criterion 
Activities of daily living’, one of the nine criteria defined in chapter three which 
needed to be weighted. The remaining two criteria defined in chapter three, 
drug interactions’ and adverse drug reactions’ were pre-weighted, as defined 
in chapter four. The other weights the panel chose varied from panellist to 
panellist, with some degree of agreement between them on some of the 
criteria, such as similar choices for ‘hallucinations’ and ‘postural hypotension’ 
but no consensus for any of the criteria. The results of the weights the panel 
chose are shown in Table 7.1.
Table 7.1 Panellists’ weights for patient scenario one 
Criterion
Hallucinations  
Postural 
hypotension 
Stage o f disease 
('o n  fusion 
Dyskinesia 
Depression 
C'ognitive 
impairment 
M otor fluctuations 
Activities o f daily  
living
Panellist one Panellist two Panellist three
7 8 9
7 9 8
5 l 1
5 6 2
4 2 3
3 3 4
2 5 6
0 4 5
l() 10 10
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Despite the differences in the weights chosen by the panellists the results that 
the model produced were very similar for each of the panellists. None of the 
panellists had identical top three recommended treatments to any of the other 
panellists, but the same drugs were recommended overall, with only 
amantadine being recommended for one panellist and not the others. The 
model’s recommended treatments for patient one are shown in Table 7.2.
Table 7.2 Model’s recommended treatments for patient scenario one
Panellist one Panellist two Panellist three
Drug 1 Rasagilinc Apom orphine Apomorphine
Drug 2 Amantadine Rasagilinc Duodopa
Drug 3 Pramipexole Duodopa Pramipexole
Patient scenario two
Again, the weights chosen by the panellists were quite different, although 
there were similarities between panellist two and panellist three and all three 
panellists gave the same criterion, Activities of daily living’ the highest 
weighting (Table 7.3).
Table 7.3 Panellists’ weights for patient scenario two
Criterion Panellist one Panellist two Panellist three
Hallucinations 2 7 8
Postural
hypotension
5 8 8
Stage o f  disease 5 2 3
Confusion 6 6 5
Dvskincsia 9 4 3
Depression
Cognitive
2 3 4
4 5 4
impairment 
M otor fluctuations 6 5 6
Activities o f daily 10 10 10
living
The results provided by the model were perhaps quite surprising, as panellists 
two and three had exactly the same results, although their weights were 
slightly different. Panellist one had chosen very different weights to the other
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two, but two of the top three recommended treatments were the same for 
panellist one as for the other two panellists. The third recommendation, 
amantadine, was however different to the other drugs recommended. 
However, there was little difference overall, despite the difference in weights 
chosen. The model’s recommended treatments for patient scenario two are 
shown in Table 7.4.
Table 7.4 Model’s recommended treatments for patient scenario two
Panellist one Panellist two Panellist three
Drug 1 Duodopa Apom orphine Apomorphine
Drug 2 Rasagiline Duodopa Duodopa
Drug 3 Amantadine Rasagiline Rasagiline
Patient scenario three
The weights chosen by the panellists for patient scenario three were quite 
distinct from each other. All panellists again gave their top weight to the same 
criterion, Activities of daily living’ and all the panellists gave the same weight, 
‘9’ to hallucinations’, but the similarities ended there. One panellist, panellist 
three, gave the same weight to all the criteria bar ‘Activities of daily living’. 
There were similarities between panellists one and two on some of the 
criteria, namely postural hypotension’, stage of disease’ and ‘motor 
fluctuations’, whilst other criteria such as ‘dyskinesia’ and ‘depression’ were 
close in the weights chosen although the figures were different. Two criteria, 
confusion’ and ‘cognitive impairment’ were scored very differently between 
panellists one and two, with an even larger difference between the weights 
chosen by panellists one and three. The panellists’ weights are shown in 
Table 7.5.
Despite the differences in weights chosen by the panellists the model still 
recommended the same top treatment for all three panellists, namely 
apomorphine’ (Table 7.6). The second and third recommended treatments 
for all three panellists were ‘Duodopa’ and ‘rasagiline’, although ‘rasagiline’ 
was the second drug and ‘Duodopa’ the third drug for panellists two and three
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Table 7.5 Panellists’ weights for patient scenario three
Criterion Panellist one Panellist two Panellist three
Hallucinations 9 9 9
Postural hypotension 5 5 9
Stage o f  disease 5 5 9
Confusion 2 8 9
Dyskinesia 4 5 9
Depression 4 5 9
C ognitive impainnent 2 7 9
M otor fluctuations 5 5 9
Activities o f daily 10 10 10
living
whilst the order of rasagiline’ and Duodopa’ was reversed for panellist one. 
Considering the differences in the weights chosen by the panellists one may 
have expected different results to have been recommended by the model.
Table 7.6 Model’s recommended treatments for patient scenario three
I .........
; Drug 1 
i Drug 2 
5 Drug 3
Panellist one Panellist two Panellist three
Apomorphine Apom orphine Apomorphine
Duodopa Rasagiline Rasagiline
Rasagiline Duodopa Duodopa
Comparison of the panel's treatment decisions and the model’s
recommendations
Patient scenario one
The choices the panel had agreed on, no drug changes or to discontinue 
pramipexole, were very different to the results the model recommended. For 
instance, despite the fact that the panel had agreed that ‘pramipexole’ should 
be discontinued two of the panellists had ‘pramipexole’ as one of their top 
three recommended treatments (Table 7.7). There was similarity between the 
results the model produced for each of the panellists, but no similarity at all 
with the choices the panel had made prior to using the model. The panel 
were surprised that the model had recommended ‘apomorphine’ for patient 
one, as the patient’s condition was not that advanced and ‘apomorphine’ is
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usually a drug that is reserved for more advanced patients, as is Duodopa’. 
The panel felt the recommendations the model had produced were unsuitable 
for patient scenario one.
Table 7.7 Comparison of the panel’s decision and the model’s 
recommendations for patient scenario one
Panellists' Model’s Model’s Model’s
choice(s) results: results: results:
panellist one panellist two panellist three
Patient 1 No drug changes Rasagiline Apomorphine / Apomorphine /
discontinue amantadine / rasagiline / Duodopa/
pramipexole pramipexole Duodopa pramipexole
Patient scenario two
The panel made various recommendations for the treatment of patient 
scenario two as consensus could not be reached on choice of treatment. As 
with patient scenario one there was little similarity between the choices the 
panel had made and the recommendations the model made (Table 7.8). The 
only similarity shown was with amantadine’ which the panel had agreed could 
be considered as a drug for patient two and which was recommended by the 
model for panellist one. Once again, the panel felt the choice of ‘Duodopa’ 
was inappropriate for patient two as their condition was not advanced enough 
for this medication. The model did not recommend discontinuing ‘pergolide’ or 
increasing ‘co-careldopa’ as the panel had suggested, as the model had only 
been designed to recommend new treatments and did not take account of 
medication that needed discontinuing or amending. However, this was all that 
a MCDA model would normally be expected to do, as its purpose is to choose 
a treatment, that is to say it makes the decision about the most effective new 
treatment for each patient. This was the objective of the model, as described 
previously in chapter one. This type of model would therefore not be 
expected to recommend amending or discontinuing a drug.
Patient scenario three
There was more similarity between the treatments chosen by the panel and 
the model’s recommendations for patient scenario three (Table 7.9). The
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Table 7.8 Comparison of the panel’s decision and the model’s 
recommendations for patient scenario two
Patient 2
Panellists'
choicc(s)
Discontinue 
pcrgolidc add 
non-ergot 
dopamine agonist / 
add Stalevo 
increase co- 
careldopa ' 
consider 
amantadine
Model's 
results: 
panellist one
Model’s 
results: 
panellist two
Model’s 
results: 
panellist three
Duodopa / 
rasagiline / 
amantadine
Apomorphine / 
Duodopa/ 
rasagiline
Apomorphine / 
Duodopa/ 
rasagiline
panel had suggested considering ‘apomorphine’ as a treatment for this patient 
and the model recommended ‘apomorphine’ for all three panellists. The panel 
had recommended increasing levodopa in whichever form and the model 
recommended adding ‘Duodopa’, which is a form of levodopa, although of 
course it could not recommend increasing any levodopa-based drugs the 
patient may already be taking due to the fact that it could only recommend 
adding new treatments, as described under patient scenario two. Although 
the model had recommended a levodopa-based drug the panel were not 
entirely happy about Duodopa’ being recommended as it is such an 
expensive drug to prescribe and is generally only prescribed in a minority of 
cases where other drugs have failed. Therefore, it may have been 
unnecessary for this particular patient.
Table 7.9 Comparison of the panel’s 
recommendations for patient scenario three
decision and the model’s
Patient 3
Panellists' Model’s Model’s Model’s
choice(s) results: results: results:
panellist one panellist two panellist three
Inerease levodopa Apomorphine / Apomorphine / Apomorphine /
/ consider Duodopa / rasagiline / rasagiline /
apomorphine rasagiline Duodopa Duodopa
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Part II - Panel’s General Comments And Suggestions 
Frequency of recommendation of ‘Duodopa*
The panel commented on the frequency with which Duodopa’ was 
recommended for each patient, despite any differences in the weights they 
may have selected. As ‘Duodopa’ is recommended for very advanced 
patients suffering from complications arising from severe motor fluctuations it 
would not be a suitable drug for all patients, although the model had 
recommended it for less advanced patients, such as patient scenarios one 
and two. The panel therefore felt it was unsuitable for many patients and 
were surprised that it was recommended for all the patients without their 
severity of symptoms being taken into account. They felt the model should be 
taking more account of the level of advancement of the patient’s disease.
Treatments for non-symptomatic relief
The panel felt that some drugs, such as rasagiline’, selegiline’ and 
entacapone’, which do not provide symptomatic relief, should not be 
recommended as treatments in the same way as drugs which do provide 
symptomatic relief, such as ‘co-beneldopa’ or ropinirole’. They suggested 
that the model should recommend only drugs that provided symptomatic relief 
where the user was expecting a treatment to be recommended for particular 
Parkinson’s disease symptoms. The other non-symptomatic relief drugs 
should be treated differently as these are generally prescribed as adjuncts to 
other treatments such as the levodopa-based drugs. The model would 
therefore need to be able to distinguish between symptomatic relief drugs and 
adjunct drugs and make recommendations accordingly.
Inclusion of more patient variables
The panel suggested that not enough patient variables were taken into 
account in the model. They felt that the criteria included in the model did not 
encompass all the possible criteria that they would need to consider when 
choosing a patient’s treatments. For example, not all the characteristics of the 
patients’ symptoms described in scenarios one, two and three, such as 
freezing, bradykinesia or mobility problems, could be entered into the model, 
which meant the model was not looking at all the aspects of the patient s
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condition that needed to be considered in order to choose the best treatment 
for that patient. Having the ability to enter more data about each patient 
would ensure that all aspects of the patient’s care were considered which 
would help ensure the most effective treatment was chosen.
Use of clinical trial data
The panel queried whether the trial data used for scoring the drug options had 
led to any bias in the treatments being recommended by the model. For 
instance, where more recent clinical trials may have encompassed all, or the 
majority, of the different criteria assessed in the model perhaps leading to 
better scores, some of the older trials would not have encompassed so many 
criteria or not have been able to assess them in the same way. For instance, 
a rating scale such as the mini-mental state examination (MMSE) would 
perhaps not have been developed when some of the earlier clinical trials were 
carried out. There could therefore have been some degree of unintentional 
bias in the scoring of the drugs because of lack of uniformity in the trial data.
Levels of disease progression
Suggestions were made by the panel regarding the consideration of the 
degree of advancement of the patient’s disease. At the current time, the 
model did not take account of how advanced the patient’s condition was, nor if 
the patient was newly diagnosed. The panel therefore suggested that it might 
be more useful to have perhaps three different versions of the model 
according to the patient’s severity of disease. So, one version would choose 
treatments for newly diagnosed patients or those in the early stages of the 
disease, such as Hoehn and Yahr stages one or two. Another version would 
choose treatments for patients who were a little more advanced and a third 
version would recommend treatments for the most advanced patients who 
had reached the complicated or palliative stages of the disease, such as those 
at Hoehn and Yahr stages four or five. This would then help to ensure that 
the model chose the most appropriate treatment(s) for each patient and could 
help to avoid drugs such as Duodopa, which are generally for the most 
advanced stage patients, being recommended for patients in the early stages 
of the disease.
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Unexpected scores for drug options
The panel felt some of the scores that had been derived for the drug options 
were unexpected. For instance, co-beneldopa scored poorly overall and 
much worse than co-careldopa, despite the similarities in the two drugs. 
Levodopa-based drugs are also considered to be the ‘gold standard’ of anti- 
Parkinson’s treatments and one would therefore expect all of them to score 
highly. There were also comments about the overall scores and some of the 
individual scores for the non-ergot dopamine agonists ropinirole’ and 
pramipexole’. The panel felt these were different to what they would have 
expected in that both drugs might be expected to score in a fairly similar vein, 
although the actual scores in the model showed that there was a difference 
between the two on a few of the criteria.
'Duodopa’ as poor response drug
One panellist raised the issue of Duodopa still being included in the list of 
recommended treatments even when it had had been selected as a poor 
response’ drug and therefore should have been excluded by having all its 
scores set to zero. However, when this was tested after the validation 
exercise it was found that it was excluded and the scores were in fact all set to 
zero. There appeared to be no explanation for this anomaly.
Patient risk alert
The panel suggested that the model could be amended to incorporate a ‘risk 
box’, where data of the criteria that patients were most at risk from, eg 
‘hallucinations’, could be entered. This data would then be taken into account 
in the model and drugs that were most likely to cause this risk factor would be 
excluded. For example, if a drug was not known to cause a particularly high 
occurrence of hallucinations it would be excluded from the treatments that 
could be recommended.
Part III -  Applicability And Practicality Of The Model And EPSS
The final stage of the validation exercise was the completion of the 
questionnaire by the panel members assessing the practicality and 
applicability of both the model and software (Appendix III).
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Parkinson's disease model
The responses from the questionnaire overall were fairly consistent, with all 
the respondents feeling that amendments needed to be made to the model. 
The respondents all felt that the criteria in the model were deficient, rating the 
criteria from ‘fair’ to ‘very poor’, with all of them stating that important criteria 
had been missed out. There was also little satisfaction with the way the 
criteria were scored, with respondents rating the scores from ‘poor’ to ‘very 
poor’. The weights too were poorly received, the respondents rating the ease 
or difficulty of weighting the criteria from ‘fair’ to very difficult’ and all the 
respondents agreeing that the weights needed rewording to improve their 
clarity. Only respondent two made a suggestion as to how the wording could 
be improved, stating that the language needed simplifying. The respondents’ 
views of the model overall were mixed, ranging from ‘good’ to ‘poor*, although 
all the respondents felt amendments would need to be made to improve the 
model. None of the respondents agreed that the methodology was suitable 
for use with PD, although only respondent three explicitly disagreed, the other 
two both being unsure. Respondent two commented that the weights should 
be more representative of real world experience and priorities and respondent 
three commented that the methodology was not suitable for PD in its current 
format but that it has potential if the recommendations were made. Similarly, 
none of the respondents felt they would definitely use the model themselves 
or recommend it to colleagues, although again only one respondent explicitly 
stated they would not use it, with the other two being unsure whether they 
would or not. Figure 7.2 shows a pie chart of the panel’s ratings of both the 
model and EPSS. This pie chart only shows the responses for questions one, 
three, four, six, ten, twelve and thirteen. A second pie chart shows the 
breakdown of the panel’s responses for questions on the model, which include 
questions one, three, four and six (Figure 7.3). The responses regarding the 
questions pertinent to the EPSS (questions 10, 12 and 13) are shown in a 
further pie chart (Figure 7.4). The panel’s responses for all the questions 
together on both the model and EPSS are shown in Table 7.10.
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Figure 7.2 Pie chart of the panel’s ratings of the model and EPSS together
Panel’s ratings of model and EPSS
□ Good
■ Fair
□ Poor
□ Very poor
■ Difficult
□ Very difficult
■ Easy
□ Very easy
■ Quick
■ Very quick
Figure 7.3 Pie chart of the panel's ratings of the model
Panel’s ratings of model
& o Good ■ Fair□ Poor□ Very poor
Figure 7.4 Pie chart of the panel’s rating of the EPSS
Panel's rating of EPSS
□ Fair 
Easy
□ Very easy
□ Quick 
Very Quick
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Table 7.10 Panel’s ratings of the model and the EPSS’s applicability and 
practicality __ __ _____________________________
I Question Respondent 1 Respondent 2 Respondent 3
| Section A: Parkinson's disease model
• I I  low do you rate the criteria 
chosen?
Poor Fair Very poor
2. Do you think any important 
criteria have been missed out?
Yes Yes Yes
! 3. How do you rate the way 
the drugs have been scored 
, against the criteria?
4. How do you rate the ease or 
difficulty o f w eighting the 
i criteria
| 5. Do the weights need 
j rewording to improve their 
I c lari tv?
Poor
Difficult
Yes
Poor Very poor
Fair Very difficult
Yes Yes
6. What is your opinion o f the 
j model overall?
Good Fair Poor
| 7. Are there any amendments 
! you think could be made to 
i improve the model?
Yes Yes Yes
X. Do you think this is a 
suitable methodology for use 
in PD?
Not sure Not sure No
9. Would you use this model 
in clinic yourself or 
! recommend it to colleagues to 
i use?
Not sure Not sure No
Section B: Software (EPSS)
l(). How easy did you find the 
EPSS to use?
Very easy Easy Fair
11. Arc there any amendments 
you think could be made to 
the EPSS to make it easier to 
use?
Yes Yes Yes
12. How well do you think the 
questions are explained on the 
EPSS?
Fair Fair Fair
13. How quick was the EPSS 
to use?
14. How would you rate your 
own knowledge and 
experience o f computers?
15. Would you be happy to 
use the EPSS in your clinic or 
to recommend it to colleagues 
to use?
Quick Quick Very quick
Poor
Yes
Good Fair
Not sure No
234
Software (EPSS)
The responses regarding the actual software (EPSS) were more positive. The 
respondents felt the ease of use of the EPSS was from ‘fair’ to ‘very easy’, 
although all the respondents felt amendments could be made to make it 
easier to use. Only respondent two made a suggestion as to how to make the 
EPSS easier to use, suggesting the ability to see all the PD drugs rather than 
having to scroll to see them. The respondents all agreed that the explanation 
of the questions on the EPSS was fair’. Likewise, all the respondents felt the 
EPSS was quick to use, the responses ranging from ‘quick’ to ‘very quick’. 
The respondents’ assessment of their own knowledge and experience of 
computers ranged from poor’ to good’. Finally, the responses to the last 
question, asking whether they would use the EPSS themselves or 
recommend it to colleagues, were mixed, ranging from ‘no’ to ‘yes’, with all the 
respondents having a different response.
Subsequent validation exercises
Due to the results obtained from the preliminary validation exercise, which 
highlighted some major issues that needed addressing such as problems with 
the scores and criteria used in the model, it was decided not to carry out the 
subsequent validation exercises that had been planned. Further work would 
be needed to modify the model and therefore it was felt that nothing would be 
gained from further validation of the model and EPSS’ at this stage.
DISCUSSION
The preliminary validation exercise carried out with the first expert panel was 
a valuable exercise which gave a good picture of the panel’s views of where 
the model and EPSS are now as well as some interesting insights into ways 
of improving the model in particular and the direction the model could be 
taken into in the future in order to make it more robust for use in clinical 
practice.
1
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The validation of the model and software described in part I of the results 
section provided some interesting and at times surprising results. Firstly, the 
panel’s choice of drugs for the three patient scenarios showed that reaching 
consensus on choice of treatment was not a straightforward or easy matter, 
with consensus only being clearly reached for patient scenario one. Patient 
scenario three in particular showed the difficulty in choosing treatments for 
patients who are at the complex stage of disease progression. Although 
some degree of agreement was reached for this patient it was more as a 
result of general agreement on choice of treatment rather than an explicit 
consensus on precise drugs.
The model’s recommendations showed some conflicting results. There 
seemed to be little parity between the weights chosen by the panel and the 
recommendations made by the model. For example, for patient scenario one 
there was a degree of similarity in the weights chosen by the panel, but only 
the top weight was the same for all panellists, yet the results chosen by the 
model were very similar. For patient scenario two the weights chosen by the 
panel were quite different, yet the results were again similar, with panellists 
two and three receiving the same results despite having chosen different 
weights. With patient scenario three there was again differences in the 
weights chosen but the recommendations made by the model were more or 
less the same. This would seem to suggest that the choice of weights was 
having little effect on the drugs recommended by the model.
Once the panel’s treatment choices and the model’s recommendations were 
compared it was easy to see that there was little similarity between the two. 
For patient scenario one the panel’s choice was very different to the model’s 
recommendations, with the panel feeling the drugs recommended were 
unsuitable for a patient who did not have advanced PD. Likewise, there was 
little similarity between the panel’s choice and the model’s recommendations 
for patient scenario two with the panel feeling that Duodopa was an 
inappropriate choice for this patient. The model was also limited in that it 
could not recommend stopping or amending a drug as the panel wished. 
There was more similarity between the panel’s choice and the model s
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recommendations for patient scenario three. This could perhaps have been 
because patient three was at a more advanced stage of disease which the 
model seemed more likely to recommend appropriate treatments for.
The panel had various comments and recommendations to make for the 
model, as were described in part II of the results. A major criticism from the 
entire panel was regarding the frequency of the recommendation of Duodopa 
by the model. This certainly showed a deficiency in the model in that it was 
not taking account of the progression of the disease appropriate to each 
patient. The stage of disease was incorporated as a criterion in the model 
and was therefore included in the scoring, but it was not included as an 
additional variable for the user to input data specific to the patient the model 
was being used for. This would be something to incorporate in revisions of 
the model in order to develop a model that was more specific to the patient’s 
stage of disease.
Another general criticism was that the model did not incorporate enough of the 
variables that would be needed to properly assess a patient and choose the 
most appropriate treatment. Examples of this might include symptoms such 
as bradykinesia and tremor, two of the more common symptoms of PD. 
Additionally, the panel had suggested incorporating ‘risks’ that were pertinent 
to each individual patient and this too could form an additional variable of 
information needed about individual patients in order to choose the most 
appropriate drug treatment. Although the patient’s response to previous drug 
treatments had been incorporated into the model the panel’s suggestions 
showed that further information would be needed to be collected about each 
treatment to inform the model.
The panel also suggested that the model should distinguish between 
symptomatic and non-symptomatic treatments. Clearly it was not appropriate 
that the model could recommend a treatment that provided non-symptomatic 
[ relief, such as rasagiline, for treatment of particular symptoms when this is not 
|fcs intended use. The model would therefore need to distinguish between 
isymptomatic and non-symptomatic relief drugs and recommend treatments
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that were appropriate for symptomatic relief and to recommend non- 
symptomatic relief drugs as adjuncts, for example.
One particularly interesting result that came out of the validation was the 
highlighting of the problem with the scores. The panellists had commented on 
unexpected scores for certain criteria on some of the drugs. The reasons for 
this were unclear although it would seem most likely that the problem was 
caused by the use of clinical trial data, something that the panellists had also 
commented on as a potential source of bias. The problem of using clinical 
trial data to calculate the scores on the drugs was partly the difficulty in 
comparing one clinical trial against another. For example, clinical trials may 
use different criteria as outcomes for their results and clinical trials conducted 
in different decades for example may have completely different assessment 
scales available to them and therefore by comparing the results from these 
clinical trials one may not actually be comparing like with like.
One of the suggestions the panel made as a way of improving the model’s 
results was to redesign the model so that it took account of individual patients’ 
stage of disease. Effectively this could mean developing three separate 
models or three modules of the same model, for example one for newly 
diagnosed patients, one for intermediate stage patients and one for advanced 
stage patients. This would mean that the user would enter the patient’s stage 
of disease as part of the patient’s background information and the model 
would be selected which was appropriate to the patient’s stage. A different 
form of the model would then be developed for each of the three major stages 
following the format and methodology developed previously, with pre-set 
criteria, the drugs scored on their performance on each criterion and the user 
selecting weights for the criteria appropriate to each patient. This could help 
to make the model more appropriate for individual patients and potentially 
solve problems such as drugs like Duodopa being inappropriately prescribed 
for less advanced patients.
t
The questionnaire testing the applicability and practicality of the model and 
EPSS described in part III showed a mixed response to the decision aid
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overall. The questionnaire, similarly to the panel’s comments, highlighted 
many problems with the model but showed that the software developed was 
satisfactory and met its intended objectives, such as speed and ease of use. 
Although the panel had given various criticisms of the model their comments 
showed that the principle of the model and therefore decision aid was 
accepted and that it could become useful for clinical practice if the 
recommendations and suggestions listed above were put into practice. The 
model itself would need much further refinement and sophistication for it to be 
able to be used in clinical practice, which by definition would mean further 
refinement of the software too in order for it to implement the model.
The number of major issues that were raised through this preliminary 
validation exercise meant that further validation exercises with expert panels 
were deemed unnecessary at this stage. The model would need further 
refinement and development, as discussed above, at which point it could 
again be validated by expert panels and this would provide more value than 
carrying out multiple validation exercises when major issues had been 
identified at an early stage in the validation process.
Therefore, the validation of the model and software proved to be a valuable 
exercise. It was shown that a model could be developed for Parkinson’s 
disease and software developed that practitioners would find quick and easy 
to use. The panel agreed that the principle of the model and decision aid 
were sound, and that it could be a useful tool in clinical practice. The 
validation exercise was also particularly useful in pinpointing areas that need 
further development and ways that this could be carried out. The panel were 
able to identify areas that needed further work and also make suggestions on 
ways to incorporate improvements so that the model would fulfil a role as an 
effective decision aid for all individual patients with PD. This meant that a 
future direction for the model and EPSS could start to be determined. Further 
development and refinement of both the model and software could lead to a 
more sophisticated decision aid being developed for Parkinson’s disease that 
would have good potential for use in a clinical setting.
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SUMMARY
The Parkinson’s disease model and software were validated by a panel of 
experts to show whether they were applicable, practical and valid for use with 
Parkinson’s disease patients.
• Consensus on choice of treatment by the panel was limited, consensus 
only being reached for one patient scenario
• The results of the model’s recommendations for each patient scenario 
were conflicting
• There was little similarity between the panel’s choices and the model’s 
recommendations
• Issues were identified with the criteria in the model, with the panel 
suggesting several variables were missing
• The scores on the criteria were shown to have problems, producing 
what the panel considered to be unexpected results
• Several recommendations were made by the panel as to ways of 
improving the model
• The questionnaire showed a mixed response to the decision aid, but 
showed that the principle of the model was accepted and the software 
was satisfactory.
• The panel’s choices were compared against the recommendations 
made by the model.
• The panel completed a questionnaire evaluating their use of the model 
and software.
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CHAPTER 8
General Discussion
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“I have yet to see any problem, however complicated, which when you looked 
at it the right way did not become still more complicated”
Poul Anderson
Medical decision-making is a complex affair, as indeed is any kind of decision­
making. However, medical decision-making in particular has an additional 
level of complexity due to not only the expectations of the patient, but also the 
considerations the clinician must make in choosing a treatment that is not only 
effective, but also maximises benefits whilst minimising risks. Decision­
making in medicine was historically based on intuition and the clinician’s 
personal experience, rather than solely on solid clinical evidence and 
therefore often incorporated bias. However, the phenomenon of evidence- 
based medicine, which became popularised in the early 1990s, changed the 
way decision-making was viewed, with the emphasis since then being on 
implementation of sound evidence from the highest sources of clinical 
evidence such as randomised clinical trials. Decision-making has moved too 
from the traditional paternalistic model to a shared model with increasing 
emphasis on incorporation of the patient’s views and wishes in the choice of 
treatment.
The development of new methods of medical decision-making led to the 
incorporation of decision analysis, both with patient decision aids and with the 
development of computer decision support systems. The development of 
such decision aids and CDSSs meant that the large volume of literature which 
clinicians would have to search for and critically appraise was automatically 
reduced, as the evidence was already incorporated through the use of 
decision analysis. Thus, one of the limitations or criticisms of evidence-based 
medicine, that it would be too time-consuming for clinicians to read and 
appraise all the available literature in their field, was naturally discredited. 
Indeed, the use of CDSSs, for example, meant that the highest level of 
evidence from randomised clinical trials or meta-analyses of trials was 
automatically incorporated.
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The review of the literature on decision aids and CDSSs described in chapter 
one showed that they are a useful means of implementing evidence-based 
medicine and improving healthcare quality, although results from trials using 
CDSSs were somewhat mixed. However, the general view was that CDSSs 
had the potential to be useful and improve decision-making. Four features 
had been identified as critical for new CDSSs to be accepted in clinical 
practice (Kawamoto, 2005), namely the automatic provision of CDSSs as part 
of the clinician s workflow; provision of a CDSS at the time and place of 
decision-making; provision of a recommendation not an assessment and the 
system being computer based. Sittig et al (2006) also established that 
CDSSs were more likely to be used if patients were elderly, on multiple 
treatments and had a chronic condition. Not all areas of medicine have 
CDSSs in use or even developed for them and there was therefore a need for 
more CDSSs to be developed, with the features identified above incorporated. 
Thus, the development of a model and CDSS to implement it was deemed to 
be the aim of this thesis.
Parkinson’s disease is a complicated disease exacerbated by the 
complications that may arise from the drug treatments used to reduce 
patients’ symptoms. Difficulties in choosing the most effective treatments for 
the disease lie in the choice of drug treatment in the early stage to minimise 
the patient’s symptoms through to dealing with complications in the advanced 
stages of the disease very often arising from the treatments themselves. 
Parkinson’s disease is therefore a complicated disease to treat and to date 
there has been no algorithm or decision aid developed to help practitioners 
choose the most effective treatment for individual patients. Thus a need was 
exhibited for a CDSS that could be applied to Parkinson’s disease which 
would incorporate evidence-based medicine and shared decision-making.
Among the many types of models used in decision analysis, such as Markov 
models, ANN and Bayesian networks, is multi-criteria decision analysis. This 
provides a means of breaking a complex problem down into more 
manageable pieces and allowing data and judgement to bear on them before 
the pieces are reassembled to give an overall picture of the decision problem.
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MCDA has been widely used in certain areas such as environmental 
management, but has had little application in medicine. The few MCDA 
models that have been developed in medicine have tended to be small and 
for relatively less complex decision problems.
A model was therefore developed for Parkinson’s disease using MCDA and 
was implemented in a CDSS. Developing the model using MCDA involved 
carrying out seven stages, as described below:
1. Establish the decision context
2. Identify the options to be appraised
3. Establish the criteria to be used
a. Divide the criteria into ‘risk’ and ‘benefit’ categories
b. Devise a value tree for the criteria
4. Develop the scores by assessing the performance of each option 
against the criteria
a. Define measurement scales
b. Develop scoring scales
c. Calculate total score for each option
5. Assign a weight to each criterion according to its importance to the 
decision problem
6. Combine the scores and weights into an overall value
7. Carry out a sensitivity analysis
The early stages of developing the model were described in chapter three, 
where the decision context was ascertained, the options described and the 
criteria developed. The rest of the model, which involved developing the 
scores and weights, was described in chapter four, with the sensitivity 
analysis carried out in chapter seven.
The decision context and available options for the model were simple to 
establish. The process of establishing the criteria was more complex and 
produced some interesting results. The initial survey sent to geriatricians, 
neurologists and Parkinson’s disease nurse specialists, which ascertained 
whether they used any kind of algorithm and whether they used personal
i
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experience for their decision-making, showed that hardly any of the 
practitioners used any kind of established algorithm and a large majority were 
using personal experience as part of their decision-making process. This 
result could be considered somewhat surprising considering the emphasis in 
recent years on the use of evidence-based medicine. One would have 
expected the role of professional judgement to perhaps have diminished with 
the growth of evidence-based medicine. Although it could be suggested that 
some degree of personal experience is still to be expected in the use of 
evidence-based medicine, especially where evidence is lacking, it is the 
degree to which it appears to still be being used in Parkinson’s disease, as 
shown by the results of this survey, that would lead one to question whether 
practitioners are really using evidence-based medicine in conjunction with 
their professional judgement.
The second survey that was sent to the same geriatricians, neurologists and 
Parkinson’s disease nurse specialists, following on from the first, showed that 
some practitioners were considering a large number of criteria in their 
decision-making for PD, up to 68 criteria. The range of criteria considered 
varied greatly, from 10 to 68. This, together with the results from the first 
survey suggested a disparity between prescribing practices for practitioners 
and a lack of uniformity in decision-making between individual consultants and 
also, one could intimate, between hospitals. Therefore, patients could be 
unlikely to receive equality of treatment.
With the criteria established, the rest of the model was then developed, as 
described in chapter four. The process of developing the scoring of the drugs 
on the criteria provided some interesting results. Some drugs, such as 
pergolide, scored much better than expected, whilst others, such as co- 
beneldopa, scored much more poorly than one would have thought, bearing in 
mind that levodopa is considered to be the ‘gold-standard’ of PD treatments. 
The scores showed that for some criteria, such as ‘depression’ and ‘postural 
hypotension’, very few of the drugs had any positive effect. Overall, the 
drugs tended to have a fairly negative effect on the criteria, to a greater or
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lesser degree. Activities of daily living’ was the only criterion for which none 
of the drugs had a negative effect.
Developing the scores raised some interesting issues in terms of the clinical 
trial data used. Collecting the data to calculate the scores from highlighted an 
initial problem: the availability of the original clinical trial data from when the 
drugs were first developed. Difficulties in obtaining original clinical trial data 
meant data had to be used from subsequent trials. However, this was not the 
only problem. Many issues surround the data that clinical trials produce. For 
example, there is a lack of uniformity in the data that clinical trials collect. This 
was most evident when trying to establish the scoring scales for the criteria. 
Many of the trials did not examine all the criteria needed for the model, 
although there were also problems in the reporting of the data established, 
such as statistical significance not always being listed. Different clinical trials 
used different measurement and assessment tools for some criteria. For 
example, for measuring the effect of the drug treatments on ‘depression’ some 
trials used the Montgomery-Asberg Depression Rating Scale, whilst others 
used the Zung self-rating depression scale. Furthermore, some clinical trials 
used a rating scale such as the UPDRS to measure certain aspects of the 
effects of their drug treatments, but did not use all the sections, so effects of 
the drugs that could have been measured were lost. This could suggest a 
deficiency in clinical trials, where an effect of a drug is missed simply because 
in the trial design it has been decided not to look at all aspects of a 
measurement scale.
An additional problem with the clinical trials was that certain patient groups 
were often excluded. For example, many of the trials excluded patients under 
the age of 30 or over the age of 80. Therefore, there is often a lack of data 
available on the effect of PD drugs on these groups of patients. This is 
particularly important for young-onset PD patients, who, whilst forming a small 
minority of patients, may still have different needs to older patients and on 
whom the drugs may have different effects. Their exclusion from clinical trials 
means we have no or little knowledge of how the drugs will perform for them. 
For patients over the age of 80, there may be many who would have been
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excluded from clinical trials anyway due to failing cognition, but for others who 
have sound cognition we again would be lacking data on how the drugs would 
perform for them in relieving their symptoms. This leads on to the issue of 
cognitive impairment and other neuro-psychiatric problems. These patients 
too were excluded from the clinical trials, and whilst there are ethical and 
other issues connected with the inclusion of such patients in clinical trials 
which are beyond the scope of this thesis to address, their exclusion does 
lead to a deficit in data on how to effectively treat this important group of 
symptoms.
The original criterion for collecting the data for the scores was to obtain all the 
data from pivotal clinical trials. Other data was obtained from searches for 
trials using the drugs in the model, although a literature review was not carried 
out at that stage due to the time limitations of the project. In retrospect, it 
would have been useful to have carried out a comprehensive literature review 
giving reference to the meta-analyses, systematic reviews and randomised 
clinical trials that were used as the evidence-base for the NICE guidelines 
(NICE, 2006). These were incorporated into the NICE guidelines as the best 
available evidence and should, therefore, have been used as the evidence- 
base for this model, perhaps eliminating some of the potential bias that was 
highlighted in the validation exercise, such as the unexpected scores 
pergolide and co-beneldopa received, for example. It is difficult to be certain 
whether or not these issues would have existed if a review of the literature 
had been carried out using the same sources as the NICE guidelines, but by 
carrying out such a review one can at least ensure that the best evidence has 
been assessed and incorporated into the model. This would also help to 
make the model more robust, an important issue if it were to be used in a 
clinical setting in the future. However, issues to do with evidence from clinical 
trials were highlighted in the NICE guidelines. For example, drugs evaluated 
from many of the early trials conducted in the 70s and 80s may have been 
found by NICE not to be efficacious. This does not though mean the drugs 
are necessarily ineffective, but the clinician would need to use their clinical 
experience as the only appropriate judgement of the drugs safety and 
efficacy. The NICE guidelines found that trials used in the systematic reviews
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incorporated into the NICE evidence-base often had methodological 
limitations. They suggest that such trials should be treated with caution 
because of this. They therefore did not give evidence statements based on 
data from individual trials. However, the purpose of this study was to develop 
an initial prototype that would assess whether a model could be developed for 
PD with MCDA. Having a more comprehensive review of the clinical evidence 
available on each drug would be part of future work carried out in developing 
the model further, with the issues identified above taken into account.
The process of trying to develop the weights showed that they would not be 
able to be pre-defined in the usual way for such a model, as allowing the user 
to develop their own weights was the only really feasible way of making the 
model unique to each patient. Two criteria were an exception to this, ‘adverse 
drug reactions’ and drug interactions’, as both of these criteria needed to 
have their weight pre-defined as they were considered to need the maximum 
weight for all patients. However, the majority of the criteria weights not being 
pre-defined was in some ways an advantage, as not only would the model 
therefore be unique for each patient it was used for but it would also mean 
that the patient could be involved in the decision-making process, enabling the 
important aspect of shared decision-making to be naturally incorporated. This 
would provide a benefit for the patient, in that their view would be considered 
and incorporated, and also for the clinician who would not have to rely on their 
own value judgements to decide which criteria were most important for the 
patient. Generally, one would expect a MCDA model to have pre-defined 
weights and scores and for the model to produce one solution to one decision 
problem. Medicine, though, is not such a straightforward field, particularly in 
the case of choosing treatments for Parkinson’s disease patients. However, 
MCDA was shown to be an adaptive methodology, in allowing in effect many 
models to be developed for many patients, by varying the weights to suit the 
individual. Thus, not just one model was developed, but the potential for as 
many variations of the model as would be needed, that is to say as many 
individual models as there are individual patients in terms of their symptoms 
and values.
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The process for calculating the weights used in the model follows the 
methodology of MCDA, but brings issues of its own. For example, swing- 
weighting is quite time consuming and cumbersome for users. It is a 
complicated methodology to understand and apply correctly without guidance 
or someone knowledgeable present to explain how to calculate the weights. 
Although a ‘help’ mechanism was added to the software to explain how to 
carry out swing-weighting it is questionable whether that would be adequate in 
a clinical situation where time is limited and a lack of understanding of the 
methodology could lead to the weightings being developed without truly using 
swing-weighting. It requires time to think about the weightings, to discuss 
them with patients, to perhaps explain some of the criteria to the patient if they 
do not understand the symptoms that are being assessed and which may 
anyway in part be irrelevant for some of them. One would have to ask 
therefore whether swing-weighting is the best way of calculating weights for 
the purpose of this type of model which ultimately one would hope to see used 
in a clinical setting. It would be necessary to assess whether there is a way of 
improving the weighting wording for example so that it is quicker and easier 
for users to choose their weights. Swing-weighting is currently considered to 
be the most apt way of calculating the weights in a MCDA model, thus if 
MCDA is to be used for this type of disease model it needs to be improved to 
make it more practical and accessible.
The issues with the data used for the scores lead to an interesting point 
regarding the use of evidence-based medicine. EBM has been advocated by 
many as the best method of medical decision-making, but this project has 
shown problems with the evidence that has been used in developing the 
model. If this is the best evidence that practitioners can access in order to 
make their treatment decisions, with all the flaws that have been identified, 
can one truly advocate the use of EBM as the best means of decision­
making? However, one could argue that the results of this study support the 
views of some, such as Sackett et al. (1996), Lacaine (2005) and Akobeng 
(2005), who have argued that the use of EBM is justified if it is used in the way 
it should be, with individual clinical expertise and personal experience being 
used alongside the best available evidence as well as patients’ opinions and
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values being incorporated. Although there may be insufficiencies in the 
evidence available, it is still the best available evidence, particularly as it is 
from randomised clinical trials, and therefore if used along with the clinician’s 
expertise and the patient’s own values provides the best basis for medical 
decision-making. Therefore, although problems have been identified in the 
scoring and weighting used in this model, if they are further refined they will 
still provide the means for the clinician to make the best informed decision 
they can which incorporates EBM, clinical judgement and shared decision­
making.
The developed model lacked a means of implementation and a CDSS was 
thus developed to implement its functionalities. Although propriety software 
exists for MCDA models, the uniqueness of this model meant it was more 
suited to bespoke software which could cater for its variation in weights, for 
example. Choosing Microsoft Excel to carry out the mathematical functions 
of the model and Visual Basic for Applications (VBA) as the interface 
development language meant two compatible applications were used 
together. Developing a user interface in VBA also meant that the user would 
not have to be involved in, or even aware of, the calculations that the model 
needed to carry out, such as multiplying the scores and weights together. The 
user interface also provided the means of allowing the user to enter data 
specific to each patient so that the user’s reaction to previous medication 
could be recorded and incorporated into the model.
The interface and overall design of the software kept the CDSS quick and 
easy to use. The interface design followed the design principles of 
Schneiderman (http://facultv.washinaton.edu, 2008) as closely as possible, 
which helped to make it simple and easy to use as well as accessible. In 
terms of the implementation of the software, Excel and VBA provided 
everything that was needed in respect of accepting the user’s data input, 
submitting data to Excel for calculations to be carried out and providing a 
result for the user to see.
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Methods were incorporated into the coding of the software application to 
ensure that all data the user entered was within the correct format, such as 
figures only or numbers between 0 and ten, as necessary for each section. 
This process of data validation was described in chapter six. Every possible 
type of data the user might enter which could be invalid was tested in a series 
of checks. A thorough evaluation of the user’s data input was therefore 
incorporated and proved to be an effective means of ensuring that only valid 
data was entered. This necessary process ensured also that the model would 
function effectively with the correct form of data provided.
The rest of chapter six looked at the process of testing the software to ensure 
it worked effectively and without any problems. This was expected to be a 
fairly straightforward process as it was a small application. However, carrying 
out all the specified tests on the application showed that testing the software 
was a very valuable exercise. Two tests that were expected to be performed 
without any hitches highlighted bugs in the coding that might otherwise have 
been overlooked. All the other tests provided results as expected, showing 
that the original coding was sound and also that the user data validation 
techniques added had ensured everything would work smoothly and perform 
as expected. The end result was that a piece of software was produced which 
performed the way it was designed to do and that had been tested as 
thoroughly as possible to ensure that all its functionalities were complete and 
effective. The CDSS also met three out of four of the features identified by 
Kawamoto (2005) as necessary to make a CDSS successful for use in clinical 
practice. These were the provision of a recommendation rather than an 
assessment, the system being computer-based and the CDSS being provided 
at the time and place of decision-making, which it would be if it were used in 
clinic. The only feature which this CDSS did not comply with was the 
automatic provision of the CDSS as part of the clinician’s workflow, which was 
beyond the scope of this study, but which could be considered as part of 
future development.
The final stage was carrying out the ‘sensitivity analysis’, which was covered 
by the validation exercise described in chapter seven. This tested whether
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the model met its objectives and whether it could provide suitable 
recommendations on treatments for Parkinson’s patients, as determined by a 
panel of experts. The validation exercise also looked at whether the panel 
considered the software to be quick and easy to use. The validation was a 
particularly interesting exercise in the results that it produced. A number of 
issues were identified by the panel but the basic principles of the model were 
also considered to be worthwhile and workable. The panel identified 
problems with both the criteria and the scores in the model. The criteria were 
not considered comprehensive enough and did not reflect all areas of the 
information about the patient that would be necessary to choose effectively 
the best treatment for each individual patient. For example, if the patient’s 
main symptoms were problems with bradykinesia and tremor, two very 
common symptoms in PD patients, the model would not currently provide any 
means of incorporating these criteria. This is due to the fact that these two 
criteria were not listed in the surveys carried out ascertaining the criteria PD 
practitioners use. This could have been due to a comprehensive enough 
procedure not having been carried out when the criteria were developed. For 
example, if a panel of experts had been involved in assessing the criteria that 
arose from the two practitioner surveys carried out they may have identified 
that essential criteria which one would consider to be the cornerstone of PD 
symptoms, such as bradykinesia and tremor, had not been identified in the 
surveys. It could also be considered that the application of the eight 
considerations to the criteria from the surveys was to some extent arbitrary. 
Having an expert panel involved in the application of the considerations may 
help to make the process more robust and accountable. One option for 
ensuring the criteria chosen were more robust and the procedure more explicit 
could be to use a procedure such as the Delphi technique. This is a 
structured technique that is used for obtaining opinions with the aim of 
obtaining consensus among a group of experts (Campbell and Cantrill, 2001). 
With the modified Delphi methodology, for example, a literature review and 
survey development are carried out, an expert panel selected and data 
collection and analysis is then carried out (Hanlon et al, 2009). Using a 
technique such as this could help to ensure that there was consensus among 
experts on the criteria that were selected for the model and also reduce over­
reliance on an evidence-based approach. For example, the higher cognitive 
aspects used by clinicians in decision-making on choice of treatment for PD, 
such as pattern recognition and individualised care assessments for patients, 
were not taken into account in the process of developing the criteria. These 
are aspects which could be incorporated in refining the criteria and which 
could ensure that a more comprehensive methodology for developing the 
criteria was carried out.
Additional problems were identified with the scoring. The panel felt that the 
scores did not accurately reflect the way the drugs perform and this therefore 
unduly biased the performance on the scoring of individual drugs, such as co- 
beneldopa for instance. The panel also identified additional problems, such 
as the frequency of the model’s recommendation of Duodopa, which they felt 
was inappropriate for less advanced patients. This is an issue that might 
perhaps have been addressed if evidence had been used from the same 
sources as the NICE guidelines, for example. As identified earlier, this may 
have eliminated some of the problems such as the unexpected scores for 
pergolide and co-beneldopa. It could also have been useful to perhaps have 
developed separate ‘modules’ for the different stages of the disease, such as 
early, middle, late, as suggested by the expert panel in the validation exercise. 
This may have overcome the problem of the model recommending 
inappropriately drugs for advanced patients, such as Duodopa, for patients 
who were less advanced. Further problems were identified with the 
weightings, which the panel firstly found difficult to understand. This was 
because of the methodology of swing-weighting for which the users had to 
consider a range of effects each drug might have on each criterion, which the 
panel felt was complicated to understand and carry out. Additionally, the 
weights were shown to have little impact on the results the model 
recommended, with the same or very similar results being provided by the 
model even when panel members had quite distinct choices of weights. As 
discussed previously, the weightings may need re-wording or a re-working of 
how the weights are calculated may be necessary. Overall, the sensitivity 
analysis showed its worth with the issues of the scores and weights that were 
highlighted, as variations in weightings should still produce a feasible result
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and this was not always the case with this model. However, overall the 
software was considered to be quick and easy to use, which was its objective. 
The panel felt both the software and model were useful tools which, with 
further refinement, could be successfully used to choose treatments for PD 
patients. The panel also felt that in principle the methodology of MCDA could 
be used for PD, although with refinements taken into consideration.
The work carried out on developing the model and the results of the validation 
exercise could lead one to question whether MCDA is the most appropriate 
methodology for developing a model for Parkinson’s disease. There are a 
number of issues to consider. Firstly, a model was successfully developed for 
Parkinson’s disease using MCDA, which shows that it is possible to do so. 
Although this model was shown to have a number of issues, the expert panel 
involved in the validation exercise did agree that it was a methodology that 
could be used for Parkinson’s disease, albeit with a number of modifications 
and refinements. A question that one might ask is whether in fact Parkinson’s 
disease is too complicated a disease to model effectively. The issues and 
problems raised through this project, such as with the criteria and scores, 
show that Parkinson’s disease was perhaps too complicated a disease to 
model effectively solely through carrying out the work covered in this thesis. It 
would perhaps have been better to have modelled just one aspect of the 
disease, such as early stage patients only to begin with. If that had been 
successful then other stages could have been modelled subsequently as 
further work. It should be remembered also, that at this stage this model is a 
prototype and “a proof of principle” consistent with the objectives of the thesis, 
it did not however meet the more rigorous aims of providing a validated 
clinical decision aid which was fit for purpose and satisfied “proof of concept” 
(PoC). It will be the effect of the further refinement and sophistication of the 
model that will determine how effective a model can be at treating this 
complex disease. However, the fact that PD is such a complicated disease 
emphasises the fact that a methodology such as MCDA is the right choice for 
this disease as it is specifically designed to deal with complicated decision 
problems and to incorporate both quantitative and qualitative data with value 
judgements.
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If one determines that it is possible to model Parkinson’s disease, one could 
conversely question whether PD is the best disease to use for developing a 
model with MCDA. Others have shown that MCDA can be used to choose 
treatments for other conditions, such as Ferrari et al.’s (2005) model 
developed to determine the most effective triptan for migraines, Hummel et 
al.’s (2005) model for tetraplegia, Singh et al.’s (2006) model for pharyngitis, a 
model for colorectal cancer screening (Dolan and Frisina, 2002) and a model 
for pyelonephritis (Dolan, 1989). However, most of the models previously 
developed for medical decision-making using MCDA have been for conditions 
or treatments that were less complex than Parkinson’s disease and which 
involved fewer criteria and fewer available options. None of the 
aforementioned studies described problems obtaining trial data, if it was used, 
and therefore did not have the same limitations that this study had. Nor did 
the previous studies develop as sophisticated a model which could 
recommend different treatments for individual patients. This project is the first 
to tackle such a complex disease with its complicated treatments using MCDA 
and shows that PD was a suitable disease to be used with this methodology. 
It also shows that MCDA could be used for other major diseases, where there 
is a need for models and decision aids to help practitioners deal with 
complicated decision-making on choice of treatments and importantly to aid in 
the implementation of evidence-based medicine. Many of these diseases and 
conditions may be less complicated than Parkinson’s disease, and therefore 
more straightforward to model with MCDA. One advantage of modelling 
Parkinson’s disease with MCDA is that it has shown that it is possible to do so 
for a complicated disease and therefore models for other diseases can follow 
the initiative of this project. The development of this model as part of a CDSS 
means that it also meets the criteria outlined in chapter one for new CDSSs, in 
that it has been shown to be quick to use, provides a comprehensive 
functionality and implements evidence-based medicine.
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LIMITATIONS OF THE STUDY
There were a number of limitations to the work carried out for this project. 
Firstly, the criteria that were developed were not comprehensive enough in 
the range of variables they incorporated. Although practitioners were 
consulted about the criteria they would use for decision-making in PD, there 
were still criteria, such as bradykinesia and tremor, which were not listed by 
practitioners and were therefore not incorporated into the model, as previously 
discussed. This was something that was highlighted by the expert panel 
during the validation exercise, as it was felt that if criteria were missing it was 
not possible for the model to truly represent the patient’s situation.
There were limitations with the scoring of the criteria. First of all, there was a 
problem with obtaining all the necessary clinical trial data from which to 
calculate the scores. There were additional limitations with the data that was 
collected on the drugs, such as the lack of uniformity of assessments used in 
the clinical trials, with different measurement and assessment tools being 
used and very often different criteria being measured. Additionally, not using 
the evidence base such as had been used in development of the NICE 
guidelines (NICE, 2006) to collect all the data on all the drugs meant that 
there may have been data on some aspects of some drugs that was missing. 
Therefore, the scores could not necessarily be considered to be completely 
accurate.
The weights proved difficult to develop. This was for a number of reasons. It 
was not possible to develop a satisfactory means of pre-determining the 
weights so the model had to be developed so that the user was choosing their 
own weights. There were thus then difficulties in phrasing the weights in such 
a way that any user would understand the methodology of swing-weighting 
and therefore calculate the weights correctly. Using swing-weighting meant 
that the weights could be time-consuming for users to choose. Overall this 
was a necessary part of the methodology, but not a very satisfactory one to 
include in the model because of the potential difficulties it could cause the 
user.
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The final limitation of the project was that full content validation was not 
carried out for each stage of development of the model. This in part 
contributed to the limitations listed above. For example, if the criteria had 
been validated by an expert panel when they were developed, such as by 
using the Delphi technique, the criteria that the panel involved in the validation 
at the end of the project mentioned that were missing, such as bradykinesia, 
may have been identified at an early stage to be included in the model. 
Additionally, an expert panel could have validated the scores that were 
developed, to ensure they represented fairly the way the drugs performed 
against the criteria. Although this would not have eliminated the problems 
mentioned previously with obtaining data and the problems with the lack of 
uniformity in the trials, it may have diminished some of the problems 
highlighted with the scores. It may have been difficult to have carried out a 
validation of the weights as these were not pre-determined, but an expert 
panel could have been involved in validating whether the methodology was 
understandable and if the wordings used for the weights were clear. In 
general, content validation of each stage of development of the model would 
help to ensure that the finished model was as robust as possible. It would 
also have been useful to have been able to provide a means of explaining to 
the user why a particular drug was recommended by the model for each 
patient, but this would have added a level of complexity to the model that 
would have taken its development beyond the scope of this PhD project. 
Finally, it could be considered that the scope of the project was too broad. 
The issues identified in developing a model that could recommend treatments 
for all Parkinson’s disease patients could be considered as too ambitious a 
project based on the results discussed in this thesis. It would perhaps have 
been better to have developed a model for one aspect of the disease, such as 
for early stage patients for example, from which further work could be carried 
out to develop the same or a similar model for other stages of the disease. 
However, this study did develop a model and CDSS for Parkinson’s disease, 
which can be considered to be a successful proof of principle. The limitations 
discussed above could be incorporated into the refinement of the prototype 
developed here and carried out in future work.
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HAVE THE OBJECTIVES BEEN MET?
In chapter one two broad objectives for the project were identified in order to 
achieve the aim of developing an electronic decision aid to help practitioners 
choose the most effective treatment for Parkinson’s disease. These were:
• To develop a model using multi-criteria decision analysis to be applied 
to Parkinson’s disease
• To develop a computer system to implement the model’s functions.
Both objectives can be said to have been met. The model was developed 
using MCDA and was applied to Parkinson’s disease. The aim of helping 
practitioners to choose the most effective drug treatment was met through 
development of the model, as the model incorporated evidence-based 
medicine and the criteria, scores and weights determined the information that 
was necessary for each patient. A piece of software was successfully 
developed using Excel and VBA which implemented the model’s functions, 
and through validation of the user’s data entry and a thorough testing process 
the software was shown to meet its objectives to be quick and easy to use 
and was therefore successful in its development. Therefore both of the 
objectives of this project were successfully met.
FURTHER WORK
In order to refine the model and increase its sophistication a number of areas 
of further work would need to be carried out, to take the work developed here 
as proof of principle into a more refined model and CDSS suitable for use in a 
clinical setting. In terms of the methodology used, three of the steps of the 
MCDA model would need further development. A need for a greater number 
of criteria was established during the validation exercise with the expert panel. 
The list of criteria established from the two surveys could be reviewed by 
including an expert panel in the further development of the criteria and a 
methodology such as the Delphi technique used to ensure that all the 
expected additional criteria, such as bradykinesia, had been added in to the
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model. The scores would also need further refinement. First of all, a 
comprehensive literature review should be carried out on all the PD drugs to 
ensure that all the available studies and evidence had been appraised, using 
for example the same sources as were used in the development of the NICE 
guidelines. If further data were obtained the measurement scales for the 
scores may need to be revised and a new set of scores developed for each of 
the drugs. The issue discussed previously regarding lack of uniformity in the 
trials is not really a problem that can be solved for this project or subsequent 
work. However, using all the evidence that is available to determine the 
scores would at least ensure that the data used to calculate the scores is 
comprehensive. Other issues identified earlier with the scores, such as the 
trial data possibly leading to potential bias in the score results could not 
necessarily be overcome, but may just be a feature of using evidence-based 
medicine. However, use of the best sources of evidence, such as from the 
NICE guidelines, would help to ensure that as a minimum the best evidence 
had been used. Having an expert panel involved in the development and 
reviewing of the scores could help to ensure that clinicians’ value judgements 
are also incorporated into the model, as has been suggested is the best way 
to use evidence-based medicine. The weights too may need some 
modification in their wording in order to make the methodology of swing- 
weighting easier for users to understand. It is also possible that an alternative 
means of deciding the weights may need to be considered so that it is quicker 
and more straightforward for clinicians to use.
It could also be useful to either develop in effect separate ‘modules’ of the 
model that apply to the different stages of the disease, such as for early or 
advanced stage patients among others, or if the model was developed to 
apply only to early stage patients, for example, further models could be 
developed for the other stages of the disease.
The issue of content validation throughout the model has been discussed 
previously. It would be useful to have an expert panel involved in each stage 
of development of the model and any variation of the CDSS to carry out 
content validation to ensure that the model is practical and meets the users
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expectations. This would help ensure that the model was robust and could 
therefore be considered for use in clinical practice.
One area which was not addressed in this project was a means of giving the 
user feedback on why a particular treatment had been recommended over all 
the others. This was felt to be beyond the scope and time-limits of this 
project. However, it is an important issue which would provide a further useful 
benefit of the decision aid and would particularly benefit less experienced 
users in clinical practice as well as medical students if it were used as a 
teaching aid. It would therefore be beneficial to incorporate an algorithm to 
provide the users with the reasoning behind the model’s recommendations in 
order to further knowledge about why one drug is recommended over another. 
This is important to help the user learn from the model’s recommendations 
and particularly pertinent for medical students and junior staff so that the 
model can become an effective learning tool. It could also be useful for more 
experienced practitioners to improve their clinical practice.
In order to implement the extended functionalities of the model, as discussed 
above, it would be necessary to refine the software. One possibility could be 
to develop an expert system to provide additional functionality. A 
computerised expert system can be developed by obtaining knowledge from a 
human expert which is then transformed into a format the computer can use to 
solve similar types of problems. The expert system uses reasoning to apply a 
set of rules to the knowledge by using some of the rules that human experts 
use (Aniba et al., 2008). The expert system therefore simulates the 
judgement and behaviour of the experts and uses their knowledge to provide 
an analysis for the user.
There are several forms of expert system that have been identified (Liao, 
2005), which include rule-based systems, case-based reasoning systems, 
neural networks and fuzzy expert systems, each of which will be outlined in 
turn.
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• Rule-based systems — these use a set of rules to analyse information 
about a class of problems and recommend one or more solutions
• Case-based reasoning systems — these systems adapt solutions that 
have been used to solve previous problems and use them to help solve 
new problems
• Neural networks -  these implement software simulations of parallel 
processes that process elements connected in a network architecture
• Fuzzy expert systems -  this type of system uses fuzzy logic to deal 
with uncertainty and is used where results often involve grey areas.
An expert system could provide more sophisticated modelling and software 
which adapts to each patient. For example, by perhaps using either case- 
based reasoning to adapt previous solutions for patients, or by using a fuzzy 
expert system which would perhaps deal more effectively with the ‘grey’ areas 
of decision-making for Parkinson’s disease patients. An expert system would 
also provide the means of incorporating further functionality than the model 
developed for this project was capable of, such as recommending dosage 
amendment or stopping a drug the patient was already taking. It would also 
be easier to provide feedback to the user regarding the recommended 
treatment path as a complicated algorithm detailing why a recommendation 
was being made would already by necessity be part of an expert system and 
so could be adapted to be returned to the user. This would also aid the 
confidence of the clinicians using the system in the suitability of the 
recommendations it made.
However, an expert system is only one suggested path for the future direction 
of a model for Parkinson’s disease. It may be necessary to examine in detail 
whether it is possible to develop a sophisticated enough model for PD using 
MCDA, with some of the aforementioned refinements encapsulated. It would 
also be useful to examine whether an expert system would be the best way to 
take the model forward. Therefore, further work could be carried out to 
examine both paths in detail with experts in the two fields involved to compare 
the two possible routes in which to take this work further forward. Once the
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best route has been established it should be possible to develop a more 
refined and sophisticated model or system which would have good potential 
for use in a clinical setting.
CONCLUSIONS
Developing this model has shown that MCDA can, with limitations, be used to 
develop a model for complex diseases. It has also been shown that a model 
can be developed for Parkinson’s disease. Bespoke software can be, and 
has been, successfully developed to fit the model and implement its function 
in order to provide a computer decision support system. This model and 
CDSS show that progress has been made in both the field of MCDA in 
medicine and in modelling Parkinson’s disease. With further refinement a 
more sophisticated CDSS could be developed that would have great potential 
for use in a clinical setting, providing clinicians with a time-saving decision aid 
unique in the field of Parkinson’s disease and a means of implementing 
evidence-based medicine. This is something that could be particularly useful 
for less experienced doctors and for PDNSs new to prescribing in helping 
them with their decision-making. It could also provide a means of training 
junior doctors and medical students in medical schools and help them to 
develop their skills in decision-making and use of evidence-based medicine. 
Through this research project progress has been made in both modelling 
using MCDA and for PD. A model has been developed for the first time for 
Parkinson’s disease and the use of MCDA extended in medicine in a way 
which has not been done before. Both PD and MCDA have been taken in a 
new direction and the potential for the use of MCDA in medicine and the 
modelling of Parkinson’s disease been taken forward. Developing this model 
and CDSS for PD have shown that there is a great potential for future work 
moving the field of decision support in medicine forward and creating the 
potential for applying the methodology to other medical conditions.
“The aim of argument, or of discussion, should not be victory, but progress”
Joseph Joub
262
references
263
(1996) Impact o f deprenyl and tocopherol treatment on Parkinson's disease in 
D A T ATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol, 
39, 37-45.
(1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's 
disease patients. Parkinson Study Group. Ann Neurol, 42, 747-55.
(2002) A controlled trial o f rasagiline in early Parkinson disease: the TEM PO  Study. 
Arch Neurol, 59, 1937-43.
A C H O U R . S. L., DOJAT, M ., R IE U X , C., B IE R L IN G , P. &  LEPAGE, E. (2001) A 
UMLS-based knowledge acquisition tool for rule-based clinical decision 
support system development. J  Am M ed  Inform  Assoc, 8, 351-60.
A G O S TIN I, J. V., CO NC ATO , J. &  IN O U Y E , S. K. (2008) Improving sedative- 
hypnotic prescribing in older hospitalized patients: provider-perceived benefits 
and barriers o f a computer-based reminder. J  Gen Intern Med, 23 Suppl 1, 32- 
6 .
AK O B EN G , A. K. (2005) Principles o f evidence based medicine. Arch Dis Child, 90, 
837-40.
A N IB A , M . R., S IG U EN ZA , S., F R IE D R IC H , A., PLEW N IA K , F., POCH, O., 
M A R C H LER -B A U E R , A. &  TH O M P S O N , J. D. (2008) Knowledge-based 
expert systems and a proof-of-concept case study for multiple sequence 
alignment construction and analysis. B rie f  Bioinform.
BAAS, H., BEISKE, A. G., GH1KA, J., JACKSON, M ., OERTEL, W. H., POEWE, 
W . &  R A N S M A Y R , G. (1997) Catechol-O-methyltransferase inhibition with 
tolcapone reduces the "wearing o f f  phenomenon and levodopa requirements 
in fluctuating parkinsonian patients. J  N eurol Neurosurg Psychiatry, 63, 421 -
8.
B A R N A TO , A. E., L L E W E L L Y N -T H O M A S , H. A., PETERS, E. M ., S1MINOFF, 
L., C O LLIN S , E. D. &  B A R R Y, M . J. (2007) Communication and decision 
making in cancer care: setting research priorities for decision support/patients' 
decision aids. M ed Decis Making, 27, 626-34.
B A R R A TT, A. (2008) Evidence Based Medicine and Shared Decision Making: The 
challenge o f getting both evidence and preferences into health care. Patient 
Educ Courts.
BA RR Y, M . J. (2002) Health decision aids to facilitate shared decision making in 
office practice. Ann Intern Med, 136, 127-35.
BASSLER, D., BUSSE, J. W ., K A R A N IC O L A S , P. J. &  G U Y  ATT, G. H. (2008a) 
Evidence-based medicine targets the individual patient, part 1: how clinicians 
can use study results to determine optimal individual care. Evid Based Med, 
13, 101-2.
BASSLER, D., BUSSE, J. W.. K A R A N IC O L A S , P. J. &  G U Y A T T , G. H. (2008b) 
Evidence-based medicine targets the individual patient, part 2: guides and 
tools for individual decision-making. E vid  Based Med, 13, 130-1.
BATES, D. W ., CO HEN, M ., LEAPE, L. L., O VER H A G E , J. M ., SHABOT, M . M. 
&  SH ER ID A N , T. (2001) Reducing the frequency o f errors in medicine using 
information technology. J  Am M ed  Inform  Assoc, 8, 299-308.
BELL, D. (2000) Software Engineering A Programming Approach 3rd Edition. 
Pearson Education Limited, H arlow .
BELSEY, J. &  SNELL, T. (2001) What is evidence-based medicine? www.evidence-
hased-medicine.co.uk/ehmfiles/lVhatisehm.pd/.
BELTO N, V. &  STEW ART, T. (2002) Multiple criteria decision analysis: an 
integrated approach. K luw er Academic Publishers, Boston.
B L U M E N T H A L , D. (2004) Decisions, decisions: why the quality o f medical 
decisions matters. Health A ff  (M illw ood), Suppl Web Exclusives, VA R  124-7.
BORRY, P., SCHO TSM ANS, P. &  D IE R IC K X , K. (2006) Evidence-based medicine 
and its role in ethical decision-making. J  E va l Clin Pract, 12, 306-11.
BRACCO, F., B A TTA G LIA , A., C H O U ZA , C., DU PO NT, E., G ERSHANIK, O., 
M A R T I MASSO, J. F. &  M O N T A S T R U C , J. L. (2004) The long-acting 
dopamine receptor agonist cabergoline in early Parkinson's disease: final 
results o f a 5-year, double-blind, levodopa-controlled study. CNS Drugs, 18, 
733-46.
BROOKS, D. J. &  SAGAR, H. (2003) Entacapone is beneficial in both fluctuating 
and non-fluctuating patients with Parkinson's disease: a randomised, placebo 
controlled, double blind, six month study. J  Neurol Neurosurg Psychiatry, 74, 
1071-9.
CHARLES, C., G A FN I, A. &  W H E L A N , T. (1997) Shared decision-making in the 
medical encounter: what does it mean? (or it takes at least two to tango). Soc 
Sci Med, 44, 681-92.
CHARLES, C., G A FN I, A. &  W H E L A N , T. (1999a) Decision-making in the 
physician-patient encounter: revisiting the shared treatment decision-making 
model. Soc Sci Med, 49, 651 -61.
CHARLES, C., W H E LA N , T. &  G A F N I, A. (1999b) What do we mean by 
partnership in making decisions about treatment? Bmj, 319, 780-2.
C H A U D H R Y , B. (2008) Computerized clinical decision support: will it transform 
healthcare? J  Gen Intern Med, 23 Suppl 1, 85-7.
CH O U , R. (2005) Evidence-based medicine and the challenge o f low back pain: 
where are we now? Pain Pract, 5, 153-78.
C H R ISTA K IS , D. A., Z IM M E R M A N , F. J., W R IG H T , J. A., GARRISON, M . M ., 
R1VARA, F. P. &  D A V IS , R. L. (2001) A randomized controlled trial o f 
point-of-care evidence to improve the antibiotic prescribing practices for otitis 
media in children. Pediatrics, 107, E l 5.
C L A N C Y , C. M . &  C R O N IN , K. (2005) Evidence-based decision making: global 
evidence, local decisions. Health A ff (M illw ood), 24, 151-62.
C L A X T O N . K., CO HEN, J. T. &  N E U M A N N , P. J. (2005) When is evidence 
sufficient? Health A ff  (M illwood), 24, 93-101.
CO IER A , E. (2003) Guide to Health Informatics 2nd Edition, Arnold, London.
C O O M A R A S A M Y , A. &  K H A N , K. S. (2004) What is the evidence that 
postgraduate teaching in evidence based medicine changes anything? A 
systematic review. Bmj, 329, 1017.
CRO SKERRY, P. (2005) The theory and practice o f clinical decision-making. Can J  
Anesth, 52, R 1-R8.
D A V E Y , P., RAJ AN, N., LEES, M . &  A R IS T ID E S , M . (2001) Cost-effectiveness o f 
pergolide compared to bromocriptine in the treatment o f Parkinson's disease: a 
decision-analytic model. Value Health, 4, 308-15.
D A V ID S O N , K. W ., G O LD STEIN , M ., K A P LA N , R. M ., K A U FM A N N , P. G., 
K N A TT E R U D , G. L., O RLEANS, C. T ., SPRING, B., TR U D EA U , K. J. &  
W H ITLO C K , E. P. (2003) Evidence-based behavioral medicine: what is it and 
how do we achieve it? Ann Behav Med, 26, 161-71.
DE G ASPARI, D., S IR I, C., L A N D I, A., C IL IA , R., BO NETTI, A., N A T U Z Z I, F., 
M O R G A N TE, L., M A R IA N I, C. B., SG ANZERLA, E., PEZZO LI, G. &  
A N TO N  IN I, A. (2006) Clinical and neuropsychological follow up at 12 
months in patients with complicated Parkinson's disease treated with
265
subcutaneous apomorphine infusion or deep brain stimulation o f the 
subthalamic nucleus. J  Neurol Neurosurg Psychiatry, 77, 450-3.
D E P A R TM E N T OF TRANSPO RT, L. G. A. T. R. (2000) Multi-criteria decision 
analysis: a manual. Office o f the Deputy Prime Minister,
vvww.odpm.uov.uk/pub/252/MulticriteriaanalvsismanualPDF1380Kb id 11422 
52.pdf.
D E V E R E A U X , P. J. &  YU SU F, S. (2003) The evolution o f the randomized 
controlled trial and its role in evidence-based decision making. J  Intern Med, 
254, 105-13.
D E W EY, R. B., JR., H U TTO N . J. T.. L E W IT T , P. A. &  FACTOR, S. A. (2001) A 
randomized, double-blind, placebo-controlled trial o f subcutaneously injected 
apomorphine for parkinsonian off-state events. Arch Neurol, 58, 1385-92.
DEYO , R. A. (2001) A key medical decision maker: the patient. Bmj, 323, 466-7.
D IN K E V IC H , E., M A R K IN S O N , A., A H S A N , S. &  LAW RENCE, B. (2006) Effect 
o f a brief intervention on evidence-based medicine skills o f pediatric residents. 
B M C  M ed Educ, 6, 1.
DO BBIE, A. E., SC HN EIDER , F. D., A N D E R S O N , A. D. &  L ITTLE FIE LD , J.
(2000) What evidence supports teaching evidence-based medicine? Acad Med, 
75, 1184-5.
D O LA N , J. G. (1989) Medical decision making using the analytic hierarchy process: 
choice o f initial antimicrobial therapy for acute pyelonephritis. M ed Decis 
Making, 9, 51 -6.
D O LA N , J. G. &  FR IS IN A , S. (2002) Randomized controlled trial o f a patient 
decision aid for colorectal cancer screening. M ed  Decis Making, 22, 125-39.
DORSCH, J. L., A IY E R , M . K. &  M E Y E R , L. E. (2004) Impact o f an evidence-based 
medicine curriculum on medical students' attitudes and skills. J  M ed Libr 
Assoc, 92, 397-406.
D O U K ETIS , J. D. &  L L O Y D , N. S. (2008) W hy A-level evidence does not make it to 
clinicians' A-list: the case o f thromboprophylaxis in medical patients. Evid  
Based Med, 13, 133-4.
DU RIF, F., D E V A U X , I., PERE, J. J., D E L U M E A U , J. C. &  B O UR DEIX , I. (2001) 
Efficacy and tolerability o f entacapone as adjunctive therapy to levodopa in 
patients with Parkinson's disease and end-of-dose deterioration in daily 
medical practice: an open, multicenter study. E ur Neurol, 45,111-8.
ED D Y , D. M . (1986) Successes and challenges o f medical decision making. Health  
A ff  (M illw ood), 5, 108-15.
ELSTEIN , A. S. (2004) On the origins and development o f evidence-based medicine 
and medical decision making. Inflam m  Res, 53 Suppl 2, S I84-9.
E L W Y N , G., ED W ARD S, A., ECCLES, M . &  R O VN ER , D. (2001a) Decision 
analysis in patient care. Lancet, 358, 571-4.
E LW Y N , G., EDW ARDS, A., G W Y N , R. &  G ROL, R. (1999a) Towards a feasible 
model for shared decision making: focus group study with general practice 
registrars. Bmj, 319, 753-6.
E LW Y N , G., EDW ARDS, A. &  K IN N E R S L E Y , P. (1999b) Shared decision-making 
in primary care: the neglected second half o f the consultation. B r J  Gen Pract, 
49, 477-82.
ELW Y N , G., EDW ARDS, A., W E N S IN G , M ., H IBBS, R., W ILK IN S O N , C. &  
GROL, R. (2001b) Shared decision making observed in clinical practice: 
visual displays o f communication sequence and patterns. J  Eval Clin Pract, 7, 
2 1 1 - 2 1 .
266
FA H N , S., M A R S D E N , C. &  C A LN E, D. (1987) Recent developments in Parkinson's 
disease. M acM illan  Healthcare Inform ation, New Jersey.
FA IR H U R ST, K. &  H U BY, G. (1998) From trial data to practical knowledge: 
qualitative study o f how general practitioners have accessed and used evidence 
about statin drugs in their management o f hypercholesterolaemia. Bmj, 317, 
1130-4.
FERRARI, M . D., G OADSBY, P. J., L IPTO N , R. B., D O D IC K , D. W., CUTRER, F. 
M ., M C C R O R Y , D. &  W IL L IA M S , P. (2005) The use o f multiattribute 
decision models in evaluating triptan treatment options in migraine. J  Neurol, 
252, 1026-32.
F U N , R., YO U N G SO N , G. &  Y U L E , S. (2007) How do surgeons make 
intraoperative decisions? Q ual S a f Health  Care, 16, 235-9.
FORBES, S. S., STEPHEN, W. J., HARPER, W . L., LOEB, M., S M ITH , R., 
CHRISTO FFERSEN, E. P. &  M C L E A N , R. F. (2008) Implementation o f 
evidence-based practices for surgical site infection prophylaxis: results o f a 
pre- and postintervention study. J  Am C o ll Surg, 207, 336-41.
FROSCH, D. L. &  KA PLA N, R. M . (1999) Shared decision making in clinical 
medicine: past research and future directions. A m J P re v  Med, 17, 285-94.
G A FN I, A., CHARLES, C. &  W H E L A N , T. (1998) The physician-patient encounter: 
the physician as a perfect agent for the patient versus the informed treatment 
decision-making model. Soc Sci Med, 47, 347-54.
G A LA N TE R , W. L., H IER , D. B., JAO, C. &  SARNE, D. (2008) Computerized 
physician order entry o f medications and clinical decision support can improve 
problem list documentation compliance. In t J  M ed  Inform.
G ARG , A. X ., A D H IK A R I, N. K., M C D O N A L D , H., ROSAS-ARELLANO, M . P., 
D E V E R E A U X , P. J., B EYEN E, J., SA M , J. &  HA YN ES, R. B. (2005) Effects 
o f computerized clinical decision support systems on practitioner performance 
and patient outcomes: a systematic review. Jama, 293, 1223-38.
G E VA ER T, O., DE SM ET, F., T IM M E R M A N , D., M O R EA U , Y. &  DE M OOR, B.
(2006) Predicting the prognosis o f breast cancer by integrating clinical and 
microarray data with Bayesian networks. Bioinformatics, 22, el 84-90.
G H A L I, W . A., SA ITZ , R., ESKEW , A. H., GUPTA, M., QUAN, H. &  
H E R S H M A N , W . Y . (2000) Successful teaching in evidence-based medicine. 
M ed Educ, 34, 18-22.
G H A L I, W . A ., S A ITZ , R., SARGIOUS, P. M . &  HERSHM AN , W. Y. (1999) 
Evidence-based medicine and the real world: understanding the controversy. J  
Eval C lin  Pract, 5, 133-8.
G R A H A M , I. D., LO GAN, J., O ’C O N N O R , A ., W EEKS, K. E., AARO N, S., 
C R A N N E Y , A., DALES, R., E L M S LIE , T., HEBERT, P., JOLLY, E., 
LA U PA C IS , A., M ITC H E LL, S. &  T U G W E L L , P. (2003) A qualitative study 
o f physicians' perceptions o f three decision aids. Patient Educ Couns, 50, 279- 
83.
G U Y A T T , G. H., M EA D E, M . O., JAESCHKE, R. Z., COOK, D. J. &  HAYNES, R.
B. (2000) Practitioners o f evidence based care. Not all clinicians need to 
appraise evidence from scratch but all need some skills. Bmj, 320, 954-5.
H A LL, K. H. (2002) Reviewing intuitive decision-making and uncertainty: the 
implications for medical education. M ed  Educ, 36, 216-24.
H A Y N E S , R. B. (2002) What kind o f evidence is it that Evidence-Based Medicine 
advocates want health care providers and consumers to pay attention to? B M C  
Health Serv Res, 2, 3.
267
H A YN ES, R. B. (2006) O f studies, syntheses, synopses, summaries, and systems: the 
"5S" evolution o f information services for evidence-based healthcare 
decisions. Evid Based Med, 11,162-4.
HOHRGER. T. J., B A LA , M . V ., R O W L A N D , C., GREER, M ., CHR1SCH1LLES, E. 
A. &  H O L L O W A Y , R. G. (1998) Cost effectiveness o f pramipexole in 
Parkinson's disease in the US. Pharmacoeconomics, 14, 541-57.
H O LM E S -R O V N E R , M ., NELSO N, W . L.. P1GNONE, M ., E LW Y N , G., ROVNER, 
D. R.. O ’CO NNO R, A. M ., C O U LTE R , A. &  CO RREA-DE-ARAUJO, R.
(2007) Are patient decision aids the best way to improve clinical decision 
making? Report o f the IPDAS Symposium. M ed Decis Making, 27, 599-608.
H O LM E S -R O V N E R , M ., V A L A D E . D., O R LO W S K I, C., DRAUS, C., N A B O ZN Y - 
V A LE R IO , B. &  KEISER, S. (2000) Implementing shared decision-making in 
routine practice: barriers and opportunities. Health Expect, 3, 182-191.
HTTP: FA C U LTY.W A SH 1N G TQ N .ED U  JTENENBG/COURSES/36Q/F04/SESS1O  
N S S C H N E ID E R M A N G O L D E N R U L E S .H T M L  (2008).
H U M M E L , J. M ., SNOEK, G. J., V A N  T IL , J. A., V A N  ROSSUM, W . &  
IJZER M A N , M . J. (2005) A multicriteria decision analysis o f augmentative 
treatment o f upper limbs in persons with tetraplegia. J  Rehabil Res Dev, 42, 
635-44.
H U 1T O N , J. T., R O LLER, W . C., A H LS K O G , J. E., PAHW A, R., HURTIG , H. I., 
STERN, M . B., H IN E R , B. C., L1EBERM AN, A., PFEIFFER, R. F., 
R O D N IT Z K Y , R. L., W A TE R S , C. H., M U EN TER , M . D., ADLER, C. H. &  
M O RRIS, J. L. (1996) Multicenter, placebo-controlled trial o f cabergoline 
taken once daily in the treatment o f Parkinson's disease. Neurology, 46, 1062- 
5.
ISKEDJIAN , M . &  E IN A R S O N , T. R. (2003) Cost analysis o f ropinirole versus 
levodopa in the treatment o f Parkinson's disease. Pharmacoeconomics, 21, 
115-27.
JOHNSTO N, J. M ., LEU N G , G. M ., T IN , K. Y ., HO, L. M ., LA M , W. &  F IELD IN G , 
R. (2004) Evaluation o f a handheld clinical decision support tool for evidence- 
based learning and practice in medical undergraduates. M ed Educ, 38, 628-37.
JOHNSTO N, M . E.. LA N G TO N , K. B., H A Y N E S , R. B. &  M A TH IE U , A. (1994) 
Effects o f computer-based clinical decision support systems on clinician 
performance and patient outcome. A critical appraisal o f research. Ann Intern  
Med, 120, 135-42.
K A M A L , K. M ., M IL L E R , L. A., K A V O O K J IA N , J. &  M A D H A V A N , S. (2006) 
Alternative decision analysis modeling in the economic evaluation o f tumor 
necrosis factor inhibitors for rheumatoid arthritis. Semin Arthritis Rheum, 36, 
50-60.
K A PLA N , B. (2001) Evaluating informatics applications-clinical decision support 
systems literature review. In t J  M ed  Inform , 64, 15-37.
K A PLA N , R. M . &  FROSCH, D. L. (2005) Decision making in medicine and health 
care. Annu Rev Clin Psychol, 1, 525-56.
KA PLA N , S. H., G A N D E K , B., G R E E N F IE L D , S., ROGERS, W. &  W ARE, J. E. 
(1995) Patient and visit characteristics related to physicians' participatory 
decision-making style. Results from the Medical Outcomes Study. M ed Care, 
33, 1176-87.
K A W A M O TO , K., H O U L IH A N , C. A ., B A LA S, E. A. &  LOBACH, D. F. (2005) 
Improving clinical practice using clinical decision support systems, a
268
systematic review o f trials to identify features critical to success. Bmj 330, 
765.
K EEN EY, R. (1992) Value-focused thinking. H a rv a rd  University Press, Cambridge, 
Massachusetts.
K E EN EY, R. &  R A IFFA , H. (1976) Decisions with Multiple Objectives. J. Wiley and 
Sons, New York.
K E H LE T, H. &  W IL M O R E , D. W. (2008) Evidence-based surgical care and the 
evolution o f fast-track surgery. Ann Surg, 248, 189-98.
KHEL1FI. O., D A L L A  G IO V A N N A , F., V R A N E S , S., LO DO LO, A. &  M IERTUS, 
S. (2006) Decision support tool for used oil regeneration technologies 
assessment and selection. J  H azard  M ater, 137, 437-42.
KO ELER, W ., G U A R N IE R I, M ., HUBBLE, J., RA BINO W 1CZ, A. L. &  SILVER,
D. (2005) An open-label evaluation o f the tolerability and safety o f Stalevo 
(carbidopa, levodopa and entacapone) in Parkinson's disease patients 
experiencing wearing-off. J  N eural Transm, 112,221 -30.
K O R C ZY N , A. D., BRUNT, E. R., LARSEN, J. P., N A G Y , Z., POEWE, W. H. &  
R U G G IER I, S. (1999) A 3-year randomized trial o f ropinirole and 
bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology, 
53, 364-70.
KO TZE, B. &  BRDARO SKA, B. (2004) Clinical decision support systems in 
psychiatry in the Information Age. Australas Psychiatry, 12, 361-4.
KRUER, M . C. &  STEINER, R. D. (2008) The role o f evidence-based medicine and 
clinical trials in rare genetic disorders. Clin Genet, 74, 197-207.
KUIPERS, B., M O S K O W ITZ , A. &  KASSIRER, J. (1988) Critical decisions under 
uncertainty: representation and structure. Cognitive Science, 12, 177-210.
LA C A IN E , F. (2005) Evidence-based medicine in surgical decision making. World J  
Surg, 29, 588-91.
LA M , W . W ., F IE L D IN G , R., JOHNSTON, J. M ., T IN , K. Y . &  LEUNG, G. M .
(2004) Identifying barriers to the adoption o f evidence-based medicine 
practice in clinical clerks: a longitudinal focus group study. M ed Educ, 38, 
987-97.
LARSEN, J. P., W ORM -PETERSEN, J., S ID EN , A ., G O R D IN , A., R E IN IK A IN E N , 
K. &  LE IN O N E N , M . (2003) The tolerability and efficacy o f entacapone over 
3 years in patients with Parkinson's disease. E u r J  Neurol, 10, 137-46.
LE M K E , M . R., BRECHT, H. M ., KOESTER, J. &  R E IC H M A N N , H. (2006) Effects 
o f the dopamine agonist pramipexole on depression, anhedonia and motor 
functioning in Parkinson's disease. J  N euro l Sci, 248, 266-70.
LEUNG , G. M ., JOHNSTON, J. M ., T IN , K. Y ., W O N G , I. O., HO, L. M ., LA M , W . 
W. &  LA M , T. H. (2003) Randomised controlled trial o f clinical decision 
support tools to improve learning o f evidence based medicine in medical 
students. Bmj, 327, 1090.
LE W ITT , P. A., LYONS, K. E. &  PA H W A , R. (2007) Advanced Parkinson disease 
treated with rotigotine transdermal system: PREFER Study. Neurology, 68, 
1262-7.
L IA O , S. (2005) Expert system methodologies and application - a decade review from 
1995 to 2004. Expert Syst Appl, 28, 93-103.
L ILFO R D , R. J., PAUKER, S. G., B R A U N H O L T Z , D. A. &  CHARD, J. (1998) 
Decision analysis and the implementation o f research findings. Bmj, 317, 405-
9.
269
LO C K W O O D . D., AR M STRO NG , M . &  G R A N T , A. (2004) Integrating evidence 
based medicine into routine clinical practice: seven years' experience at the 
Hospital for Tropical Diseases. London. Bmj, 329, 1020-3.
L IJG INGER. E.. W EN N IN G , G. K.. BOSCH. S. &  POEW E, W. (2000) Beneficial 
effects o f amantadine on L-dopa-induced dyskinesias in Parkinson's disease. 
M ov Disord, 15, 873-8.
LU RIE . J. D. &  SOX. H. C. (1999) Principles o f medical decision making. Spine, 24, 
493-8.
M C A LIS TE R . F. A.. G R A H A M . L. KARR. G. W . &  LAUPACIS, A. (1999) 
Evidence-based medicine and the practicing clinician. J  Gen Intern Med, 14, 
236-42.
M CG REG O R. J. C\. WEEKES. E., FORREST, G. N., STANDIFO RD. H. C., 
PER EN C EVIC H . E. N.. FURUNO. J. P. &  HA R R IS . A. D. (2006) Impact o f 
a computeri/ed clinical decision support system on reducing inappropriate 
antimicrobial use: a randomized controlled trial. J  Am M ed Inform Assoc, 13, 
378-84.
M C K IN S T R Y . B. (2000) Do patients wish to be involved in decision making in the 
consultation? A cross sectional survey with video vignettes. Bmj, 321, 867-71.
M IC R O SO FT (2008) http: msdn.microsoft.com en-us isv hbl90540.aspx.
M O H A R A R I, R. S.. R A H IM I. E., NAJAFI, A .. K H A S H A Y A R , P., K H A JA VI, M . R. 
&  M E Y S A M IE . A. P. (2008) Teaching critical appraisal and statistics in 
anesthesia journal club. Qjm.
M O LE N A A R , S., SPRANGERS, M . A., P O S T M A -S C H U IT , F. C., RUTGERS, E. 
J., N O O R LA N D E R . J., HEND RIKS, J. &  DE HAES, H. C. (2000) Feasibility 
and effects o f decision aids. M ed Decis M aking, 20, 112-27.
M U R R A Y , E., D A V IS . H.. TA I, S. S., C O U LTE R . A., G RAY, A. &  HAINES, A. 
(2001a) Randomised controlled trial o f an interactive multimedia decision aid 
on benign prostatic hypertrophy in primary care. Bmj, 323,493-6.
M U R R A Y . E.. D A V IS , H., T A I. S. S., C O U LTER , A.. G RAY, A. &  HAINES, A. 
(2001b) Randomised controlled trial o f an interactive multimedia decision aid 
on hormone replacement therapy in primary care. Bmj, 323,490-3.
M Y L L Y L A . V.. H A A P A N IE M I. T.. K A A K K O L A , S., K IN N U N EN , E., 
H A R T IK A IN E N , P., N U U T IN E N , J., R ISSA N EN , A., KUOPIO, A. M ., 
JO LM A, T.. SA TO M A A , O. &  H E IK K IN E N , H. (2006) Patient satisfaction 
with switching to Stalevo: an open-label evaluation in PD patients 
experiencing wearing-off (Simcom Study). Acta Neurol Scand, 114, 181-6.
M Y L L Y L A , V. V ., K U L T A L A H T I, E. R., H A A P A N IE M I, H. &  LEINONEN, M .
(2001) Twelve-month safety o f entacapone in patients with Parkinson's 
disease. F u r J  Neurol, 8, 53-60.
N IC E (2006) National clinical guidelines for diagnosis and management in primary 
and secondary care, innt .nice.ors uk/niccmedia/pdf/c2()35full2uideline.pdf.
N IC H O LSO N . L. J., W ARDE, C. M . &  BO KER, J. R. (2007) Faculty training in 
evidence-based medicine: improving evidence acquisition and critical
appraisal. J  Contin Educ Health Prof, 27, 28-33.
N IER EN BER G , A. A., SM OLLER, J. W ., E ID E L M A N , P., W U, Y. P. &  T IL L E Y ,
C. A. (2008) Critical thinking about adverse drug effects: lessons from the 
psychology o f risk and medical decision-making for clinical 
psychopharmacology. Psychother Psychosom, 77, 201-8.
270
N O R M A N . G. R. &  SHANNON, S. I. (1998) Effectiveness of instruction in critical 
appraisal (evidence-based medicine) skills: a critical appraisal. Cmaj, 158, 
177-81.
NUIJTEN. M . J.. VA N  IPEREN. P.. PA LM ER . C., V A N  H ILTE N . B. J. &  
SN YD ER . E. (2001) Cost-effectiveness analysis o f entacapone in Parkinson's 
disease: a Markov process analysis. Value Health, 4, 316-28.
N Y H O L M . D.. N ILSSON R E M A H L. A. 1., D1ZDAR, N., CO NSTAN TINESCU , R., 
H O LM B E R G . B.. JANSSON. R.. A Q U IL O N IU S . S. M . &  A SK M A R K . H.
(2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in 
advanced Parkinson disease. Neurology, 64, 216-23.
O 'CONNO R. A. M .. LLE W E LLY N -TH O M A S . H. A. &  FLOOD, A. B. (2004) 
Modifying unwarranted variations in health care: shared decision making 
using patient decision aids. Health A ff (M illw ood), Suppl Web Exclusives, 
VAR63-72.
O 'CONNO R. A. M .. ROSTOM. A., FISET. V .. TETR O E, J., ENTW ISTLE, V., 
L L E W E L L Y N -T H O M A S , H.. H O LM E S -R O V N E R , M ., BARRY, M . &  
JONES, J. (1999) Decision aids for patients facing health treatment or 
screening decisions: systematic review. Bmj, 319, 731-4.
O D IN , P.. O E H L W E IN , C., STORCH, A., PO LZER, U., W ERNER, G., RENNER, 
R.. SH IN G . M ., LUDOLPH. A. &  SC HU LER , P. (2006) Efficacy and safety 
o f high-dose cabergoline in Parkinson's disease. Acta Neurol Scand, 113, 18- 
24.
O ERTEL, W . H.. W OLTERS, E., S A M P A IO , C., G IM EN EZ-R O LD A N , S., 
BERG AM ASCO , B., DUJARDIN , M .. GROSSET, D. G., ARNO LD, G., 
LEENDERS, K. L., H U N D EM ER , H. P., LLE D O , A., W OOD, A., FREWER, 
P. &  SC H W A R Z, J. (2006) Pergolide versus levodopa monotherapy in early 
Parkinson’s disease patients: The PELM O PET study. M ov Disord, 21, 343-53.
O LA N O W . C. W ., HAUSER, R. A., G AUG ER , L., M A LA P IR A , T., ROLLER, W., 
H U B B LE. J., BUSHENBARK, K., L IL IE N F E L D , D. &  ESTERLITZ, J. 
(1995) The effect o f deprenyl and levodopa on the progression o f Parkinson's 
disease. Ann Neurol, 38, 771-7.
PA LH A G EN . S.. H E IN O N EN , E., H A G G L U N D , J.. KAUGESAAR, T.. MAR1- 
IK O LA . O. &  PALM , R. (2006) Selegiline slows the progression o f the 
symptoms o f Parkinson disease. Neurology, 66, 1200-6.
PA LM ER. C. S.. NU IJTEN . M . J., SC H M IE R , L  K ., SUBEDI, P. &  SNYDER, E. H.
(2002) Cost effectiveness o f treatment o f Parkinson's disease with entacapone 
in the United States. Pharmacoeconomics, 20, 617-28.
PA PA ZO G LO U, I. A., BONANOS. G. S., N IV O L 1A N IT O U , Z. S., DUIJM, N. J. &  
RA SM USSEN , B. (2000) Supporting decision makers in land use planning 
around chemical sites. Case study: expansion o f an oil refinery. J  H azard  
M ater, 71,343-73.
PARKES. J., H Y D E , C.. DEERS, J. &  M IL N E , R. (2001) Teaching critical appraisal 
skills in health care settings. Cochrane Database Svst Rev, CD001270.
PAYNE, T. H. (2000) Computer decision support systems. Chest, 118,47S-52S.
PDRGUR (1999) Comparisons o f therapeutic effects o f levodopa, levodopa and 
selegiline, and bromocriptine in patients with early, mild Parkinson's disease: 
three year interim report. BMJ, 307, 469-472.
POEWE, W. H., DEUSCHL, G., G O R D IN , A., R U L T A L A H T I, E. R. &  
LE IN O N EN , M. (2002) Efficacy and safety o f entacapone in Parkinson's 
disease patients with suboptimal levodopa response: a 6-month randomized
271
placebo-controlled double-blind study in Germany and Austria (Celomen 
study). Acta Neurol Scand, 105, 245-55.
RAJPUT. A. H.. M A R T IN , W., SA1NT-HILA1RE, M . H., DO RFLINGER, E. &  
PEDDER, S. (1997) Tolcapone improves motor function in parkinsonian 
patients with the "wearing-off’ phenomenon: a double-blind, placebo- 
controlled. multicenter trial. Neurology', 49, 1066-71.
RASCOL. O.. BROOKS. D. J., K O R C ZY N , A. D.. DE D E Y N , P. P.. CLARK E. C. E. 
&  LA NG . A. E. (2000) A five-year study o f the incidence o f dyskinesia in 
patients with early Parkinson’s disease who were treated with ropinirole or 
levodopa. 056 Study Group. N  Engl J  Med, 342, 1484-91.
R A TLIFF. A.. A N G ELL. M „ DO W . R. W .. K U PP ER M A N N , M .. NEASE, R. F., 
JR.. FISHER, R.. FISHER. E. S., R E D E LM E IE R , D. A.. FA U G H N A N , M .
E.. R IM ER . B. K.. PAUKER. S. P.. PA UK ER , S. G. &  SOX. H. C. (1999) 
What is a good decision? E ff d i n  Pract, 2, 185-97.
R E K TO R O VA . I.. REKTOR. I.. BARES, M ., DO STAL, V., EHLER, E.. 
FA N FR D LO V A , Z.. F IED LER . J., K LA JB LO V A , H., KU LIST'A K , P., 
RESSNER, P., S V A TO V A . J.. U R B A N E K , K. &  VE LIS K O V A , J. (2003) 
Pramipexole and pergolide in the treatment o f depression in Parkinson's 
disease: a national multicentre prospective randomized study. Eur J  Neurol, 
10,399-406.
RIGG, J. R., JA M R O ZIK . K. &  M Y L E S , P. S. (1999) Evidence-based methods to 
improve anaesthesia and intensive care. C u rr Opin Anaesthesiol, 12, 221-7.
ROFF, J. (2003) U M L  A Beginner's Guide. M cG raw-H ill/Osborne, Berkeley, 
California.
ROSENBERG, W. &  D O N A LD , A. (1995) Evidence based medicine: an approach to 
clinical problem-solving. Bmj, 310, 1122-6.
R U O T TIN E N , H. M . &  R IN N E. U. K. (1996) Entacapone prolongs levodopa 
response in a one month double blind study in parkinsonian patients with 
levodopa related fluctuations. J  N euro l Neurosurg Psychiatry, 60, 36-40.
S A A M I. A., N U T T . J. &  RANSO M , B. (2004) Parkinson's disease. The Lancet, 363, 
1783-1793.
SA CK ETT. D. L. &  ROSENBERG. W . M . (1995a) The need for evidence-based 
medicine. J  R Soc Med, 88, 620-4.
SA CK ETT, D. L. &  ROSENBERG, W . M . (1995b) On the need for evidence-based 
medicine. J  Public Health Med, 17, 330-4.
SA CK ETT, D. L.. ROSENBERG, W . M ., G R A Y , J. A., HAYNES, R. B. &  
R IC H A R D S O N , W. S. (1996) Evidence based medicine: what it is and what it 
isn't. Bmj, 312, 71-2.
SACKETT, D. L. &  STRAUS. S. E. (1998) Finding and applying evidence during 
clinical rounds: the "evidence cart". Jama, 280, 1336-8.
SAM O RE, M . H., B A TEM A N . K.. A LD E R , S. C.. H A N N A H , E., D O N N E LLY , S., 
STO D D A R D , G. J.. H A D D A D IN , B., R U B IN , M . A., W IL L IA M S O N , J., 
STULTS, B., RUPPER. R. &  STEVEN SO N , K. (2005) Clinical decision 
support and appropriateness o f antimicrobial prescribing: a randomized trial. 
Jama, 294,2305-14.
S C H ILL IN G , K., W IE C H A , J., P O LIN E N I, D. &  K H A L IL , S. (2006) An interactive 
web-based curriculum on evidence-based medicine: design and effectiveness. 
Earn Med, 38, 126-32.
SCOTT, I. (2007) The evolving science o f translating research evidence into clinical 
practice. Evid Based Med, 12, 4-7.
272
SHEBL, N. A., FR A N K LIN , B. D. &  BARBER, N. (2007) Clinical decision support 
systems and antibiotic use. Pharm W orld Sci, 29, 342-9.
SH IM B O . T.. H IR A , K., T A K E M U R A , M . &  F U K U I, T. (2001) Cost-effectiveness 
analysis o f dopamine agonists in the treatment o f Parkinson’s disease in Japan. 
Pharmacoeconomics, 19, 875-86.
SHO ULSO N. I.. OAKES, D., FAHN, S., LA N G , A., LANG STO N. J. W., LEW ITT, 
P., O LA N O W , C. W ., PENNEY, J. B.. TA N N E R , C., K IEB UR TZ, K. &  
RU DO LPH . A. (2002) Impact o f sustained deprenyl (selegiline) in levodopa- 
treated Parkinson's disease: a randomized placebo-con trolled extension o f the 
deprenyl and tocopherol antioxidative therapy o f parkinsonism trial. Ann 
Neurol, 51, 604-12.
S H U V A L. K.. BERKO VITS. E.. N E TZE R , D.. H EKSELM AN , I., L IN N , S., 
BREZIS. M . &  REIS, S. (2007a) Evaluating the impact o f an evidence-based 
medicine educational intervention on primary care doctors' attitudes, 
knowledge and clinical behaviour: a controlled trial and before and after study. 
J  Eval Clin Pract, 13, 581 -98.
S H U V A L, K.. SH A C H A K , A., L IN N , S., BREZIS, M ., FEDER-BUBIS, P. &  REIS, 
S. (2007b) The impact o f an evidence-based medicine educational intervention 
on primary care physicians: a qualitative study. J  Gen Intern Med, 22, 327-31.
S IM . I., G O R M A N . P., G REENES, R. A., HA YN ES, R. B., KA PLA N, B., 
L E H M A N N , H. &  T A N G , P. C. (2001) Clinical decision support systems for 
the practice o f evidence-based medicine. J  Am M ed Inform Assoc, 8, 527-34.
S ING H, S., D O LA N , J. G. &  CENTO R, R. M . (2006) Optimal management o f adults 
with pharyngitis—a multi-criteria decision analysis. B M C  M ed Inform Decis 
Mak, 6, 14.
S IN TC H E N K O , V .. C O IE R A , E. &  G ILB ER T, G. L. (2008) Decision support 
systems for antibiotic prescribing. C u rr Opin Infect Dis, 21, 573-9.
S IN TC H E N K O , V .. IR E D E LL , J. R., G ILB ER T, G. L. &  COIERA, E. (2005) 
Handheld computer-based decision support reduces patient length o f stay and 
antibiotic prescribing in critical care. J  Am M ed  Inform Assoc, 12, 398-402.
S IN T C H E N K O , V., M A G R A B I, F. &  TIPPER, S. (2007) Are we measuring the right 
end-points? Variables that affect the impact o f computerised decision support 
on patient outcomes: a systematic review. M ed Inform  Internet Med, 32, 225- 
40.
S ITT IG , D. F., K R A LL , M . A., D Y K STR A . R. H., RUSSELL, A. &  C H IN , H. L.
(2006) A survey o f factors affecting clinician acceptance o f clinical decision 
support. B M C  M ed  Inform Decis Mak, 6, 6.
S M A L A , A. M ., SPOTTKE, E. A., M A C H A T . O.. SIEBERT, U., M EYER, D., 
K O H N E -V O L L A N D , R., REUTHER, M ., D U C H A N E , J., OERTEL, W . H., 
BERGER, K. B. &  DODEL, R. C. (2003) Cabergoline versus levodopa 
monotherapy: a decision analysis. M ov Disord, 18, 898-905.
S M ITH , C. A., G ANSCH O W , P. S., R E IL LY , B. M ., EVANS, A. T., M C N U TT, R. 
A., OSEI, A., SAQUIB, M ., SURA BH I, S. &  Y A D A V , S. (2000) Teaching 
residents evidence-based medicine skills: a controlled trial o f effectiveness and 
assessment o f durability. J  Gen Intern Med, 15, 710-5.
S M IT H , R. (1996) What clinical information do doctors need? Bmj, 313, 1062-8.
S O LV A Y  (2008) Company internal report.
S O M M E R V IL L E , I. (2001) Software Engineering 6th Edition. Pearson Education 
Limited, H arlow .
273
STEELE, A. W ., EISERT, S., D A V ID S O N , A., SANDISON, T., LYONS, P., 
G A R R ETT, N., GABOW , P. &  O R TIZ , E. (2005) Using computerized 
clinical decision support for latent tuberculosis infection screening. Am J  Prev 
Med. 28,281-4 .
STEVENSO N . F. A. (2003) General practitioners' views on shared decision making: a 
qualitative analysis. Patient Educ Couns, 50, 291-3.
STEVENSO N , F. A., BARRY, C. A., B R ITTEN , N ., BARBER, N. &  BR ADLEY, C. 
P. (2000) Doctor-patient communication about drugs: the evidence for shared 
decision making. Soc Sci Med. 50, 829-40.
STOCCHI. F. (2003) Prevention and treatment o f motor fluctuations. Parkinsonism  
Rclat Disord. 9 Suppl 2, S73-81.
STORCH. A.. TR E N K W A LD E R , C.. O E H L W E IN , C., W IN K E L M A N N , J., 
POLZER. IJ., H U N D E M E R . H. P. &  SCHW ARZ, J. (2005) High-dose 
treatment with pergolide in Parkinson's disease patients with motor 
fluctuations and dyskinesias. Parkinsonism Rclat Disord, 11, 393-8.
STRAUS. S. E., B A LL , C., BA LC O M B E, N., SHELDON, J. &  M CALISTER, F. A. 
(2005) Teaching evidence-based medicine skills can change practice in a 
community hospital. J  Gen Intern Med, 20, 340-3.
SUCHER, J. F., M O O R E . F. A., TO D D , S. R., SAILORS, R. M . &  M C K IN L E Y , B. 
A. (2008) Computerized clinical decision support: a technology to implement 
and validate evidence based guidelines. J  Trauma, 64, 520-37.
TA N , K., DEAR, P. R. &  N EW ELL, S. J. (2005) Clinical decision support systems 
for neonatal care. Cochrane Database Syst Rev, CD004211.
T A V A K O L I, M .. D A V IE S , H. T. &  TH O M S O N , R. (2000) Decision analysis in 
evidence-based decision making. J  Eval C lin Pract, 6, 111-20.
T A Y LO R , R., REEVES, B., EW INGS, P., B IN N S , S., KEAST, J. &  MEARS, R. 
(2000) A systematic review o f the effectiveness o f critical appraisal skills 
training for clinicians. M ed Educ, 34, 120-5.
TE IC H , J. M .. OSHEROFF, J. A., PIFER, E. A., S ITT IG , D. F. &  JENDERS, R. A.
(2005) Clinical decision support in electronic prescribing: recommendations 
and an action plan: report o f the joint clinical decision support workgroup. J  
Am M ed  Inform  Assoc, 12, 365-76.
TH O B O IS. S., D E LA M A R R E -D A M IE R , F. &  DERK IN DEREN , P. (2005) 
Treatment o f motor dysfunction in Parkinson's disease: an overview. Clin 
N euro l Neurosurg, 107, 269-81.
T H O M , D. H.. H A U G E N , J., SOMMERS. P. S. &  LO V E TT, P. (2004) Description 
and evaluation o f an EBM curriculum using a block rotation. B M C  M ed Educ, 
4, 19.
TH O M A S , A., IA C O N O , D., LU CIANO , A. L.. A R M E L L IN O , K., DI IORIO , A. &  
ONOFRJ, M . (2004) Duration o f amantadine benefit on dyskinesia o f severe 
Parkinson's disease. J  Neurol Neurosurg Psychiatry, 75, 141-3.
TH O M S O N , P., D O W D IN G , D., SW ANSO N. V., BLA N D , R., M A IR , C., 
M O R R ISO N , A., TA YLO R , A., BEECHEY, C. &  N IV E N , C. A. (2006) A 
computerised guidance tree (decision aid) for hypertension, based on decision 
analysis: development and preliminary evaluation. Eur J  Cardiovasc Nurs, 5, 
146-9.
TH O M S O N , R., ROBINSON, A., G R E E N A W A Y , J. &  LOW E, P. (2002) 
Development and description o f a decision analysis based decision support 
tool for stroke prevention in atrial fibrillation. Q ual Saf Health Care, 11, 25- 
31.
274
T H U R S K Y , K. A., BU ISING, K. L., BAR, N., M ACG REG O R, L., STREET, A. C., 
M A C IN T Y R E , C. R., PRESNEILL, J. J., C A D E, J. F. &  BROW N, G. v !
(2006) Reduction o f broad-spectrum antibiotic use with computerized decision 
support in an intensive care unit. In t J  Q ua/ Health  Care, 18, 224-31.
TIJHU IS , G. J., JANSEN, S. J., ST IG G ELB O U T, A. M ., ZW IN D E R M A N , A. H., 
HAZES, J. M . &  V L IE LA N D , T. P. (2000) Value o f the time trade o ff method 
for measuring utilities in patients with rheumatoid arthritis. Ann Rheum Dis 
59, 892-7.
T IM M E R M A N S , D., V A N  BOCKEL. H. &  K IE V IT , J. (2001) Improving the quality 
o f surgeons' treatment decisions: a comparison o f clinical decision making 
with a computerised evidence based decision analytical model. QuaI Health  
Care, 10,4-9.
IO R R A N C E , G. W ., FEENY, D. &  FURLO NG , W . (2001) Visual analog scales: do 
they have a role in the measurement o f preferences for health states? M ed  
Decis Making, 21, 329-34.
VH R H A G EN  M E T M A N , L., DEL D O TTO , P.. V A N  DEN M U N C K H O F, P., 
FANG , J., M O U R A D IA N , M. M . &  CH ASE. T. N. (1998) Amantadine as 
treatment for dyskinesias and motor fluctuations in Parkinson's disease. 
Neurology, 50, 1323-6.
W A LLER . P. C. &  EVANS, S. J. (2003) A model for the future conduct o f 
pharmacovigilance. Pharmacoepidemiol D ru g  Saf, 12, 17-29.
W A N V A R IE , S., SA TH A PA TA Y A V O N G S, B., S IR IN A V IN , S., ING SATHIT, A., 
U N G K A N O N T , A. &  S IR IN A N , C. (2006) Evidence-based medicine in 
clinical curriculum. Ann Acad M ed Singapore, 35, 615-8.
W ATERS, C. H. (2002) Treatment o f advanced stage patients with Parkinson's 
disease. Parkinsonism Relat Disord, 9, 15-21.
W A TTS, R. L., JA N K O VIC , J., W ATERS, C., RAJPUT, A., BOROOJERDI, B. &  
RAO, J. (2007) Randomized, blind, controlled trial o f transdermal rotigotine 
in early Parkinson disease. Neurology, 68, 272-6.
W ESTO N, W. W. (2001) Informed and shared decision-making: the crux o f patient- 
centered care. Cmaj, 165, 438-9.
W H IT N E Y , S. N. (2003) A new model o f medical decisions: exploring the limits o f 
shared decision making. M ed Decis Making, 23, 275-80.
W H O N E , A. L., W ATTS, R. L., STOESSL, A. J., D A V IS , M ., RESKE, S., 
N A H M IA S , C., LANG, A. E., RASCOL, O., R IBEIRO, M . J., R EM Y, P., 
POEW E, W . H., HAUSER, R. A. &  BROOKS, D. J. (2003) Slower 
progression o f Parkinson's disease with ropinirole versus levodopa: The 
R EA L-PET study. Ann Neurol, 54, 93-101.
w w w .a l l i a n c e p h a r m a .c o .u k
http://www.alliancephanna.co.uk/uploads/SymmetrelcapsulesSPCUK006.pdf.
W W W .A P O -G O .C O .U K /L ITE R A TU R E /A P G A M P  SPC V4%20.07.2007.PDF.
W W W .B N F.O R G  (2008).
W W W .B N F.O R G /B N F/B N F/54/129827.H TM
http://www.bnf.org/hnf/bnf/54/129827.htrn.
W W W .B N F.O R G /B N F/B N F/54/129828.H TM
http://www.bnf.org/bnf/bnf/54/129828.htm.
W W W .BNF.O RG /BNF/BNF/54/12983Q .HTM
http://www.bnf.org/bnf/bnf/54/129830.htm.
W W W .B N F.O R G /B N F/B N F/56/2057.H TM ?O ==% 22ANTICHOLINERG ICS% 22#HI
T.
275
il
W W W .DO CM C.AC.uk/-ND /SURPR1SE 96/JOU RN A L /V O L  14/C S11 /REPORT.H  
TM  L Accessed 14.07.06.
W W W .O Z G R lD .C O M  (2008).
W W W . P A R K 1N SON S .ORG. U K http://www.parkinsons.orR.uk/about-
parkinsons/treatinR-parkinsons/druRS/mao-b-inhibitors.aspx.
W W W .SPREADSHEETS.A BO UT.CO M  (2008)
www.spreadshcets.about.com/od/tipsandfaqs/f/excel _use.htm.
W W W .T H E A B N .O R G http://www.theabn.orR.
W W W .TH EBN F.O R G  http://www.thebnf.ora/bnf/bnf/54/129828.htm.
Y E N TIS . S. M . (2006) Decision analysis in anaesthesia: a tool for developing and 
analysing clinical management plans. Anaesthesia, 61, 651-8.
Y E W . K. S. &  REID , A. (2008) Teaching evidence-based medicine skills: an 
exploratory study o f residency graduates' practice habits. Fam Med, 40, 24-31.
Y O U R M A N . L., CO NCATO , J. &  A G O S TIN I, J. V. (2008) Use o f computer 
decision support interventions to improve medication prescribing in older 
adults: a systematic review. Am J  G eria tr Pharmacother, 6, 119-29.
276
PUBLICATIONS
Clare H Dowding, Claire L Shenton, SamS Salek 2006 A Review Of The 
Health-Related Quality Of Life And Economic Impact Of Parkinson’s Disease 
Drugs and Aging 2006; 23 (9)
C. Shenton, S. Salek, C. Dowding, S. Raha, L. Ebenezer, E. Morgan, P. 
Pooviah, Z. Ikram, S. Ahmed And D. Sastry(2006) The Impact Of PD 
Treatment Complications On Patient HRQoL. Age and Ageing. Nov 2006. 35; 
Supplement 3: i56-i59 (Neurology/Neurosciences) Abstract
C Shenton, C Dowding, S Salek, S Raha, L Ebenezer, E Morgan, P Pooviah, 
Z Ikram, D Sastry (2006) The Influence Of Treatment Complications On 
Patient Reported Outcomes In PD. [www.isoqol.org/2006mtgabstracts] The 
QLR Journal, A-54, Abstract #1328
Shenton, C., Dowding, C., Salek, S., Raha, S., Ebenezer, L., Morgan, E., 
Pooviah, P., Ikram, Z., & Sastry, D (2006). Assessment of HRQoL in PD and 
its Impact on Minimising Treatment Complications. Movement Disorders. Sep 
2006. 21 (S15); S466 (P508) Abstract
S.K. Raha, L. Ebenezer, C.L. Shenton, C.H. Dowding, S.S. Salek (2007) 
Antiparkinson’s Drugs And Motor Fluctuations In A Movement Disorder Clinic 
Neurodegenerative Dis 2007;4(Suppl.1):175. Abstract
C Dowding, S Salek, D Sastry, S Raha, L Morgan, L Ebenezer, AJ Bater, A 
Bayer (2007) Electronic Capturing Of HRQoL In The Management Of Patients 
With PD. [www.isoqol.org/2007mtgabstracts.pdf] Quality of Life Research 
supplement, A-86, Abstract #1292
Claire L Shenton, Sam Salek, Clare Dowding, Sandip Raha, Louise 
Ebenezer, Elizabeth Morgan, Dwarak Sastry (2007) How Do Treatment 
Complications Affect The Health Related Quality Of Life Of Patients With 
Parkinson’s Disease Over Time? [www isoqol.org/2007mtgabstracts.pdf] 
Quality of Life Research supplement, A-86, Abstract #1352
277
APPENDIX I
Data Collection on Parkinson’s Disease Drugs
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Drug Criteria Comparator Stage of disease Primary
endpoint
Significance
level
How performs
Amantadine Motor
fluctuations
Placebo H&Y II to V
UPDRS IV q39 
Mean diary 
scores
Variance of diary 
scores
op 
o
 
o 
o 
o
V 
V 
V 
Q_ 
Q- 
O
l
“on” time (hrs) 2.4 baseline, 2.1 (15 days), 1.9 
(30 days), 2.3(60-240 days)
“off” time (hrs) 2.9 baseline, 2.5 (15 days), 2.0 
(30 days), 2.4 (60-240 days) (Thomas et al., 
2004)
UPDRS IV q39 amantadine mean 1 vs placebo 
1.5; mean diary scores amantadine 1.03 vs 
placebo 1.62; variance of diary scores 
amantadine 1.3 vs placebo 3.3 (Verhagen 
Metman et al., 1998)
Cognitive
impairment
Confusion
Hallucinations ADR (SPC -  www.alliancepharma.co.uk) 
ADR (www.bnf.org)
Dyskinesias Placebo
Placebo
Placebo
Advanced -  H&Y 
3 to 5 (off) 1 to 3 
(on)
Advanced 
H&Y II to V
VAS from diary 
assessment, 
cumulative 
dyskinesia scores 
calculated 
UPDRS IV items
32 and 33
UPDRS IV 32-34
Dyskinesia rating 
scale
UPDRS IV 32 &
33
P<0.05
P<0.05
P<0.001
P<0.001
P<0.001
Reduction cumulative dyskinesia score by 53% 
11.9 vs 25.6 placebo 
Dyskinesia duration and disability signif 
reduced, baseline 3.4 to post-Rx 1.7(Luginger et 
al., 2000)
Baseline score 6.7 compared to 2.0 (15 days), 
2.3 (30 days), 6.1 (60-240 days)
DRS -  19.6 baseline, 10.5 (15 days), 10.3 (30 
days), 18.4 (60-240 days) (Thomas et al., 2004) 
Amantadine mean 1 vs placebo mean 4 (scale 0 
to 4) (Verhagen et al., 1998)
Postural
hypotension
ADR (www.alliancepharma.co.uk)
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Patient's choice No data
Mobility No data
Depression ADR (www.alliancepharma.co.uk)
ADLs Placebo H&Y II to V UPDRS II P<0.01 Amantadine 8.0 'on' vs 10.6 placebo ‘on’; 
amantadine17.8 ‘off vs 21.0 placebo ‘off 
(Verhagen et al., 1998)
Cost-
effectiveness
No data
Stage of disease 
(H&Y)
No data
Drug
contraindications
Hypersensitivity to amantadine or excipients, 
convulsions, gastric ulceration, severe renal 
disease, pregnancy, breast-feeding. Use with 
caution in cardiovascular disorders -  congestive 
heart failure
Epilepsy, history of gastric ulceration, 
pregnancy, breast-feeding (BNF)
Drug interactions Increased risk of antimuscarinic side-effects 
when given with antimuscarinics, increased risk 
of side-effects when given with bupropion, 
increased risk of CNS toxicity when given with 
memantine (manufacturer of memantine advises 
avoid concomitant use), increased risk of 
extrapyramidal side-effects when given with 
methyldopa, metoclopramide, tetrabenazine, 
antipsychotics, domperidone (BNF)
Adverse drug 
reactions
Anorexia, nausea, nervousness, inability to 
concentrate, insomnia, dizziness, convulsions, 
hallucinations or feelings of detachment, blurred 
vision, Gl disturbances, livedo reticularis, 
peripheral oedema, rarely leucopenia, rashes 
(BNF)
Apomorphine Motor
fluctuations
Placebo
Advanced -  with 
motor fluctuations
UPDRS motor 
score
P<0.001
Therapeutic indication.
Off-state score 39.7 vs 36.3 placebo, on-state 
score 15.8 vs 36.2 placebo, %change -62 vs -1
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placebo (Dewey et al., 2001)
Cognitive DBS Advanced California verbal NS CVLT 45.62 baseline to 53.65 12 mths
impairment learning test 
(verbal memory) 
Corsi block 
tapping span test 
(spatial memory) NS
Corsi 4.90 baseline to 4.25 12 mths (De Gaspari 
et al., 2006)
Contraindicated for dementia (www.apo-
go.co.uk/literature/apgamp_spc_v4%20.07.2007
.pdf)
Confusion ADR -  mild confusion twww.aDO-ao.co.uk) 
ADR (Dewey et al., 2001)
ADR (BNF)
Hallucinations ADR twww.aDO-ao.co.uk) 
ADR (Dewey et al., 2001) 
ADR (BNF)
Dyskinesias Placebo Advanced Dyskinesia score 
(7UPDRS)
P<0.001 Off-state 0, on-state 1, score change 1 vs 
0,0,NA placebo (Dewey et al., 2001)
ADR (BNF)
Intermittent apomorphine not suitable if severe 
dyskinesia (www.apo-qo.co.uk)
Postural
hypotension
ADR (BNF)
Caution advised if pre-existing post hyp 
(www.apo-qo.co.uk)
Patient's choice No data
Mobility No data
Depression DBS Advanced -  
H&Y>=3
HDRS-17 NS Baseline score 10.00 to 12 month score 7.46 
(Gaspari et al., 2006)
ADLs No data
Cost-
effectiveness
No data
Stage of disease 
(H&Y)
No data
Drug
contraindications
Contra-indicated for children under 18 years of 
age; pts with respiratory depression, dementia,
280
m-
| psychotic diseases or hepatic insufficiency;
! intermittent apogo not suitable if severe 
dyskinesia or dystonia; known hypersensitivity to 
apomorphine or its excipients 
Caution with pts with renal, pulmonary or 
cardiovascular disease, pts prone to nausea & 
vomiting; pre-existing cardiac disease or pts 
taking vasoactive medicinal products eg 
antihpertensives, especially if pre-existing 
postural hypotension; some pts neuropsychiatric 
disturbances may be exacerbated 
Respiratory depression, hypersensitivity to 
opioids, not suitable if 'on' response to levodopa 
marred by severe dyskinesia, hypotonia or 
psychiatric effects, hepatic impairment, breast- 
feedinq (BNF)
Drug interactions Potential interaction between clozapine and 
apogo, clozapine may be used to reduce 
symptoms of neuropsych complications; caution 
advised antihypertensive and cardiac active 
drugs; caution pregnant women/childbearing 
age; avoid during breast-feeding 
Effects of apomorphine antagonised by 
antipsychotics, effects of apomorphine possibly 
enhanced by entacapone (BNF)
Adverse drug 
reactions
Nausea, vomiting, drowsiness, confusion, 
hallucinations, injection-site reactions, less 
commonly, postural hypotension, breathing 
difficulties, dyskinesia during ‘on’, haemolytic 
anaemia with levodopa, rarely: oesinophilia, 
pathological gambling, increased libido, 
hypersexuality (BNF)
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fBromocriptine Motor
fluctuations
Ropinirole H&Y 1 to III UPDRS III P=0.086 (NS) Motor score improvement mean % 31 ropinirole 
vs 22 bromocriptine 23.1 to 16.94 (Korczyn et 
al., 1999)
Cognitive
impairment
No data
Confusion ADR (BNF)
Hallucinations ADR (BNF)
Dyskinesias
Levodopa 
DCI/Levodop 
aDCI and 
selegiline
H&Y 1 to V As ADR
ADR (BNF)
After 3 yr follow up incidence of dyskinesia 2% 
for brom vs 27% levodopa/34% for 
Idopa/selegiline (PDRGUK, 1999)
Postural
hypotension
ADR (BNF)
Patient’s choice No data
Mobility No data
Depression 11.3% ropinirole vs 10.2% bromocriptine 
(Korczyn et al., 1999)
ADLs Ropinirole H&Y 1 to III UPDRS III P=0.009 Mean score ropinirole 5.83 vs bromocriptine 
7.28 (Korczyn et al., 1999)
Cost-
effectiveness
Levodopa
Pergolide
Pramipexole
Generic bromocriptine cost-effective (Shimbo et 
al., 2001)
Pergolide cost saving and more effective than 
Bromocriptine (Davey et al., 2001)
More expensive and less effective than 
pramipexole (Hoerger et al., 1998)
Stage of disease 
(H&Y)
LevodopaDC 
1/LevodopaD 
Cl and 
selegiline
H&Y 1 to V Disability score -  
Webster rating 
scales
P<0.0058
P<0.0002
Significant improvement for levodopa vs 
bromocriptine (PDRGUK, 1999)
Significant improvement for Idpa/selegiline vs 
bromocriptine (PDRGUK, 1999)
Drug
contraindications
Hypersensitivity to bromocriptine or other ergot 
alkaloids, toxaemia of pregnancy, hypertension 
in pregnant women or in peurperium (BNF)
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Drug interactions r..................... .... hypoprolactinaemic and antiparkinsonian effects 
of bromocriptine antagonised by antipsychotics, 
hypoprolactinaemic effect of bromocriptine 
possibly antagonised by domperidone and 
metoclopramide, plasma concentration of 
bromocriptine increased by erythromycin 
(increased risk of toxicity) and octreotide and 
possibly increased by macrolides (increased risk 
of toxicity), risk of toxicity when bromocriptine 
given with isometheptene and 
phenylpropanolamine (BNF)
Adverse drug 
reactions
Nausea, constipation, headache, drowsiness, 
nasal congestion, less commonly: vomiting, 
postural hypotension, fatigue, dizziness, 
dyskinesia, dry mouth, leg cramps, high closes: 
confusion, psychomotor excitation, 
hallucinations, rarely, constrictive pericarditis, 
pericardial effusion, pleural effusion, 
retroperitoneal fibrosis, hair loss, allergic skin 
reactions, very rarely: Gl bleeding, gastric ulcer, 
vasospasm of fingers and toes (particularly in 
Raynaud’s), neuroleptic malignant syndrome on 
withdrawal, pathological gambling, increased 
libido, hypersexuality (BNF)
Cabergoline Motor
fluctuations
None
Placebo
H&Y 1 to IV 
Median H&Y II
CDRS score 
UPDRS III 
UPDRS III 
Patient diaries
P<0.0001
P<0.05 (wk 
16)
P=0.06055 
(wk 26)
Wk 12 
p=0.014, wk 
24 p=0.031 I
Reduction % time awake with ‘severe o ff 
symptoms from mean 30.78 baseline to 17.19 
wk 26 (Odin et al., 2006)
Severity ‘o ff periods improved from 39.8 
baseline to 29.1 wk 16, to 25.5 wk 26
Cabergoline grp signif better at wk 12 and wk 24 
vs placebo, Cabergoline improved 16% wk 24 
from baseline vs 6% placebo 
‘on’ time increased Cabergoline grp signif wk 12 
and wk 24 vs placebo
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Levodopa H&Y 1 to III
UPDRS IV q39 
UPDRS III
Wk12
p=0.005, wk 
24 p=0 022 
Wk 12 
p=0.009, wk 
24 p=0.012 
P<0.01
Cabergoline grp less off’ time at wk 12 and wk 
24 vs placebo (Hutton et al., 1996)
Mean scores lower for Idopa grp than 
cabergoline grp -  13.8 vs 12.9 at 1 yr, 18.6 vs 
17.2 at 3yrs and 19.2 vs 16.3 at 5yrs (Bracco et 
al., 2004)
Cognitive
impairment
Levodopa H&Y 1 to III MMSE NS No change over time in cognitive function 
(Bracco et al., 2004)
Confusion ADR (BNF)
Hallucinations ADR (BNF)
ADR (Odin et al., 2006)
Dyskinesias
None
Levodopa
H&Y 1 to IV 
H&Y 1 to III
CDRS score 
UPDRS II
P<0.001
??
ADR (BNF)
Time ‘on with dyskinesias’ reduced from 20.67% 
baseline to 8.57% 26 weeks (Odin et al., 2006) 
ADR (Odin et al., 2006)
Occurred at a lower rate in Cabergoline grp than 
levodopa grp 9.5% vs 21.2% after 5 years 
(Bracco et al., 2004)
Postural
hypotension
ADR (BNF)
Patient's choice No data No data No data No data No data
Mobility No data No data No data No data No data
Depression
Levodopa H&Y 1 to III Zung SDS NS
ADR (BNF)
No change over time in depression (Bracco et 
al., 2004)
ADLs Placebo
Levodopa
Median H&Y II 
H&Y 1 to III
UPDRS II 
UPDRS II
Wk 12 
p=0.043, wk 
24 p=0.032
P<0.02
Cabergoline grp scores significantly better at wk 
12 and wk 24 than placebo, improvement 19% 
from wk 0 vs 4% placebo grp (Hutton et al., 
1996)
Slight higher improvement for Idopa vs caberg 
signif only at 12 mths, declined for both groups 
after that
Cost- Levodopa Cost-effective for patients £60 yrs (Smala et al.,
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effectiveness 2003)
Stage of disease 
(H&Y)
No data No data No data No data No data
Drug
contraindications
Pregnancy; breast-feeding; history of 
pulmonary, pericardial or retroperitoneal fibrotic 
disorders; cardiac valvulopathy (BNF)
Drug interactions Hypoprolactinaemic and antiparkinsonian effects 
antagonised by antipsychotics, 
hypoprolactinaemic effect of cabergoline 
antagonised by metoclopramide and possibly 
domperidone, plasma concentration of 
cabergoline increased by erythromycin 
(increased risk of toxicity) and possibly 
macrolides (BNF)
Adverse drug 
reactions
Nausea, constipation, headache, drowsiness, 
nasal congestion, less commonly: vomiting, 
postural hypotension, fatigue, dizziness, 
dyskinesia, dry mouth, leg cramps, high doses: 
confusion, psychomotor excitation, 
hallucinations, rarely, constrictive pericarditis, 
pericardial effusion, pleural effusion, 
retroperitoneal fibrosis, hair loss, allergic skin 
reactions, very rarely: Gl bleeding, gastric ulcer, 
vasospasm of fingers and toes (particularly in 
Raynaud's), neuroleptic malignant syndrome on 
withdrawal, pathological gambling, increased 
libido, hypersexuality. Also; dyspepsia, 
epigastric and abdominal pain, syncope, breast 
pain, palpitation, angina, cardiac valvulopathy, 
epistaxis, peripheral oedema, hemianopia, 
asthenia, paraesthesia, erthyromelalgia, hot 
flushes, depression (BNF)
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mDuodopa Motor
fluctuations
G roup l: PD 
meds 3 wks 
/duodopa 
3wks 
Group 2: 
duodopa 
3wks/ PD 
meds 3wks
Advanced Primary: %time 
‘on’
Secondary: 
%time ‘o ff and 
%time 'on with 
dyskinesias' 
UPDRS III
on’ increased from 81 to 100%, decrease in o ff 
state and no increase in dyskinesia (Nyholm et 
al., 2005)
ADR
Cognitive
impairment
Advanced Dementia ADR (Nyholm et al., 2005)
Confusion Advanced ADR (Nyholm et al., 2005)
Hallucinations Advanced ADR (Nyholm et al., 2005)
Dyskinesias Advanced No change. ADR (Nyholm et al., 2005)
Postural
hypotension
ADR (BNF - levodopa)
Patient’s choice Advanced 16 out of 18 (89%) pts completing study chose 
duodopa infusion vs conventional therapy 
(Nyholm et al., 2005)
Mobility No data
Depression No change. ADR (Nyholm et al., 2005) 
ADR (BNF)
ADLs Groupl: PD 
meds 3 wks 
/duodopa 
3wks 
Group 2: 
duodopa 
3wks/ PD 
meds 3wks
Advanced UPDRS pt II P<0.01 Improvement against conventional meds median 
11 and mean 11.1 duodopa vs median 14 and 
mean 15.3 conventional meds (Nyholm et al., 
2005)
Cost-
effectiveness
Advanced NNT for one year for benefit is 1.1. Yearly drug 
cost is £28,105 (Solvay, 2008)
Stage of disease 
(H&Y)
No data
Drug
contraindications
Advanced Hypersensitivity to levodopa, carbidopa or any 
of excipients: narrow-angle glaucoma; severe
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liver and renal insufficiency; severe heart failure; 
severe cardiac arrhythmia; acute stroke 
Pregnancy, breast-feeding (BNF) (levodopa)
Drug interactions Advanced Antihypertensives, antidepressants (tricyclic), 
anticholinergics, dopamine receptor antagonists 
can reduce therapeutic effect of levodopa, 
selegiline -  serious orthostatic hypotension, see 
others to adjust doses of. Selegiline -  orthostatic 
hypotension
Enhanced hypotensive effect; ACE inhibitors, 
adrenergic neurone blockers, alpha-blockers, 
antiotensin-ll receptor antagonists, beta- 
blockers, calcium-channel blockers, clonidine, 
diazoxide, diuretics, hydralazine, methyldopa, 
minoxidil, nitrates, sodium nitroprusside; 
amisulpiride manufacturer advises advoidance; 
risk arrhythmias with volatile liquid GAs; 
absorption of Idopa poss reduced by: 
antimuscarinics, oral iron, phenytoin; effects of 
Idopa antagonised by: antipsychotics, possibly 
benzodiazipines; agitation, confusion & 
hallucinations with baclofen; increased risk side 
effects with buproprion, moclobemide; risk 
hypertensive crisis with MAOIs; enhanced effect 
and increased toxicity with selegiline (reduce 
dose Idopa) (levodopa -  BNF)
Adverse drug 
reactions
Anorexia, nausea and vomiting, insomnia, 
agitation, postural hypotension, dizziness, 
tachycardia, arrhythmias, reddish discolouration 
of urine and bodily fluids, rarely hypersensitivity, 
abnormal involuntary movements & psych 
symptoms (inc hypomania and psychosis) may 
be dose-limiting, depression, drowsiness, 
headache, flushing, sweating, Gl bleeding, 
peripheral neuropathy, taste disturbance,
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pathological gambling, increased libido, 
hypersexuality, pruritus, rash and livery enzyme 
changes reported, syndrome resembling 
neuroleptic malignant syndrome reported on 
withdrawal, very rarely angle-closure glaucoma 
(BNF - levodopa)
Entacapone Motor
fluctuations
Placebo
Placebo
None
Placebo
Placebo
Placebo
None
Advanced
H&Y mean 2.9
H&Y 1.5 to IV 
Mean H&Y 2.4 
H&Y all stages
UPDRS III 
UPDRS III
Secondary: 
UPDRS III
UPDRS III
P<0.05
P=0.001
P<0.0001
P<0.0001
P<0.0001
P<0.05
P<0.05
P<0.05
P=0.003
P<0.01
NS
Increased proportion daily ON time from 58% to 
65% vs placebo 60% to 61%, UPDRS II and III 
not stat significant vs placebo (fluctuators). 
(Brooks and Sagar, 2003)
Mean "on” time increased by 24% vs placebo 
(Ruottinen and Rinne, 1996)
Decrease in 'o ff time of 0.4 
Pt pop receiving DAs decrease 1.7 to 1.3 
Pop not on Das decrease 1.7 to 1.2 
At baseline no pts with no ‘o ff time, at end of 
study 8% had no ‘o ff time (Durif et al., 2001) 
Proportion daily ‘on’ time increased from 62% to 
72% vs 59% to 65%
‘O ff time decreased significantly vs placebo 
Fluctuating pts with 5-10 Idopa doses per day 
increased ‘on’ time 1.7h vs 0.5h placebo (Poewe 
et al., 2002)
Mean % ‘on’ time signif higher vs placebo -  5% 
(1997)(PSG, 1997)
UPDRS III increased after withdrawal from 20.8 
to 23.7 vs placebo 20.2 to 20.3 (Myllyla et al., 
2001)
UPDRS III not signif different from baseline at 
36mths
Proportion pts with predictable ‘offs’ decreased 
from 97% to 84% - (Larsen et al., 2003)
Cognitive
impairment
No data
Confusion ADR:(Ruottinen and Rinne, 1996), ADR (Durif et
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t ! al.. 2001). ADR (BNF)
Hallucinations ADR: (Brooks et al., 2003, Poewe et al., 2002, 
PSG, 1997, Larsen et al., 2003)
Dyskinesias ADR: (Brooks et al., 2003, Ruottinen & Rinne, 
1996, Poewe et al., 2002, PSG, 1997, Myllyla et 
al., 2001, Larsen et al., 2003)
Postural
hypotension
ADR : (Larsen et al., 2003, Durif et al., 2001, 
Myllyla et al., 2001)
Patient's choice No data
Mobility No data
Depression ADR: (Brooks et al., 2003, Larsen et al., 2003)
ADLs Placebo
Placebo
Placebo
Placebo
None
H&Y mean 2.9
H&Y 1.5 to 4
H&Y 1.5 to 4 
H&Y all stages
UPDRS II 
UPDRS II 
UPDRS II
UPDRS II
UPDRS II 
UPDRS II
UPDRS II
NS
P<0.01
P<0.0001
P<0.0001
P<0.05
NS
P=0.06
P<0.001
NS
Slight improvement UPDRS II but not stat 
significant (fluctuators) 12.5 baseline to 12.0 
6mths (Brooks et al., 2003)
UPDRS II improved from 10.6 to 10 vs reduction 
0.1 placebo, (non-fluctuators) (Brooks et al., 
2003)
Mean score decreased by 1.8 (Durif et al., 2001) 
Pt pop on DAs change from baseline -1.9 vs - 
1.5 for pts not on DAs, stat signif compared to 
baseline but not compared to each other (Durif 
et al., 2001)
UPDRS II score improved from 12.4 to 11.1 vs 
12.0 to 12.4 placebo
Non-fluctuating pts: improved from 11.3 to 10.3 
vs 9.8 to 11.3 placebo (Poewe et al., 2002)
0.8 improvement in score vs placebo (PSG, 
1997)
UPDRS II score increased after withdrawal from 
9.3 to 10.3 vs placebo 9.0 to 8.9 (Myllyla et al., 
2001)
At 36mths UPDRS similar to baseline (Larsen et 
al., 2003)
Cost-
effectiveness
Cost-effective -  (Nuijten et al., 2001) (Palmer et 
al., 2002)
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| Stage of disease 
S  (H&Y)
Unchanged for both groups (Poewe et al.. 2002)
Drug
contraindications
Pregnancy, breast-feeding, hepatic impairment, 
phaeochromocytoma, history of neuroleptic 
malignant syndrome or non-traumatic 
rhabdomyolysis (BNF)
Drug interactions Possibly enhances effects of: adrenaline, 
apomorphine, dobutamine, dopamine, 
methyldopa, noradrenaline; Manufacturer 
advises caution with: tricyclics, moclobemide, 
paroxetine, venlafaxine; absorption of 
entacapone reduced by oral iron; avoid use with 
non-selective MAOIs; possibly reduces plasma 
concentration of rasagiline; manufacturer 
advises max dose 10mg selegiline; enhances 
anticoagulant effect of warfarin (BNF)
Adverse drug 
reactions
Nausea, vomiting, abdominal pain, constipation, 
diarrhoea, urine may be coloured reddish- 
brown, dry mouth; confusion, dizziness, 
abnormal dreams, fatigue, insomnia, dystonia, 
dyskinesia, hallucinations; increased sweating; 
rarely hepatic dysfunction and rash; very rarely 
anorexia, weight loss, agitation, and urticaria; 
also reported colitis, neuroleptic malignant 
syndrome, rhabdomyolysis, and skin, hair, and 
nail discoloration (BNF)
Madopar Motor
fluctuations
Ropinirole H&Y 1 to III UPDRS III P=0.008 Decrease from baseline of 0.8ropinirole vs 4.8 
levodopa (Rascol et al., 2000)
Cognitive
impairment
Dementia ADR (BNF)
Confusion ADR (BNF)
Hallucinations ADR (Rascol et al., 2000) 
ADR (BNF)
Dyskinesias ropinirole H&Y 1 to III UPDRS Dyskinesias developed in 20% ropinirole grp vs 
45% levodopa grp
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P<0.001
P=0.002
No at risk after 5 yrs: ropinirole 85 vs 45 
levodopa
Risk disabling dyskinesia signif lower ropinirole 
grp, hazard ratio to be free disabling dyskinesia 
3.02 ropinirole vs levodopa, 8% ropinirole vs 
23% levodopa had disabling dyskinesias 
ADR (Rascol et al., 2000)
Postural
hypotension
ADR (Rascol et al., 2000) 
ADR (BNF)
Patient’s choice No data
Mobility No data
Depression ADR (Rascol et al., 2000) 
ADR (BNF)
ADLs Ropinirole H&Y 1 to III UPDRS II P=0.08 (NS) Mean change from baseline 1.6 ropinirole vs 
0.0 levodopa (Rascol et al., 2000)
Cost-
effectiveness
Bromocriptin
e,
cabergoline
ropinirole
Not cost-effective against bromocriptine 
(Shimbo et al 2001), cabergoline (Smala et al 
2003), or ropinirole (Iskedjian and Einarson, 
2003)
Stage of disease 
(H&Y)
No data No data No data No data No data
Drug
contraindications
Pregnancy, breast-feeding (BNF)
Drug interactions Enhanced hypotensive effect: ACE inhibitors, 
adrenergic neurone blockers, alpha-blockers, 
antiotensin-ll receptor antagonists, beta- 
blockers, calcium-channel blockers, clonidine, 
diazoxide, diuretics, hydralazine, methyldopa, 
minoxidil, nitrates, sodium nitroprusside; 
amisulpiride manufacturer advises advoidance; 
risk arrhythmias with volatile liquid GAs; 
absorption of Idopa poss reduced by: 
antimuscarinics, oral iron, phenytoin; effects of 
Idopa antagonised by: antipsychotics, possibly 
benzodiazipines; agitation, confusion &
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Adverse drug 
reactions
hallucinations with baclofen; increased risk side j 
effects with buproprion, moclobemide; risk 
hypertensive crisis with MAOIs; enhanced effect 
and increased toxicity with selegiline (reduce
dose Idopa) (BNF)___________________________
Nausea, vomiting, taste disturbances, dry 
mouth, anorexia, arrhythmias, postural 
hypotension, syncope, drowsiness (including 
sudden onset of sleep), fatigue, dementia, 
psychoses, hallucinations, confusion, euphoria, 
abnormal dreams, insomnia, depression (very 
rarely with suicidal ideation), anxiety, dizziness, 
dystonia, dyskinesia, and chorea. Less 
commonly weight loss or gain, constipation, 
diarrhoea, hypersalivation, dysphagia, 
flatulence, hypertension, chest pain, oedema, 
hoarseness, ataxia, increased hand tremor, 
malaise, muscle cramps, and reddish 
discoloration of the urine and other body fluids 
may occur. Rare side-effects include abdominal 
pain, gastro-intestinal bleeding, dyspepsia, 
phlebitis, dyspnoea, agitation, paraesthesia, 
bruxism, trismus, hiccups, neuroleptic malignant 
syndrome (associated with abrupt withdrawal), 
convulsions, reduced mental acuity, 
disorientation, headache, urinary retention, 
urinary incontinence, priapism, activation of 
malignant melanoma, leucopenia, haemolytic 
and non-haemolytic anaemia, 
thrombocytopenia, agranulocytosis, blurred 
vision, blepharopasm, diplopia, activation of 
Horner’s syndrome, pupil dilatation, oculogyric 
crisis, angioedema, rash, urticaria, pruritus, 
flushing, alopecia, exanthema, Henoch- 
Schonlein purpura, and increased sweating.
Very rarely angle-closure glaucoma may occur; 
pathological gambling, increased libido, 
hypersexuality, and false positive tests for 
urinary ketones have also been reported. (BNF)
Pergolide Motor
fluctuations
None H&Y II to V UPDRS III 
Patient diaries
P<0.001
P<0.001
P<0.001
Improved from median 32 baseline to 8 at 
endpoint (Storch et al., 2005)
Total motor fluctuations Mean of 10.5h per day 
baseline to 2.8h per day at endpoint, ‘o ff hrs per 
day decreased from 7.3h per day baseline to 
1.7h per day endpoint (Storch et al., 2005)
Cognitive
impairment
No data
Confusion ADR(BNF)
Hallucinations ADR (BNF)
Dyskinesias Levodopa
None
Early (1 to 2.5) 
H&Y II to V
UPDRS IV
UPDRS IV 
Patient diaries
P< 001
P<0.001
P<0.001
3x as many pts on l-dopa had dyskinesias at 
3yr endpoint compared to pergolide (Oertel et 
al., 2006)
Improved from median 10 baseline to 2 at 
endpoint
Reduced from mean of 5.0h per day to 1.4h per 
day at endpoint (Storch et al., 2005)
ADR (BNF)
Postural
hypotension
Levodopa Early (1 to 2.5) Difference in proportion of pts in each group 
with post hypotension not significantly significant 
(but greater number in pergolide group) (Oertel 
et al., 2006)
ADR (BNF)
Patient’s choice No data
Mobility No data
Depression Pramipexole Mean H&Y III Zung self-rating 
depression scale 
MADRS
P=0.01
NS
Zung score decreased from mean 60.4 to 43.4 
vs 59.6 to 49.1 pramipexole (Rektorova et al., 
2003)
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Reduction from 11.25 to 10.06 vs 15.11 to 9.28 
pramipexole (baseline values different for ppx 
and prg -  authors say cannot exclude bias, be 
cautious with results) (Rektorova et al., 2003)
ADLs Pramipexole Mean H&Y III UPDRS II
UPDRS VI 
(Schwab & 
England)
not given 
not given
Mean score reduced from 15.5 to 7.2 vs 15.2 to 
7.6 pramipexole (Rektorova et al., 2003)
Score changed from 70% 1st visit to 85% 6th visit 
(8 months) vs 72% to 83% pramipexole 
(Rektorova et al., 2003)
Cost-
effectiveness
Bromocriptin
e
Levodopa
Cost-
effectiveness 
(Markov model) 
Cost-
effectiveness 
(Markov model)
Pergolide cost saving and more effective than 
bromocriptine (Davey et al., 2001)
Cost-effective for H&Y stage III or more (Shimbo 
et al., 2001)
Stage of disease 
(H&Y)
Levodopa
None
Early (1 to 2.5) 
H&Y 2 to 5
H&Y
H&Y
P=0.001 Change from baseline after 3 years -  0.6 perg 
vs 0.1 l-dopa
Improved by 0.5 to 1.5 in 63% pts, 34% had 
same score (Storch et al., 2005)
Contraindications History fibrotic disorders, cardiac valve disorders 
(BNF)
Drug interactions Effects antagonised by antipsychotics; 
antiparkinsonian effect antagonised by 
metoclopramide (BNF)
Adverse drug 
reactions
Early (1 to 2.5) Nausea, vomiting, dyspepsia, abdominal pain, 
dyspnoea, rhinitis, hallucinations, dyskinesias, 
drowsiness, diplopia, constipation, diarrhoea, 
tachycardia, atrial premature contractions, 
palpitation, hypotension, syncope, raynaud's
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phenomenon, cardiac valvulopathy, pericarditis, 
pericardial effusion, pleuritis, pleural effusion, 
pleural fibrosis, insomnia, confusion, dizziness, 
pathological gambling, neuroleptic malignant 
syndrome, fever, increased libido, 
hypersexuality, rash (BNF)
Pramipexole Motor
fluctuations
Placebo
None
Advanced 
H&Y 1 to V
UPDRS II and III 
SPES
P<0.001
Mean number o ff hours per day reduced from 6 
to 4 for pramipexole group vs 6 to 6 for placebo 
group
Baseline 16.17 to 9.93 endpoint (Lemke et al., 
2006)
Cognitive
impairment
No data
Confusion ADR (advanced PD) (Lemke et al., 2006) 
ADR (BNF)
Hallucinations Placebo Early/advanced UPDRS Early -  9% vs 2.A% placebo 
Advanced -  16.5% vs 3.8% placebo 
Caused discontinuation 3.1% early and 2.7% 
advanced vs 0.4% placebo both groups 
Increases risk hallucinations:
Early -  risk 1.9x > placebo if pt <65 
6.8x > if pt >65
Advanced -  3.5x > placebo if <65 
5.2x > placebo if >65 
ADR (Lemke et al., 2006)
ADR (BNF)
Dyskinesias ADR (advanced PD) (Lemke et al., 2006) 
ADR (BNF)
Postural
hypotension
Placebo Early/advanced Dopamine agonists impair systemic regulation of 
BP with resulting orthostatic hypotension, 
especially during dose escalation. Requires 
careful monitoring. Reported incidence wasn’t 
greater for pramipexole pts than for placebo 
group, (pts with significant orthostatic 
hypotension at baseline excluded from trial).
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(Lemke et al., 2006) 
ADR (BNF)
Patient’s choice No data
Mobility No data
Depression None H&Y 1 to V SPES-
depression
P<0.001 Moderate to severe depression baseline 22.5% 
to endpoint 6.8%, mild depression baseline 
46.6% to endpoint 37.6% (Lemke et al., 2006)
ADLs None H&Y 1 to V SPES P<0.001 8.5 baseline to 6.26 endpoint (Lemke et al., 
2006)
Cost-
effectiveness
No data
Stage of disease 
(H&Y)
No data
Drug
contraindications
placebo Early/advanced Hypersensitivity to drug or ingredients 
Breast-feeding (BNF)
Drug interactions Dopamine antagonists (neuroleptics -  
phenothiazines, butyrophenones, thixanthenes 
or metoclopramide) may diminish effectiveness 
of pramipexole
Amantadine -  may slightly decrease the oral 
clearance of pramipexole 
Avoid antipsychotics -  antagonism of effect 
(BNF)
Adverse drug 
reactions
Pramipexole 
vs Placebo -  
early
Pramipexole 
& levodopa 
vs Placebo 
and
levodopa -
advanced
PD
Early/advanced UPDRS Nausea, constipation; postural hypotension, 
hypotension, headache, confusion, drowsiness 
(including sudden onset of sleep), fatigue, 
insomnia, dizziness, hallucinations (mostly 
visual), dyskinesia, peripheral oedema; 
hyperkinesia, delusions, abnormal dreams, 
paradoxical worsening of restless legs 
syndrome, and behavioural changes including 
pathological gambling, binge eating, 
hypersexuality, and changes in libido also 
reported (BNF)
Rasagiline Motor Placebo Early - <= H&Y 3 UPDRS total P<0.001 Benefit for 1 mg and 2mg vs placebo for total
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ife
fluctuations score baseline to 
26 weeks, 
secondary: H&Y, 
Schwab-England 
ADL, BDI, timed 
motor tests, 
PDQUALIF
Not given
UPDRS score
Motor subscale -2.71 (1 mg) and -1.68 (2mg) 
both vs placebo
Timed motor score: -0.55 (1mg) and -0.36 (2mg) 
both vs placebo (2002)(PSG, 2002)
1mg or 2mg 
vs 2mg 
delayed
Entacapone 
and placebo
H&Y <5 in o ff 
state
(TEMPO)
Primary: change 
from baseline to 
treatment in 
mean total daily 
off-time as 
measured by 24h 
diaries.
Secondary: CGI 
’on’; UPDRS III
?
P=0.0001
P=0.0130
-1.06 1mg and -0.99 2mg vs 2mg delayed for 
UPDRS motor (PSG, 2002)
Mean total daily off-time reduced from baseline 
to endpoint by more than 1 h, almost three times 
more than by placebo
UPDRS III score -5.64 vs placebo (Rascol et al., 
2005)
Cognitive
impairment
No data
Confusion No data
Hallucinations ADR (BNF)
Dyskinesias Entacapone 
and placebo
H&Y <5 in 'o ff 
state
UPDRS NS
p=0.7711
UPDRS dyskinesia score -0.03 vs placebo 
(Rascol et al., 2005)
Postural
hypotension
ADR for 2% pts vs 0% placebo grp (PSG, 2002)
Patient’s choice No data
Mobility No data
Depression Placebo <= H&Y 3 BDI Not given -0.35 (1mg) and -0.21 (2mg) both vs placebo 
(PSG, 2002)
ADR (BNF)
ADLs Placebo
Placebo
2mg delayed
<= H&Y 3 
<=H&Y3
<=H&Y3
UPDRS II 
Schwab & 
England 
UPDRS II
Not given 
Not given
P=0.005
-1.04 (1 mg) and -1.22 (2mg) both vs placebo 
0.77 (1mg) and 0.39 (2mg) both vs placebo 
(PSG, 2002)
-0.48 (1mg) and -0.96 (2mg) vs 2mg delayed
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Placebo and 
entacapone
H&Y <5
UPDRS II
P<0.0001 (PSG. 2002)
UPDRS II -1.71 vs placebo (Rascol et al., 2005)
Cost-
effectiveness
No data
Stage of disease 
(H&Y)
Placebo 
2mg delayed
<= H&Y 3 
<=H&Y3
H&Y
H&Y
Not given 
NS
-0.04 (1mg) and -0.04 (2mg) both vs placebo 
(PSG, 2002
0.08 (1mg) and 0.04 (2mg) vs 2mg delayed 
(PSG, 2002)
Drug
contraindications
Hepatic impairment, pregnancy, breastfeeding 
(BNF)
Drug interactions Avoid dextromethorphan and 
sympathomimetics; increased risk of CNS 
toxicity with antidepressants (SSRIs & 
Tricyclics); wait 2 weeks before using: 
fluoxetine, fluvoxamine, MAOIs, pethidine; 
plasma concentration of rasagiline reduced by 
entacapone (BNF)
Adverse drug 
reactions
Dry mouth, dyspepsia, constipation; angina; 
headache, depression, anorexia, weight loss, 
abnormal dreams, vertigo, hallucinations; 
influenza-like symptoms; urinary urgency; 
leucopenia; arthralgia; conjunctivitis; rash; less 
commonly myocardial infarction, and 
cerebrovascular accident (BNF)
Ropinirole Motor
fluctuations
Bromocriptin
e
Levodopa
(madopar)
H&Y ll-IV
H&Y 1 To III 
H&Y 1 to III
>-20%
improvement 
UPDRS III, 
reduction >-20% 
off duration per 
day,
UPDRS III
NS
NS
P=0.008 
P=0.086 (NS)
70% reduction UPDRS motor score >-20% vs 
63.3 bromocriptine group (no signif difference); 
81% reduction in off duration >-20% vs 52.4% 
bromocriptine group (not stat signif) (Whone et 
al., 2003)
Decrease from baseline of 0.8 ropinirole vs 4.8 
levodopa (Rascol et al., 2000)
Motor score improvement mean % 31 ropinirole 
vs 22 bromocriptine (Korczyn et al., 1999)
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Bromocriptin
e
UPDRS III
Cognitive
impairment
No data
Confusion 5 pts as adverse event vs 1 levodopa (Rascol et 
al., 2000)
ADR (BNF)
ADR (Korczyn et al., 1999)
Hallucinations 6 pts as adverse event vs 1 levodopa (Rascol et 
al.. 2000)
ADR (BNF)
Dyskinesias Levodopa
Levodopa
H&Y 1 to 2.5 
H&Y 1 to III
UPDRS q32 
(dyskinesias)
UPDRS
1X0.001
P<0.001
P=0.002
3.4% developed dyskinesia vs 26.7% levodopa 
group (Rascol et al., 2000)
ADR (BNF)
Dyskinesias developed in 20% ropinirole grp vs 
45% levodopa grp
No at risk after 5 yrs: ropinirole 85 vs 45 
levodopa
Risk disabling dyskinesia signif lower ropinirole 
grp, hazard ratio to be free disabling dyskinesia 
3.02 ropinirole vs levodopa, 8% ropinirole vs 
23% levodopa had disabling dyskinesias 
(Rascol et al., 2000)
Postural
hypotension
Hypotension ADR (BNF) 
ADR (Korczyn et al., 1999)
Patient’s choice No data
Mobility No data
Depression 6 patients as adverse event vs 7 levodopa 
(Rascol et al., 2000)
11.3% ropinirole vs 10.2 bromocriptine ADR 
(Korczyn et al., 1999)
ADLs Levodopa
Bromocriptin
e
H&Y 1 to III 
H&Y 1 to III
UPDRS II 
UPDRS II
P=0.08 (NS) 
P=0.009
Mean change from baseline 1.6 ropinirole vs 0.0 
levodopa (Rascol et al., 2000)
Mean score ropinirole 5.83 vs bromocriptine 
7.28 (Korczyn et al., 1999)
299
Cost-
effectiveness
Levodopa Cost-
minimization
analysis
Cost-saving from societal perspective, due to 
avoiding dyskinesias (Iskedjian & Einarson 
2003)
Stage of disease 
(H&Y)
No data
Drug
contraindications
Pregnancy, breast-feeding; caution: severe 
cardiovascular disease, major psychotic 
disorders, hepatic impairment, renal impairment 
(BNF)
Drug interactions Avoid antipsychotics, metoclopramide; 
metabolism inhibited by: ciprofloxacin; plasma 
concentration increased by oestrogens (BNF)
Adverse drug 
reactions
levodopa Nausea, vomiting, abdominal pain, dyspepsia; 
hypotension, syncope, leg oedema; drowsiness 
(including sudden onset of sleep), dizziness, 
nervousness, fatigue, dyskinesia, hallucinations, 
confusion; less commonly psychosis, 
pathological gambling, hypersexuality, and 
increased libido; very rarely hepatic disorders; 
also reported paradoxical worsening of restless 
legs syndrome (BNF)
Rotigotine Motor
fluctuations
Placebo Advanced (II to 
IV)
No daily hours 
‘o ff
UPDRS ll,lll,IV
P<0.0001/0.0
031
P<0.0001/0.0
012
P
0.0871/0.649
9
P<0.0001/0.0
078
P
0.001/0.0195
P
0.0185/0.000
“o ff  time -2.7h/-2.1h vs 0.9h placebo
"on"time -  3.1 h/2.3h vs 1.1 h placebo
"on with dyskinesia” - 0.4h/0.1h vs-0.1h placebo
“on without dyskinesia" -  3.5h/2.2h vs 1.1 h
placebo
No daily "o ff periods - 1 .5/-1.3 vs -0.7 placebo 
UPDRS III -6.8/-8.7 vs -3.4 (LeWitt et al., 2007)
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Cognitive
impairment
No data
Confusion No data
Hallucinations Placebo Advanced UPDRS II and III ADR - 7%/14% vs 3% placebo (LeWitt et al., 
2007)
Dyskinesias Placebo Advanced UPDRS II and III ADR - 1 4%/17& vs 7% placebo (LeWitt et al., 
2007)
Postural
hypotension
Placebo Early UPDRS II and III Stat signif ADR - 2% vs 4% placebo (Watts et al., 2007)
Patient’s choice No data
Mobility No data
Depression No data
ADLs Placebo
Placebo
Early
Advanced (II to 
IV)
UPDRS II 
UPDRS II
Stat signif
P0.0004/0.00 
23
Improved (?by how much -  part II and III scores 
combined, not broken down) (Watts et al., 2007)
Improved (LeWitt et al., 2007)
Cost-
effectiveness
No data
Stage of disease 
(H&Y)
No data
Drug
contraindications
Hypersensitivity to rotigotine or components of 
transdermal system 
Sulphite sensitivity
Treat pts with severe cardiovascular disease 
with caution -  not known to what extent 
incidence of syncope occurs in these pts 
Preqnancy, breast-feeding (BNF)
Drug interactions Antipsychotics / metoclopramide could diminish 
effectiveness of rotigotine 
Possible additive effects, use caution with 
sedating medication, CNS depressants 
(benzodiazepines, antipsychotics, 
antidepressants)
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Manufacturer of rotigotine advises avoid 
concomitant use of antipsychotics (antagonism 
of effect) manufacturer of rotigotine advises 
avoid concomitant use of metoclopramide 
(antagonism of effect) (BNF)
Adverse drug 
reactions
Nausea, vomiting, constipation, dry mouth, 
diarrhoea, dyspepsia, weight changes, postural 
hypotension, peripheral oedema, confusion, 
drowsiness, sleep disorders, dizziness, 
headache, dyskinesia, asthenia, hallucinations, 
hyperhydrosis, rash, pruritis, less commonly: 
abdominal pain, anorexia, taste disturbance, 
palpitation, tachycardia, hypotension, 
hypertension, atrial fibrillation, syncope, 
dyspnoea, cough, hiccup, tremor, psychosis, 
pathological gambling, anxiety, impaired 
attention, dystonia, paraesthesia, impaired 
memory, erectile dysfunction, increased libido, 
arthralgia, visual disturbances, rarely: 
convulsions, loss of consciousness (BNF)
Selegiline Motor
fluctuations
Placebo
Placebo
Placebo
Placebo/toco
pherol/
Deprenyl+to
copherol
Placebo & 
levodopa
H&Y 1 to III 
H&Y 1 to III
Mean H&Y 2.10 
vs 2.11
H&Y dep mean 
1.73
/placebol .78/ 
Tocopherol 1.63/ 
dep+toc 1.73
UPDRS III 
UPDRS III
UPDRS III 
UPDRS III
UPDRS III
NS
Signif
P<0.001
P=0.0006
P<0.05
NS
6mth -1.5, 12 mth 0.7 (Palhagen et al., 2006) 
Increase 0. depenyl vs 4.1 placebo 
(total UPDRS score (ll& lll) increase 0.4 vs 5.8 
placebo) (Olanow et al., 1995)
Increase deprenyl 0.7 vs 3.8 placebo (Shoulson 
et al., 2002)
Dep +2.1 vs dep+toc -0.5 vs toe -1.4 vs placebo 
-0.7 (1996)(PSG, 1996)
After 60 months: selegiline 17.6 vs 24.1 placebo 
(Palhagen et al., 2006)
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Cognitive
impairment Placebo
Placebo
Placebo & 
levodopa
................
H&Y 1 to III
H&Y mean 2.10 
vs 2.11
?
........... —
MMSE
UPDRS mental 
Measurement? 
MMSE
NS
P=0.07
P=0.75
P=0.74
contraindication -  psychosis
MMSE score 0.7 6mth, 0.5 12 mth change from
baseline (Palhagen et al., 2006)
Increase deprenyl 0.6 vs 0.8 placebo (Shoulson 
et al., 2002)
Dementia 3.9 deprenyl vs 3.0 placebo 
(Shoulson et al., 2002)
No difference between treatment groups
Confusion
Placebo H&Y mean 2.10 
vs 2.11
UPDRS mental 
Measurement?
P=0.07
P=0.96
contraindication -  psychosis 
ADR (BNF)
Increase deprenyl 0.6 vs 0.8 placebo (Shoulson 
et al., 2002)
Confusion 6.6% deprenyl vs 6.6% placebo new 
cases (Shoulson et al., 2002)
Hallucinations ADR(BNF)
ADR (Shoulson et al., 2002) 
ADR (Palhagen et al 2006)
Dyskinesias
Placebo H&Y mean 2.10 
vs 2.11
Measurement? P=0.006
ADR(BNF)
Deprenyl 33.8% new cases vs 19.4% placebo 
(Shoulson et al., 2002)
Postural
hypotension
ADR (BNF)
ADR (Shoulson et al., 2002)
Patient’s choice No data
Mobility No data
Depression
Placebo
Placebo & 
levodopa
H&Y I to III HADRS
HADRS
NS
P=0.016,p=0.
0001
Hardly any change in HADRS score (no figs 
given)
ADR (Shoulson et al., 2002)
Mean scores lower for selegiline and difference 
increased with time (Palhagen et al., 2006)
ADLs Placebo
Placebo
H&Y I to III 
H&Y mean 2.10
UPDRS II 
UPDRS II
NS
Signif ?? (not
given)
P=0.0045
6mth 0.0, 12mth 0.5 change
Decrease -0.2 vs increase 1.8 placebo (Olanow
et al., 1995)
Increase deprenyl 1.1 vs 2.4 placebo (Shoulson
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Placebo/toco 
pherol / 
Deprenyl+to 
copherol
Placebo & 
levodopa
vs 2.11
H&Y dep mean 
1.73/placebo 
1.78/tocopherol 
1.63/dep+toc 
1.73
S&England
S&England
UPDRS II
P=0.053 
P<0.05 (?)
P<0.05
et al., 2002)
Schwab & England score deprenyl -2.4 vs -4.5 
placebo (Shoulson et al., 2002)
S&E score dep -2.9 vs dep+toc -4.8 vs toe -4.9 
vs -3.9 placebo (PSG, 1996)
60 month mean selegiline 9.4 vs 12.1 placebo 
(Palhagen et al., 2006)
Cost-
effectiveness
No data
Stage of disease 
(H&Y)
Placebo
Placebo/toco
pherol/
Deprenyl+to
copherol
H&Y 2.10 vs 2.11 
mean
H&Y dep mean 
1.73/placebo 
1.78/tocopherol 
1.63/dep+toc 
1.73
H&Y stage 
H&Y stage
P=0.37 (NS) 
P<0.05
Deprenyl mean 0.1 vs 0.2 placebo (Shoulson et 
al., 2002)
Deprenyl -0.27 vs deprenyl+tocopherol -0.35 vs 
tocopherol -0.33 vs placebo -0.19 (tocopherol 
worst) (PSG, 1996)
Drug
contraindications
Pregnancy, breast feeding. Cautions: gastric 
and duodenal ulceration, uncontrolled 
hypertension, arrhythmias, angina, psychosis, s- 
e Idopa may be increased, reduce Idopa dosage 
10-20% (BNF)
Drug interactions CNS toxicity: tricyclics; risk serotonin syndrome: 
citalopram; risk hypertensive crisis: dopamine; 
max dose 10mg selegiline advised by 
manufacturer of entacapone; caution advised by 
manufacturer of escitalopram; increased risk 
hypertension and CNS excitation: fluoxetine, 
fluvoxamine, paroxetine, sertraline, venlafaxine; 
enhanced effect and increased toxicity: 
levodopa; enhanced hypotensive effect: MAOIs; 
effects selegiline enhanced: Memantine; avoid
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use: moclobemide; plasma concentration 
increased: oestrogens, progesterone; 
hyperpyrexia and CNS toxicity (avoid use): 
pethidine; manufacturer advises caution: 
tramadol (BNF)
Adverse drug 
reactions
Nausea, constipation, diarrhoea, dry mouth, 
postural hypotension, dyskinesia, vertigo, 
sleeping disorders, confusion, hallucinations, 
arthralgia, myalgia, mouth ulcers with oral 
lyophilisate, rarely: arrhythmias, agitation, 
headache, micturition difficulties, skin reactions, 
also reported chest pain (BNF)
Sinemet Motor
fluctuations
Pramipexole
Ropinriole
Pergolide
H&Y 1 to III 
H&Y 1 to 11.5 
H&Y 1 to 11.5
UPDRS III 
UPDRS III 
UPDRS III
P<0.001 
P<=0.002
Not given
P=0.006
P=0.038
P<0.001
-3.9 difference in treatment pramipexole minus 
levodopa
Improvement levodopa group from baseline to 
each follow up significant vs pramipexole for 
motor UPDRS score
Initial improvements in on-treamtent UPDRS 
motor scores retained over 2 yrs for Idopa but 
not ropinirole; mean ‘on’ UPDRS motor score 
increased by 0.70 from baseline to endpoint for 
ropinirole vs decrease by 5.64 levodopa (Whone 
et al., 2003)
Improvement UPDRS score at 1 year -3.2 
pergolide vs -5.2 Idopa, estimate of treatment 
difference -1.92; time to onset of motor 
complications in 1st yr greater in pergolide grp 
than Idopa grp (Oertel et al., 2006)
3yr endpoint Idopa -2.8 vs 2.8 pergolide
Cognitive
impairment
No data
Confusion No data
Hallucinations ADR (PSG, 2000)
Dyskinesias Abnormal involuntary movements -  ADR (BNF) 
Ropinirole grp (3.4%) developed dyskinesias vs
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Ropinirole
Pergolide
H&Y 1 to 11.5 
H&Y 1 to 11.5
UPDRS q32 
UPDRS IVa q32
P<0.001
P<0.001
P<0.001
Idopa (26.7%);
Time to develop dyskinesia in favour of 
ropinirole vs Idopa (hazard ratio 8.28) (Whone et 
al.. 2003)
Incidence of dyskinesias 26.0% Idopa vs 8.2% 
pergolide (Oertel et al., 2006)
ADR (Oertel et al., 2006)
Postural
hypotension
Enhanced hypotensive effect; ACE inhibitors, 
adrenergic neurone blockers, alpha-blockers, 
antiotensin-ll receptor antagonists, beta- 
blockers, calcium-channel blockers, clonidine, 
diazoxide, diuretics, hydralazine, methyldopa, 
minoxidil, nitrates, sodium 
nitroprusside;(interactions from BNF)
ADR (BNF)
ADR (Oertel et al., 2006)
Patient’s choice No data
Mobility No data
Depression ADR (BNF)
ADR (Oertel et al., 2006)
ADLs Pramipexole H&Y 1 to III UPDRS II P<=0.002 Improvement levodopa group from baseline to 
each follow up significant vs pramipexole for 
ADL UPDRS score
Pergolide H&Y 1 to 11.5 UPDRS II 
Schwab & 
England
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Improvement -0.6 Idopa vs 2.3 pergolide 
Ldopa 0.1 vs 0.5 pergolide (Oertel et al., 2006)
Cost-
effectiveness
No data
Stage of disease 
(H&Y)
No data
Drug
contraindications
Pregnancy, breast-feeding (BNF)
Drug interactions Enhanced hypotensive effect; ACE inhibitors, 
adrenergic neurone blockers, alpha-blockers, 
antiotensin-ll receptor antagonists, beta-
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Adverse drug 
reactions
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blockers, calcium-channel blockers, clonidine, 
diazoxide, diuretics, hydralazine, methyldopa, 
minoxidil, nitrates, sodium nitroprusside; 
amisulpiride manufacturer advises advoidance; 
risk arrhythmias with volatile liquid GAs; 
absorption of Idopa poss reduced by: 
antimuscarinics, oral iron, phenytoin; effects of 
Idopa antagonised by: antipsychotics, possibly 
benzodiazipines; agitation, confusion & 
hallucinations with baclofen; increased risk side 
effects with buproprion, moclobemide; risk 
hypertensive crisis with MAOIs; enhanced effect 
and increased toxicity with selegiline (reduce
dose Idopa) (BNF)_________________________
Nausea, vomiting, taste disturbances, dry 
mouth, anorexia, arrhythmias, postural 
hypotension, syncope, drowsiness (including 
sudden onset of sleep), fatigue, dementia, 
psychoses, hallucinations, confusion, euphoria, 
abnormal dreams, insomnia, depression (very 
rarely with suicidal ideation), anxiety, dizziness, 
dystonia, dyskinesia, and chorea. Less 
commonly weight loss or gain, constipation, 
diarrhoea, hypersalivation, dysphagia, 
flatulence, hypertension, chest pain, oedema, 
hoarseness, ataxia, increased hand tremor, 
malaise, muscle cramps, and reddish 
discoloration of the urine and other body fluids 
may occur. Rare side-effects include abdominal 
pain, gastro-intestinal bleeding, dyspepsia, 
phlebitis, dyspnoea, agitation, paraesthesia, 
bruxism, trismus, hiccups, neuroleptic malignant 
syndrome (associated with abrupt withdrawal), 
convulsions, reduced mental acuity, 
disorientation, headache, urinary retention,
urinary incontinence, priapism, activation of 
malignant melanoma, leucopenia, haemolytic 
and non-haemolytic anaemia, 
thrombocytopenia, agranulocytosis, blurred 
vision, blepharopasm, diplopia, activation of 
Horner's syndrome, pupil dilatation, oculogyric 
crisis, angioedema, rash, urticaria, pruritus, 
flushing, alopecia, exanthema, Henoch- 
Schonlein purpura, and increased sweating. 
Very rarely angle-closure glaucoma may occur; 
pathological gambling, increased libido, 
hypersexuality, and false positive tests for 
urinary ketones have also been reported. (BNF)
Stalevo Motor
fluctuations
None H&Y mean 2.28 UPDRS III (level of 
significance set 
at 0.05)
0.001
P<0.001
31.7% decreased at least one quartile of o ff 
time
Mean baseline 24.4 to endpoint mean 20.4 
(Koller et al., 2005)
Cognitive
impairment
No data
Confusion ADR - entacapone (BNF)
Hallucinations ADR -  entacapone (BNF)
Dyskinesias As above 70.05 8.5% developed dyskinesias, 43.6% pre­
existing dyskinesias worsened -  majority had 
improvement in dyskinesia with reduction in 
stalevo dose
ADR -  entacapone (BNF)
Postural
hypotension
ADR - levodopa (BNF)
Patient’s choice No data
Mobility No data
Depression ADR -  levodopa (BNF)
Interacts with some antidepressants
ADLs
None Mean H&Y 2.28
UPDRS II 
UPDRS II
0.001
P<0.001
Improved from baseline to endpoint 
Baseline mean 11.0 to endpoint mean 9.3 
(Koller et al., 2005)
Improvement general UPDRS scores -  not 
broken down into sections (Myllyla et al., 2006)
Cost-
effectiveness
No data
Stage of disease 
(H&Y)
No data
Drug
contraindications
Pregnancy, breast-feeding (BNF) (levodopa) 
Non-selective MAO-A and MAO-B inhibitors. 
Concomitant use of selective MAO-A, selective 
MAO-B inhibitor and entacapone.
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Drug
interactions
Adverse drug 
reactions
Administer cautiously with products metabolised 
by COMT (rimiterole, isoprenaline, adrenaline, 
noradrenaline, dopamine, dobutamine, alpha- 
methyldopa and apomorphine) (Entacapone) 
Enhanced hypotensive effect: ACE inhibitors, 
adrenergic neurone blockers, alpha-blockers, 
antiotensin-ll receptor antagonists, beta- 
blockers, calcium-channel blockers, clonidine, 
diazoxide, diuretics, hydralazine, methyldopa, 
minoxidil, nitrates, sodium nitroprusside; 
amisulpiride manufacturer advises advoidance; 
risk arrhythmias with volatile liquid GAs; 
absorption of Idopa poss reduced by: 
antimuscarinics, oral iron, phenytoin; effects of 
Idopa antagonised by: antipsychotics, possibly 
benzodiazipines; agitation, confusion & 
hallucinations with baclofen; increased risk side 
effects with buproprion, moclobemide; risk 
hypertensive crisis with MAOIs; enhanced effect 
and increased toxicity with selegiline (reduce 
dose Idopa) (levodopa -  BNF)
Possibly enhances effects of: adrenaline, 
apomorphine, dobutamine, dopamine, 
methyldopa, noradrenaline; Manufacturer 
advises caution with: tricyclics, moclobemide, 
paroxetine, venlafaxine; absorption of 
entacapone reduced by oral iron; avoid use with 
non-selective MAOIs; possibly reduces plasma 
concentration of rasagiline; manufacturer 
advises max dose 10mg selegiline; enhances 
anticoagulant effect of warfarin (BNF -
entacapone) ____________________________
Anorexia, nausea and vomiting, insomnia, 
agitation, postural hypotension, dizziness, 
tachycardia, arrhythmias, reddish discolouration
of urine and bodily fluids, rarely hypersensitivity, 
abnormal involuntary movements & psych 
symptoms (inc hypomania and psychosis) may 
be dose-limiting, depression, drowsiness, 
headache, flushing, sweating, Gl bleeding, 
peripheral neuropathy, taste disturbance, 
pathological gambling, increased libido, 
hypersexuality, pruritus, rash and livery enzyme 
changes reported, syndrome resembling 
neuroleptic malignant syndrome reported on 
withdrawal, very rarely angle-closure glaucoma 
(BNF - levodopa)
Nausea, vomiting, abdominal pain, constipation, 
diarrhoea, urine may be reddish-brown, 
confusion, dizziness, abnormal dreams, fatigue, 
insomnia, dystonia, dyskinesia, hallucinations, 
increased sweating, rarely: hepatic dysfunction 
and rash, very rarely: anorexia, weight loss, 
agitation, urticaria, also reported: colitis, 
neuroleptic malignant syndrome, 
rhabdomyolysis, skin hair and nail 
discolouration (BNF -  entacapone)
Tolcapone Motor
fluctuations
Placebo
Placebo
H&Y 1 to IV 
H&Y 1 to IV
‘off’ and ‘on’ time, 
IGA, UPDRS III
‘off’ and ‘on’ time, 
IGA, UPDRS III
P<0.01 (200mg)
P<0.01 (100mg & 
200mg)
P<0.01 (100mg & 
200mg)
P<0.05 (100mg) 
200mg NS
P<0.01 (200mg) 
100mg NS
100mg -2.3h (NS) 200mg -3.2h vs -1.4h 
placebo
Wearing-off effect (IGA) 68% (100mg) 95% 
(200mg) vs 37% placebo (Rajput et al., 1997) 
‘On’ time (% change?): 10.8 (100mg & 200mg) 
vs -0.7 placebo (maintained until month 9 -  
200mg only)
‘O ff time (% change?): -12.7 (100mg) -9.8 
(200mg) vs -4.2 placebo (maintained until 
month 9 -  200mg & 100mg)
UPDRS III score -4.2 (100mg) -6.5 (200mg vs - 
2.1 placebo (Baas et al., 1997)
Cognitive No data
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impairment
Confusion ADR (BNF)
Hallucinations ADR (Rajput et al., 1997 
ADR (BNF)
Dyskinesias Severe dyskinesia contraindication (BNF) 
ADR (BNF)
Postural
hypotension
ADR
Patient’s choice No data
Mobility No data
Depression No data
ADLs Placebo H&Y 1 to IV UPDRS II NS -0.8 (100mg) 0.2 (200mg) vs -0.3 placebo 
(Rajput et al., 1997)
Cost-
effectiveness
No data
Stage of disease 
(H&Y)
No data
Drug
contraindications
Hepatic impairment, raised liver enzymes, 
severe dyskinesia, phaeochromocytoma, 
previous history neuroleptic malignant 
syndrome, rhabdomyolosis, hyperthermia, 
breast-feeding. Cautions: renal impairment, 
pregnancy, reduce levodopa by 30% if on 
>600mg/day (BNF)
Drug
interactions
Avoid MAOIs (BNF)
Adverse drug 
reactions
Diarrhoea, constipation, dyspepsia, abdominal 
pain, nausea, vomiting, anorexia, xerostomia, 
hepatotoxicity, chest pain, confusion, dystonia, 
dyskinesia, drowsiness, headache, dizziness, 
sleep disturbance, excessive dreaming, 
hallucinations, syncope, urine discolouration, 
sweating, neuroleptic malignant syndrome and 
rhabdomyolysis reported on dose reduction or 
withdrawal (BNF)
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APPENDIX II
Visual Basic for Applications Coding
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VBA Coding
Private Sub CmdHelpQ4_Click()
MsgBox "Each criterion needs to be weighed up against all the others to 
determine the figure to be given. You must consider the range of effects the 
drug can cause for each criterion. For example, when choosing a car cost 
may be an important criterion, but if you have £10,000 to spend and the 
difference between 1 car and another is only £100 cost becomes less 
important than another criterion where the difference is much bigger. In this 
case with PD drugs it may be very important for your patient that the drugs 
don't cause dyskinesias or postural hypotension: the range of effects the 
drugs have on dyskinesias is quite extensive, whereas for postural 
hypotension the range is quite small. Therefore, dyskinesias might be given a 
high value, whereas postural hypotension might be given a small value even 
though both are important for your patient."
End Sub
'prevent the user from closing the form other than by 'close' button 
Private Sub UserForm_QueryClose(Cancel As Integer, CloseMode As 
Integer)
If CloseMode = vbFormControlMenu Then 
Cancel = True
MsgBox "You must use the 'Close' button to close the form"
End If 
End Sub
'Carry out multiplication of scores and weights and sum multiplication values 
Private Sub cmdCalculate_Click()
Dim WeightRow As Integer 'weight row
Dim DrugCol As Integer 'drug column
Dim DrugRow As Integer 'drug row
Dim MultiCol As Integer 'column to be multiplied
Dim MultiRow As Integer 'row to be multiplied
Dim Result As Double 'result of multiplication
Dim Rng As Range ’range of multiplication results
Dim SortResult As String 'result of sort
If Range("A56").Value = "True" Then
'start from column C and loop through to column R 
DrugCol = 3 
Do Until DrugCol = 19
'start from row 2 and loop through to row 12 
WeightRow = 2 
Do Until WeightRow =13
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'multiply score by weight, loop down rows and across columns, 
position results underneath each column
Cells(WeightRow + 13, DrugCol).Value = Cells(WeightRow, 2).Value * 
Cells(WeightRow, DrugCol).Value
WeightRow = WeightRow + 1 
Loop
DrugCol = DrugCol + 1 
Loop
'sum multiplication values - (no sum function)
'start from column C, loop through to column R 
MultiCol = 3 
Do Until MultiCol = 19
'put result of addition 2 rows below scores 
Cells(28, MultiCol).Value = (Cells(15, MultiCol).Value + Cells(16, 
MultiCol).Value + Cells(17, MultiCol).Value + Cells(18, MultiCol).Value + 
Cells(19, MultiCol).Value + Cells(20, MultiCol).Value + Cells(21, 
MultiCol).Value + Cells(22, MultiCol).Value + Cells(23, MultiCol).Value + 
Cells(24, MultiCol).Value + Cells(25, MultiCol).Value) \ 100
MultiCol = MultiCol + 1 
Loop
'copy rows with names of drugs and results of multiplication and cautions 
and comorbidities
Range("C27: R30").Select 
Selection.Copy
'paste drug names into row 33, results to row 34, cautions to row 35 and 
comorbidities to row 36 
RangeCC33:R36").Select
Selection.PasteSpecial Paste:=xlPasteValues, Operation:=xlNone, 
SkipBlanks _
:=False, Transpose:=False
'select drug names, results, cautions and comorbidities and sort in 
ascending order
Range(MC33:R36").Select
Selection.Sort Key1 :=Range(''C34"), Orderl :=xlAscending, Header:=xlNo,
OrderCustom:=1, MatchCase:=False, Orientation:=xlLeftToRight, _ 
DataOptionl :=xlSortNormal
'take top 3 results in columns R, Q and P and return their names in 
message box with their cautions and comorbidities
'results 1,2 and 3 return results for top drug with cautions and comorbidities 
SortResultl = Cells(33, 18). Value 
SortResult2 = Cells(35, 18). Value 
SortResult3 = Cells(36, 18). Value
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'results 4,5 and 6 return results for 2nd drug with cautions and 
comorbidities
SortResult4 = Cells(33, 17). Value 
SortResult5 = Cells(35, 17). Value 
SortResult6 = Cells(36, 17). Value
'results 7, 8 and 9 return results for 3rd drug with cautions and 
comorbidities
SortResult7 = Ce!ls(33, 16). Value 
SortResult8 = Cells(35, 16). Value 
SortResult9 = Cells(36, 16). Value
'show results of sort in ResultsForm - top 3 recommended treatments 
ResultsForm.TextBoxI = SortResultl & vbCrLf & vbCrLf & SortResult2 & 
vbCrLf & vbCrLf & SortResult3
ResultsForm.TextBox2 = SortResult4 & vbCrLf & vbCrLf & SortResult5 & 
vbCrLf & vbCrLf & SortResult6
ResultsForm.TextBox3 = SortResult7 & vbCrLf & vbCrLf & SortResult8 & 
vbCrLf & vbCrLf & SortResult9 
ResultsForm.Show
Else
MsgBox "You must select figures for section 4 and click 'submit 
responses’ before you can receive the recommended treatments"
End If
End Sub
Private Sub CmdListResult_Click()
If Range("A60").Value = "True" Then
'list the results of all the drugs with their scores in a message box 
SortResultl = Cells(33, 18). Value 
SortResultl Fig = Cells(34, 18).Value 
SortResult4 = Cells(33, 17). Value 
SortResult4Fig = Cells(34, 17).Value 
SortResult7 = Cells(33, 16). Value 
SortResult7Fig = Cells(34, 16).Value 
SortResultl 0 = Cells(33, 15). Value 
SortResultl OFig = Cells(34, 15). Value 
SortResultl 1 = Cells(33, 14). Value 
SortResultl 1 Fig = Cells(34, 14). Value 
SortResultl 2 = Cells(33, 13). Value 
SortResultl 2Fig = Cells(34, 13). Value 
SortResultl 3 = Cells(33, 12). Value 
SortResultl 3Fig = Cells(34, 12). Value 
SortResultl 4 = Cells(33, 11). Value 
SortResultl 4Fig = Cells(34, 11). Value
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SortResultl 5 = Cells(33, 10). Value 
SortResultl 5Fig = Cells(34, 10). Value 
SortResultl 6 = Cells(33, 9).Value 
SortResultl 6Fig = Cells(34, 9).Value 
SortResultl 7 = Cells(33, 8).Value 
SortResultl 7Fig = Cells(34, 8).Value 
SortResultl 8 = Cells(33, 7).Value 
SortResultl 8Fig = Cells(34, 7).Value 
SortResultl 9 = Cells(33, 6).Value 
SortResultl 9Fig = Cells(34, 6).Value 
SortResult20 = Cells(33, 5).Value 
SortResult20Fig = Cells(34, 5).Value 
SortResult21 = Cells(33, 4).Value 
SortResult21 Fig = Cells(34, 4).Value 
SortResult22 = Cells(33, 3).Value 
SortResult22Fig = Cells(34, 3).Value
MsgBox "The results for all the drugs are as follows:" & vbCrLf & "1." & 
SortResultl & " "  & SortResultl Fig & vbCrLf & "2 ." & SortResult4 & " "  & 
SortResult4Fig & vbCrLf & "3." & SortResult7 & " "  & SortResult7Fig & vbCrLf 
& "4 ." & SortResultl 0 & " "  & SortResultl OFig & vbCrLf & "5." & SortResultl 1 
& " "  & SortResultl 1 Fig & vbCrLf & "6." & SortResultl 2 & " "  &
SortResultl 2Fig & vbCrLf & "7." & SortResultl 3 & " "  & SortResultl 3Fig & 
vbCrLf & "8 ." & SortResultl 4 & " "  & SortResultl 4Fig & vbCrLf & "9." & 
SortResultl 5 & " "  & SortResultl 5Fig & vbCrLf & "10." & SortResultl6 & " "  & 
SortResultl 6Fig & vbCrLf & "11." & SortResultl 7 & " "  & SortResultl 7Fig & 
vbCrLf & "12." & SortResultl 8 & " "  & SortResultl 9Fig & vbCrLf & "13." & 
SortResultl 9 & ” " & SortResultl 9Fig & vbCrLf & "14." & SortResult20 & " "  & 
SortResult20Fig & vbCrLf & "15." & SortResult21 & " "  & SortResult21Fig & 
vbCrLf & "16." & SortResult22 & " "  & SortResult22Fig
Else
MsgBox "You must enter data for all the sections, click 'submit section 2' 
and 'submit responses' before you can view the results"
End If 
End Sub
Public Sub CmdReset_Click()
'Copy original scores from cells C41 to R51 
Range("C41 :R51").Select 
Selection.Copy
'Paste scores back into cells C2 to R12 after poor responses have been 
selected 
Range("C2:R12").Select
Selection.PasteSpecial Paste:=xlPasteValues, Operation:=xlNone, 
SkipBlanks _
:=False, Transpose:=False
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'set reset_done cell flag to TRUE here 
Range("A54").Value = "TRUE"
End Sub
'Help facility
Private Sub CmdHelp_Click()
MsgBox "Complete sections 1 and 2 of the page," & vbCrLf & "Click 'Submit 
section 2”’ & vbCrLf & "Then complete sections 3 and 4" & vbCrLf & "Click 
Submit response and Calculate answer." & vbCrLf & "A message box will 
show on screen with your result" & vbCrLf & "Click 'List all results’ to see all 
the drugs with their results" & vbCrLf & "Click 'reset' once you have viewed 
your result"
End Sub
'on 'clear' re-set option boxes to null 
Private Sub cmdClear_Click()
OptMotorFlucs.Value = Null 
OptCoglmpair. Value = Null 
OptConfusion.Value = Null 
OptHallucns.Value = Null 
OptDyskinesias.Value = Null 
OptDepression.Value = Null 
OptPostHyptn. Value = Null 
OptStage.Value = Null 
OptADL.Value = Null
TextBoxMotorFlucs. Value = Null 
TextBoxCoglmpair. Value = Null 
TextBoxConfusion. Value = Null 
TextBoxHallucns. Value = Null 
TextBoxDyskinesias. Value = Null 
TextBoxDepression. Value = Null 
TextBoxPostHyptn. Value = Null 
TextBoxStage. Value = Null 
TextBoxADL. Value = Null
'Clear any poor response drugs selected when click 'clear' 
ListBoxPoorResp.Selected(O) = False 
ListBoxPoorResp.Selected(l) = False 
ListBoxPoorResp.Selected(2) = False 
ListBoxPoorResp.Selected(3) = False 
ListBoxPoorResp.Selected(4) = False 
ListBoxPoorResp.Selected(5) = False
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ListBoxPoorResp.Selected(6) = False 
ListBoxPoorResp.Selected(7) = False 
ListBoxPoorResp.Selected(8) = False 
ListBoxPoorResp.Selected(9) = False 
ListBoxPoorResp.Selected(IO) = False 
ListBoxPoorResp.Selected(11) = False 
ListBoxPoorResp.Selected(12) = False 
ListBoxPoorResp.Selected(13) = False 
ListBoxPoorResp.Selected(14) = False 
ListBoxPoorResp.Selected(15) = False 
ListBoxPoorResp.Selected(16) = False
End Sub
'Close application
Public Sub cmdClose_Click()
'test reset cell flag here 
If Range("A54").Value = "True" Then 
Unload Me 
Else
MsgBox "You must click ’reset' before you can close the form"
End If
End Sub
'submit data for highest weight into relevant text box in section 4 on 'submit 
section 2’
Private Sub CmdSubmit1_Click()
'set reset flag cell 
Range("A54"). Value = "FALSE"
'set reset flag cell for validation that responses submitted before calculate 
answer
Range("A56").Value = "FALSE"
'set reset flag cell to false for validation for list all responses 
Range("A60").Value = "FALSE"
'set scores to 0 for any poor responses selected 
'Not applicable
If ListBoxPoorResp.Selected(O) = True Then 
'Do Nothing 
End If 
'Co - beneldopa
If ListBoxPoorResp.Selected(1) = True Then 
Range("C2:C12").Value = 0 
End If 
'Co - careldopa
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If ListBoxPoorResp.Selected(2) = True Then 
Range(HD2:D12").Value = 0 
End If 
'Stalevo
If ListBoxPoorResp.Selected(3) = True Then 
Range("E2:E12M).Value = 0 
End If 
’Duodopa
If ListBoxPoorResp.Selected(4) = True Then 
Range(”F2:F12").Value = 0 
End If 
'Ropinirole
If ListBoxPoorResp.Selected(5) = True Then 
Range("G2:G12M). Value = 0 
End If 
'Pramipexole
If ListBoxPoorResp.Selected(6) = True Then 
Range("H2:H12H).Value = 0 
End If 
'Rotigotine
If ListBoxPoorResp.Selected(7) = True Then 
Range(Ml2:l12M).Value = 0 
End If 
'Pergolide
If ListBoxPoorResp.Selected(8) = True Then 
Range(MJ2:J12”).Value = 0 
End If 
'Bromocriptine
If ListBoxPoorResp.Selected(9) = True Then 
Range("K2:K12"). Value = 0 
End If 
'Cabergoline
If ListBoxPoorResp.Selected(IO) = True Then 
Range("L2:L12").Value = 0 
End If 
'Apomorphine
If ListBoxPoorResp.Selected(11) = True Then 
Range(”M2:M12").Value = 0 
End If 
'Selegiline
If ListBoxPoorResp.Selected(12) = True Then 
Range("N2:N12").Value = 0 
End If 
'Rasagiline
If ListBoxPoorResp.Selected(13) = True Then 
Range("02:012").Value = 0 
End If 
'Amantadine
If ListBoxPoorResp.Selected(14) = True Then 
Range("P2:P12").Value = 0
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End If 
'Entacapone
If ListBoxPoorResp.Selected(15) = True Then 
Range("Q2:Q12").Value = 0 
End If 
'Tolcapone
If ListBoxPoorResp.Selected(16) = True Then 
Range("R2:R12").Value = 0 
End If
ActiveWorkbook.Sheets("Sheet3").Activate 
Range(”A1 ").Select 
If IsEmpty(ActiveCell) = False Then 
ActiveCell.Offset(1, 1). Select 
End If
'Enter weight for chosen criterion with score of 10 
If OptMotorFlucs.Value = True Then 
ActiveCell. Value = 10 
TextBoxMotorFlucs. Value = 10 
Elself OptCoglmpair.Value = True Then 
ActiveCell.Offset(1, 0).Value = 10 
TextBoxCoglmpair. Value = 10 
Elself OptConfusion.Value = True Then 
ActiveCell.Offset(2, 0).Value = 10 
TextBoxConfusion. Value = 10 
Elself OptHallucns.Value = True Then 
ActiveCell.Offset(3, 0).Value = 10 
TextBoxHallucns. Value = 10 
Elself OptDyskinesias.Value = True Then 
ActiveCell.Offset(4, 0).Value = 10 
TextBoxDyskinesias. Value = 10 
Elself OptDepression.Value = True Then 
ActiveCell.Offset(5, 0).Value = 10 
TextBoxDepression. Value = 10 
Elself OptPostHyptn.Value = True Then 
ActiveCell.Offset(6, 0).Value = 10 
TextBoxPostHyptn.Value = 10 
Elself OptStage.Value = True Then 
ActiveCell.Offset(7, 0).Value = 10 
TextBoxStage. Value = 10 
Elself OptADL.Value = True Then 
ActiveCell.Offset(8, 0).Value = 10 
TextBoxADL. Value = 10
Else
'validate that a weight in section 2 has been selected
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MsgBox "You must select an option for section 2 
before you click 'submit section 2'"
End If
End Sub
'Submit values for all other weights into spreadsheet 
Private Sub cmdSubmitWeights_Click()
ActiveWorkbook.Sheets("Sheet3").Activate 
Range("A1 ").Select 
If IsEmpty(ActiveCell) = False Then 
ActiveCell.Offset(1, 1).Select 
End If
'data validation - check input is not non-numeric character, not negative 
number, not more than 10 and not blank
If IsNull(TextBoxMotorFlucs) Or Me.TextBoxMotorFlucs = "" Then 
MsgBox "You must complete a value for motor fluctuations"
Elself lsNumeric(TextBoxMotorFlucs.Value) And 
Val(TextBoxMotorFlucs.Value) < 0 Then
MsgBox "Number must be 0 or more for motor fluctuations"
Elself Val(TextBoxMotorFlucs.Value) >10 Then 
MsgBox "You must choose a number between 0 and 10 for motor 
fluctuations"
Elself Not IsNumeric(TextBoxMotorFlucs.Value) Then 
MsgBox "Enter numerals and not any other characters for motor 
fluctuations"
End If
If IsNull(TextBoxCoglmpair) Or Me.TextBoxCoglmpair = "" Then 
MsgBox "You must complete a value for cognitive impairment"
Elself Not lsNumeric(TextBoxCoglmpair.Value) Then 
MsgBox "Enter numerals and not any other characters for cognitive 
impairment"
Elself lsNumeric(TextBoxCoglmpair.Value) And 
Val(TextBoxCoglmpair.Value) < 0 Then
MsgBox "Number must be 0 or more for cognitive impairment"
Elself Val(TextBoxCoglmpair.Value) >10 Then 
MsgBox "You must choose a number between 0 and 10 for cognitive 
impairment"
End If
If IsNull(TextBoxConfusion) Or Me.TextBoxConfusion = "" Then 
MsgBox "You must complete a value for confusion"
Elself Not lsNumeric(TextBoxConfusion.Value) Then
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9. Would you use this model in clinic yourself or recommend it to colleagues to use?
Yes No Not sure
□ □ Er
Please give details, for example, would you use it yourself for difficult cases
only, would you recommend it for junior colleagues:
B. Software (EPSS)
10. How easy did you find the EPSS to use? Please tick one option
Very easy Easy^ Fair Difficult Very difficult
□ U □ □ □
11. Are there any amendments you think could be made to the EPSS to make it easier 
to use?
Y es/ No Not sure
m a n
Please give any suggestions here:___________________________________
- S  <z^-Kc^ Q -&
12. How well do you think the questions are explained on the EPSS?
Very well Well Fa ir^  Poorly Very poorly
□  □  Er □  □
13. How quick was the EPSS to use?
Very quick Quiclr Fair Slow Very slow
□ of □ □ □
14. How would you rate your own knowledge and experience o f computers?
Very good G o o ^  Fair Poor Very poor□ 0  □ □ □
15. Would you be happy to use the EPSS in your clinic or to recommend it to
colleagues to use?
Yes No Not sufe□ □ W
Please give any details: _____________
Evaluation of Parkinson’s disease model and Electronic Prescribing
Support System (EPSS)
Please complete both sections:
A. Parkinson’s disease Model
1. How do you rate the criteria chosen? Please choose one option
Very good Good Fair Poor Very^joor
□  □  □  □  ET
2. Do you think any important criteria have been missed out?
Y e s ^  No Not sure
Er □ □
3.1 low do you rate the way the drugs have been scored against the criteria?
Very good Good Fair Poor Verypoor□ □ □ □
4. How do you rate the ease or difficulty o f weighting the criteria?
Very easy Easy Fair D ifficu lt Very difficult□ □ □ □
5. Do the weights need rewording to improve their clarity?
Yes . No Not sure
Cr □ □
I f  yes, please give any suggestions here:
r j
6. What is your opinion of the model overall?
Very good Good Fair P o o r / "  Very poor
□ □ □ Er □
7. Are there any amendments you think could be made to improve the model?
Yes No Not sure□ □
8. Do you think this is a suitable methodology for use in PD?
Yes No ^  Not sure
□  EK □
Please give details:
C - r t . f l . t r v 'T  . ( S o - t  V \ A S
? ^'V'GrVv T \ * > \ A  TVv^vi /VtA 'ft
1
MsgBox "Enter numerals and not any other characters for confusion" 
Elself lsNumeric(TextBoxConfusion.Value) And 
Val(TextBoxConfusion.Value) < 0 Then
MsgBox "Number must be 0 or more for confusion"
Elself Val(TextBoxConfusion.Value) >10 Then 
MsgBox "You must choose a number between 0 and 10 for 
confusion"
End If
If IsNull(TextBoxHallucns) Or Me.TextBoxHallucns = "" Then 
MsgBox "You must complete a value for hallucinations"
Elself Not lsNumeric(TextBoxHallucns.Value) Then 
MsgBox "Enter numerals and not any other characters for 
hallucinations"
Elself IsNumeric(TextBoxHallucns.Value) And 
Val(TextBoxHallucns.Value) < 0 Then
MsgBox "Number must be 0 or more for hallucinations"
Elself Val(TextBoxHallucns.Value) > 10 Then 
MsgBox "You must choose a number between 0 and 10 for 
hallucinations"
End If
If IsNull(TextBoxDyskinesias) Or Me.TextBoxDyskinesias = "" Then 
MsgBox "You must complete a value for dyskinesias"
Elself Not IsNumeric(TextBoxDyskinesias.Value) Then 
MsgBox "Enter numerals and not any other characters for dyskinesias" 
Elself lsNumeric(TextBoxDyskinesias.Value) And 
Val(TextBoxDyskinesias.Value) < 0 Then
MsgBox "Number must be 0 or more for dyskinesias"
Elself Val(TextBoxDyskinesias.Value) >10 Then 
MsgBox "You must choose a number between 0 and 10 for 
dyskinesias"
End If
If IsNull(TextBoxDepression) Or Me.TextBoxDepression = "" Then 
MsgBox "You must complete a value for depression"
Elself Not lsNumeric(TextBoxDepression.Value) Then 
MsgBox "Enter numerals and not any other characters for depression" 
Elself lsNumeric(TextBoxDepression. Value) And 
Val(TextBoxDepression.Value) < 0 Then
MsgBox "Number must be 0 or more for depression"
Elself Val(TextBoxDepression.Value) >10 Then 
MsgBox "You must choose a number between 0 and 10 for 
depression"
End If
If IsNull(TextBoxPostHyptn) Or Me.TextBoxPostHyptn = "" Then 
MsgBox "You must complete a value for postural hypotension"
Elself Not IsNumeric(TextBoxPostHyptn.Value) Then
323
MsgBox "Enter numerals and not any other characters for postural 
hypotension"
Elself lsNumeric(TextBoxPostHyptn.Value) And 
Val(TextBoxPostHyptn.Value) < 0 Then
MsgBox "Number must be 0 or more for postural hypotension"
Elself Val(TextBoxPostHyptn.Value) > 10 Then 
MsgBox "You must choose a number between 0 and 10 for postural 
hypotension"
End If
If IsNull(TextBoxStage) Or Me.TextBoxStage = "" Then 
MsgBox "You must complete a value for stage of disease"
Elself Not lsNumeric(TextBoxStage.Value) Then 
MsgBox "Enter numerals and not any other characters for stage of 
disease"
Elself lsNumeric(TextBoxStage.Value) And Val(TextBoxStage.Value) 
< 0 Then
MsgBox "Number must be 0 or more for stage of disease"
Elself Val(TextBoxStage.Value) >10 Then
MsgBox "You must choose a number between 0 and 10 for stage of
disease"
End If
If IsNull(TextBoxADL) Or Me.TextBoxADL = "" Then 
MsgBox "You must complete a value for ADL"
Elself Not lsNumeric(TextBoxADL. Value) Then
MsgBox "Enter numerals and not any other characters for ADL"
Elself IsNumeric(TextBoxADL.Value) And Val(TextBoxADL.Value) < 0
Then
MsgBox "Number must be 0 or more for ADL"
Elself Val(TextBoxADL.Value) >10 Then 
MsgBox "You must choose a number between 0 and 10 for ADL" 
End If
’Put values of weights chosen for rest of criteria
ActiveCell.Offset(0, 0).Value 
ActiveCell.Offset(1, 0).Value 
ActiveCell.Offset(2, 0).Value 
ActiveCell.Offset(3, 0).Value 
ActiveCell.Offset(4, 0).Value 
ActiveCell.Offset(5, 0).Value 
ActiveCell.Offset(6, 0).Value 
ActiveCell.Offset(7, 0).Value 
ActiveCell.Offset(8, 0).Value
= TextBoxMotorFlucs. Value 
= TextBoxCoglmpair. Value 
= TextBoxConfusion. Value 
= TextBoxHallucns.Value 
= TextBoxDyskinesias. Value 
= TextBoxDepression. Value 
= TextBoxPostHyptn. Value 
= TextBoxStage. Value 
= TextBoxADL. Value
’set reset flag cell to true as this section has been completed 
Range(’’A56").Value = "TRUE"
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'set reset flag cell to true when this section completed for validation of list 
results
Range("A60").Value = ’TRUE"
End Sub
’Add list box selections on initialisation 
Private Sub UserForm_lnitialize()
'set list box to null on initialisation 
ListBoxPoorResp.Value = "H
'add medications to combi box list 
With ListBoxPoorResp 
.AddItem "Not Applicable"
.Add Item "Co-beneldopa"
.AddItem "Co-careldopa"
.AddItem "Stalevo"
.Add Item "Duodopa"
.Add Item "Ropinirole"
.AddItem "Pramipexole”
.AddItem "Rotigotine"
.AddItem "Pergolide"
.AddItem "Bromocriptine"
.AddItem "Cabergoline"
.AddItem "Apomorphine"
.Addltem "Selegiline"
.Addltem "Rasagiline"
.Addltem "Amanatdine"
.Addltem "Entacapone"
.Addltem "Tolcapone"
End With
'set cursor to 'poor response’ list box on initialisation 
ListBoxPoorResp.SetFocus
End Sub
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APPENDIX III
Computer Decision Support System Evaluation
Questionnaires
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Evaluation of Parkinson’s disease model and Electronic Prescribing
Support System (EPSS)
S '
Please complete both sections:
A. Parkinson’s disease Model
1. How  do you rate the criteria chosen? Please choose one option
Very good Good Fair Poor' Very poor□ □ □ & □
2. Do you think any important criteria have been missed out?
N o Not sure□ □
3. How  do you rate the way the drugs have been scored against the criteria?
Very good Good Fair Poof Very poor
□  □  □  O f  □
4. How  do you rate the ease or difficulty o f weighting the criteria?
Very easy Easy Fair D ifficult Very difficult
□ /  □ □ U  □
5. D o the weights need rewording to improve their clarity?
Ye? N o Not sure□ □
I f  yes, please give any suggestions here:
6. What is your opinion o f theinodel overall?
Very good Gopu Fair Poor Very poor□ 0  □ □ □
7. Are there ariy amendments you think could be made to improve the model?
Yes No Not sure
0  □  □
8. Do you think this is a suitable methodolog)Kfor use in PD?
Yes No Noustire□ □ is
Please give details:
1
9. Would you use this model in clinic yourself or recommend it to colleagues to use? 
Yes N o Not sure□ □
Please give details, for example, would you use it yourself for difficult cases 
only, would you recommend it for junior colleagues:
B. Software (EPSS)
10. How easy did you find the EPSS to use? Please tick one option
Very easy Easy Fair D ifficult Very difficult□ □ □ □
11. Are there any amendments you think could be made to the EPSS to make it easier 
to use?
Yes N o Not sure□ □
Please give any suggestions here:_______________________________________
12. How well do you think the questions are explained on the EPSS?
Very well Well Fair ^  Poorly Very poorly
□  □  E K  □  □
13. How quick was the EPSS to use?
Very guick Quick Fair Slow Very slow
EK  □  □  □  □
14. How would you rate your own knowledge and experience of computers?
Very good Good Fair Poor Very poor□ □ □ □
15. Would you be happy to use the EPSS in your clinic or to recommend it to 
colleagues to use?
Yes No . Not sure
□  GK □
Please give any details:
9. Would you use this model in clinic yourspnor recommend it to colleagues to use? 
Yes No Not/^ure□ □
Please give details, for example, would you use it yourself for difficult cases 
only, would you recommend it for junior colleagues:
B. Software (ERSS)
10. How easy diu you find the EPSS to use? Please tick one option
Very easy Easy Fair Difficult Very difficult
H □ □ □ □
11. Are there any amendments you think could be made to the EPSS to make it easier 
to use? y
Yes/ No Not sure
m a n
Please give any suggestions here:____________________________________
12. How well do you think the questions are explained on the EPSS?
Very well Well F a i r / '  Poorly Very poorly
□ □ nr □ □
13. How quick was the EPSS toju^e?
Very quick Quicx Fair Slow Very slow□ m □ □ □
14. How would you rate your own knowledge and experience o f  computers?
Very good Good Fair P o o r /^  Very poor□ □ □ M  □
15. Would you behappy to use the EPSS in your clinic or to recommend it to 
colleagues to us£?
Y e / '  No Not sure
a □ □
Please give any details:
Evaluation of Parkinson’s disease model and Electronic Prescribing
Support System (EPSS)
Please complete both sections: 
A. Parkinson’s disease Model
1. How do you rate the criteria chosen? Please choose one option
Very good Good Fait/ Poor Very poor
□ □ M □ □
2. Do you think any important criteria have been missed out?
Yes' No Not sure
0 □ □
3. How do you rate the way the drugs have been scored against the criteria?
Very good Good Fair Poop- Very poor
□ □ □ 0  □
4. How do you rate the ease or difficulty o f weighting the criteria?
Very easy Easy Fair. Difficult Very difficult□ □ n  □ □
5. Do the weights need rewording to improve their clarity?
Yes, No Not sure
I3 □  □
I f  yes, please give any suggestions here:
6. What is your opinion o f the model overall?
Very good Good Fair Poor Very poor□ □ M  □ □
7. Are there any amendments you think could be made to improve the model?
Yes^ No Not sure□ □ □
8. Do you think this is a suitable methodology for use in PD?
Yes No Norsure
□  □  M
Please give details:
( / W b 2
